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ABSTRACT 
Introduction 
Endovascular Aneurysm Repair (EVAR) is the commonest form of repair of Abdominal 
Aortic Aneurysms (AAA). EVAR involves the placement of a stent-graft that seals into 
the arteries proximally and distally containing blood flow through the AAA. EVAR 
suffers from complications and treatment failures and patients are enrolled on a 
surveillance programme to identify these so corrective secondary intervention might be 
undertaken. Surveillance contributes significantly to the cost of treatment and is 
inefficient.  
Efficient surveillance requires adequate knowledge of the; nature and timing of 
complications, diagnostic merits of surveillance imaging, factors which limit patient 
compliance and ability to predict the risk of future complications.  This work addresses 
deficiencies in these areas. 
Methods 
A database of a city wide vascular surgical service and surveillance imaging reports for 
2008-15 were analysed under ethical approved. The nature / incidence of secondary 
interventions and degree of compliance with surveillance were reported using 
descriptive statistics and incidence. Association between patient factors and non-
compliance were examined using adjusted odds ratios (AOR). 
Missing datapoints in imaging data were addressed using multiple imputation utilising 
chained equations. Surveillance imaging findings were assessed for association with 
subsequent secondary intervention using Kaplan-Myer plots, log rank test and AORs. 
AOR were calculated using multivariate models.  
A piecewise exponential model (PEM) was created to predict future risk of secondary 
intervention at different times following EVAR. This was internally validated using a 
bootstrapping technique and assessed using Hosmer–Lemeshow test and receiver 
operator characteristics (ROC).  
A prospective imaging study of Contrast Enhanced Ultrasound Scan (CEUS) and time-
resolved Computer Tomography Angiography (tCTA) was undertaken, the diagnostic 
values of CEUS to diagnose a graft-related endoleak were obtained. 
 Results 
A total of 2901 patient years of follow-up in 756 individuals were analysed. The 
intended purpose of  the 178 secondary interventions was, 85(48%) maintaining distal 
perfusion and 93(52%) maintaining effective aneurysm treatment.  The incidence of 
secondary interventions following EVAR varied at different stages of follow-up 
between approximately 35 and 60 interventions per 1000 patient years. 
Compliance was maintained above 95% until 10 years after EVAR. The factors most 
associated with compliance were; years after EVAR (AOR 0.62), calendar year EVAR 
performed (0.67), age at time (0.96) and previously undergone a secondary intervention 
(1.13). 
Evaluation of Colour Duplex Ultrasound Scan (CDUS) and Abdominal Radiography 
(AXR) findings demonstrated that reducing the number of collected findings did not 
lead to changes in the overall association with secondary intervention. 
Internal validation of the PEM model demonstrated an area under the curve of 0.72 
(95% CI 0.68 – 0.76) on ROC analysis and Hosmer–Lemeshow test produced a median 
p-value of 0.51, demonstrating satisfactory discrimination and calibration. 
On blinded prospective study CEUS has a sensitivity of 0.56 (95% confidence interval 
0.23 – 0.88) and specificity of 0.90 (0.78 – 1.00) to diagnose a graft related endoleak, 
with tCTA as the comparator standard. 
Conclusion 
This work demonstrates the changing epidemiology of secondary interventions after 
EVAR, that CDUS & AXR reporting can be simplified and those findings can be used 
to predict future risk of secondary interventions.  Excellent compliance with EVAR 
surveillance is achievable and is associated with a small number of patient factors.  
Finally, CEUS is demonstrated to have poor graft related endoleak diagnostic values 
when compared to tCTA.  
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1 INTRODUCTION: 
ABDOMINAL AORTIC 
ANEURYSMS, 
ENDOVASCULAR REPAIR 
AND SUBSEQUENT 
SURVEILLANCE 
The aorta is the largest artery in the body. It can, as the result of deterioration or injury, 
dilate to form an aneurysm. The commonest site of an aortic aneurysm is in the 
abdomen, below the renal arteries. Abdominal aortic aneurysms (AAA) grow over time 
and can rupture, leading to haemorrhage and often resulting in death. Prophylactic 
repair of AAA has been developed to prevent such deaths. The most common method of 
prophylactic repair in the United Kingdom is Endovascular Aneurysm Repair (EVAR). 
EVAR involves the placement of a stent-graft into the aneurysm, under X-ray guidance, 
in a minimally invasive manner. The EVAR stent-graft seals proximally and distally 
and carries the contained blood through the aneurysm, so preventing rupture. EVAR is 
imperfect and there is a rate of failure of the stent-grafts implanted, it is therefore 
recommended all patients undergoing EVAR should be enrolled on to a regimen of 
surveillance imaging to detect such failures, so corrective secondary interventions might 
be undertaken. The best imaging modality and regimen for EVAR surveillance is not 
yet fully understood. 
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1.1 Abdominal Aortic Aneurysms  
Abdominal aortic aneurysm (AAA) is a dilatation of the largest artery in the abdomen 
and the commonest position of an AAA is inferior to the renal arteries, Figure 1 (page 
2). AAA is conventionally defined as an aorta of diameter greater than 30mm. 1-3 The 
most common alternative definition is an aortic diameter 150% of the adjacent normal 
segment diameter, this definition has the benefit of accounting for individual and sex 
variance in normal aortic diameter. 4 5 
Figure 1: Infrarenal Abdominal Aortic Aneurysm 
 
The major vessels of the trunk with an aneurysm of the aorta below the renal arteries. 
Credit: Blausen Medical Communications, Inc. Reproduced under the CC BY-SA 4.0 License 
1.1.1 Prevalence 
The prevalence of AAAs has been investigated by several screening studies of selected 
populations. Two large UK studies provided the main evidence base for the creation of 
the National Health Service Abdominal Aortic Aneurysm Screening Programme 
(NHSAAASP), which in turn provides contemporary information on AAA prevalence 
in 65 year old males in the UK. 
Scott et al. undertook a randomised control trial of screening for AAA in Chichester, 
UK and the surrounding district between 1988 and 1990.6 15,775 male and female 
patients between 65 and 80 years old were randomised to invitation to undergo 
ultrasound screening for AAA or no invitation. Of the 5394 who attended for ultrasound 
AAA screening, 218 (4.0%) had an AAA detected on the initial screening. There was a 
marked difference in AAA prevalence between sexes, with 178 of 2342 (7.6%) screened 
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males having an aneurysm compared to 40 of 3052 (1.3%) of females. This low 
incidence in the female population has been confirmed on systematic review and meta-
analysis of contemporary studies in which screening was performed after the year 
2000.7  The second UK screening study was the Multicentre Aneurysm Screening 
Study; they randomised 67,770 men aged 65-74 to either invitation to ultrasound 
aneurysm screening or a control group who were not invited. 1,333 men had an 
aneurysm detected out of 27,147 who attended for surveillance, a prevalence of 4.9%.8 
The NHSAAASP is available for all men aged 65 and over, in England. In 2016/17 the 
NHSAAASP invited 281,965 men to screening at the age of 65. 228,563 underwent 
ultrasound surveillance and 2,471 had an AAA diagnosed, a prevalence of 1.1%.9 
1.1.2 Natural History (Expansion Rates and Rupture Risk) 
AAAs expand over time and have a corresponding increasing risk of rupture the larger 
they are. Expansion (measured as an increase in diameter) is best estimated using 
statistical likelihood methods (rather than linear regression) as patients are typically 
referred to treatment following their first measurement that is in excess of the treatment 
threshold.10 This means that any over estimation at final measurement is not corrected 
for by future measurements and leads to an over estimation of the overall expansion rate 
using linear regression modelling.  Serial Aneurysm measurements from the UK Small 
Aneurysm Trial,11 is the largest series of UK data to have been analysed in this manner. 
Brady et al,12 demonstrated a mean expansion rate of 2.6mm a year (95% confidence 
interval (CI) 2.5-2.6 mm/year) when fitted to a linear likelihoods model, there is 
however a large variation between individuals, 95% reference range -1.0 to 6.1 
mm/year. When fitted to the more appropriate quadratic model the coefficient on the 
mean quadratic term for time was 0.11mm/year, 95% CI 0.07-0.16. 13 Expansion rates 
in the linear model were not associated with age or sex but were associated with 
diameter at baseline, aneurysms expanded 1.29mm/year (95% CI 1.05-1.35) faster for 
every 10mm larger they were at baseline. Current smokers also had an increased rate of 
expansion of 0.42mm/year (95% CI 0.17-0.68) when compared to ex-smokers. This 
association is present even after adjustment for potential confounding factors. 
Hypertension, systolic blood pressure at baseline, anti-hypertensive medication, 
ischemic heart disease on ECG, body mass index (BMI), total cholesterol, white cell 
count, triglycerides and HDL Cholesterol were not associated with expansion rates. 
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Larger aneurysms are more likely to rupture, has been observed in several studies.14-16 
European guidelines17 have summarised this risk (stratified by size), Table 1 (page 4), 
contemporary data from the NHSAAASP has shown that men over 65 with a 30-44mm 
diameter AAA have a rupture risk of 0.03% per an annum and those with a AAA 45-
55mm diameter AAA only have 0.28% per annum risk of rupture.18 These much lower 
risks could be the result of improved medical management of cardiovascular risk factors 
or changes in lifestyle in the population. The factors known to be associated with 
increased risk of AAA rupture is also associated with female sex,19-21 smoking,22 
hypertension,19 20 23 and rate of AAA expansion.20 24-26 The strength of evidence 
supporting these associations is variable and not as strong as the association with size. 
Table 1: Abdominal Aortic Aneurysm Rupture Risk by Diameter 
Abdominal Aortic Aneurysm Diameter 
(mm) 
Risk of Rupture in 12 Months 
(%) 
30-39 0 
40-49 1.0 
50-59 1.0-11 
60-69 10-22 
>70 30-33 
Credit: Created from data in Eur J Vasc Endovasc Surg 2011;41 Suppl 1:S1-S58. doi: 
10.1016/j.ejvs.2010.09.011 
1.1.3 Rationale and Evidence for Repair 
Repair of AAA is undertaken to prevent a premature death from rupture. As such the 
risk of death without AAA repair should be higher than the risk of death of and after 
undergoing AAA repair. The risk of death following AAA rupture is in excess of 80% - 
when emergency AAA repair is available,27 this multiplied by the risk of rupture, added 
to the patients risk of mortality from other causes calculates their risk of mortality 
without repair. The risk of mortality with AAA repair is: the risk of mortality associated 
with the AAA repair, any persistent risk of AAA mortality following repair added to the 
patients risk of mortality from other causes. As the patient’s risk of mortality from other 
causes falls on both sides of this equation it could, for simplicity, be discounted to 
create an AAA mortality only consideration. The risk of rupture vs the risk of repair, are 
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the dominate factors in such a calculation, in clinical practice the risk of AAA rupture is 
quantified by AAA size and rates of change thereof. These were studied in the “UK 
Small Aneurysm Trial” and the “American Aneurysm Detection And Management 
Study” where patients with asymptomatic AAAs between 40 - 55mm where randomised 
to immediate open surgical repair or continued AAA surveillance and repair at a 55mm 
threshold.  A Cochrane review analysis of participant level data showed that repair 
below 55mm was not associated with improved survival, compared to continued 
surveillance and considered repair at 55mm, with a hazard ratio of 0.99 (95% CI 0.83-
1.18). 28  
In the UK patients with an AAA larger than 55mm are routinely offered repair if they 
are physiologically fit to undergo such a repair. Such patients are assessed on a total 
mortality with and without AAA repair basis. Aneurysm size (and therefore rupture 
risk) has significant influence, however patient physiological status both to withstand 
surgical repair (mortality risk at time of repair) and the overall patient life expectancy 
without repair will significantly influence this judgement. This is a complex calculation 
that often relies on an element of physician intuition and experience. Several predictive 
risk models have been proposed but none have entered clinical use. The more recent 
British Aneurysm Repair Score looks to have much better discrimination and if 
confirmed on validation studies would offer a more standardised approach to the 
decision making process.29 
1.2 Open Surgical Repair 
The first open surgical repair (OSR) of AAA that approximates current technique was 
reported by Dubost et al. in 1951, where the aortic aneurysm was totally resected and 
replaced with a cadaveric homograft.30 DeBakey substituted the use of homografts with 
polyester fabric tubes in the same aneurysm resection technique in 1958.31 This was 
refined to an inlay technique, removing the need for aneurysm resection, by Creech in 
1966 and popularised in the UK by Orr and Davies in 1974.32 33 The inlay technique 
remains the standard of care for OSR, a laparotomy and retroperitoneal dissection are 
performed to allow clamping of the aorta proximal and the iliac arteries distal to the 
AAA. The aneurysm is then opened anteriorly and the origin of any bleeding aortic side 
branches are over sewn. A synthetic graft is then laid into the AAA and anastomosed to 
the aorta proximally and either the aorta or iliac arteries distally, Figure 2 (page 6). The 
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aneurysm is then closed over the synthetic graft, retroperitoneum closed and laparotomy 
closure completed. 
OSR is a major operation that has significant associated morbidity and mortality, a 2017 
UK audit demonstrated an in hospital mortality of 3.2% and 5.5% of patients were 
readmitted to hospital within 30 days. This mortality is a significant improvement on 
the 6.7% mortality rate reported in 2001 by the UK National Vascular Database which 
had not significantly improved in the previous 21 years in some centres.34 The 
improvement from 6.7% to 3.2% may represent a difference in case selection as a result 
of wider uptake of EVAR for higher risk cases. 
Figure 2: Open Surgical Repair of an Abdominal Aortic Aneurysm 
 
Intact Abdominal Aortic Aneurysm and depiction of partially completed open surgical repair: 
demonstrating a proximal aortic clamp just below the renal arteries, a completed proximal anastomosis of 
aorta to synthetic graft, a partial completed distal anastomosis and distal clamps on the iliac arteries. 
Credit: DOI:10.1056/NEJMcp1401430 35 Reproduced with permission, ©Massachusetts Medical Society 
OSR is a durable procedure with only 0.9 aneurysm related deaths per 100 patient years 
in the 15 years follow-up of the UK EVAR trial 1.36 Overall (all cause) mortality 
following OSR was 8.9 deaths per 100 patient years. The rate of secondary intervention 
(complications) was 1.0 per 100 patient years confirming previous study’s observations 
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regarding OSR durability.37 The UK EVAR trial 1 did, however, initially fail to record 
common incision related complications such as hernias. 
1.3 Endovascular Aneurysm Repair 
In 1991 Volodos et al. and Parodi et al., independently, proposed EVAR as a new 
treatment for AAA based on the principles of endovascular interventions.38 39 EVAR is 
designed to exclude pressurised blood flow from the AAA wall, therefore excluding the 
possibility of rupture. During EVAR a stent graft is inserted under fluoroscopic X-ray 
guidance into the aorta. It achieves its therapeutic aim by being deployed and sealing 
into healthy artery proximal and distal to the AAA, as such the blood is transmitted 
through the stent-graft, which lies within the aneurysm, without pressurising the AAA. 
In vascular interventions a stent-graft is distinguished from a [simple] stent by the intent 
of its use, a stent graft is intended to replace the function of a portion of vessel while a 
stent is a scaffold placed inside a vessel to relieve an obstruction.  Stent-grafts always 
consist of a fabric tube with various forms of structural support while stents typically do 
not have of a fabric tube, although may contain fabric in some circumstances. 
The main stages of a standard EVAR procedure are depicted, Figure 3 (page 7). Initially 
transfemoral access is obtained by either percutaneous ultrasound guided puncture or 
surgical exposure and direct puncture of the common femoral arteries. A wire is used to 
transverse the aneurysm (distal to proximal) under fluoroscopic guidance. The main 
body of the stent graft is then positioned at the proximal landing zone via one femoral 
and a catheter via the other femoral. The catheter is used to inject contrast material to 
define the origins of the renal arteries, which is the proximal most point of the landing 
zone. The main body of the stent graft is then deployed creating a seal proximally and 
normally extends and seals into the iliac vessel down one limb of the EVAR. The 
contra-lateral limb is relatively short, this limb is then cannulated via the contralateral 
femoral artery access point, that previously conveyed the contrast catheter. The 
contralateral limb extension is then placed inside the short limb of the body component 
and deployed, it seals within the short limb proximally and the iliac artery distally.  
Figure 3: Stages of a Bifurcated Endovascular Aneurysm Repairt 
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A) Main body of stent-graft, within its delivery system, has been introduced over a wire to the level of the 
renal arteries via the right and a contrast catheter has been placed via the left. B) The main body, with 
supra renal fixation is deployed sealing proximally in aorta and distally in right iliac artery. A wire has 
cannulated the short contralateral limb and a limb extension within its delivery system is position on the 
left. C)The left limb extension has been deployed completing the seal into the left iliac artery. 
Credit: www.pngwave.com/png-clip-art-dabij 
1.3.1 Evidence for EVAR 
EVAR has been compared to OSR in 4 different randomised controlled trials (RCT).40-
43 Survival at different times following randomisation, from an individual patient data 
meta-analysis of these 4 trials,44 demonstrates a statistically significant early, 0-6 
months, advantage in survival in those who underwent EVAR but showed no survival 
advantage from 6 months – 4 years or > 4years follow-up, Figure 4 (page 9). The 
overall survival is equivalent between OSR and EVAR across the follow-up in the 
trials. A small percentage of EVARs fail to prevent aneurysm rupture, which has been 
recognised since the technique’s inception. This was confirmed by a lower AAA 
specific survival rate after 15 years follow up in the UK EVAR 1 trial, EVAR had a 
83% survival (95% CI 76-88% CI) vs OSR 88% (95% CI 78-95%), this did not reach 
statistical significance. 36 45 
EVAR intervention was compared to best medical therapy, in patients deemed unfit for 
OSR, in a single RCT – UK EVAR trial 2. It showed no difference in overall survival 
between the two groups.46 
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Figure 4: Survival Ratios Over Time from Meta-Analysis of 4 EVAR RCTs 
 
Forrest Plot or 4 RCTS demonstrating no overall survival benefit of either EVAR or OSR, a small 
survival benefit exists for EVAR between 0- 6 months that is not sustained after 6month till >4years. 
(EVAR= Endovascular Aneurysm Repair, OSR= Open Surgical Repair). 
Credit: DOI: 10.3310/hta22050 36 Reproduced as per National Institute for Health Research permission 
1.3.2 EVAR Complications and Secondary Interventions 
EVAR is associated with a higher rate of complications that require secondary 
interventions when compared with OSR, 16% vs 2.4% at 3 years.41 These complications 
and secondary interventions to maintain treatment efficacy have been recognised since 
the inception of the technique and confirmed by EVARs secondary failure rate in 
observational studies as well as multiple RCTs.40-43 
1.3.2.1 Endoleak 
The commonest complication following EVAR is an endoleak,47 endoleaks are blood 
flow outside the stent-graft but within the AAA. The accepted endoleaks classification 
is based on the source of blood flow into the AAA, Figure 5 (page 10).48 49 In short 
endoleaks are classified as: type I is an ineffective seal of the stent-graft to native vessel 
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either proximally or distally; type II is blood flowing into the AAA from an aortic side 
branch; type III is due to a defect within or between different stent-graft components; 
type IV is due to porosity in the stent-graft fabric; and type V is AAA growth without a 
detectable endoleak.  
Figure 5: Accepted Classification of Endoleaks Following EVAR 
 
Endoleak Classificication: Type I-Flow into the aneurysm past the proximal or distal seal zone, Type II- 
Flow into the aneurysm from an aortic side branch, Type III- Flow into the aneurysm from a defect in or 
between stent-graft components, Type IV- Flow into the aneurysm by stent-graft material porosity (rather 
than defect), Type V- Growth of the aneurysm without evident flow. 
Credit: DOI: 10.1590/S1807-59322011001200005.
50
 Reproduced under the CC BY-NC 3.0 License 
Type IV endoleaks have rarely been reported since the first generation of EVAR stent-
grafts as graft porosity has been addressed by manufacturers. Type V endoleaks are 
generally acknowledged to likely be an endoleak that is intermittent in nature or not 
detected on imaging. Endoleaks can therefore be grouped into stent-graft related (types I 
and III) and type II (non stent-graft related) endoleaks. Stent-graft related endoleaks 
generally transmit high pressure causing a high risk of aneurysm expansion/rupture 
(treatment failure).51 52 The frequency of stent-graft related endoleaks is estimated to be 
6-8% in the first 5 years following EVAR.53 In contrast, type II endoleaks generally run 
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a benign course,51 52 particularly in the absence of aneurysm expansion.54 The frequency 
of type II endoleaks is estimated to be 20-40% in the first 5 years following EVAR.53 
Endoleak diagnosis involves two distinct components: detection of an endoleaks 
presence and characterisation/classification of that endoleak into a class or type of 
endoleak. 
1.3.2.2 Stent-Graft Migration, Effacement and Component Separation 
Type I endoleaks may occur due to: ineffective initial seal, disease progression in the 
native vessel or stent-graft movement, additionally components that combine to form an 
EVAR stent-graft can separate and lead to a type III endoleak. Given the risk of 
aneurysm rupture associated with stent-graft related endoleaks, the detection of 
impending failure is preferable to waiting for actual failure to occur. As such: 
movement of the stent-graft in relation to the vessel (migration), movement of 
components away from each other (component separation) and reduction in length of a 
sealing zone without migration (effacement) are often monitored to observe for 
impending failures. 
Migration is typically defined as movement of the stent-graft of more than 5mm in 
relation to the vessel, it is typically distal movement at the proximal end of the stent-
graft and proximal movement at the distal end of the stent-graft. 5mm was selected as it 
was twice the minimum interval (2.5mm) of axial imaging available on CT scans at the 
time of EVARs development, therefore guaranteeing true movement if diagnosed.55 
Stent-grafts have design features to help prevent migration these include: hooks or 
barbs, continual radial force and stent-grafts are designed to smooth sharp angulations. 
Barbs at the upper extent of the stent-graft penetrate the vessel wall so providing 
physical anchoring and resistance to distal migration. Stent-grafts are designed to 
expand to a larger size than the vessel into which they are placed providing radial force 
and a friction coefficient with the vessel wall so preventing migration. Finally stent 
graft design has evolved to allow them to conform around angulations in the AAAs 
morphology in a manner that reduces the ‘pull out’ force created.56 The appropriateness 
of EVAR in individual AAA anatomical characteristics also influences the risk of 
migration. Individual stent-graft manufactures have Instruction For Use (IFU) for their 
products, based on their understanding of the stent-grafts performance in differing 
anatomical scenarios. This IFU details the manufacturers tolerances for safe anatomical 
limits for: minimum seal length (proximally and distally), AAA angulation and quality 
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of vessel at the seal zones, use of EVAR outside these IFUs is associated with higher 
rates of secondary intervention and adverse events.57 
‘Effacement’ describes attenuation of seal zones from centrifugal enlargement of the 
arterial wall forming them and is commonly associated with AAA enlargement. As 
attenuation of seal zone occurs the reactive centripetal force applied by native aorta 
upon the stent-graft is proportionally reduced leading to stent-graft dilation or [partial] 
‘loss of constraint’. Proximal stent-graft dilation is observed for as a potential indicator 
of effacement but can occur without effacement present. The pathology of AAA 
formation is complex and while the vessels may macroscopically appear and be of 
normal diameter at seal zones the vessel is microscopically abnormal. Following EVAR 
the increases in proximal seal zone diameter have been measured as 2mm at 34 months 
and 5.3mm at 48 months,58 59 the extent of dilation is associated with the extent of radial 
force applied by the stent-graft.60 If sufficient dilation occurs the stent-graft will reach 
its maximum diameter thus preventing radial force, [total] ‘loss of constraint’, and loss 
of seal leads to a type I endoleak and pressurisation of the AAA with rupture risk. 
Migration and effacement often occur concurrently, this may occur as the applied radial 
force diminishes due to effacement and the closer a stent-graft gets to its maximum 
diameter reduces one of the forces resisting migration or migration may occur first 
reducing the length of seal meaning that less seal can be lost before significant 
effacement has occurred. 
Stent-graft components typically rely on radial force of one component on another and 
the friction coefficient between the components to prevent them being pulled apart. 
AAA size following EVAR can increase or more often reduce significantly changing 
the AAA and therefore stent-graft morphology. This change in morphology, or indeed 
the original morphology, can mean the forces applied to the stent-graft result in 
separation of components. Separation of components leads to a type III endoleak and 
pressurisation of the AAA and associated rupture risk. 
1.3.2.3 Limb Stenosis or Kinking and Occlusion 
Flow through an EVAR stent-graft is imperative to perfuse the pelvis and lower limbs, 
loss of perfusion of a lower limb can ultimately lead to ischemia and amputation. The 
IMPROVE trial (an RCT comparing OSR and EVAR in ruptured AAA) included a 
patient group who unanimously ranked leg amputation as the most feared secondary 
intervention, ahead of even graft infection (Section 1.3.2.4, page 13).61 Restriction of 
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flow through a stent-graft most commonly occurs within individual limbs and the point 
of restriction is referred to as a stenosis. A stenosis can occur as a result of; a narrowing 
processes within the lumen (thrombus formation or intimal hyperplasia), the limb itself 
taking a narrowed form (kinking) or from external compression of the limb (often one 
limb compressing another in a confined space). Limb occlusion is not rare with 
consistent reporting of 3-10% risk of suffering a limb occlusion following EVAR.62 63 
AAA size changes following EVAR change stent-graft morphology, the commonest 
clinical manifestation of these changes are lower limb symptoms as the result of 
impaired flow to the legs. 
1.3.2.4 Infection and Other Complications 
Stent-graft infection is a serious complication following EVAR, it can occur at any time 
following operation and is rare, with incidence reported at between 0.2 and 1%.64 65 
Curative treatment can only be achieved by surgical resection of the infected graft and 
anatomical or extra anatomical restoration of blood flow to the lower limbs and pelvis. 
The best reports of outcomes are case series, these demonstrate persistent infection 
following reconstruction in 25% of patients and a mortality of up to 60% in 5 years.66 
Many patients are not fit for or decline such surgery and as such are managed on 
antibiotic therapy with an expectation of ultimate palliation due to systemic infection or 
rupture of the aorta. 
Aorto-enteric fistula (a connection between the aorta and bowel) are often associated 
with stent-graft infection but can also occur independently in approximately 0.5% of 
EVAR cases.53 Surgical repair is complex as it involves enteric repair or diversion in 
addition to stent-graft resection and is often required in patients with active bleeding 
and/or shock. As such endovascular occlusion of the inflow to the fistula is often used 
as a bridge to stabilise the patient and perform excision of grafts on a planned basis.67  
1.3.3 Rationale, Aims and Evidence for Surveillance 
Owing to the risk of complications following EVAR, surveillance imaging is mandated 
following EVAR.17 68 The requirement for enrolling patients in post-EVAR surveillance 
is almost ubiquitous among practitioners undertaking EVAR. Surveillances’ value is 
further highlighted by the results of 15-year follow-up after EVAR in the landmark 
RCT,45 which showed higher late aneurysm related mortalities in the EVAR arm 
compared to OSR arm which is suggestive of treatment failure. Surveillance involves 
diagnostic tests and its objectives are similar to that of population screening. The World 
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Health Organisations criteria for an effective screening programme offer a helpful 
framework for highlighting areas for improvement.69 EVAR surveillance should detect 
conditions that are better treated earlier than later and have effective interventions for 
those conditions. It should also have an agreed test and definitions for diagnosis of the 
condition.  
No RCT regarding the efficacy (detection and treatment of surveillance findings) of 
surveillance has been, or is ever likely to be, undertaken. Two sizeable studies have 
attempted to assess the efficacy of EVAR surveillance using national administrative 
databases. The first study by Garg et al. looked at 9,503 Medicare patients who 
underwent EVAR between 2002 and 2005 and binarily categorised them as receiving 
complete or incomplete surveillance (as defined by [American] Society for Vascular 
Surgery).70 43% of patients were compliant, the two groups were then propensity 
matched for patient demographics, treating hospital volume and patient co-morbidities. 
The groups outcomes were then compared at the end of the follow-up period. They 
showed, with a mean follow-up of 5.2 years, that patients in the incomplete surveillance 
group experienced lower rates of total complications (2.1% vs 14.0%; p < 0.001), late 
rupture (1.1%vs 5.3%; p < 0.001), major or minor reinterventions (1.4%vs 10.0%; p < 
0.001), aneurysm-related mortality (0.4%vs 1.3%; p < .001), and all-cause mortality 
(30.9%vs 68.8%, p < 0.001).  
The second study by de Mastral et al. used health databases in Ontario, Canada, to 
identify 4988 patients who underwent EVAR between 2004 and 2014.71 They defined 
compliance with surveillance as a CT scan or ultrasound of the abdomen within 90 days 
of EVAR as well as every 15 months thereafter, available confounding variables were 
then adjusted for. Consistent compliance was associated with a lower risk of death when 
compared with missing the first imaging follow-up within 90 days (HR 0.82, 95% CI 
0.69-0.96, p = 0.014), or when compared with having first imaging follow-up within 90 
days but subsequently not compliant (HR 0.78, 95% CI 0.68-0.91, p < 0.001). While 
only 58% of patients met these criteria over the entirety of their follow-up, de Mastral et 
al. looked at the proportion of follow-up time compliant and the higher the proportion of 
time the lower the risk of death (HR 0.87, 95% CI 0.79-0.96, p =0.019) per 25% 
increment in time compliant at 10 years of follow-up. 
There is therefore disagreement in the literature regarding the efficacy of EVAR 
surveillance, likely as the result of the studies differing methodology. Garg et al’s study 
retrospectively assigns a binary attribute of compliant or non-compliant to each patients 
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entire follow-up regardless of timing of non-compliance and then assesses events 
throughout follow-up to those end of follow-up categories. This means events that 
occurred prior to non-compliance are attributed to a yet to occur variable.  The reason 
for ultimate non-compliance is an obvious unknown confounder which can / is not be 
compensated for in that study. de Mastral et al similarly performed a binary whole 
follow-up analysis but also looked at each segment of follow-up and eloquently 
demonstrates increasing time compliant with surveillance was associated with a lower 
risk of death, this analysis reduces the importance the reason for non-compliance 
confounder, as non-compliance is changed to a ordinal rather than binary variable. As 
such the Ontario study is likely a superior study to base prospective decision on future 
patents care but both studies are limited by not knowing the reasons for patient non-
compliance (57 and 42% respectively) due to the data sources.  
The imaging modalities described for EVAR surveillance are discussed below. 
1.3.4 Computer Tomography +/- Angiography 
Computer Tomography (CT) was invented by Godfrey Hounsfield and synchronously 
by Allan Cormack in 1972. It uses digital processing to generate a three-dimensional 
(3D) volume of the inside of the patient from a series of two-dimensional radiographic 
(x-ray) exposures taken around a single axis of rotation, termed a slice. This is repeated 
in series, along the required length of the patient, thereby generating a 3D volume of the 
extent required. The granularity of the volume depends on both the size and number of 
radiographic exposures per a rotation and the increment of length between the rotations. 
Each 3D unit of granularity in the construction is termed a voxel and is encoded with 
the average density of its contents, this is on the Hounsfield scale which runs from 
+3,071 (most dense) to −1,024 (least dense). The X-rays used in the radiographic 
exposure are a form of electromagnetic radiation, the number of X-rays and energy with 
which they are expelled from the machine can be varied. The higher the energy, 
measured in Electron kinetic energy (keV), an X-ray has the denser the material it can 
pass through to reach the detector and the larger the number of X-rays used, measured 
in milliamperes (mA) the greater the resolution of densities that can be measured. 
Effectively keV determines the range of densities that can be delineated and mA 
determines the increments of different densities that can be delineated. 
This volume is reviewed as an image in one plane or multi-planar reconstruction (MPR) 
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to make a diagnosis and can even be rendered into a 3D reconstruction to aid 
understanding.  
The administration of iodinated intravenous contrast and then acquisition of the CT 
volume when that contrast has reached the arterial or venous circulation in the anatomy 
of interest is termed Computer Tomography Angiography (CTA). This adds an 
additional variable as it requires the timing of the CT volumes acquisition to coincide 
with the contrast passing through the vascular anatomy of interest. The delay between 
intravenous injection and contrast arrival is dependent on a large number of patient and 
administration variables. CTA is used to delineate blood and perfused tissues from other 
surrounding body tissues that may have very similar densities but no perfusion. This is 
imperative in EVAR surveillance as blood and thrombus have very similar densities and 
differentiating graft occlusions and endoleaks (which typically run in AAAs filled with 
thrombus) are key diagnostic criteria. It is also possible to perform multiple CT’s or 
phases following the administration of a single dose of contrast to view the anatomy at 
various states of perfusion. 
Concerns regarding the use of CTA in EVAR surveillance relate to the cost, use of the 
potentially nephrotoxic contrast agents and the repeated radiation exposure potentially 
leading to increased rates of neoplasm.45  CTA is often referred to as the ‘Gold 
Standard’ of EVAR surveillance, this is predominantly due to it being the non-invasive 
modality of surveillance used from the inception of the technique.39 Modern CTA has 
never been compared to a theoretically superior comparative standard for detecting 
endoleaks ([invasive] catheter directed digital subtraction angiography could be used) 
therefore its own sensitivity and specificity are unknown, despite this it is often used as 
the comparative standard for other modalities.72 There is not a published consensus of: 
optimum CT settings, contrast type, contrast volume, delay of acquisition or even 
number of phases that should be used for CTA in EVAR surveillance. The technology 
of CTA has advanced in every definition of imaging quality, since the time EVAR was 
first used, despite this almost all comparative studies between EVAR surveillance 
imaging modalities use the term CTA for every generation of the technology 
ubiquitously. Individual studies reporting diagnostic accuracy of CTA to detect various 
complications of EVAR rarely report adequate detail of the CTA settings used to allow 
duplication of that version in clinical practice and subsequent meta-analysis of these 
results simply group all CTA’s together regardless of even the number of phases 
acquired.72 73 
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Regarding endoleak detection CTA has been compared to Colour Duplex Ultrasound 
Scans (CDUS) and Contrast Enhanced Ultrasound (CUES) in multiple studies and these 
have been in turn subjected to multiple meta-analyses.72 73 All but one, assume CTA to 
be the ‘Gold standard’, the result of which are reported below, section 1.3.6 (page 19) 
and 1.3.7 (page 21) respectively. Karthikesalingam et al. conducted a secondary 
analysis inverting the above assumption, testing that CEUS was in fact superior to CTA 
and found “CTA would have low pooled sensitivity of 0.70 (95%CI 0.53 – 0.82) but 
high pooled specificity of 0.98 (95%CI 0.94 – 1.00) in relation to CEUS”.73 Few of the 
included studies offer sufficient detail of the CTA protocols to allow replication. 
With regard stent-graft migration and effacement CTA is unchallenged as the gold 
standard in diagnosis and quantification of both. The use of contrast and MPR allow 
clear and detailed interrogation of the stent-graft and native arterial wall to allow 
quantification of both migration and/or effacement. No other imaging modality allows 
as detailed interrogation of both of these elements. Standardised Abdominal 
Radiography (AXR) allows comparison of stent-graft position to bony landmarks, 
surrogate as reference points, to assess for migration. Optimum CTA settings to detect 
migration and or effacement have not been investigated. Component separation is likely 
best detected on a radiographic image,74 similar images can be reconstructed from a CT 
volume but can equally be acquired separately and with a lower radiation exposure. 
Stenosis or reduction in the size of a flow channel cross section can be delineated and 
quantified on CTA. Limb stenosis or kinking can therefore be diagnosed on CTA, 
however looking at the flow lumen at each point along its length is time consuming and 
unlikely to be completed routinely in clinical practice. It is more common practice for 
gross abnormalities to be noticed during other interrogation of the CTA and then 
selectively reported. 
Infection of an aortic graft is defined by the “The Management of Aortic Graft Infection 
Collaboration” (MAGIC) criteria,75 the major imaging criteria are all CT based and 
therefore the only [routine] imaging technique that can definitively contribute to this 
diagnosis is CT. The substantially more expensive and less available 
fluorodeoxyglucose positron emission computer tomography may have a confirmatory 
role but is not an appropriate initial test.53 
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1.3.5 Plain Abdominal Radiography (X-Ray) 
Plain Abdominal Radiography (AXR) is acquired by placing the patient between a 
source of X-rays and a detector plate, the source emits X-rays in single plane over a 
defined area and the length of the exposure can also be varied to increase penetration of 
X-rays through to the detector. As AXR are taken by placing the patient between a 
source of X-rays and a detector changes in the orientation and distances of the these can 
lead to variation in geometry that can distort the apparent position of the stent-graft 
relative to bony landmarks on the resulting AXR.76 A standard set of AXR acquisition 
settings and patient position was developed to minimise these effects, the Liverpool – 
Perth protocol.74 
AXR with anteroposterior and lateral projections has been used during EVAR 
surveillance for detection of component separation, effacement and migration.77 This 
was initially due to CT not having an adequate resolution to definitively define all the 
required components of the stent-grafts to allow for diagnosis,74 and more recently has 
been to allow detection of these complications without routine use of CT.78 AXR has a 
significantly lower radiation exposure than CT and does not suffer from metallic coil–
related artefact as Magnetic Resonance Angiogram (MRA) does, it is also a fraction of 
the cost of cross-sectional modalities such as CTA and MRA. AXR is not an adequate 
EVAR surveillance imaging modality in isolation as it is unable to measure AAA size 
or detect endoleaks. 
Migration is detected on AXR by comparing stent-graft position (and angulation) in 
relation to bone landmarks on serial images. Baseline images taken shortly after 
implantation or at the same time as a CTA allow changes compared to bony landmarks 
to be inferred as movements in comparison to the arterial vessel wall. Potential 
effacement is suspected and can be further investigated when serial comparison of stent-
graft appearance at the seal zone demonstrates dilation or changes in morphology of the 
stent that lies within the seal zone. Stent-graft component separation is detected by 
comparing relative positions of stent-graft components in serial images. Each stent-graft 
component have radio opaque markers used at the time of insertion that aid this 
detection. 
Stent graft distortion, in the form of kinking of the metallic structure of the composite 
stent-graft, can be diagnosed on single AXRs and evolution of this can be described 
over serial images. AXR cannot however reveal what is happening to the flow through 
the corresponding lumen which is radiopaque on AXR. In the literature migration is the 
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most described complication detected on AXR,78 and normally prompts a CTA to be 
performed to confirm and quantify the extent of migration as well as plan any secondary 
intervention that is required. 
1.3.6 Ultrasound and Colour Duplex Ultrasound Scan 
Medical ultrasound scans use soundwaves with frequencies up to 20,000 Hz to form 
images of tissues within the body. The simplest form of these is B-mode (brightness), 
this forms a single planar greyscale image of the tissues. This is formed by the 
ultrasound probe, while in contact with the body surface, emitting a series of pulses of 
sound waves and recording the reflected echoes of these pulses. Differing tissues have 
differing reflective properties and as such tissues can be differentiated by intensity of 
reflections. Fluid has very low reflective properties (appearing black on images) while 
solid objects typically have very high reflective properties appearing white on images. 
Varying the frequency and amplitude (gain) of sound used as well as the depth of focus 
and shape of probe (changes the shape of the array of sound emitted) can be used to 
increase the range of body areas that can be imaged. Ultrasound waves must be able to 
conduct through the tissue to be able to form images, structures that have high 
impedance and cannot conduct sound waves of these frequencies (typically air) simple 
fail to conduct waves and create a “shadow” or missing element of the resultant images.  
3D ultrasound can be created by sweeping the probe over a portion of the body then 
using post processing it is possible to combine this series of 2D images into a 3D 
reconstruction. This is rarely used in clinical EVAR surveillance. B-Mode ultrasound 
can be used to interrogate the AAA size in EVAR surveillance and morphology of the 
aneurysm and outflow. Proximal (neck) imaging can be hindered by air in the first part 
of small bowel (duodenum) and similarly colonic gas can hinder views of the iliac 
(outflow) vessels – this is almost guaranteed if the patient has a stoma which typically 
overlies iliac vessels. 
Colour Duplex Ultrasound Scan (CDUS), combines B-Mode ultrasound with 
intermittent use of two forms of Doppler imaging. This imaging relies of the principles 
of Doppler shift described by Christian Doppler in 1842, he observed that when a wave 
is reflected (or emitted) by an object that is itself moving it increased the frequency of 
that wave. The reverse is also true, objects moving away reflect waves with a lower 
frequency. Ultrasound machines can delineate the frequency of the reflected waves and 
can present this information in various ways and display it on or with the B-Mode 
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image. Colour [Doppler] Mode Ultrasound scans present a B-Mode ultrasound with a 
colour overlay to delineate any movement within the image displayed. The sensitivity to 
movement and range of velocities displayed can be varied by the ultrasound operator. In 
EVAR surveillance this allows the presence of blood flow to be confirmed so can 
demonstrate the patency of stent-grafts and limbs, it can also demonstrate flow outside 
the stent-graft but within the AAA therefore detecting an endoleak. Skilled operators in 
favourable patients can trace endoleak flow to its origin and therefore characterise 
endoleak type using Colour Mode Ultrasound. Similarly, skilled operators can 
demonstrate turbulent flow suggestive of stenosis within the stent-graft lumen using 
colour mode. Duplex Ultrasound typically refers to the use of B-mode ultrasound and 
pulsed wave Doppler on the same image. Pulsed wave Doppler presents velocity 
information sampled from a small area of a B-Mode image and presents that 
information on a timeline allowing quantification of the velocities observed over several 
cardiac cycles. Fluid under a consistent pressure will flow more rapidly in a vessel that 
becomes narrowed, therefore allowing quantification of the extent of the narrowing. 
Within EVAR surveillance Duplex Ultrasound is therefore used to determine 
directionality of flow in endoleaks (helping to delineate types) and to quantify the extent 
of stenosis in the stent-graft flow lumen. 
B-Mode, Colour Mode and Duplex Ultrasound are all used at a variety of times in a 
single scan in the majority of EVAR surveillance performed by ultrasound as such 
“Colour Duplex Ultrasound Scan” - CDUS is the most appropriate term. The skill in 
selecting the optimum ultrasound settings, mode and obtaining quality images or 
measurements in the setting of EVAR surveillance results in inter-operator variability. 
CDUS offers “repeated and reliable measurement of maximum aneurysm diameter at 
low cost”,53 however the measurements taken on CDUS are not directly comparable to 
CTA and the 95% confidence interval for difference in measurements is less than 
10.6mm.79 These serial measurements of size allow diagnosis of type IV or occult 
endoleaks and type II endoleaks to be stratified into low risk and high risk endoleaks, 
based on growth or stasis/decay of aneurysm size.54 Graft-related endoleaks are often 
associated with size increases but should be further investigated/treated even in the 
absence of changes in size, as they may have only recently developed. 
On meta-analysis, using (undefined) CTA as the comparator standard, CDUS can detect 
any endoleak with a sensitivity of 0.82 (95%CI 0.66 – 0.91) and a specificity of 0.93 
(0.87 – 0.96).72 CDUS is similarly successful in detecting and differentiating graft-
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related endoleaks, with a sensitivity of 0.83 (0.40 – 0.97) and specificity of 1.00 (0.97 – 
1.00).73 Both of these meta-analyses are however based almost exclusively on the same 
cohort of retrospective observational studies, these have a risk of bias due to a lack of 
blinding particularly with respect to characterisation of endoleak type. The meta-
analyses themselves are equally flawed in that they don’t account for differences in 
technique or protocol in acquisition of CDUS and CTA and the use CTA as a gold 
standard when it is itself has unknown diagnostic ability is questionable. 
CDUS examination of limb stenosis and subsequent rates of occlusion or secondary 
interventions are sparse in the literature. This is in part due to the subjective nature of 
screening using B-Mode and Colour Doppler ultrasound that are relatively poorly 
described. There is some evidence that duplex measurements at the distal seal zones in 
the iliac arteries can predict limb occlusions or secondary interventions. A retrospective 
review of measurements in an EVAR surveillance programme showed that a peak 
systolic velocity (taken as part of duplex measurements) >300m/s had a sensitivity of 
100% and a specificity of 98% for suffering a limb occlusion.63 This system to 
differentiate patients has not been validated in another centre or been tested for 
inter/intra observer variability. 
1.3.7 Contrast Enhanced Ultrasound Scan 
Agents introduced into the bloodstream that have high sonic reflective qualities have 
long been recognised to better delineate blood flow on ultrasound. Gramiak et al. 
described the first use of this in medical imaging in 1969, using non-specific contrast 
agents that had such short half-lives in the blood stream that they required catheters to 
facilitate direct injection into the heart for contrast echocardiography.80 The lack of a 
stable contrast agent, that could therefore be injected intravenously, prevented the wide 
spread use of Contrast Enhanced Ultrasound (CEUS) until the 1990’s. Since the 
availability of the first stable contrast agent an increasing variety of applications for 
CEUS have been found, including EVAR surveillance. All commercially available 
ultrasound contrast agents now consist of microbubbles with a diameter <10µm and 
constitute a shell with a gaseous interior that have half-lives long enough to allow 
intravenous injection and meaningful ultrasound interrogation in the patient’s tissue. 
Microbubbles are commonly made of lipid shells which the body ultimately 
metabolises, and a gas centre that is expired by the respiratory system following bubble 
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rupture. Microbubble contrasts are remarkably safe with adverse event rates as low as 
0.020%.81 
CEUS initially relied purely upon the high reflective properties of contrast agents, that 
were the result of the acoustic-impedance mismatch between blood and the gas 
contained within the microbubbles. This was visualised in B-Mode or Colour [Doppler] 
mode as increased signal making blood flow easier to delineate, in comparison to 
surrounding tissues. This method did however still require the operator to interpret high 
intensity on the image was the result of contrast agent and not highly reflective tissues. 
CEUS imaging was refined further when the phenomenon of Harmonic Imaging (HI) 
and later Pulse or Phase Inversion Imaging (PII) were implemented, HI and PII are 
collectively referred to as Coherent contrast imaging. Coherent contrast imaging is a 
technological solution which uses HI or PII techniques that both rely of the physics of 
the ultrasound waves interaction with microbubble contrast agents to allow the operator 
to observe increased delineation of microbubbles on the ultrasound image.  
Spherical microbubbles are compressed when subjected to high pressure elements of 
sound waves, but eventually can compress no further and reflect the remaining element 
of the positive pressure. As the pressure decreases the bubbles expands and releases this 
stored energy creating an over expansion of the bubble in the low-pressure phase of the 
wave leading to a second positive pressure wave. This means for each incident wave the 
bubble reflects two complete (lower energy) waves – a doubling of frequency. This 
phenomenon is termed non-linear reflection, the resultant wave forms are demonstrated 
in section A of Figure 6 (page 23). Other tissues in the body can, to a much lesser 
degree, also create this phenomenon but typically return a linear reflection, by 
optimising the emitted wave characteristics and adjusting the ultrasound machine 
settings it is possible to significantly improve delineation of the contrast from tissue and 
therefore delineation of blood flow from surrounding tissues. Essentially the level of 
opacification of any part of the image on the ultrasound screen is no longer a function of 
just amplitude of the reflected wave but of the frequency and amplitude of the reflected 
wave. The microbubbles expand and contract to each wave they are exposed to, so 
microscopically look to be vibrating, hence the term Harmonic Imaging.  
PII sends two ultrasound pulses of inverse waveforms, in quick succession. Linear 
reflection waves are therefore also directly mirrored, while non-linear reflections are 
manifestly not, section A and B of Figure 6 (page 23). In PII the two reflected 
waveforms are added (summed) upon receipt and displayed, linear/tissue reflections 
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cancel each other out leading to no signal displayed on screen while non-linear 
reflections are asymmetrical and do not cancel each other out leading to high signal 
being displayed, section C of Figure 6 (page 23). This leads to much better delineation 
of the contrast agents from surrounding tissues than HI. PII is often displayed as a split 
screen, half the screen displays only the standard incidence wave response (B-mode 
ultrasound) while the other displays the sum of the incidence and inverse incidence 
waves response (PII).  This split screen allows B-Mode to be used to delineate anatomy 
and positioning while the PII demonstrates the contrast enhancement, Figure 7 (page 
24). 
One study has been undertaken regarding the optimum quantity of microbubble contrast 
agents required in Coherent Contrast Imaging within EVAR surveillance, it used HI and 
found that 2.4mls was superior to 1.2mls, of second generation microbubble contrast 
agent, in visual delineation of endoleaks.82 
Figure 6: Waveforms in Coherent Contrast Ultrasound Imaging 
A) Incident and reflected waveforms demonstrating linear and non-linear waveforms used in Harmonic 
Imaging, B) Inverse incident and reflected waveforms of A, C) Sum of (A and B) reflected waveforms 
used in Phase Inversion Imaging 
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CEUS can be used for endoleak detection and characterisation in EVAR surveillance, it 
is typically combined with CDUS as an adjunct that is perceived to increase endoleak 
detection. CEUS is not known to improve any of the other EVAR surveillance attributes 
of CDUS. As described above, CEUS is a global term for 3 technological solutions that 
have incrementally increased detection/delineation of contrast and therefore endoleaks 
over the 2 decades that it has been used in EVAR. Despite this the description of the 
CEUS technique and contrast agent / quantity used are poorly described in individual 
studies and often universally combined for evidence synthesis and comparison by meta-
analysis. 
Similarly to CDUS, meta-analysis of CEUS endoleak detection and characterisations is 
based on studies that often use undefined CTA as the comparator standard, CEUS can 
detect any endoleak with a sensitivity of 0.94 (95%CI 0.85 – 0.98) and a specificity of 
0.95 (0.90 – 0.98).72 CEUS is reported as highly successful in detecting and 
differentiating graft-related endoleaks, with a sensitivity of 0.99 (0.25 – 1.00) and 
specificity of 1.00 (0.98 – 1.00).73 These primary studies and meta-analyses share the 
same methodological flaw as the analyses for CDUS. 
Figure 7: Ultrasound Display from Contrast Enhanced Ultrasound Using Phase 
Inversion Imaging 
 
CEUS using PII: A) Phase Inversion Image, B) B-Mode Ultrasound Image, 1) EVAR limbs -containing 
microbubble contrast, 2) Type III Endoleak arsing from side of EVAR limb. 
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1.4 Surveillance Regimens Following EVAR 
Parodi et al. followed their initial cases of EVAR with CTA and CDUS, initially to 
confirm the treatment’s efficacy but quickly recognised the potential complications and 
need for continued surveillance.39 As EVAR technology evolved, the need for 
surveillance was maintained49 and remains recommended to this day.53 83 The 
manufacturers of the commonest EVAR stent-grafts used in the UK still suggest use of 
AXR and CTA,84-86 suggesting at least annual intervals,84 or up to 4 imaging visits in 
the first year before then reducing intensity to simple annual follow-up.85 86 The 
European Society for Vascular Surgery suggest that a combination of CTA and/or 
CDUS can be used in differing combinations and intensities depending on patient risk, 
with up to 5 years between surveillance visits for low risk patients.53 The [American] 
Society for Vascular Surgery recommend a combination of CTA and CDUS at differing 
intensities dependent on patient risk with at most 1 year between surveillance visits.83 
Actual UK practice in 41 centres in 2011 was similarly varied with centres differing in 
their primary imaging modality (CTA or CDUS or CTA and CDUS) and AXR was used 
as an adjunct in a minority of centres only.87 Practice had evolved by 2019 when 6 out 
of 10 UK centres used AXR routinely and all used a combination of both CTA and 
CDUS, with less frequent CTA in the first 5 years following EVAR.88 
There are no randomised trials comparing regimens of either imaging modalities or 
intensity of EVAR surveillance. Most published evidence is either the comparison of 
cohorts between different centres,88 or different regimens at different time within the 
same centre.78 All of these cohort studies suffer from significant confounding as a result 
of differences in practice, experience and stent-graft use that occur over time and 
between centres. As such most surveillance regimens are derived from expert opinion.17 
83 These typically base decisions on the most appropriate imaging modality around their 
perceived accuracy as well as cost and risks. Some regimens also stratify the risk of 
individual patients based upon certain characteristics.53 
Risk stratifying patients for EVAR surveillance has been attempted several times but 
there are two notable systems. The St George’s Vascular Institute score uses pre-
operative aneurysm size data to predict post EVAR risk of requiring secondary 
intervention, it has been extensively validated both within the UK and internationally.89 
90 Even in the initial paper this method had a secondary intervention rate of 12% in the 
low risk group by 5 years, this is likely the result of being unable to account for the 
quality of the repair performed. Bastos et al. categorised patients as low risk (proximal 
Surveillance Following Endovascular Repair of Abdominal Aortic Aneurysm 
26  Iain Nicholas Roy - August 2020 
and distal sealing zone at least 10 mm and no endoleak) or high risk (sealing zone less 
than 10 mm proximally or distally and/or presence of any endoleak) on the first CTA 
following EVAR.91 On a validation study the low risk group had a secondary 
intervention rate of 7% by 5 years, however there were only 129 patients at risk by this 
time which will give this prediction wide confidence intervals.92 Neither the original or 
validation study publish their CTA acquisition protocol to allow replication in real 
world clinical practice, despite this they form the basis on which The European Society 
for Vascular Surgery guidelines suggest stratifying surveillance intensity.53 
1.5 Summary 
Post-EVAR surveillance has been standard practice since introduction of EVAR. 
Although initially proposed only because of uncertainties regarding the new treatment, 
surveillance soon revealed a variety of complications occurring throughout follow-up 
into the long term. Modes and mechanisms through which these complications occur, 
and cause treatment failure have been described along with their relative significance. 
Improvements in stent-graft technology and physician understanding of how to best 
utilise EVAR technology have likely resulted in a reduction but not elimination of these 
complications. Surveillance remains essential to identify these complications so that 
remedial secondary interventions might be undertaken before failure of treatment 
occurs. However, the evidence-base to guide best practice regarding surveillance 
remains insufficient.  
Several imaging modalities are in use for surveillance with AXR, CDUS, CEUS and 
CTA being the main modalities. Each of these modalities has its unique advantages and 
disadvantages but all are vulnerable to variations in diagnostic accuracy due to 
variations in acquisition and reporting standards. Imaging reports comprise observation 
relating to numerous aspects of stent-graft and vascular anatomy but relative importance 
of these remains undetermined. Almost universally, surveillance imaging is offered to 
all patients at same intervals despite a recognition that individual risk varies, sometimes 
markedly so, leading to wasted imaging in some patients while others present with 
failure of treatment between surveillance intervals. Personalised surveillance based on 
findings readily detectable on standard imaging modalities at each point of follow-up 
has the potential to render surveillance clinically more effective as well as potentially 
cheaper and more tolerable to patients. Patient compliance with surveillance is poor in 
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many centres due to poorly understood causes and improving compliance is essential 
for a surveillance programme to be effective. 
1.6 Hypotheses and Aims 
1.6.1 Incidence and Indication for Secondary Intervention 
Current published literature on secondary interventions following EVAR reports either 
“Freedom from [First] Secondary Intervention” or “[mean] Incidence of Secondary 
Interventions” as well as the types of secondary intervention over the period of follow-
up in that study. These outcome measures offer pre-operative information for patients as 
to their risk of requiring any secondary intervention and data for health economic 
calculations respectively, but do not offer enough granularity of information to help 
inform surveillance regimen design. 
Hypothesis: 
The incidence of, and indication for secondary interventions varies over time following 
EVAR 
Aim: 
Describe the indication and incidence of secondary interventions at different time points 
following EVAR 
1.6.2 Rate of Compliance with EVAR Surveillance 
Compliance with EVAR surveillance is variable but generally reported to be poor, it is 
also typically reported as a binary state for each patient across the entire follow-up 
period studied. An individual patients’ compliance can vary over time and therefore a 
single binary measurement of compliance may be misleading depending on the timing 
of the measurement. 
Hypothesis: 
Overall compliance rates with EVAR surveillance vary over time following EVAR 
Aim: 
Describe the rate of compliance with EVAR surveillance at different time points 
following EVAR 
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1.6.3 Factors Associated with EVAR Compliance 
Multiple patient related factors have been shown to be associated with decreased EVAR 
surveillance compliance, but no study has adequately examined the interactions between 
these associations - to assess for confounding between factors. A study in a centre with 
good compliance, therefore removing system-based factors as a further confounder, 
could highlight the best targets for patient-based research to improve compliance. 
Hypothesis: 
There is a high degree of confounding between the factors considered to be associated 
with poor EVAR compliance 
Aim: 
Describe the level of association between the proposed factors and EVAR surveillance 
compliance, adjusted for co-linearity / confounding between variables. 
1.6.4 Findings on CDUS and AXR 
CDUS with AXR are the most common EVAR surveillance imaging modalities used in 
the UK. While there have been multiple diagnostic imaging studies labelled with these 
overarching technologies, little is known about which specific findings available on 
CDUS and AXR are associated with secondary interventions and if in fact the number 
of findings recorded could be reduced. 
Hypothesis: 
Different findings available on CDUS and AXR have different levels of association 
with subsequent secondary interventions and reducing the total number of findings 
collected can be achieved without reducing the overall association. 
Aim: 
Describe the level of association of individual findings available on CDUS and AXR 
and assess the impact of reducing the number of findings recorded on association with 
subsequent secondary interventions. 
1.6.5 Secondary Intervention Risk Prediction 
Current proposals to rationalise EVAR surveillance, by stratifying patient risk, all rely 
on single peri-operative snapshots to risk stratify patients into high or low risk groups. 
This means predictions have large confidence intervals after a few years and large 
patient numbers are required to generate accurate predictions. Such a system also 
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naturally has a limited ability to improve surveillance programme efficiency. A model 
that can be used at any time after EVAR and predict future risk, could vary intervals of 
surveillance directly proportional to the patients’ risk, which offers high efficiencies 
with greater predictive accuracy as patients feed into the model at multiple time points. 
Hypothesis: 
It is possible to accurately predict the risk of secondary intervention at multiple time 
points during EVAR surveillance. 
Aim:  
To create a risk prediction model that can accurately predict future risk of requiring a 
secondary intervention based on variables readily accessible on a routine surveillance 
visit. 
1.6.6 CEUS Endoleak Detection Rate 
Current literature does not adequately describe the CTA and CEUS protocols used to 
allow replication in clinical practice. As such it is not clear if CEUS has an equivalent 
ability to diagnose endoleaks as CTA. The cost of CEUS means that it likely needs to be 
equivocal or superior to CTA to form part of a routine ultrasound-based surveillance 
programme. A high-quality prospective study comparing endoleak diagnosis on CEUS 
compared to a well-defined, reproducible, CTA standard is required. 
Hypothesis:  
CEUS is near equivalent to CTA in graft-related endoleak diagnosis. 
Aim: 
Compare CEUS to a well-defined, optimised form of CTA in endoleak diagnosis and 
compare these to a “Gold standard” of final diagnosis. 
1.6.7 CTA phase Optimisation 
The number and timing of CTA phases in EVAR surveillance is poorly described and 
with little scientific basis. A more scientific approach to their design requires an 
understanding of the timing of endoleak opacification on CTA. 
Hypothesis: 
Endoleak opacification on CTA differs by endoleak type. 
Aim:  
Describe the timing of opacification of different endoleaks on CTA. 
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2 ANALYSIS OF A COLOUR 
DUPLEX ULTRASOUND 
SCAN AND PLAIN 
ABDOMINAL X-RAY 
SURVEILLANCE REGIMEN 
Surveillance following Endovascular Aneurysm Repair (EVAR) was initially 
empirically designed by pioneers of the technique. It remains mandated, in various 
forms, by nearly all practitioners who undertake EVAR. Stent-graft manufacturers 
continue to advocate similar surveillance regimens to the pioneers, mainly due to a lack 
of a robust evidence base to endorse a more efficient alternative. 
Significantly more is now known about the overall rates of initial failure of stent-grafts 
following EVAR, but the mode(s) and timing of these and subsequent failures remain 
poorly described. This is particularly true after the initial few years following EVAR 
repair, as prospective cohorts of patients suffer from censoring due to the end of the 
study follow-up. These issues are exacerbated by poor compliance with surveillance. 
Risk of secondary intervention is thought to vary significantly between individuals and 
within individuals over time. Despite this, generic surveillance regimens are commonly 
applied to all patients and at all time points following EVAR. Accurately predicting risk 
for individual patients at different time points would allow much more efficient bespoke 
surveillance regimens to be created. 
While various forms of imaging techniques have been investigated regarding their 
efficacy to detect individual findings in EVAR surveillance, little is known about which 
of these findings within these techniques are associated with subsequent secondary 
interventions to correct or prevent a stent-graft failure. 
This study examines the above lacunae, in the published evidence, using a prospective 
database from the Liverpool Vascular and Endovascular Service (LiVES). 
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2.1 Background 
The randomised controlled trials (RCT) that demonstrated the equivalent efficacy of 
EVAR to open surgical repair (OSR) reported secondary interventions in the form of the 
survival metric “freedom from secondary intervention”, which is useful when 
describing the risk to an individual patient.40-42 45 The UK EVAR trial 1 also reported 
the overall incidence of secondary interventions throughout follow up, which is useful 
in health economic calculations that simplify down to mean rates and costs.36 Neither of 
these two metrics, however, provide adequate granularity of information to aid the 
design of an efficient and safe EVAR surveillance programme. The RCTs and 
subsequent cohort studies also suffer from attrition in patient numbers as follow-up 
extends, given the nature of prospective studies. Given the knowledge that no one 
imaging modality is superior in the diagnosis of all complications a more detailed 
understanding of which complications are likely to occur and at what time following 
EVAR is required to make an evidence-based decision regarding the optimum imaging 
modality for and timing of surveillance. An equally important feature of secondary 
interventions, that requires greater understanding, is which are triggered by surveillance 
and which are the result of patients self-presenting with symptoms. 
Compliance with EVAR surveillance is poor,70 71 the factors which influence this are 
poorly understood but are likely a combination of surveillance system factors and 
patient specific factors. Differences in surveillance imaging regimens in the UK have 
been well described,87 88 but no descriptions of the actual administration system used to 
deliver those imaging regimens exist in the literature. Variation in rates of compliance 
between centres may be associated with the administartion,88 centres with high 
compliance can be presumed to have good surveillance administration systems which 
allows patient factors to be investigated to identify those independently associated with 
non-compliance. Such factors would be good targets for patient-based intervention 
research to see to improve surveillance compliance is achievable. 
Colour Duplex Ultrasound Scan (CDUS) and Abdominal Radiography (AXR) are 
overarching technologies that are the commonest forms of EVAR surveillance imaging 
in the UK.88 Large numbers of different observations and measurements can be obtained 
using CDUS and AXR within EVAR surveillance, despite this diagnostic accuracy 
studies almost ubiquitously simply refer to the technology and ascribe diagnostic values 
to them without sufficient description of the specific observations that are used to 
derived such diagnoses. Little to no description exists in the literature of which 
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observations on CDUS or AXR are associated with actually triggering a secondary 
intervention. Understanding which observations are associated with subsequent 
secondary interventions is key to the accuracy and reproducibility of these surveillance 
imaging modalities. If multiple observations are being taken during CDUS and AXR 
that aren’t associated with the risk of requiring a secondary intervention, then these 
observations could potentially be removed from surveillance imaging protocols and 
improve efficiency of imaging acquisition. 
Universal surveillance regimens do not account for the differing risk between patients 
and within patients’ over time following EVAR. Current systems to stratify patients 
based on their individual risk are all based on a single time point and create binary (high 
or low) risk profiles, these systems intrinsically offer limited surveillance regimen 
efficiencies and produce predictions with broad confidence intervals.89 92 A system that 
is repeatable at multiple time points following EVAR and that produces an analogue 
risk prediction would offer the greatest regimen efficiencies, as well as narrower 
confidence intervals in predication because it can be repeated on multiple occasions 
during each patients follow-up. Such a system should ideally be based upon findings 
routinely taken during surveillance using the commonest imaging modality. 
2.2 Aims 
The aims of this study were to use the prospectively maintained clinical database of 
patients who have undergone EVAR in LiVES to investigate several lacunae in the 
evidence regarding EVAR surveillance. 
These were: 
• Define the nature and timing of secondary interventions 
o Particularly beyond the 5 years following repair (that the majority of 
published data is limited to). 
• Investigate patient compliance with surveillance  
o Establish if patient compliance varies over time in follow-up 
o Establish which patient factors are independently associated with 
compliance.  
• Investigate which findings on AXR and CDUS are associated with a secondary 
intervention. 
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• Establish if findings on AXR and CDUS can accurately predict the need, or lack 
there of, for a secondary intervention over time. 
2.3 Methods 
2.3.1 Study Design 
This was a single centre, cross sectional, data analysis of anonymised data from a 
prospectively maintained EVAR surveillance database. All patients underwent infra-
renal EVAR under LiVES, a city-wide vascular service in the UK. Routine EVAR 
surveillance is predominately undertaken using CDUS and AXR in LiVES.78 
2.3.2 LiVES Surveillance Protocol and EVAR Database 
LiVES was formed by the combination of the Vascular services from The Royal 
Liverpool University Hospital, Aintree University Hospital and Southport Hospital in 
2012. Prior to their combining the Royal Liverpool University Hospital had maintained 
a prospective database of all patients who had undergone EVAR since 1996. All 
patients subsequently undergoing EVAR under LiVES were entered into this database 
and all patients in the database underwent surveillance to the LiVES protocol.  
The database was initially primarily maintained to record the details of the devices 
implanted into patients however was rapidly adapted to record and administer 
subsequent surveillance. 
2.3.2.1 LiVES Surveillance Protocol 
On 1st August 2005 LiVES post-EVAR surveillance was changed from the 
EUROSTAR and UK-EVAR trials protocols,93 both requiring annual CTA, to a 
modified protocol, Table 2 (page 35). This modified protocol involving annual CDUS, 
to a Standard Operating Procedure (Appendix 1, page 188) and AXR to the Liverpool-
Perth protocol,74 with CTA performed only when potential complications were 
identified or CDUS was not sufficiently diagnostic. CDUS in place of CTA was well 
established by the start of the data sample used in this study, in 2008. The change away 
from CTA surveillance had been closely monitored.78 
At administration level, the database was reviewed monthly to obtain a list of all 
individuals who were due surveillance the following month. These individuals were 
then booked for these investigations. As part of that booking process those who had 
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died would be identified, by central administrative NHS databases, and the cause of 
death would be investigated with primary care and recorded in the database.  
This search process would also flag all those individuals who are overdue surveillance 
scans and the cause for this explored, often by an administrator speaking to the patient 
over the phone but ultimately patients would be recalled to outpatient clinic if no 
contact could be made. 
Patients were actively discharged from the surveillance programme if they were no 
longer physiologically suitable for any secondary intervention. Dates of transfer to other 
providers were also recorded if the patient moved out of the area. 
Table 2: LiVES EVAR Surveillance Imaging Protocol 
2.3.2.2 LiVES EVAR Database 
LiVES database contains 3 main tables: patient level data, secondary interventions and 
surveillance visits. Patients are entered into the database on or shortly after the date they 
undergo an EVAR. These data pertinent to this study from the patient level table is 
outlined in Table 3 (page 36), but also includes, for example, serial numbers of the 
devices used and physicians involved in their procedure. These pertinent data from the 
secondary intervention table is outlined in Table 4 (page 36), but also included details of 
whom undertook the procedure and a comments field. Data were entered into the 
secondary intervention table as and when it came to the attention of the surveillance 
administrator, as such it was the least comprehensive element of the database. 
  
Timing Imaging 
Prior to discharge AXR to Liverpool-Perth Protocol 
1 Month after EVAR 
CDUS  
Arterial Phase CTA 
12 Months after 
EVAR and Annually 
thereafter 
AXR to Liverpool-Perth Protocol 
CDUS 
Arterial phase CTA -if non-diagnostic or problems identified 
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Table 3: Relevant Patient Level Data Held in the LiVES EVAR Database 
Unique Hospital Identifier 
NHS Number (National Identifier) 
Date of Birth 
Date of Death 
Cause of Death (If Known) 
Gender 
Patient Post Code 
Date of Operation 
 Pre-op AAA Size (mm) 
Pre-op Max Iliac Size (mm) 
EVAR Device Implanted 
EVAR Device Manufacturer 
Date of Discharge from Surveillance 
Reason Discharged from Surveillance 
 
Table 4: Secondary Intervention Data Held in the LiVES EVAR Database 
Unique Hospital Identifier 
Date of Intervention 
Performed as Emergency 
Complication Intervention Treating 
Intervention 
Laterality (Right/Left/Both) 
Patient had symptoms 
Complication Detected on Screening 
 
Data Field 
Data Field 
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2.3.2.3 Corroborating LiVES Database 
It was felt judicious to corroborate these data in the LiVES database as it was not 
initially intended for audit or research use, although the intended purpose of co-
ordinating patient care and recording details of implanted devices demands equally high 
data standards. As such, where possible, completeness and accuracy of the data in the 
LiVES database was corroborated from other primary data sources. This was performed 
as part of a local trust service evaluation reviewing outcomes. 
2.3.2.3.1 Patient Level Data 
The completeness of the patient list was confirmed by reviewing all coding data and 
electronic theatre records the trust had available for all aortic aneurysm repairs 
performed. Review of 2348 coding episodes and 946 electronic theatre records was 
undertaken. No new patients who had undergone infra-renal EVAR were found. As 
such a robust patient list was confirmed and used to corroborate other data points. 
Date of Birth, NHS number, Date of death, Gender, Postcode and Cause of death were 
cross referenced against the NHS trusts electronic patient indexing records. Most of 
these variables are automatically updated from national records (via the “NHS spine”). 
While a series of typographic errors were found in numeric entries very few omissions 
were corrected. Date of death was updated in a substantial proportion of patients – 
likely due to the annual nature of checking by surveillance administrative staff and that 
if a patient was discharged or moved away these data would not be further updated in 
the database. Finally cause of death was known within the database for far more patients 
than the whole trust database, this was likely due to the active checking of surveillance 
administrative staff with primary care following the demise of a patient rather than the 
passive trust system that almost exclusively only captures causes of death that occur 
within the trust. 
Patient device and manufacturer were accurately recorded when compared to the paper 
record of a sample of 348 records. The pre-operative sizes as recorded on the paper 
EVAR planning sheet was updated when not recorded in the database and was within 0-
4mm of the size recorded in the database. This was felt likely to be related to inter-
observer variability. A few larger discrepancies were detected but these were in cases 
where the primary indication was iliac artery aneurysm repair but with concomitant 
small aortic aneurysm.  
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Date of discharge from surveillance was only partially verifiable by the date of last 
surveillance scan (as below) and reasons recorded were only verifiable in recent cases 
that were accompanied by letters in electronic patient notes. 
2.3.2.3.2 Secondary Interventions Data 
Secondary intervention data were corroborated from 4 data sources: Coding data, 
electronic patient notes, electronic theatre records and review of all imaging undertaken 
within the trust. All 4 sources were only available in combination for a 7-year period 
during 2008 till 2015 (when this work was commenced). Using the patient data, Section 
2.3.2.3.1 (page 37), a list of hospital identifiers (which included multiple / merged 
identifiers for some single patients) was created from the hospitals’ patient indexing 
system. This list was then used to search the theatre, coding and imaging systems. These 
were used to create a list of potential secondary interventions which were then verified 
and corroborated by interrogation of the electronic patient records at the suggested 
dates. All patients’ electronic letters for the entire 2008-2015 period were also reviewed. 
Theatre data were used to confirm the date of the original operation when it fell in the 
available data. The largest variation between the dates recorded in the database and 
theatre record was 2 days, in these cases the earliest date record was taken to be a true 
and accurate record. All subsequent operations that occurred after the original EVAR 
were reviewed for their potential to be a secondary intervention.  All subsequent coding 
episodes after the original EVAR were reviewed and any procedures or admission that 
may have included a procedure that potentially represented a secondary intervention 
were reviewed.  The imaging performed for each patient on or subsequent to the 
original EVAR was reviewed. The data points as listed below, Section 2.3.2.3.3 (page 
39), were available for all imaging performed.  
The reports of all interventional radiology procedures were reviewed, and data recorded 
for those that represented secondary interventions. With regards to procedures that were 
prompted by lower limb mal-perfusion (claudication, rest pain or tissue loss): if these 
included intervention above the inguinal ligament they were treated as secondary 
interventions - as the placement of EVAR had likely influenced this disease, if all 
intervention(s) were below the inguinal ligament then this was felt to be peripheral 
vascular disease not contributed to / worsened by the EVAR. 
The report of all surveillance scans were reviewed as discussed below, Section 2.3.2.3.3 
(page 39), if these reports included discussion or evidence of a previous secondary 
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intervention then the previous report was reviewed to create a time frame in which this 
intervention had occurred and the clinical record reviewed. 
Finally, the clinical letters of each patient were reviewed for the time frame and any 
letters suggesting secondary intervention were planned / had occurred led to further 
investigation that time frame or record the date of secondary interventions if recorded. 
These data sources created a list of potential secondary interventions that were then 
further investigated by reviewing the clinical notes and source imaging to complete any 
missing data points, Table 4 (page 36). 
A secondary intervention was defined as any surgical or interventional radiology 
procedure that occurred after the patient had left the theatre for their primary EVAR. 
These were deemed as emergencies if done outside a planned vascular / interventional 
radiology list while they remained an inpatient following initial EVAR or if admitted in 
an unplanned manner following initial discharge. They were deemed symptomatic if the 
notes recorded symptoms that could be attributable to the complication being treated. If 
the secondary intervention was precipitated by a surveillance scan this was recorded as 
detected on surveillance, this was not always a direct trigger: CDUS often suggested a 
potential complication that then lead to further investigation followed by discussion in a 
Multidisciplinary Team Meeting (MDT) which then triggered much more intensive 
surveillance imaging followed by secondary intervention when findings were 
worsening. This was more often true of flow related complications than aneurysm 
related complications. 
2.3.2.3.3 Surveillance Scans 
All radiological reports were retrieved as part of the service evaluation to ensure no 
secondary interventions were missed. The reports that were for CDUS and AXR as part 
of EVAR surveillance were broken down to component parts of the report as specified 
in the standard operating procedure. Figure 8 (page 40) shows a completed example of 
the, Microsoft Access 356 ProPlus© (Version 1907), form used to break a CDUS 
written report down to the component sections of the standard operating procedure. 
When broken down to constituent parts the data processor was therefore completely 
blinded to the details of outcomes and of that patient as they were not identifiable. Each 
CDUS reported was broken down to the findings shown in Table 5 (page 41). 
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Figure 8: Form to Break Down CDUS Report to Constituent Findings 
 
Microsoft Access Form used to break CDUS reports into constituent parts. Anonymised CDUS report 
displayed at top and user competed constituent parts below. 
AXR were acquired according to the Liverpool Perth protocol,74 which is designed to 
allow optimum imaging for the diagnosis of those factors outline in the paper. An initial 
sample of 250 AXR reports were broken down into these constituent parts. The majority 
of reports were relational, stating that there was no observed difference from a previous 
set of imaging (or were themselves the baseline imaging). A report stating “No Change” 
was taken as all these points being negative compared to the last or specified 
comparator film. After reviewing the comments section of these 250 reports it became 
apparent that limb kinking was also being detected and reported on AXR so this was 
added to the pro-forma and all the AXR were broken down to their constituent parts (re-
doing the 250 case sample). The findings are displayed in Table 6 (page 42).  
The dates of CTAs and the few Magnetic Resonance Angiograms (MRAs) performed 
were also recorded. These modalities were not reported to a standardised protocol or 
apparent pattern so were not broken up into their constituent findings. 
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Table 5: Constituent Part Of CDUS Reports In LiVES EVAR Surveillance, 
Possible Responses And Data Completeness Levels. 
Variable Responses 
Data Completeness 
(n=3208) 
Diagnostic TRUE or FALSE 100% 
Diagnostic 
Comments 
Free text, typically recording why a 
CDUS was not diagnostic 
86.2% (of non-
diagnostic scans) 
Max AAA Diameter Size in mm 99.96% 
Right CIA Diameter Size in mm 0.09% 
Left CIA Diameter Size in mm 0.06% 
Thrombus in 
Aneurysm Mixed 
TRUE or FALSE 
100% (assumed FALSE 
if not mentioned) 
Endoleak Present TRUE or FALSE 
100% (assumed FALSE 
if not mentioned) 
Endoleak Type(s) 
Type Ia, Type Ib, Type II, Type III, 
Other/Unkown 
98.9% (of those with 
endoleak) 
Endoelak Text 
Free text, typically recording inflow 
and outflow points if recorded 
77.4% (of those with 
endoleak) 
Limb Complication TRUE or FALSE 
100% (assumed FALSE 
if not mentioned) 
Limb Effected LEFT, RIGHT or BOTH 
97.8% (of those with 
limb complication) 
Limb Complication 
Type 
Reduced Flow, Deffined Stenosis, 
Occlusion 
98.8% (of those with 
limb complication) 
Limb Text 
Free text, Typically location of 
stenosis and pre-post PSV or max 
PSV 
94.5% (of those with 
limb complication) 
Comments 
General comments on other 
observations. 
10.9% 
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Table 6: Constituent Parts of AXR Reports in LiVES EVAR Surveillance and 
Possible Responses 
2.3.3 Ethical and Research Approval 
The Research Department of the Royal Liverpool and Broadgreen University Hospitals 
NHS Trust granted full sponsorship (reference 5518), the study protocol was peer-
reviewed as part of the sponsorship application process. 
The study was conducted in compliance with the principles of the Declaration of 
Helsinki (1996), the principles of Good Clinical Practice and in accordance with all 
applicable regulatory requirements including but not limited to the Research 
Governance Framework. The only ethical issue raised by the study was the use of 
patient’s data without consent. This was addressed by the total anonymisation of the 
data during the research elements so preventing any identification. It is also further 
mitigated by the fact the researchers worked within the same institution as the patients 
so meaning there was no external transfers of data. Finally, the patient representative 
consulted had assumed that there would be, at least conditional, access to these data for 
research. 
Variable Reason Recorded Response 
Baseline Image  TRUE/FALSE 
Date compared to  
Date (coverted to 
time interval on 
anonymisation) 
Migration Liverpool Perth Protocol TRUE/FALSE 
Left Limb Kink Regularly reported - result of sample TRUE/FALSE 
Right Limb Kink Regularly reported - result of sample TRUE/FALSE 
Structural Failure 
Liverpool Perth Protocol (Barb / Strut 
failure or component seperation) 
TRUE/FALSE 
Effacement Liverpool Perth Protocol TRUE/FALSE 
Comment  Free Text 
Non-EVAR Finding Free text of non-EVAR findings Free Text 
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The study protocol was reviewed by and a favourable ethical opinion was obtained from 
the NHS Health Research Authority, National Research Ethics Service, North of 
Scotland Research Ethics Service, reference 17/NS/0088. Annual progress and final 
report at conclusion of the study were submitted to the sponsor and ethics committee. 
2.3.4 Analysis 
Data was processed in Rstudio (version 1.2.5),94 using R (version 3.6.1),95 with 
packages: tidyverse,96 survival,97 scales,98 survminer,99 Cairo,100 epitools,101 caret,102 
MASS,103 corrplot,104 mice,105 ResourceSelection,106 and DecTools.107 The full R Code 
for data processing and analysis is available in Appendix 2 (page 190). The saved 
results of the Multiple Imputation and other computational data processing are also 
included to allow exact replication of the results presented. A subgroup of patients who 
underwent their EVAR after the start of the observational period was created to allow 
comparison of LiVES outcomes to the published literature. 
2.3.4.1 Demographics 
Descriptive statistics were used to demonstrate the baseline demographics of the 
patients included in the study. Year of original EVAR procedure and numbers 
performed in relation to observational period were plotted using a histogram. Kaplan-
Meier survival plot for all patients, and intervention free survival for patients 
undergoing EVAR within the observational period were created, for comparison to the 
contemporary literature. Patient distance to the surveillance centre was calculated using 
the patients’ current postcode, or that at the time of death or discharge from EVAR 
surveillance. This distance is ‘as the crow flies’ and was calculated using Code-Point® 
Open,* under the Open Government Licence. 
* Contains OS data © Crown copyright and database right 2018, Contains Royal Mail 
data © Royal Mail copyright and Database right 2018, Contains National Statistics data 
© Crown copyright and database right 2018. 
2.3.4.2 Nature and Incidence of Secondary Intervention 
Each secondary intervention, that occurred during the observational period, was 
analysed for its trigger, if the patient was symptomatic and to stipulate if it occurred as 
an emergency. Simple descriptive statistics were used to describe the types and 
characteristics of the secondary interventions along with the triggers. Secondary 
interventions were grouped into two broad categories – those intended to preserve flow 
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through the EVAR stent-graft and those intended to maintain the efficacy of the EVAR 
stent-graft as a treatment to prevent rupture of AAA. 
Finally, the incidence of secondary interventions was calculated using the observational 
data available in this study. For this analysis patients at risk were established as those 
who had not been actively discharged from surveillance of the LiVES centre and 
remained alive for the time points after initial EVAR being assessed. The number of 
secondary interventions for the previous 12 months were established for each time point 
from 1.00 year after EVAR and divided by the sum of the number of patient years (or 
part years) at risk and presented in a graph as an incidence of secondary intervention per 
1000 patient years. The analysis was discontinued at 15 years after EVAR, the current 
limit of the published data.45 This analysis was then repeated for secondary intervention 
of each different class to ascertain if the causality of the interventions changed over 
time. Best fit lines were created using a local regression model, weighted for the number 
of patient years at risk and calculated using a 0.75 span.108 Square root of time was used 
in the model to create the best fit line, this was to account for the known early 
preponderance of secondary interventions following EVAR. 
2.3.4.3 Compliance 
The rate of compliance was calculated at each 100th of a year after EVAR. As for the 
secondary intervention analysis, a list of all patients that were eligible was created for 
each time point. They were deemed to be “at risk” if they had been alive, not discharged 
from surveillance and the whole time frame had fallen in the period of observation (ie 
any surveillance scan would have been captured) for the previous 18 months. Each 
patient at risk was then tested to ascertain if they had indeed had a surveillance scan and 
a percentage compliance calculated for that time point. This was repeated for all time 
points up to 15 years after EVAR. 
Patient factors that may be predictive of future compliance were investigated by a 
similar method. Time points were created for each 10th of a year after EVAR up to 15 
years. Each patient alive, after EVAR and not discharged from surveillance, who fell 
into the observational period who also met those criteria for the following 18 months 
was deemed at risk. Whether they had any surveillance scan in that 18 month period 
was used to define compliance (or non-compliance). Patient factors available were then 
entered into a binominal general linear model to calculate individual variable odds 
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ratios. These were reviewed individually (unadjusted) to assess them and for 
comparison to the literature. 
Data were then split 80:20 into a training and test group. Individual variables in the 
training group were recalculated with all variables in the model to get an adjusted odds 
ratio (to remove confounding between variables). Finally, a stepwise regression was 
undertaken to remove those variables that had minimal effect on the model to remove 
the variables that had statistically little effect thereby focusing the model on the most 
important variables. This effectively removed variables with no effect or close co-
linearity with other variables. 
This simpler and the original full model were then used in a test group data sample to 
compare predictive capability and to ensure the removal of these factors had not 
significantly impacted predictive ability.  
2.3.4.4 Surveillance Scan Findings Correlation to Secondary 
Intervention 
To investigate which imaging findings were pertinent to triggering secondary 
interventions each individual finding was investigated using a univariate survival 
analysis. The time frame, however, over which this causative effect should be measured 
was not defined in the literature. As such this was initially defined as described in 
section 2.3.4.4.1 (page 46). 
Individual surveillance scan findings were felt to be more likely to trigger either flow 
related, or aneurysm related secondary interventions. To prevent surveillance scan 
findings that trigger rarer (but clinically important) secondary interventions being 
unreasonably excluded, because of their rarity, aneurysm and flow related secondary 
interventions were examined separately. Only findings, on surveillance scan, with a 
perceived causal effect on instigating a secondary intervention were investigated i.e. if a 
type II endoleak was present was not investigated to look at to see if it instigated flow 
related secondary interventions, as no causal effect could be hypothesised. 
AXR has never been considered an adequate independent surveillance imaging modality 
and is always used as an adjunct to other modalities, as such AXR variables were 
considered in relation to the other imaging modality that they were pair with – in LiVES 
this was CDUS. As such all CDUS scans were paired with the most contemporary 
AXR, that occurred that day or previously. This allowed assessment of the CDUS 
variables in conjunction with the AXR findings available at that time. 
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2.3.4.4.1 Timeframe of Assessment 
It is assumed that any finding on an individual surveillance scan is much less likely to 
be the causal trigger for a secondary intervention as time passes. It was not known how 
long this effect is present for. While a true finding of a graft related endoleak would 
logically lead to a rapid sequence of events to trigger a secondary intervention, a true 
finding of a limb stenosis may lead to an interval scan to assess for progression of 
haemodynamic effects, multi-disciplinary team discussion, routine clinic appointment to 
discuss the risks and benefits of intervention with the patient followed by a planned 
secondary intervention. As such an initial analysis was undertaken to ascertain the 
global risk of secondary intervention following a surveillance scan. 
This was performed, by first creating a Nelson–Aalen estimator of the cumulative 
hazard ratio of secondary interventions for the 2 years following surveillance scan. This 
was then converted into an actual point hazard ratio at individual time points following 
the scan. This individual time point hazard ratio was created through the conversion of a 
best fit line, fitted to the Nelson-Aalen estimator. The time of accelerated secondary 
interventions was observed in the first 6 months following the scan before the baseline 
risk of secondary intervention was seen. 
The early preponderance of surveillance imaging and high percentage of observed 
secondary interventions immediately following EVAR risked influencing this analysis. 
To ensure there was no selection bias in the observed relative hazard ratio, the analysis 
was repeated for surveillance scans that had occurred at least ¾ year or later after initial 
EVAR, chosen based on data in Figure 11 (page 54). This confirmed the same interval 
to be appropriate even after the immediate post-op period. 
2.3.4.4.2 Findings on Surveillance Scans that Correlated with 
Secondary Interventions 
Data were censored at the time of a secondary intervention that was not in the group of 
interventions being assessed in that analysis (flow related, or aneurysm related). This 
was due to the assumption that a patient who underwent a secondary intervention [for 
another reason] was likely to have had a further surveillance scan following that 
intervention so findings were potentially being assessed twice. In categorical variables 
survival analysis was undertaken in the form of Kaplan–Meier survival plot and log 
rank test for categorical variables, if multiple variables (in categorical variables) were 
similar they were grouped together if this was a clinically logical grouping. Results of 
Cox proportional hazard models were reported as hazard ratios, 95% confidence interval 
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of that hazard ratio and p values. Continuous variables survival analysis was more 
complex due to less complete data. In variables with complete data, Cox proportional 
hazard models were fitted using the continuous variables. Results of Cox proportional 
hazard models were reported as hazard ratios (per described increment), 95% 
confidence interval of hazard ratio and p values  
2.1.1.1.1.1 Missingness and Multiple Imputations 
Missing values can be absent for many reasons but the cause of its missingness can 
introduce bias into statistical analyses. Missing data is therefore usually classified into 
one of three categories:  
• Missing Completely at Random 
• Missing at Random (MAR) 
• Not Missing at Random (NMAR) 
Missing Completely at Random data will introduce no bias to analyses as it is 
completely random. MAR data do not depend on the unobserved values of these data 
but do depend on these observed data so analysis of all these data will compensate for 
these MAR data due the relationship between these available data and MAR data. 
NMAR, is essentially non-response bias, meaning these missing data will introduce bias 
to analysis if not compensated for. 
For categorical variables data missingness was grossly assessed by event rates in the 
missing data compared to the other categories. If the event rate was notably different 
then an assumption of NMAR was made and multiple imputation methods were used in 
analyses. 
In continuous variables a dummy binary variable (0 for missing or 1 for present) were 
created for data missingness and any missing variable replaced with a numerical 0 
value. The missingness binary variable was divided by the variable being investigated in 
the formula of a Cox proportional hazard model with the time and event data. If for any 
of the created models the missingness variable became statistically significant this was 
interpreted as data potentially being NMAR. In such cases multiple imputation was 
undertaken as detailed below. If not, data was taken to be MAR. If no data was missing 
or data was MAR, analysis was undertaken using the original data with cases omitted 
that had MAR data and any associated events. 
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Multiple imputation was used in cases of data NMAR. It reduces uncertainty created 
about missing values by creating several versions of the same data set and calculating 
several likely imputations or replacements for the missing values. These versions are 
then subjected to the required statistical analysis. The output of this analysis is then 
“pooled” and the most likely outcome reported. This improves validity and increases 
precision. 
Within this study, multiple imputation was undertaken using the “mice” package 
(Version 3.6.0) in R.105 This uses “chained equations” to form its multivariate 
imputations. Chained equations specify the statistical model type, that creates the 
imputation, separately for each variable with missing data, these models can follow 
different distributions or methods. MICE loops through an iterative process: In the first 
iteration, the model for the variable with the least missing values is estimated using only 
complete data. Next, the variable with the second least missing values is imputed using 
the complete data and the imputed values from the last iteration. After each variable has 
been through this process, the cycle is repeated using the data from the last iteration. 
After the last cycle is completed the values are saved as one imputed data set. 
Within this study continuous (numeric) variables were iterated by a predictive mean 
matching model, logical (True/False) by Bayesian logistic regression model and 
unordered categorical variables by Bayesian polytomous logistic regression model. All 
the models were constructed with input from all the variables in the dataset being used, 
including the outcome variable. 
Predictive mean matching forms a small set (5 in this study) of candidate donors, from 
all complete cases, that have values closest to the other variables for case with the 
NMAR variable. One donor is randomly drawn from the candidates, and the observed 
value of the donor is taken to replace the NMAR variable. The assumption is the 
distribution of the missing cell is the same as the observed data of the candidate donor. 
500 imputed datasets were generated given the modest amount of computing power 
required to generate a single set. 
2.1.1.1.1.2 Assessment of Co-Linearity and Confounding Between 
Variables that Could Allow Rationalisation of Variables 
It was envisaged that variables were likely to have confounding or co-linearity between 
them in relation to secondary interventions. As such a multi variable Cox proportional 
hazard model was created for both flow related and aneurysm related secondary 
Chapter 2: Analysis of a Colour Duplex Ultrasound Scan and Plain Abdominal X-ray Surveillance Regimen 
Iain Nicholas Roy - August 2020   49 
interventions to assess for these and rationalise these variables to those, that combined 
offer the highest predictive ability and therefore likeliest, when measured, to aid 
clinicians in identifying the need for secondary intervention. This was undertaken using 
a backwards stepwise procedure using: clinical knowledge, hazard ratios and p values to 
select the order of candidate variables for exclusion. The multiple imputed data was 
used to assess each new iteration till backwards exclusion of further variables increased 
the Akaike information criterion (AIC) by greater than 4. The hazard ratios and p values 
for each variable in the simplified and full models are reported, however it is 
highlighted that the model is being used as a surrogate for the clinician decision making 
processes to assess the impact of less data being collected or being available for 
decisions. 
This simplified model was assessed in comparison to the full model based on two 
characteristics: calibration and discrimination. Calibration was assessed by visual 
scatter plot comparison of the simplified and full model numeric predictions using all 
sufficiently complete data. This relationship was then quantified by a linear model with 
reporting of the co-efficient and numeric offset for comparison. Discrimination was 
assessed by ROC curve production and AUC calculation for both models for 
comparison. 
2.3.4.5 Creation of Model to Predict Secondary Intervention 
To find if future risk of secondary intervention could be accurately predicted a model 
was created and internally validated. Given that the risk of secondary intervention had 
already been established to be variable over time a single model that covered all time 
points was felt unlikely to achieve the high predicative ability demanded in clinical use. 
As such a Piecewise Exponential Model (PEM) was used. 
2.3.4.5.1 Piecewise Exponential Model 
The PEM, as proposed by Freidman et al.,109 is a methodology for modelling risk under 
an assumption of proportional hazards but with the inclusion of a parametric form for 
the underlying hazard function. It is often preferred over the more standard Cox model 
when absolute levels of risk are of interest as well as relative measures between 
covariate levels (e.g. hazard ratios). While simpler parametric models are available, 
these can lack the flexibility of the PEM to accurately model changes in risk, within 
subjects, over time. 
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The PEM was constructed, by Dr R Jackson, by first defining a time grid, a partition of 
the time axis into a number of segments or timeframes. Within each time frame, an 
exponential parameter is fit under the assumption that the underlying risk of an event 
remains constant. The definition of the time grid partitions was set according to clinical 
relevance, for example setting a partition (0- 6 months) will allow for the risk of an 
event within the first 6 months of the period of interest. Within each segment, the model 
fit is analogous to log-linear regression. Here the number of events can be assumed to 
follow a Poisson distribution and the underlying risk is estimated by the number of 
events observed as a ratio of the total patient time at risk in that segment. Including 
covariates into the model allows for the baseline risk to be adjusted due to 
clinical/prognostic factors of interest as with standard regression. The effects due to 
these covariates are considered to be equal across all segments of the time grid and do 
not differ between time segments. The parameters for the underlying risk, of an event, 
then define the average risk for each time-segments and along with adjusting covariates 
can lead to estimation of predictive event rates in a way that Cox models are unable to 
achieve. Estimation of model parameters are obtained via standard maximum likelihood 
approach. 
2.3.4.5.2 Piecewise Exponential Model Creation 
The time frames for the PEM were primarily set based upon the relevant findings in the 
incidence of secondary interventions, Section 2.4.2.2 (page 57). The number of patients 
at risk at given time points was a secondary consideration to ensure enough data fell 
within each time frame for model creation and validation. 
All variables from the previous CDUS analysis, Section 2.3.4.4 (page 45), Table 16 
(page 93) and Table 17 (page 94), were available in the model creation. In addition, a 
number of patient variables were also available (Table 7, page 52). Model creation was 
undertaken on the principle of using the minimum number of variables needed to 
acquire the best AIC, trial selection and elimination in a stepwise manner were based on 
the previous findings in this study and published knowledge.  Each step that rendered a 
decrease in AIC was compared directly with the Χ2 distribution. With a decrease of 4 or 
more being indicative of a co-variate worth retaining in the model.  
2.3.4.5.3 Internal Validation 
The validation of the PEM examined 2 characteristics, the first was the calibration of 
the model. Calibration is the measure of agreement between observed outcomes and 
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predictions. The second characteristic is discrimination, this is the PEMs accuracy in 
predicting who will develop an event earlier and who will develop an event later (or not 
at all).  
Internal validation was undertaken using a bootstrap technique. The data were randomly 
split 80:20 for model training and validation, respectively. This process was repeated 
5000 times. On each of these occasions; the model was re-fitted (relative weighting of 
variables adjusted) on the model training data set, a Receiver Operator Characteristics 
(ROC) with an Area Under The Curve (AUC) to assess discrimination and Hosmer–
Lemeshow test to assess calibration were then calculated on the validation data set. The 
relative weighting of the variables, area under the curve and Hosmer–Lemeshow test p 
value, respectively, were recorded for each of the 5000 repeats. ROC was used to assess 
discrimination, this is the PEMs accuracy in predicting who will develop an event 
earlier and who will develop an event later (or not at all) calibration was assessed using 
Hosmer–Lemeshow test p value, which should be non significant, a significant value 
signifies a significant number of patients had an event that the model did not predicted. 
The co-efficient (estimate and standard error) and p value for each variable in the model 
was recorded for each round of internal validation. The mean of these recorded values is 
reported. 
Finally example prediction graphs where produced to demonstrate the models potential 
practical clinical use. Assessment patients were created for this purpose with low, mean 
and high risk findings to demonstrate how risk predictions would be displayed. The 
values used for these patients was the first quartile, median and third quantile from the 
original dataset for each variable used in the model.  
2.4 Results 
The anonymised data from the LiVES database and imaging variables are available in 
Appendix 3 (page 235). 
2.4.1 Demographics 
Table 7 (page 52) demonstrates the patient variables for all infra-renal EVAR patients in 
the LiVES EVAR database.  
LiVES performed less than 25 EVAR cases a year till 2005, then there was an 
increasing use up to a maximum case load of between 100 – 115 between 2009-2011, 
this then slowly declined to ~60 cases a year by 2014, Figure 9 (page 53). Numbers of 
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patients that had their primary operation before or during the study observational period 
of the study are displayed in differing colours. All cause survival following EVAR 
follows a broadly linear decline from 100 to ~20% over 18 years, Figure 10 (page 54). 
Freedom from secondary intervention can only be reliably calculated for those patients 
who had a procedure after 2008, the start of this studies observational period. Freedom 
from secondary intervention shows a sharp decline to approximately 90% in the first 6 
months then grossly linear decline to approximately 75% over the following 5 years, 
Figure 11 (page 54). 
Table 7: LiVES Surveillance Database - Patient Demographics 
 
Of 906 cases, the manufacturer of the device implanted was Cook Medical 
(Bloomington, Indiana, U.S.A) in 415 cases, Medtronic (Dublin, Ireland) in 292 cases, 
W. L. Gore and Associates (Newark, Delaware, U.S.A) in 158 cases and others in 41 
cases. The 6 most common individual device types use are listed in Table 8 (page 53). 
  
Variable Median (IQR) Data Completeness 
Calander Year of Operation 2009 (2007-2012) 100% 
Age at Operation (years) 76 (71 – 81) 100% 
Gender 86.5% Male 100% 
Pre operative max AAA size (mm) 62 (57 – 70) 94% 
Pre operative max iliac size (mm) 17 (14 – 20) 32% 
Distance to surveillance centre (km) 11.5 (6.38 – 22.63) 95% 
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Table 8: LiVES EVARs – 6 Commonest EVAR devices 
 
Figure 9:Histogram of EVARs performed in LiVES for each calendar Year 
 
Histogram of number of EVARs performed in LiVES per calendar year between 1996 and 2015. Cases 
are differentiated by if they were performed before or during the period of the observational study, the 
majority being during the study.   
EVAR Device Manufacturer Number (% of Total) 
Endurant Medtronic 206 (23%) 
Zenith Flex Cook Medical 192 (21%) 
Zenith Cook Medical 144 (16%) 
Excluder C3 Gore 97 (11%) 
Endurant II Medtronic 59 (7%) 
Excluder Gore 54 (6%) 
Others - 154 (17%) 
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Figure 10: All cause survival following EVAR in LiVES 
 
Kaplan-Meier plot demonstrating a grossly linear decline in all cause survival, to ~25% by 14 years, 
following EVAR in LiVES 
Figure 11: Freedom from Secondary Intervention Following EVAR in LiVES 
 
Kaplan-Meier plot demonstrating freedom from [any] secondary intervention following EVAR in LiVES 
deteriotes to 90% with 6 months then in a linear fashion to 80% by 5 years. 
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2.4.2 Secondary Interventions 
2.4.2.1 Nature of Secondary Interventions 
A total of 178 secondary interventions occurred during the 7 year period observed in 
this study. These secondary interventions occurred in 119 unique individuals. They 
occurred between 0.00 and 16.46 years after initial EVAR procedure. Of these 24 (13%) 
cases were treated as an emergency, 9 of which occurred prior to discharge from the 
initial EVAR. Of 178 secondary intervention in this observational period only 15 (8%) 
resulted in a new emergency admission. 
The patient had symptoms in 44 (25%) of 175 interventions that could be interrogated, 3 
cases had no clinical notes/correspondence to review and while the procedure and 
indication could be ascertained from imaging the presence/absence of symptoms was 
unlikely to have been recorded in those locations. Of these 44, 15 had symptoms on 
direct questioning but had failed to self-present or waited till their next surveillance visit 
to voice their symptoms. The remaining 29 cases either self presented or had incidental 
findings on non-surveillance imaging that prompted referral and treatment. 
Patients were asymptomatic of their complication in 131 (75%) of the interventions. 
Only 7 of these asymptomatic interventions were not deemed the direct result of 
surveillance imaging. These 7 were the result of findings on non-surveillance imaging 
that promoted referral back to the LiVES service. 
Secondary interventions fell broadly into 2 main categories: Those intended to maintain 
the efficacy of the aneurysm treatment and those intended to maintain distal perfusion 
through the stent-graft to the lower limbs. Further procedures to treat complications of a 
secondary intervention were labelled under the category of the initial secondary 
intervention. 86 (48%) were to treat flow related complications and 92 (52%) were to 
maintain aneurysm treatment efficacy, Table 9 (page 56). Of these secondary 
interventions 128 (72%) were endovascular and 43 (28%) were open surgical 
procedures, Table 10 (page 57). 
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Table 9: Indications for Secondary Interventions follow EVAR in LiVES 
 
  
Indication 
Number of Secondary interventions  
(% of Total n=178) 
Maitaining Aneurysm Treatment Efficacy (n= 92) 
All Endoleaks 
Type Ia 
Type Ib 
Type II 
Type III 
Uncharacterised Endoleak 
Endotension 
68 (38%) 
12 
15 
23 
10 (1 not present at intervention) 
3 
5 
Rupture 3 (2%) 
Impending Failure 
Effacement 
Migration 
12 (7%) 
4 
8 
Various immediate post procedure 
complications 
9 (5%) 
Maintaining Flow (n=86) 
Limb Stenosis  
(6 not confimred on angiography) 
60 (34%) 
Limb, CFA or Bypass Oclussion  
(Including 2 acute limb ischemias) 
21 (12%) 
Pseudoaneurysm or peripheral bleeding 5 (3%) 
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Table 10: Cross-Section of Secondary Interventions at all times after EVAR in a 
single Tertiary UK Vascular Centre 
2.4.2.2 Incidence of Secondary Interventions 
Calculation of the number of patient years at risk was undertaken, Table 11, (page 58), 
shows the sum of all the complete and partial patient years that were at risk in the 
previous 12 months. This shows 567 patient years at risk in the first 12 months 
decreasing relatively linearly to 16.5 patient years in the 12 months up to 15 years post 
EVAR. Averaged throughout follow-up this represents 61.3 interventions per 1000 
patient years. 
Secondary Intervention Number of Secondary interventions  
(% of Total n=178) 
Endovascular Interventions 
Limb Stenting  
Limb Extension 
Endoleak Embolisation 
Angiogram - No Intervention Performed 
Limb Angioplasty 
Relinning (+/- FEVAR cuff) 
Proximal Endovascular Cuff 
Palmaz Stent 
Isolated Viseral Artery Interevention 
Thrombectomy and Limb Stenting 
128 (72%) 
45 
22 
21 
12 
8 
8 
7 
2 
2 
1 
Open Vascular Surgery 
Arterial Bypass 
Open AAA Conversion / Repair 
Surgical Pseudoaneurysm Repair 
Femoral artery Endarterectomy 
Fasciotomy 
Major Limb Amputation 
43 (24%) 
17 
15 
5 
4 
1 
1 
Abdominal Surgery 
Colectomy 
Other Laparotomy/Laparostomy 
7 (4%) 
4 
3 
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Table 11: Number of patient years at risk at differing time points in observational 
study following EVAR 
There is modest variance in the trend in secondary interventions between approximately 
60 and 30 secondary interventions, in the previous 12 months, per 1000 patient years at 
risk, Figure 12 (page 59). This variance takes the form of an initial downward trend 
between years 1 to 2 ½ years from 60 to approximately 35 events, where it remains 
relatively static until a more gradual upward trend in years 9 to 15 takes the rate back up 
to approximately 60 events. 
The incidence of secondary interventions following EVAR classed as aneurysm related 
and flow related are demonstrated in Figure 13 (page 59) and Figure 14 (page 60) 
respectively. Aneurysm related secondary interventions are initially rare, ~12 events per 
12 months increasing to 25 events by year 3 and then relatively static thereafter. Flow 
Years following EVAR Number of patient years at risk in previous 12 months 
1 567.0 
2 521.2 
3 454.9 
4 349.9 
5 257.9 
6 190.9 
7 126.8 
8 103.6 
9 79.9 
10 66.35 
11 56.4 
12 47.95 
13 36.4 
14 25.8 
15 16.5 
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related secondary interventions are very frequent initially with an event rate of 50 in the 
first year which quickly reduces to approximately 12 by year 3. This remains somewhat 
static till year 11 when it then gradually increases again, reaching 30 events by year 15. 
Figure 12: Incidence of Secondary interventions in the previous 12 months at 
differing time points following EVAR, with trend line 
 
Black line: true incidence of any secondary interventions in previous 12 months per 1000 patient years at 
risk. Red Line: line of best fit weighted by number of patient years at risk. 
Figure 13: Incidence of Aneurysm Related Secondary Interventions in the 
Previous 12 Months Following EVAR, with trend line 
 
Black line: true incidence of aneurysm related secondary interventions in previous 12 months per 1000 
patient years at risk. Green Line: line of best fit weighted by number of patient years at risk. 
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Figure 14: Incidence of Flow Related Secondary Interventions in the Previous 12 
Months Following EVAR, with trend line 
 
Black line: true incidence of flow related secondary interventions in previous 12 months per 1000 patient 
years at risk. Blue Line: line of best fit weighted by number of patient years at risk. 
Figure 15: Trend Lines of Frequency, by Type, of Secondary Intervention 
Following EVAR 
 
Lines of best fit, weighted by number of patient years at risk, of incidence of secondary interventions of 
defined type in the previous 12 months per 1000 patient years at risk. Demonstrating the varying 
indications over time after EVAR. 
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The trend lines of frequency for: flow related, aneurysm related and all secondary 
interventions are presented in Figure 15 (page 60). This allows the direct comparison of 
the differing event rates over time. They demonstrate that the early predominance of 
secondary interventions is caused by flow related secondary interventions. This is 
somewhat offset by a low initial rate of aneurysm related secondary interventions, 
which by year 3 remain static in available analysis. The increasing rate of secondary 
interventions from year 10 onwards happens almost exclusively as the result of flow 
related secondary interventions. 
2.4.3 Compliance 
A total of 13,817 imaging events occurred during the observational period and were 
reviewed. They occurred in 849 individuals who had undergone EVAR in LiVES. 7,387 
of the 13,817 imaging events were deemed to be related to EVAR surveillance. Of these 
3,062 AXR’s and 114 CEUS studies were not felt sufficient to be classified as 
surveillance in their own right. A total of 3256 CDUS, 947 CTA and 8 Magnetic 
Resonance Imaging Angiograms (MRA) were all deemed to constitute surveillance 
visits for this analysis. Many of these imaging modalities will have occurred on the 
same day. The MRA scans were all conducted with concomitant AXRs. 
2.4.3.1 Compliance Following EVAR 
The rate of compliance, defined as a specific surveillance scan within 18 months, over 
time following EVAR is present in Figure 16 (page 62). It demonstrates excellent 
compliance, in excess of 95% until year 10, then a near linear reduction in compliance 
from years 10 to 15 reaching ~55% compliance by year 15.  Table 12 (page 63) presents 
the number of patients at risk, in whole year intervals, for this compliance analysis. 
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Figure 16: Compliance with EVAR surveillance: Percentage of patients to have 
undergone a Surveillance scan in the previous 18 months 
Graph of percentage of patients at risk who were compliant with surveillance imaging in the previous 18 
months for different times after EVAR up to 15 years. Shows >95% compliance till 10 years after EVAR 
then gradual decline to <55% by 15 years. 
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Table 12: Number of patient years at risk at differing time points for compliance 
analysis  
2.4.3.2 Patient Characteristics Associated with Future Compliance 
These data were used as described in the methods section for fitting a binomial 
regression model.  
Using these data, odds ratios were then calculated for future compliance in both 
unadjusted and adjusted (for other variables) forms. Adjusted Odds ratios were 
calculated using a model utilising all the described variables, thereby accounting for 
confounding between variables. The exclusion of the variable “Age at Operation” is the 
result of absolute co-linearity with “Age at Surveillance Scan” and “Time after EVAR”.  
Table 15 (page 65) demonstrates the Odds ratios of the most important variables that 
were left after stepwise regression modelling. This simplified and the original full 
model were then used in the test data sample to compare their predictive capability and 
Years following EVAR At risk for 18 Month definition of compliance 
2 381 
3 337 
4 255 
5 186 
6 123 
7 92 
8 72 
9 53 
10 45 
11 43 
12 33 
13 22 
14 22 
15 13 
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to ensure the removal of these factors has not impacted predictive ability. The full 
model and the simpler stepwise model both accurately predicted compliance in 81.7% 
of cases in the test sample. 
Table 13: Data points and Distribution Used in Analysis Determining Patient 
Factors Associated with Surveilliance Compliance 
 
  
Variable Median (IQR) Data Completeness 
Calander Year of Operation 2009 (2006-2011) 100% 
Age at Operation (years) 75 (70 – 80) 100% 
Age at Surveillance Scan 78.9 (74.2 – 83.8) 100% 
Time after EVAR 2.8 (1.3 – 5.1) 100% 
Gender 87.6% Male 100% 
Pre operative max AAA diameter (mm) 62 (57 – 70) 95% 
Distance to surveillance centre (km) 11.78 (6.20 – 23.30) 96% 
Previous Secondary Intervention 12.8% TRUE 100% 
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Table 14: Unadjusted and Adjusted odds ratios, of patient variables, for future 
compliance with EVAR surveilence. 
 
Table 15: Variables which influence compliance following a stepwise regression of 
full model. 
Variable 
Unadjusted Odds 
Ratio for EVAR 
Surveillance 
compliance (95% 
CI) 
Adjusted Odds 
Ratio for EVAR 
surveillance 
compliance (95% 
CI) 
Calander Year of Operation (per year) 0.97 (0.96-0.98) 0.67 (0.66-0.685) 
Age at Operation (per year) 0.975 (0.97-0.98) - 
Age at Surveillance Scan 0.95 (0.95-0.96) 0.96 (0.96 – 0.97) 
Time after EVAR (per year) 0.91 (0.90-0.92) 0.62 (0.60-0.63) 
Gender (MALE) 1.05 (0.95 -1.17) 1.02 (0.91 – 1.14) 
Pre operative max AAA size ( /mm) 1.00(0.995 – 1.00) 1.00 (1.00 -1.00) 
Distance to surveillance centre ( /10 km) 1.02 (1.01-1.03) 1.00 (1.00 – 1.00) 
Previous Secondary Intervention 0.91 (0.82-1.01) 1.13 (1.01 – 1.25) 
Variable Final Odds Ratio 
Statistical 
Significance (p) 
Calander Year of Operation (/year) 0.67 (0.66-0.685) >0.001 
Age at Surveillance Scan (/year) 0.96(0.96-0.97) >0.001 
Time after EVAR (/year) 0.60 (0.60-0.61) >0.001 
Distance to surveillance centre (/10 km) 1.03 (1.01-1.04) >0.001 
Previous Secondary Intervention 1.13 (1.01-1.26) 0.03 
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2.4.4 Surveillance Scan Findings Correlation to Secondary Intervention 
2.4.4.1 Interval of Effect 
3092 CDUS scans in 756 individuals were considered, secondary intervention data were 
right censored at 2 years- as the maximal time that any effect of CDUS on secondary 
intervention rates could be conceived. 168 scans were followed by a secondary 
intervention in this available follow-up to 2 years. The best fit line to the Log 
conversion of the Nelson-Aalen cumulative hazard estimator, Figure 17 (page 66), 
demonstrates an inverse exponential function with the majority of the risk accumulated 
by 0.3 years and linear accumulation of risk definitively established by 0.5 years 
onwards. 
Figure 17: Cumulative Hazard Ratio of Undergoing Secondary Intervention 
Following Post Operative EVAR Surveillance Scan 
 
Black Points: Log conversion of a cumulative hazard estimator points - of requiring a secondary 
intervention following an EVAR surveillance scan. Red Line: best fit line demonstrating an inverse 
exponential function of hazard as time passes. 
The best fit line was then transformed into absolute point (in time) hazard ratios. This 
absolute point hazard ratio, Figure 18 (page 67), demonstrate an increased hazard of 
secondary intervention following surveillance scan followed by a gradual reduction in 
hazard down to a stable baseline hazard by 0.5 years, which then remains essentially 
static.  
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Figure 18: Point Hazard Ratio of Undergoing Secondary Intervention Following 
Post-Operative EVAR Surveillance Scan 
 
Absolute risk or requiring a secondary intervention at any given time after EVAR surveillance scan, 
showing very high risk immediately following surveillance scan but settling to a relatively low baseline 
risk by 0.5 years after scan. 
Figure 19: Point Hazard Ratio of Undergoing Secondary Intervention Following 
Post-Operative EVAR Surveillance Scan That Occurred at Least 0.75 Years 
Following EVAR. 
 
Absolute risk or requiring a secondary intervention at any given time after an EVAR surveillance scan, 
when at least 0.75years after initial EVAR. Demonstrates a moderate risk immediately following 
surveillance scan but settling to a low baseline risk by 0.5 years after scan.  
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This entire hazard analysis was repeated for surveillance scans that occurred at least 
0.75 years following that individuals initial EVAR procedure. This repeat analysis was 
designed to remove any confounding that may have occurred due to the co-linearity of 
secondary interventions and surveillance scans immediately following initial EVAR 
procedure. The repeat analysis was undertaken on 2395 scans in 666 individuals. 88 
scans were followed by a secondary intervention in the follow-up, censored at 2 years, 
following scan. The point hazard ratio of this repeat analysis, Figure 19 (page 67), 
demonstrates the same distribution, at lower hazard ratios, as the initial analysis with 
baseline risk achieved by 0.5 years. 0.5 years was therefore assessed to be the 
appropriate timeframe to assess correlation between individual surveillance scan 
findings and secondary interventions. 
2.4.4.2 Surveillance Scan Findings Correlation with Flow Related 
And Aneurysm Related Secondary Interventions 
A total of 3092 surveillance visits in 756 individuals were assessed with 57 flow related 
and 49 aneurysm related secondary interventions occurring within 0.5 years. 72 CDUS 
scans had no AXR findings available, the time interval between AXR and CDUS had a 
Median of 0.00 years, Mean 0.06 years and inter-quartile range of 0.00 to 0.00 years. 
Confirming the great majority of CDUS and AXR scan findings combined for analysis 
occurred contemporaneously. 
2.4.4.2.1 Colour Duplex Ultrasound Scan: Deemed Diagnostic 
Achieving diagnostic views and findings was assessed in 3092 CDUS scans, 443 (14%) 
were reported as not fully diagnostic while the remaining 2649 (86%) were deemed to 
be diagnostic. No data was missing due to assessment methodology. A causal 
relationship could be hypothesised for flow related and aneurysm related secondary 
interventions. 
The Kaplan-Meier plot for freedom from flow related secondary intervention, Figure 
20(page 69), demonstrates no significant difference between the survival curves for 
diagnostic and undiagnostic CDUS, p=0.29. Cox proportional hazard model to the six 
months following scan, demonstrated those who had an undiagnostic CDUS had a non-
significantly relationship with secondary interventions, hazard ratio 1.42 (95% CI 0.74 
– 2.72, p=0.29).  
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Figure 20: Freedom from Flow Related Secondary Intervention Following EVAR 
Surveillance Scan, Differentiated by Diagnostic CDUS 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from flow related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if the current CDUS was 
undiagnostic.  It demonstrates no significant difference in secondary interventions between the two 
groups. 
The Kaplan-Meier plot for freedom from aneurysm related secondary intervention, 
Figure 21 (page 70), demonstrates almost exactly matching survival curves of 
diagnostic and undiagnostic CDUS, p=0.67. Cox proportional hazard model to the six 
months following scan, fails to demonstrate any perceivable relationship between 
diagnostic CDUS and freedom from aneurysm related secondary intervention, hazard 
ratio 0.83 (95% CI 0.52 – 2.79, p=0.67).  
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Figure 21: Freedom from aneurysm related Secondary Intervention Following 
EVAR Surveillance Scan, Differentiated by Diagnostic CDUS 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from aneurysm related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if the current CDUS was 
undiagnostic.  It demonstrates no significant difference in secondary interventions between the two 
groups. 
2.4.4.2.2 Colour Duplex Ultrasound Scan: Cumulative Deemed 
Diagnostic 
A cumulative finding of diagnostic scans was calculated based on previous or current 
CDUS. This was measured at the point of 3092 current CDUS scans, 999 (32%) had 1 
or more CDUSs that were not fully diagnostic while the remaining 2093 (68%) were 
deemed to have a full history of diagnostic CDUSs. No data was missing due to 
assessment methodology. A causal relationship could be hypothesised for flow related 
and aneurysm related secondary interventions. 
The Kaplan-Meier plot for freedom from flow related secondary intervention, Figure 22 
(page 71), demonstrates a similar generally linear freedom from secondary intervention 
between the groups that did not demonstrate statistical significance, p=0.20. Cox 
proportional hazard model to the six months following scan, demonstrated those who 
had an undiagnostic CDUS had a non-significant reduced risk of freedom from flow 
related secondary intervention, hazard ratio 0.67 (95% CI 0.37 – 1.22, p=0.20).  
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Figure 22: Freedom from flow related Secondary Intervention Following EVAR 
Surveillance Scan, Differentiated by Cumulative Diagnostic CDUSs 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from flow related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if the current or any 
previous CDUS was undiagnostic.  It demonstrates no significant difference in secondary interventions 
between the two groups. 
The Kaplan-Meier plot for freedom from aneurysm related secondary intervention, 
Figure 23 (page 72), demonstrates a initial and continuing divergence between 
diagnostic and undiagnostic groups. The group with all diagnostic scans were 
statistically significantly more at risk of requiring a secondary intervention, p=0.015. 
Cox proportional hazard model to the six months following scan, demonstrated those 
who had a history of all CDUS being diagnostic had significantly correlation with 
undergoing an aneurysm related secondary intervention, hazard ratio 0.40 (95% CI 0.19 
– 0.85, p=0.02).  
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Figure 23: Freedom from Aneurysm Related Secondary Intervention Following 
EVAR Surveillance Scan, Differentiated by Cumulative Diagnostic CDUS 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from aneurysm related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if the current or any 
previous CDUS was undiagnostic.  It demonstrates if all previous CDUS were diagnostic secondary rates 
were higher than if any were undiagnostic. 
2.4.4.2.3 Colour Duplex Ultrasound Scan: Any Endoleak 
Assessment of presence / absence of any endoleak was assessed in 3092 CDUS scans, 
543 (18%) demonstrated an endoleak while the remaining 2549 (82%) did not. No data 
was missing due to assessment methodology. A causal relationship could only be 
hypothesised to aneurysm related secondary interventions. 
The Kaplan-Meier plot for freedom from aneurysm related secondary intervention, 
Figure 24 (page 73), demonstrates a marked immediate and continually increasing risk 
of aneurysm related secondary intervention following CDUS demonstrating any 
endoleak, virtually no secondary interventions were performed for those who had no 
endoleak detected, p<0.0001. Cox proportional hazard model to the six months 
following scan, demonstrated those who had an endoleak detected on CDUS had a 
significantly higher chance of undergoing an aneurysm related secondary intervention, 
hazard ratio 8.30 (95% CI 4.69 – 14.71, p<0.0001). 
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Figure 24: Freedom from Aneurysm Related Secondary Intervention Following 
EVAR Surveillance Scan, Differentiated by Any Endoleak Detected 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from aneurysm related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if any endoleak was 
detected on the current CDUS.  It demonstrates a significantly higher secondary intervention rate if an 
endoleak was diagnosed. 
2.4.4.2.4 Colour Duplex Ultrasound Scan: Cumulative Any Endoleak 
A cumulative finding of any endoleak was calculated based on presence on any 
previous or the current CDUS. This was measured at the point of 3092 current CDUS 
scans, 1001 (32%) had 1 or more CDUSs that detected an endoleak while the remaining 
2091 (68%) did not have an endoleak detected. No data was missing due to the 
assessment methodology. A causal relationship could be inferred to only aneurysm 
related secondary interventions. 
The Kaplan-Meier plot for freedom from aneurysm related secondary intervention, 
Figure 25 (page 74), demonstrates a marked immediate and continually increasing 
difference in the risk of aneurysm related secondary intervention following CDUS with 
at least 1 endoleak detected on any CDUS, with <1% risk of secondary interventions 
performed for those who had no endoleak detected, p<0.0001. Cox proportional hazard 
model to the six months following scan, demonstrated those who had an endoleak 
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detected on any CDUS had a significantly higher chance of undergoing an aneurysm 
related secondary intervention, hazard ratio 5.38 (95% CI 2.93 – 9.92, p<0.0001). 
Figure 25: Freedom from Aneurysm Related Secondary Intervention Following 
EVAR Surveillance Scan, Differentiated by Cumulative Any Endoleak on CDUS 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from aneurysm related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if any endoleak was 
detected on the current or any previous CDUS.  It demonstrates a significantly higher secondary 
intervention rate if an endoleak was diagnosed on current or previous CDUS. 
2.4.4.2.5 Colour Duplex Ultrasound Scan: Graft Related Endoleak 
Assessment of presence / absence of a graft related endoleak was assessed on 3092 
CDUS scans, 73 (2%) demonstrated an endoleak while the remaining 3019 (98%) did 
not. No data was missing due to assessment methodology. A causal relationship could 
only be hypothesised to aneurysm related secondary interventions. 
The Kaplan-Meier plot for freedom from aneurysm related secondary intervention, 
Figure 26 (page 75), demonstrates immediate, continued and significant increased risk 
of those who had a graft related endoleak detected compared to those who did not, who 
had 0% risk of undergoing an aneurysm related secondary intervention, p<0.0001. Cox 
proportional hazard model to the six months following scan, demonstrated those who 
had a graft related endoleak detected on CDUS had a significantly higher chance of 
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undergoing a aneurysm related secondary intervention, hazard ratio 30.49 (95% CI 
17.31 – 53.71, p<0.0001). 
Figure 26: Freedom from Aneurysm Related Secondary Intervention Following 
EVAR Surveillance Scan, Differentiated by Graft Related Endoleak Detected 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from aneurysm related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if a graft related endoleak 
was detected on the current CDUS.  It demonstrates a significantly higher secondary intervention rate if a 
graft related endoleak was diagnosed on the current CDUS. 
 
2.4.4.2.6 Colour Duplex Ultrasound Scan: Cumulative Graft Related 
Endoleak 
A cumulative finding of graft related endoleak was calculated based on presence on any 
previous or the current CDUS. This was measured at the point of 3092 current CDUS 
scans, 236 (8%) had 1 or more CDUSs that detected a graft related endoleak while the 
remaining 2856 (92%) did not. No data was missing due to the assessment 
methodology. A causal relationship could be hypothesised to only aneurysm related 
secondary interventions. 
The Kaplan-Meier plot for freedom from aneurysm related secondary intervention, 
Figure 27 (page 76), demonstrates early and continued divergence of risk for those with 
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a graft related endoleak compared to those without, p<0.0001. Cox proportional hazard 
model to the six months following scan, demonstrated those who had a graft related 
endoleak detected on any CDUS had a significantly higher chance on undergoing an 
aneurysm related secondary intervention, hazard ratio 10.52 (95% CI 6.04 – 18.32, 
p<0.0001). 
Figure 27: Freedom from aneurysm related Secondary Intervention Following 
EVAR Surveillance Scan, Differentiated by Cumulative Graft Related Endoleak 
on CDUS 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from aneurysm related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if a graft related endoleak 
was detected on the current or any previous CDUS.  It demonstrates a significantly higher secondary 
intervention rate if a graft related endoleak was diagnosed on the current or any previous CDUS. 
2.4.4.2.7 Colour Duplex Ultrasound Scan: Type II Related Endoleak 
Assessment of presence / absence of a type II endoleak was assessed on 3092 CDUS 
scans, 465 (15%) demonstrated a type II endoleak while the remaining 2627 (85%) did 
not. No data was missing due to assessment methodology. A causal relationship could 
only be hypothesised to aneurysm related secondary interventions. 
The Kaplan-Meier plot for freedom from aneurysm related secondary intervention, 
Figure 28 (page 77), demonstrates those with and without Type II endoleaks on current 
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CDUS had no statistical difference, p=0.062, but the curves are potentially diverging at 
the end of the 6 months. Cox proportional hazard model to the six months following 
scan, demonstrated presence or absence of a type II related endoleak detected on CDUS 
did not have a significant correlation with the chance of undergoing a aneurysm related 
secondary intervention, hazard ratio 1.84 (95% CI 0.97 – 3.50, p=0.07).  
Figure 28: Freedom from aneurysm related Secondary Intervention Following 
EVAR Surveillance Scan, Differentiated by Type II Endoleak Detected 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from aneurysm related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if a type II endoleak was 
detected on the current CDUS.  It demonstrates no significant difference in secondary intervention rate if 
a type II endoleak was diagnosed on the current CDUS. 
2.4.4.2.8 Colour Duplex Ultrasound Scan: Cumulative Type II Related 
Endoleak 
A cumulative finding of type II endoleak was calculated based on presence on any 
previous or the current CDUS. This was measured at the point of 3092 current CDUS 
scans, 857 (28%) had 1 or more CDUSs that detected a type II endoleak while the 
remaining 2235 (72%) did not. No data was missing due to the assessment 
methodology. A causal relationship could be hypothesised to only aneurysm related 
secondary interventions. 
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The Kaplan-Meier plot for freedom from aneurysm related secondary intervention, 
Figure 29 (page 78), demonstrates those with or without Type II endoleaks on any 
CDUS had no discernible difference in risk, p=0.075. Cox proportional hazard model to 
the six months following scan, demonstrated that the presence absence of a type II 
endoleak detected on any CDUS had no significantly relationship to undergoing an 
aneurysm related secondary intervention, hazard ratio 1.68 (95% CI 0.95 – 2.95, 
p=0.08). 
Figure 29: Freedom from aneurysm Related Secondary Intervention Following 
EVAR Surveillance Scan, Differentiated by Cumulative Type II Endoleak on 
CDUS 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from aneurysm related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if a type II endoleak was 
detected on the current or any previous CDUS.  It demonstrates no significant difference in secondary 
intervention rate if a type II endoleak was diagnosed on the current or any previous CDUS. 
2.4.4.2.9 Colour Duplex Ultrasound Scan: Limb Abnormality 
Assessment of EVAR limbs is part of the standard operating procedure for a CDUS 
surveillance scan post EVAR. Continuous variables (such as flow velocities) were only 
reported if a gross abnormality was observed by the operator.  As such these continuous 
variables have biases introduced and only the initial binary assessment of any pathology 
(present / absent) is suitable for analysis. 3092 CDUS scans were assessed, 385 (12%) 
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had limb abnormalities detected on that scan while the remaining 2707 (88%) did not. 
No data was missing due to assessment methodology. Causal relationship could only be 
inferred to flow related secondary interventions. 
The Kaplan-Meier plot for freedom from flow related secondary intervention Figure 30 
(page 79), demonstrates approximately linear increasing in risk for those with a limb 
abnormality with almost no risk by 0.5 years for those without, p<0.0001. Cox 
proportional hazard model to the six months following scan, demonstrated those who 
had a limb abnormality detected had significantly less chance of remaining free from 
flow related secondary intervention, hazard ratio 14.935 (95% CI 8.69 – 25.70, 
p<0.0001).  
Figure 30: Freedom from Flow Related Secondary Intervention Following EVAR 
Surveillance Scan, Differentiated by Detection of Limb Abnormality on CDUS 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from flow related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if a limb abnormality was 
detected on the current CDUS.  It demonstrates a significant increase in secondary intervention rate if a 
limb abnormality was diagnosed on the current CDUS. 
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2.4.4.2.10 Colour Duplex Ultrasound Scan: Cumulative Limb Findings 
A cumulative finding of any limb abnormality detected on previous or current CDUS 
was calculated. 3092 CDUS scans were assessed, 635 (21%) had limb abnormalities 
detected on the current or previous scan while the remaining 2457 (79%) did not.  
The Kaplan-Meier plot for freedom from flow related secondary intervention, Figure 31 
(page 80), demonstrates approximately linear increasing in risk for those with a limb 
abnormality with almost no risk by 0.5 years for those without, p<0.0001. Cox 
proportional hazard model to the six months following scan demonstrated those who 
had a limb abnormality detected at any time had significantly less chance of remaining 
free from flow related secondary intervention, hazard ratio 8.71 (95% CI 5.02 – 15.09, 
p<0.0001).  
Figure 31: Freedom from Flow Related Secondary Intervention Following EVAR 
Surveillance Scan, Differentiated by Detection of Limb Abnormality on Current or 
Previous CDUS 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from flow related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if a limb abnormality was 
detected on the current or any previous CDUS.  It demonstrates a significant increase in secondary 
intervention rate if a limb abnormality was diagnosed on the current or any previous CDUS. 
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2.4.4.2.11 Colour Duplex Ultrasound Scan: AAA Size (mm) 
AAA size was assessed as part of 3092 CDUS scans, 125 (4%) did not have a recorded 
size measurement. Median and mean size were 56 and 57mm respectively, inter-quartile 
range was 45 to 65mm. Causal relationship could be hypothesised for both flow related, 
and aneurysm related secondary interventions. 
Cox proportional hazard modelling with a variable for missingness showed that the 
missingness variable was statistically significant for both flow related, and aneurysm 
related secondary interventions, p=0.004 and p=0.0002 respectively. As such the data 
was assessed to be NMAR. 
Cox proportional hazard models on the multiple imputed data to the six months 
following CDUS showed absolute aneurysm size had no significant relationship with 
flow related secondary intervention, hazard ratio 1.01 (95% CI 0.99 – 1.02, p=0.41), per 
1mm size increase. Cox proportional hazard models on the multiple imputed data to the 
six months following CDUS showed absolute aneurysm size had a highly significant 
relationship with aneurysm related secondary intervention, hazard ratio 1.04 (95% CI 
1.03 – 1.05, p<0.0001), per 1mm size increase. 
2.4.4.2.12 Colour Duplex Ultrasound Scan: Maximum Growth 
A variable was calculated to show the absolute growth between the smallest size 
measured on any surveillance scan and the current size. This difference could only be a 
positive size in millimetres or 0 (if current scan were the smallest). If no other 
measurements were available as this was the first surveillance scan in the observational 
period this was also recorded as 0. In total 3092 CDUS scans were assessed, 125 (4%) 
did not have a recorded size measurement. Median and Mean maximum growth were 0 
and 2.2mm respectively. Inter-quartile range was 0 to 2mm. Causal relationship could 
be inferred for both flow related and aneurysm related secondary interventions. 
Cox proportional hazard modelling with a variable for missingness showed that the 
missingness variable was statistically significant for flow related but not aneurysm 
related secondary interventions, p=0.002 and p=0.23 respectively. As such the data was 
assessed to be NMAR for the flow related analysis. 
Cox proportional hazard models on the multiple imputed data to the six months 
following CDUS showed maximum aneurysm growth had significant inverse 
relationship with flow related secondary intervention, hazard ratio 0.81 (95% CI 0.67 – 
0.98, p=0.03), per 1mm size increase. Cox proportional hazard models on available data 
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to the six months following CDUS showed maximum aneurysm growth had significant 
direct relationship with aneurysm related secondary interventions, hazard ratio 1.06 
(95% CI 1.04 – 1.09, p<0.0001), per 1mm size increase. 
2.4.4.2.13 Colour Duplex Ultrasound Scan: Recent Growth 
A variable was calculated to show the recent growth between the size measured on the 
previous surveillance scan and the size on the current scan. The previous scan must 
have been over 3 months ago. 3092 CDUS scans were assessed, 988 (32%) did not have 
the necessary size measurements to calculate a recent growth, the majority of which 
were scan in the first 3 months of surveillance. Median and Mean growth rates were -1 
and -1.4mm respectively. Inter-quartile range was -4 to +2mm. Causal relationship 
could be inferred for both flow related and aneurysm related secondary interventions. 
Cox proportional hazard modelling with a variable for missingness showed that the 
missingness variable was statistically significant for both flow related and aneurysm 
related secondary interventions, p<0.0001 and p=0.004 respectively, as such the data 
was assessed to be NMAR. 
Cox proportional hazard models on the multiple imputation data to the six months 
following CDUS showed recent growth had no significant relationship with flow related 
secondary intervention, hazard ratio 1.03 (95% CI 0.94 – 1.12, p=0.54), per 1mm size 
increase. Cox proportional hazard models on the multiple imputed data to the six 
months following CDUS showed absolute recent growth had a highly significant 
relationship with aneurysm related secondary intervention, hazard ratio 1.11 (95% CI 
1.07 – 1.16, p<0.0001), per 1mm size increase. 
2.4.4.2.14 Colour Duplex Ultrasound Scan: Recent Growth Rate 
A variable was calculated to show the recent growth between the size measured on the 
previous surveillance scan and the current size divided by the time (in years) since the 
previous scan, which must have been over 3 months ago. 3092 CDUS scans were 
assessed, 988 (32%) did not have sufficient size measurements to calculate a recent 
growth, the majority of which were scan in the first 3 months of surveillance. Median 
and mean growth rates were -1.00 and -1.44 mm/year respectively. Inter-quartile range 
was -4.00 to +2.00 mm/year. Causal relationships could be hypothesised for both flow 
related and aneurysm related secondary interventions. 
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Cox proportional hazard modelling with a variable for missingness showed that the 
missingness variable was statistically significant in assessment of flow related and 
aneurysm related secondary interventions, p<0.0001 and p=0.004 respectively. As such 
these data were assessed to be NMAR 
Cox proportional hazard models on the multiple imputation data to the six months 
following CDUS showed recent growth rate had no significant relationship with flow 
related secondary intervention, hazard ratio 1.01 (95% CI 0.95 – 1.07, p=0.82), per 
1mm/year size increase. Cox proportional hazard models on the multiple imputed data 
to the six months following CDUS showed absolute recent growth had a highly 
significant relationship with aneurysm related secondary intervention, hazard ratio 1.06 
(95% CI 1.04 – 1.09, p<0.0001), per 1mm/year size increase. 
2.4.4.2.15 Plain Abdominal Radiograph: Effacement Finding 
A True / False finding of effacement was created for each AXR. All AXR findings were 
assessed in relation to the most recent AXR for each CDUS performed.  3092 CDUS 
scans were assessed, 76 (2%) had had no AXR findings available. 70 (2%) 
demonstrated findings indicative of effacement, 2946 (95%) did not. Causal inference 
could only be hypothesised for aneurysm related secondary interventions. 
The Kaplan-Meier plot for freedom from aneurysm related secondary intervention, 
Figure 32 (page 84), demonstrates an initially similar risk in effacement and no 
effacement group but at 0.2 years those with effacement have an increasing risk of 
secondary intervention, p<0.0001. 
Those with missing data had a similar rate (9%) of aneurysm related secondary 
intervention as those with effacement (9%) but much higher than those with no 
effacement (1%). These data were therefore assessed as being NMAR. Cox proportional 
hazard model, on multiple imputed data, to the six months following scan, demonstrated 
those who had effacement detected had significantly less chance of remaining free from 
aneurysm related secondary intervention, hazard ratio 7.03 (95% CI 3.00 – 16.46, 
p<0.0001).  
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Figure 32: Freedom from Aneurysm Related Secondary Intervention Following 
EVAR Surveillance Scan, Differentiated by Detection of Effacement on AXR 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from aneurysm related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if effacement was 
detected on the most recent AXR.  It demonstrates a significant increase in secondary intervention rate if 
effacement was detected on the most recent AXR. 
2.4.4.2.16 Plain Abdominal Radiograph: Cumulative Effacement Finding 
A True / False finding of effacement on current or any previous AXR was created for 
each CDUS visit. 3092 CDUS scans were assessed, 76 (2%) had had no AXR findings 
available. 225 (7%) demonstrated effacement currently or in the past, 2791 (90%) did 
not. Causal inference could only be hypothesised for aneurysm related secondary 
interventions. 
The Kaplan-Meier plot for freedom from aneurysm related secondary intervention, 
Figure 33 (page 85), demonstrates an initially similar risk in effacement and no 
effacement on any AXR groups, but at 0.15 years those with effacement have an 
increasing risk of secondary intervention, p=0.02. 
Those with missing data had a much higher rate (9%) of aneurysm related secondary 
intervention than those with effacement (3%) and no cumulative effacement (1%). 
These data were therefore assessed as being NMAR. Cox proportional hazard model, on 
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multiple imputed data, to the six months following scan, demonstrated those who had 
effacement detected on any AXR had significantly less chance of remaining free from 
aneurysm related secondary intervention, hazard ratio 2.54 (95% CI 1.14 – 5.64, 
p=0.02).  
Figure 33: Freedom from Aneurysm Related Secondary Intervention Following 
EVAR Surveillance Scan, Differentiated by Detection of Effacement on any AXR 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from aneurysm related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if effacement was 
detected on the most recent or any previous AXR.  It demonstrates a significant increase in secondary 
intervention rate if effacement was detected on the most recent or any previous AXR. 
2.4.4.2.17 Plain Abdominal Radiograph: Structural Failure Finding 
A True / False finding of structural failure was created for each AXR. All AXR findings 
were assess in relation to the most recent AXR for each CDUS performed. 3092 CDUS 
scans were assessed, 76 (2%) had had no AXR findings available. 75 (2%) 
demonstrated structural failure, 2941 (95%) did not. Causal inference could only be 
hypothesised for aneurysm related secondary interventions.  
The Kaplan-Meier plot for freedom from aneurysm related secondary interventions, 
Figure 34 (page 86), shows slow but consistent increase in risk for those with structural 
failure detected, compared to a relatively stable risk for those without structural failure, 
p=0.0032. 
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Those with missing data had a much higher rate (9%) of secondary intervention than 
those with structural failure (5%) and no structural failure (1%) respectively. These data 
were therefore assessed as being NMAR. Cox proportional hazard model, on multiple 
imputed data, to the six months following scan, demonstrated those who had structural 
failure detected had significantly less chance of remaining free from aneurysm related 
secondary intervention, hazard ratio 4.16 (95% CI 1.51 – 11.48, p=0.006).  
Figure 34: Freedom from Aneurysm Related Secondary Intervention Following 
EVAR Surveillance Scan, Differentiated by Detection of Structural Failure on 
AXR 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from aneurysm related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if a structural failure was 
detected on the most recent AXR.  It demonstrates a significant increase in secondary intervention rate if 
a structural failure was detected on the most recent AXR. 
2.4.4.2.18 Plain Abdominal Radiograph: Cumulative Structural Failure 
Finding 
A True / False finding of a structural failure on current or any previous AXR was 
created for each CDUS visit. 3092 CDUS scans were assessed, 76 (2%) had had no 
AXR findings available. 196 (6%) demonstrated effacement currently or in the past, 
2820 (91%) did not. Causal inference could only be hypothesised for aneurysm related 
secondary interventions. 
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The Kaplan-Meier plot for freedom from aneurysm related secondary interventions, 
Figure 35 (page 87), shows no discernible difference between the groups, p=0.42.  
Those with missing data had a much higher rate of aneurysm related secondary 
intervention (9%) than those with cumulative findings of structural failure (2%) and no 
cumulative finding of structural failure (1%). These data were therefore assessed as 
being NMAR. Cox proportional hazard model, on multiple imputed data, to the six 
months following scan, demonstrated that a structural failure detected on any AXR had 
no relationship to remaining free from aneurysm related secondary intervention, hazard 
ratio 1.53 (95% CI 0.55– 4.21, p=0.42).  
Figure 35: Freedom from Aneurysm Related Secondary Intervention Following 
EVAR Surveillance Scan, Differentiated by Detection of Structural Failure on any 
AXR 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from aneurysm related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if a structural failure was 
detected on the most recent or any previous AXR.  It demonstrates no significant difference in secondary 
intervention rates if a structural failure was detected on the most recent or any previous AXR. 
2.4.4.2.19 Plain Abdominal Radiograph: Limb Abnormality Findings 
AXR variables were assessed in relation to the corresponding 3092 CDUS scans, 
contemporary or previous AXRs were available for all but 76 of these scans. Therefore, 
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no data on limb abnormalities on AXR was available for 2% of CDUS surveillance 
visits under investigation. 105 (3%) of visits had limb abnormalities detected on AXR 
while the remaining 2911 (94%) did not. Causal inference could only be hypothesised 
for flow related secondary interventions. 
The Kaplan-Meier plot for freedom from flow related secondary interventions, Figure 
36 (page 88), shows slow but consistent increase in risk for those with limb 
abnormality, compared to a relatively stable risk for those without limb abnormality, 
p<0.0001.  
Those with missing data had a 5% rate of flow related secondary intervention compared 
to those with findings of limb abnormality (7%) and no limb abnormality (2%). These 
data were therefore assessed as being NMAR. Cox proportional hazard models on the 
multiple imputed data to the six months following scan demonstrated those who had a 
limb abnormality detected had significantly less chance of remaining free from flow 
related secondary intervention, hazard ratio 4.32 (95% CI 1.98 – 9.46, p=0.0003).  
Figure 36: Freedom from Flow Related Secondary Intervention Following EVAR 
Surveillance Scan, Differentiated by Detection of Limb Abnormality on AXR 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from flow related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if limb kink was detected 
on the most recent AXR.  It demonstrates a significant increase in secondary intervention rates if a limb 
kink was detected on the most recent AXR. 
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2.4.4.2.20 Plain Abdominal Radiograph: Cumulative Limb Abnormality 
Findings 
A cumulative finding of any limb abnormality detected on previous or current AXR was 
calculated. This variable was assessed in relation to the corresponding 3092 CDUS 
scans, responses were available for all but 76 of these scans. Therefore, no data on 
cumulative limb abnormalities on AXR was available for 2% of CDUS surveillance 
visits under investigation. 275(9%) of visits had limb abnormalities detected on any 
AXR while the remaining 2741 (89%%) did not. Causal inference could only be 
hypothesised for flow related secondary interventions. 
The Kaplan-Meier plot for freedom from flow related secondary interventions, Figure 
37 (page 89), shows slow but consistent increase in risk for those with limb abnormality 
on any AXR, compared to an initially increasing risk which then stabilises out at 
approximately 0.2 years for those without limb abnormality, p=0.12.  
Figure 37: Freedom from Flow Related Secondary Intervention Following EVAR 
Surveillance Scan, Differentiated by Detection of Limb Abnormality on Current or 
Previous AXR 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from flow related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if limb kink was detected 
on the most recent or any previous AXR.  It demonstrates no significant difference in secondary 
intervention rates if a limb kink was detected on the most recent or any previous AXR.  
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Those with missing data had a 5% rate of flow related secondary intervention compared 
to those with findings of limb abnormality and no limb abnormality, 3% and 2% 
respectively. These data were therefore assessed as being NMAR. Cox proportional 
hazard models on the multiple imputed data to the six months following scan showed a 
limb abnormality detected on the current or any previous AXR had no significant 
relationship with flow related secondary intervention, hazard ratio 1.80 (95% CI 0.86 – 
3.77, p=0.13). 
2.4.4.2.21 Plain Abdominal Radiograph: Migration Findings 
AXR variables were assessed in relation to the corresponding 3092 CDUS scans, 
contemporary or previous AXRs were available for all but 76 of these scans. Therefore, 
no data on limb abnormalities on AXR was available for 2% of CDUS surveillance 
visits under investigation. 2839 (92%) had no migration detected while 177 (6%) did 
have migration identified. Migration was subcategorised: barb engagement (63), minor 
migration (54), definite migration (51) and undefined (9). Causal inference could only 
be hypothesised for aneurysm related secondary interventions. 
Kaplan-Meier plot, Figure 38 (page 91), comparing the various findings demonstrated 
there was only a significant difference between definite migration and the other 
findings. No other individual or group of findings demonstrated significance in freedom 
from secondary intervention. As such all other findings were grouped together to allow 
the calculation of hazard ratios and a cumulative finding to be investigated.  
The Kaplan-Meier plot for freedom from aneurysm related secondary interventions, 
Figure 39 (page 92), shows steady but consistent increase in risk for those with definite 
migration on AXR, compared to little to no risk for those without definite migration, 
p=0.0053.  
Cox proportional hazard models on, multiple imputed, data to the six months following 
AXR show definite migration on a AXR has a significant relationship with aneurysm 
related secondary intervention, hazard ratio 4.57 (95% CI 1.44 – 14.52, p=0.01). 
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Figure 38: Freedom from aneurysm Related Secondary Intervention Following 
EVAR Surveillance Scan, Differentiated by Categories of Migration Detected on 
Most Recent AXR 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from aneurysm related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by categories of migration 
detected on the most recent AXR.  It demonstrates a no significant increase in secondary intervention 
rates between all categories of migration on the most recent AXR. There is a progressive increase in 
secondary intervention rates demonstrated the more significant the migration detected. 
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Figure 39: Freedom from Aneurysm Related Secondary Intervention Following 
EVAR Surveillance Scan, Differentiated by Definite Migration Detected on Most 
Recent AXR 
 
Kaplan-Meier plot, with log rank test p-value, demonstrating freedom from aneurysm related secondary 
intervention following EVAR surveillance CDUS scan. Plot is differentiated by if definite migration was 
detected on the most recent AXR.  It demonstrates a significant increase in secondary intervention rates if 
definite migration was detected on the most recent AXR. 
2.4.4.3 Summary of Statistical Importance of CDUS and AXR 
Findings  
Table 16 (page 92), summarises all the investigated findings and their univariate 
association with flow related secondary interventions. 
Table 17 (page 94) summarises all the investigated findings that had a perceived causal 
relationship with aneurysm related secondary interventions is displayed below. 
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Table 16: CDUS and AXR findings and Related Hazard Ratios to Subsequent 
Flow Related Secondary Intervention in the Subsequent 6 Months 
 
  
Finding 
Hazard Ratio  
(95% Confidence 
Interval) 
Statistical 
Significance 
p Value 
CDUS Findings 
Scan Diagnostic (True) 1.42 (0.74 – 2.72) 0.29 
All Scans Diagnostic (True) 0.67 (0.37 – 1.22) 0.20 
Limb Abnormality (True) 14.935 (8.69 – 25.70) <0.0001 
Limb Abnormality on current or Previous Scan 
(True) 
8.71 (5.02 – 15.09) <0.0001 
AAA diameter (/mm) 1.01 (0.99 – 1.02) 0.41 
AAA Growth compared to largest previous 
measurement (/mm) 
0.81 (0.67 – 0.98) 0.03 
AAA size change since last scan (/mm) 1.03 (0.94 – 1.12) 0.54 
AAA size change rate since last scan 
(/mm/year) 
1.01 (0.95 – 1.07) 0.82 
AXR Findings 
Limb Abnormality (True) 4.32 (1.98 – 9.46) 0.0003 
Limb Abnormality on current or Previous Scan 
(True) 
1.80 (0.86 – 3.77) 0.13 
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Table 17: CDUS and AXR findings and related Hazard Ratios to subsequent 
Aneurysm Related secondary intervention in the subsequent 6 months 
 
Finding Hazard Ratio (95% 
Confidence Interval) 
p Value 
CDUS Findings 
Scan Diagnostic (True) 0.83 (0.52 – 2.79) 0.67 
All Scans Diagnostic (True) 0.40 (0.19 – 0.85) 0.02 
Any Endoleak (True) 8.30 (4.69 – 14.71) <0.0001 
Any Endoleak on current or Previous Scan (True) 5.38 (2.93 – 9.92) <0.0001 
Graft Related Endoeak (True) 30.49 (17.31 – 53.71) <0.0001 
Graft Related Endoeak on current or Previous Scan 
(True) 
10.52 (6.04 – 18.32) <0.0001 
Type II Endoeak (True) 1.84 (0.97 – 3.50) 0.07 
Type II Endoeak on current or Previous Scan (True) 1.68 (0.95 – 2.95) 0.08 
AAA diatmeter (/mm) 1.04 (1.03 – 1.05) <0.0001 
AAA Growth compared to largest previous 
measurement (/mm) 
1.06 (1.04 – 1.09) <0.0001 
AAA size change since last scan (/mm) 1.11 (1.07 – 1.16) <0.0001 
AAA size change rate since last scan (/mm/year) 1.06 (1.04 – 1.09) <0.0001 
AXR Findings 
Effacement (True) 7.03 (3.00 – 16.46) <0.0001 
Effacement on current or Previous Scan (True) 2.54 (1.14 – 5.64) 0.02 
Structural Failure (True) 4.16 (1.51 – 11.48) 0.006 
Structural Failure on current or Previous Scan (True) 1.53 (0.55 – 4.21) 0.42 
Definite Migration (True) 4.57 (1.44 – 14.52) 0.01 
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2.4.4.4 Assessment of Confounding Between Surveillance Findings in 
Association to Secondary Interventions 
Cox proportional hazard modelling using backwards stepwise exclusion of variables 
was undertaken to ascertain if the number of variables measured could be reduced 
without materially impacting the association with flow related secondary interventions. 
The initial full model which includes all variables, Table 18 (page 95), was assessed for 
association with flow related secondary interventions and had an AIC of 741. 
Table 18 : Variable Hazard Ratios to subsequent Flow Related secondary 
intervention within 6 months from a Full multivariate Cox PH model 
Stepwise removal of variables from the model is shown in the analysis R code 
(Appendix 2, page 190), but in short:  
Variable Hazard Ratio within Model 
(95% Confidence Interval) 
p Value 
CDUS Findings 
Scan Diagnostic (True) 1.22 (0.92 – 12.64) 0.07 
All Scans Diagnostic (True) 0.33 (0.10 – 1.09) 0.08 
Limb Abnormality (True) 17.25 (2.38 – 124.95) 0.005 
Limb Abnormality on current or Previous 
Scan (True) 
0.81 (0.11 – 6.02) 0.84 
AAA diameter (/mm) 1.01 (1.00 – 1.03) 0.13 
AAA Growth compared to largest previous 
measurement (/mm) 
0.80 (0.64 – 0.99) 0.05 
AAA size change since last scan (/mm) 1.10 (0.89 – 1.36) 0.38 
AAA size change rate since last scan 
(/mm/year) 
0.97 (0.85 – 1.12) 0.71 
AXR Findings 
Limb Abnormality (True) 6.48 (0.78 – 53.75) 0.09 
Limb Abnormality on current or Previous 
Scan (True) 
0.37 (0.05 – 2.26) 0.37 
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“Limb Abnormality on current or Previous Scan (True)” was removed -AIC 738, 
“All Scans Diagnostic (True)” was removed -AIC 741, then  
“Limb Abnormality on current or Previous AXR (True)” was removed - AIC 741, then 
“Scan Diagnostic (True)” was removed -AIC 740, and finally 
“AAA size (mm)” was removed -AIC 742  
All further changes failed to maintain or improve AIC substantially. Table 19 (page 96), 
demonstrates the variables in the simplified model had an AIC of 742. Comparison of 
the full and simplified models numeric predictions are displayed in Figure 40, page 97. 
There was a very close linear relationship throughout the range of values of predictions 
between full and simplified model. Comparison of the models linear relationship 
demonstrates near perfect linearity coefficient of 0.93 (standard error 0.01). The 
relationship is offset by -0.51, meaning the simplified model, generally, predicts slightly 
lower risks but could be easily adjusted. The ROC and AUC value for both full and 
simplified models demonstrates both have an AUC of 0.95 and essentially identical 
discriminatory properties, Figure 41 (page 98). 
Table 19: Variable Hazard Ratios to Subsequent Flow Related Secondary 
Intervention Within 6 Months From a Simplified Multivariate Cox PH Model 
 
  
Vaiable Hazard Ratio within Model  
(95% Confidence Interval) 
p Value 
CDUS Findings 
Limb Abnormality (True) 13.15 (7.44 – 23.25) <0.0001 
AAA Growth compared to largest 
previous measurement (/mm) 
0.79 (0.63 – 0.99) 0.04 
AAA size change since last scan (/mm) 1.07 (0.95 – 1.20) 0.25 
Limb Kink on AXR (True) 2.89 (1.28 – 6.56) 0.01 
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Figure 40: Numeric predictions of flow related secondary interventions from a Full 
and Simplified Cox Proportional Hazard Model of surveillance variables  
 
Scatter plot demonstrating the close linear relationship between the numerical values produced by two 
models, one using a full set of surveillance scan variables and a the other a simplified/reduced set of those 
variables to predict flow related secondary interventions. 
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Figure 41: ROC (with AUC) from a Full and Simplified Cox Proportional Hazard 
Model of surveillance variables to predict secondary intervention in 6 months 
 
Receiver Operator Characteristics plots, with Area under Curve (AUC) values for two models’ abilities to 
predict flow related secondary interventions.  One model is created using a full set of surveillance scan 
variables and the other a simplified/reduced set of those variables.  They demonstrate almost identical 
characteristics and AUC. 
In a similar manner Cox proportional hazard modelling using backwards stepwise 
exclusion of variables was undertaken to see if the number of variables measured could 
be reduced without materially impacting the association with aneurysm related 
secondary interventions. The initial full model of all variables investigated for 
association with aneurysm related secondary interventions, Table 20 (page 99), had an 
AIC of 515. 
Stepwise removal of variables from the full model is shown in the analysis R code 
(appendix x), but in short:  
“Scan Diagnostic (True)” was removed -AIC 513, then  
AXR “Structural Failure (True)” was remove -AIC 515, then  
“AAA size (mm)” was removed – AIC 517 and finally  
AXR “ Definite Migration (True)” was removed – AIC 516.  
All further changes failed to maintain or improve AIC. Table 21 (page 100) 
demonstrates the variables in the simplified model with the AIC of 516. Comparison of 
the full and simplified models numeric predictions are displayed in Figure 42 (page 
101). This demonstrates a very close linear relationship throughout the range of values 
of predictions. Comparison of the models linear relationship demonstrates a very good 
linearity coefficient of 0.83 (standard error 0.01). The relationship is offset by-0.81, 
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meaning the simplified model, generally, predicts slightly lower risks. Figure 43, page 
101, demonstrates the ROC and AUC value for both full and simplified models, they 
have an AUC of 0.92 and 0.91 respectively meaning they have almost identical 
discriminatory properties. 
Table 20: Variable Hazard Ratios to Subsequent aneurysm Related Secondary 
Intervention Within 6 Months From The Full Multivariate Cox PH Model 
 
  
Variable Hazard Ratio within Model 
(95% Confidence Interval) 
p Value 
CDUS Findings 
Scan Diagnostic (True) 1.03 (0.38 – 2.81) 0.95 
Any Endoleak (True) - - 
Graft Related Endoleak (True) 19.90 (6.14 – 64.50) <0.0001 
Type II Endoleak (True) 3.22 (1.35 – 7.73) 0.01 
AAA (/mm) 1.02 (0.99 - 1.05) 0.14 
AAA Growth compared to largest previous 
measurement (/mm) 
1.02 (0.92 – 1.12) 0.75 
AAA size change since last scan (/mm) 1.05 (0.82 – 1.34) 0.70 
AAA size change rate since last scan 
(/mm/year) 
1.00 (0.87 – 1.13) 0.91 
AXR Findings 
Effacement (True) 8.49 (3.23 – 22.31) <0.0001 
Structural Failure (True) 3.30 (1.04 – 10.48) 0.05 
Definite Migration (True) 2.22 (0.59 – 8.38) 0.25 
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Table 21: Variable Hazard Ratios to Subsequent Aneurysm Related Secondary 
Intervention Within 6 Months From a Simplified Multivariate Cox PH Model 
 
  
Variable Hazard Ratio within Model  
(95% Confidence Interval) 
p Value 
CDUS Findings 
Graft Related Endoeak (True) 23.94 (8.04 – 71.28) <0.0001 
Type II Endoeak (True) 3.65 (1.61 – 8.26) 0.002 
AAA Growth compared to largest 
previous measurement (/mm) 
1.04 (0.95 – 1.14) 0.42 
AAA size change since last scan (/mm) 1.04 (0.83 – 1.33) 0.71 
AAA size change rate since last scan 
(/mm/year) 
0.99 (0.88 – 1.13) 0.94 
AXR Findings 
Effacement (True) 9.85 (3.82 – 25.38) <0.0001 
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Figure 42: Numeric predictions of aneurysm related secondary interventions from 
a Full and Simplified Cox Proportional Hazard Model of surveillance variables 
 
Scatter plot demonstrating the close linear relationship between the numerical values produced by two 
models, one using a full set of surveillance scan variables and a the other a simplified/reduced set of those 
variables to predict aneurysm related secondary interventions. 
Figure 43: ROC (with AUC) from a Full and Simplified Cox Proportional Hazard 
Model of Surveillance Variables to Predict Aneurysm Related Secondary 
intervention within 6 months 
 
Receiver Operator Characteristics plots, with Area under Curve (AUC) values for two models’ abilities to 
predict aneurysm related secondary interventions.  One model is created using a full set of surveillance 
scan variables and the other a simplified/reduced set of those variables.  They demonstrate almost 
identical characteristics and AUC. 
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2.4.5 Predictive Model 
2.4.5.1 Piecewise Exponential Model Creation 
3092 CDUS scans, with related AXR findings, were used in the creation of the PEM. In 
total 242 of these scans were followed by secondary interventions in the available 
follow-up.  These data were not censored at a particular time point therefore the full 
follow-up available was used. Follow-up had a mean duration of 2.34 years, median 
1.99 (IQR 0.91 – 3.46). 
The PEM timeframes were divided as described in the methods, Section 2.3.4.5.2 (page 
50). That division was checked, Table 22 (page 102), to ensure a sufficient number of 
events occurred and patients at risk within each time frame to allow modelling and 
validation. 
Table 22: Timeframes in Piecewise Exponential Model to Predicit Secondary 
Intervention following EVAR Surveillance Scan 
Following the described stepwise process, the following variables were selected into the 
model, in addition to the time intervals: 
• Pre-operative AAA diameter (mm) 
• AAA diameter on current CDUS scan (mm) 
• Patient age at time of EVAR (years) 
Time Interval following EVAR 
(Years) 
Number at Risk Number of Events (%) 
0 – 0.5 650 97 (14.9) 
0.5 – 1 214 10 (4.7) 
1 – 2 466 37 (7.9) 
2 – 3 441 29 (6.6) 
3 – 4 355 20 (5.6) 
4 – 5 245 14 (5.7) 
5 – 7.5 390 11 (2.8) 
7.5 – 10 168 9 (5.4) 
10 – 20  155 12 (7.7) 
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• Presence of any endoleak on CDUS (True / False) 
2.4.5.2 Model Internal Validation 
Internal bootstrapping validation as described in the methods, section 2.3.4.5.3 (page 
50), returned the following coefficients for the variables in PEM. 
Table 23: Variable Coefficients with produced PEM to predict secondary 
intervention following EVAR surveillance scan. 
 
The area under the curve (AUC) of the predictions the internal validation created had a 
mean and median value of 0.72, and an inter quartile range of 0.68 – 0.76 demonstrating 
both excellent and reproducible discrimination for this predictive model. The histogram 
and density curve of AUC results are displayed, Figure 44 (page 104).  
Variable Estimate (Standard Error) p Value 
Time of Surveillance Scan following EVAR– Only one selected 
0 – 0.5 Years -2.55 (0.130) <0.0001 
0.5 – 1 Years -3.97 (0.322) <0.0001 
1 – 2 Years -3.12 (0.178) <0.0001 
2 – 3 Years -3.27 (0.201) <0.0001 
3 – 4 Years -3.43 (0.237) <0.0001 
4 – 5 Years -3.43 (0.277) <0.0001 
5 – 7.5 Years -4.55 (0.336) <0.0001 
7.5 – 10 Years -4.34 (0.344) <0.0001 
10 – 20 Years -5.61 (0.307) <0.0001 
Patient / CDUS Variables 
Preoperative AAA Size (mm) -0.03 (0.005) <0.0001 
CDUS AAA Size (mm) 0.03 (0.004) <0.0001 
Patient Age at Operation (Years) -0.05 (0.010) <0.0001 
CDUS Any Endoleak (True) 0.69 (0.147) <0.0001 
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Figure 44: Histogram and Density Plot of AUC Results from Internal Validation of 
a Predictive Model of Risk of Secondary Intervention Following EVAR 
Surveillance Scan 
 
Histogram demonstrating a normal distribution of Area Under Curve (AUC) values from bootstrapping 
internal validation of a Piecewise Exponential Model to predict risk of secondary intervention. 
Distribution of the AUC values is cantered on 0.72. 
Assessment of the individual bootstrap models against their 20% validation data 
demonstrated a median Hosmer-Lemeshow test p value of 0.51. The pattern of 
distribution of the p values was reviewed, Figure 45 (page 105). This shows less 
(~1.7%) than the permissible 5% of validation models fell within the <0.05 range. The 
validation models were therefore demonstrated satisfactory calibration (non-significant 
Hosmer-Lemeshow test) for its predictions. 
The values selected for the variables in the low, mean and high risk assessment patients 
are displayed in Table 24 (page 106). The mean interval to next surveillance visit across 
the surveillance programme was 0.88 years. The cumulative risk of secondary 
intervention in that time following surveillance scan in these data was 4.1%. 
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The risk predictions of these pilot patients shows a generally linear increasing risk, with 
a dramatically faster incline for the ‘High risk’ patient compared to Mean and Low risk 
patients. 
Figure 45: Histogram and distribution curve of p Value of Hosmer–Lemeshow 
Test in a boot strap validation of predictive score following EVAR surveillance 
 
Histogram demonstrating the distribution of p values from Hosmer-Lemeshow tests of bootstrapping 
internal validation of a Piecewise Exponential Model to predict risk of secondary intervention. The 
distribution below 0.05% is below 5% demonstrating adequate calibration. 
The risk predictions of these pilot patients shows a generally linear increasing risk, with 
a dramatically faster incline for the ‘High risk’ patient compared to Mean and Low risk 
patients, Figure 46 (page 106). It demonstrates the low risk patient has a gradual 
increase in cumulative risk, reaching 4.1% chance of requiring a secondary intervention 
at 2 years following their surveillance scan. In turn, the mean risk patient has a more 
modest incline in risk, that is not as linear, reaching a cumulative 4.1% risk at 
approximately 0.75 years. The high risk patient has a rapid rise in risk, that is also non-
linear, reaching 4.1% before even 0.25 years have elapsed.  
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Table 24: Patient Variables for Low, Mean and High Risk Assessment Patients 
 
Figure 46: Predicted risk of secondary intervention using PEM model for Low, 
Mean and High Risk Assessment Patients 
 
Future cumulative risk predictions using a Piecewise Exponential Model based on patients with low risk 
characteristics, mean risk characteristics and high risk characteristics. Demonstrates most of the 
cumulative risk is accumulated in the high risk individual. 
2.5 Discussion 
This observational study uses a cross-section, in time, of a complete EVAR surveillance 
programme to answer a number of deficits in the published literature. It is the first 
Patient Variable Low Risk Mean Risk High Risk 
Time After EVAR of Surveillance Scan 
(Years) 
4.34 3.16 0.11 
Preoperative AAA Size (mm) 70 65 57 
CDUS AAA Size (mm) 45 57 65 
Patient Age at Operation (Years) 80 75 70 
CDUS Any Endoleak False False True 
Chapter 2: Analysis of a Colour Duplex Ultrasound Scan and Plain Abdominal X-ray Surveillance Regimen 
Iain Nicholas Roy - August 2020   107 
substantial cohort to be examined in this manner in the field of post-operative EVAR 
surveillance.  
It is the first study to suggest that rationalisation of EVAR surveillance can be 
performed on an individual basis at multiple time points throughout the post-operative 
period. It is also the first to address the area of which measurements and findings within 
each surveillance visit are likely to be pertinent to triggering a secondary intervention, 
the purpose of the surveillance visit.  
2.5.1 Methodology 
A cross sectional study (not prospective or retrospective cohorts) has several advantages 
over previously published studies. Regarding post-operative course of patients 
undergoing EVAR, the cross-sectional nature means that secondary interventions and 
surveillance compliance can be investigated for all time points following EVAR without 
having to follow a single cohort for the whole time frame, therefore offering 
observations that would otherwise take decades to obtain prospectively and require 
unrealistically large cohorts to compensate for patient attrition. These data could be 
collected retrospectively but this would then require looking back over a similar time 
frame and the problems of data loss, missing data and inaccuracies would be difficult to 
overcome. 
Regarding surveillance scans, analysis of a cross-section of all scans performed in a 
surveillance programme means that these analyses naturally give appropriate weight to 
the volume of patients at various time points following EVAR. This particularly 
addresses the deficit of analysis in patients who are later in the post-operative EVAR 
surveillance course. 
Limitations of the cross-sectional nature in this study include the inability to define 
what data is/was collected as would be possible in a prospective study. This places 
limitations on particularly multivariate analysis looking for independent associations, 
that might lead to causation research, as the data collected has not be collected for this 
purpose. It also means we were collecting information on patients with EVAR stent-
grafts that are no longer available for insertion which can raise questions of applicability 
to future practice but equally does make it applicable to the current patients in 
surveillance. 
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2.5.1.1 Lives EVAR Surveillance Protocol and Database 
This study would not have been possible without the foresight and organisational 
culture instigated by those clinicians within LiVES that set up the database and instilled 
the clinical importance of rigorous surveillance post EVAR. From the outset of the 
techniques use in Liverpool there were robust systems in place to ensure patients 
continued in surveillance until it was deemed that they were unfit for secondary 
intervention. The system was designed in such a manner that it was not possible for a 
patient to be accidently missed or forgotten and would require deliberate discharge from 
the surveillance programme.  
The robust system underlying the protocol and database are what underpins such 
excellent compliance and records of the EVAR surveillance program. This is evidenced 
by the fact that of the 10 UK centres that participated in the EVAR-screen study,88 
Liverpool achieved the best compliance (88%) of all the centres. The clinical 
importance and scientific rigor placed on surveillance is also demonstrated by the 
critical evaluation undertaken when transitioning from CTA based surveillance to 
CDUS first surveillance.78 The Liverpool – Perth protocol to standardise AXR 
acquisition also demonstrated the desire for standardised high quality practice.74 
Data stipulated to be collected in the Surveillance protocol was remarkably complete 
and accurate within the database. Given the database’s size, very few errors were 
discovered or corrected when corroborating the database to other primary sources of 
data. It is worthy of note that not a single patient who had undergone EVAR could be 
identified who had not been entered into the database. There was a relatively small 
dataset of pre-operative and peri-operative variables available within the LiVES 
database, this likely relates to the fact its was created close to the introduction of the 
technique to clinical practice and many variables now known to relate to outcomes were 
still to be discovered.  While this data could have been retrospectively collected for 
contemporary patients, it was not available for historical patients who remained in 
surveillance several years after EVAR.  The selective introduction of the available data 
(which would not have been corroborated for a second source) would potentially have 
introduced bias. 
Secondary interventions were recorded into the database in an ad-hoc manner. They did 
not form part of the original dataset but had been added by the surveillance 
administrators to allow assessment of why an individual may be out of sync with the 
expected surveillance regimen. As such these data were significantly added to by the 
Chapter 2: Analysis of a Colour Duplex Ultrasound Scan and Plain Abdominal X-ray Surveillance Regimen 
Iain Nicholas Roy - August 2020   109 
process of data checking and significantly more detail obtained about those that had 
occurred. The data around symptoms may be particularly prone to poor quality given 
that it was retrieved retrospectively from what was recorded in the clinical and imaging 
notes. The thorough search of multiple data sources has led to a comprehensive list of 
those interventions performed within the service but does leave open the possibility of 
interventions having been performed in other centres and not reported back to LiVES. A 
small quantity of such interventions did occur and were recorded in clinic letters or 
subsequent imaging reports. Any missed secondary interventions may mean the 
incidence of secondary interventions is under reported or may influence the accuracy 
(for better or worse) of the scan findings or predictive model. 
2.5.1.2 Surveillance Scans 
Both CDUS and AXR were reported in a structured manner. In CDUS this was due to a 
standard operative procedure to their acquisition. In AXR it was due to a standard 
acquisition, relatively limited range of findings and the fact that the vast majority were 
reported by a single individual. 
The breaking down of these reports to their constituent findings was undertaken in a 
blinded manner (blinded to patient details and outcomes) so being as unbiased as 
possible. As this was all performed by a single individual, the possibility of introduction 
of bias should be acknowledged but given the absolute nature of most findings being 
recorded, this system was felt to be proportional. 
The level of consistency of CTA reporting was disappointing and would have required 
review of the core images, which was not covered by the ethical or service evaluation 
approvals. As such their role in this study was limited to dates of scan for compliance 
analysis and review of report for details of impending or previous secondary 
interventions. 
2.5.2 Analysis 
2.5.2.1 Incidence of Secondary Interventions 
Incidence requires the number of events (secondary interventions) as well as the number 
of patients at risk to be defined. Secondary interventions were defined as detailed above. 
The number of patients at risk required calculation. The start point for an individual 
patient being at risk is unlikely to be contentious: it is either the start of the period being 
assessed or the time the patient started EVAR surveillance, if this was part way through 
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the period of data capture (because they had an EVAR or re-located to the region and 
joined the surveillance programme). The end point has the potential to be contentious: 
those patients who died, re-located away and were still in the surveillance programme at 
the end of the period being assessed have unambiguous end points. The small number of 
patients actively discharged from any further surveillance are more difficult. The 
majority of these were patients deemed to be physiologically unfit for a secondary 
intervention, we took the view that they were not at risk as they would never have had a 
secondary intervention, as it was felt they would not benefit from them. It could be 
contended that they could have had an EVAR complication that could have been treated 
by secondary intervention if the original EVAR had been placed in a physiologically 
more robust individual. This contention does not, however, reflect the reality of actual 
clinical practice. There were also a small number of patients who were actively 
discharged from EVAR surveillance before the cross sectional study period who were 
still alive and had no reason for discharge recorded. There was no method to 
corroborate that these patients were in fact discharged as they would not gain benefit. 
The reporting of incidence over a 12 month period is a relatively standard measure. To 
make our outcomes relevant to clinical practice it then had to be stratified according to 
patient time after EVAR. This meant that, particularly in late follow-up, rates were more 
prone to fluctuations due to reduced numbers of patients at risk. This can be seen by the 
black lines fluctuating from zero to higher numbers, for example in Figure 13 (page 59). 
To compensate for this a best fit line was created that took account of the rate, which 
was given proportional weighting for the number of patients at risk. This best fit line 
was calculated using 75% of the time frame centred on the time point being calculated. 
Time in this calculation was log transformation, as such a high proportion of events 
occur in the first 6 months after EVAR. This best fit line gives a good visual 
approximation of true trends without the “noise” of fluctuations that result from data 
sparsity and analysis techniques. 
2.5.2.2 Compliance 
Analysis of achieved compliance has similar benefits and limitations to the secondary 
intervention analysis, Section 2.5.2.1 (page 109). The appropriateness of exclusion of 
patients actively discharged from the surveillance programme from the ‘at risk’ group is 
less contentious in this analysis, as patients who are not being invited for surveillance 
clearly cannot be compliant. 
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The patient characteristics association with compliance analysis was undertaken on a 
forward-looking (prospective) basis, as this is the perspective encountered clinically. 
The available patient demographics as well as time after surgery (based on the above 
findings) were all placed into the model. Univariate analysis was first undertaken for 
comparison to the literature and then multivariate analysis was undertaken to assess for 
co-linearity / confounding between factors. An automated backward stepwise selection 
was performed to look for variables that were co-linear with other variables. 
2.5.2.3 Individual Surveillance Findings 
2.5.2.3.1 Interval of Analysis 
The association of surveillance scans and secondary interventions could be 
hypothesised to be the result of initial (most prevalent) surveillance scans occurring 
within the first month of EVAR and the high initial prevalence of secondary 
interventions after EVAR. As such the secondary analysis of hazard ratios once the rate 
of secondary interventions had settled was undertaken to ensure this was not simply co-
linearity with time of scan. Visual interpretation of the point hazard curves was felt 
most appropriate and efficient. 
2.5.2.3.2 Individual Findings Analysis 
Missing data is an inevitable consequence of the methods of data collection in this 
study. The level of missing data in this study was low for most variables, often due to 
assumed negative response, with only calculated variable and size variables showing 
any significant level of missingness in the data set. 
Assessing if data was NMAR is an important concept. There is not yet a single accepted 
method that is applied to this analysis in cohort studies. This was undertaken in this 
study by assigning missingness a variable and replacing the original variable, these were 
then placed into a model to predict outcome. If the missingness variable achieved 
statistical significance it indicated that the missing data may have been of value in 
predicating outcome, therefore it is potentially important and as such it was assigned the 
label NMAR. Multiple imputation was used in such instances. 
Multiple imputations using chained equations is a relatively accepted standard method 
in medical research, it is used on the national UK vascular datasets.110 The 
independently set methods for each variable model/calculation/imputation allows great 
flexibility. For logical and categorical variables, the use of Bayesian models, using all 
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other available data (including outcome) is the accepted standard. For continuous 
variables, predicative models can be individually created for each variable, however 
Predicative Mean Matching has been shown to be similar in outcome and is less 
computationally and statistically demanding. In the context of missing covariate data, 
Marshall et al. concluded that predictive mean matching “produced the least biased 
estimates and better model performance measures”.111 Kleinke similarly found that it 
performed well across a wide variety of scenarios, but warned it cannot address severe 
skewness or small samples.112 The data in this study was not a small sample and none of 
the inter-quartile ranges demonstrated severe skewness. 
Analysis of variables was only undertaken for association where a causative link could 
be hypothesised. This was to reduce the number of analyses and reduce the chance of 
type I error due to multiple comparisons. No adjustments were made to statistical 
significance levels to prevent discounting potentially important variables from further 
investigation.113 This is valid in the fact that this was an investigation looking for 
important variables for further prospective investigation and not looking to assign 
causality to individual variables. 
Actual analysis, within each imputation, of the data was performed using standard 
techniques; continuous variables were assessed using Cox proportional hazard models 
and categorical variables were dual analysed with Kaplan-Meier plot / log rank and Cox 
proportional hazard models to allow assessment of how the absolute risk developed 
over time as well as proportional hazard (odd ratios).  
Using AXR in relation to CDUS may underplay the significance of findings on AXRs 
given some of the findings may be significantly older, however this method does reflect 
the likely clinical scenario encountered. AXR is unlikely to be used in isolation and in 
LiVES is normally obtained in concert with a CDUS. This is reflected by the mean, 
median and inter-quartile range between CDUS and AXR acquisition, section 2.4.4.2 
(page 68). 
2.5.2.3.3 Assessment of Confounding and Co-Linearity Between 
Variables by Stepwise Regression 
Univariate analysis is informative when assessing association between that variable and 
outcome, but CDUS and AXR measure multiple variables and there will be significant 
interaction between these. The simplest method to assess the extent of these interactions 
(co-linearity and confounding) is to place them all into a predictive model (multivariate 
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analysis). This allows the confounding to be excluded and the true influence on the level 
of association (in the presence of all the other variables), to be articulated. This gives an 
indication of the weight that should be placed on each of these findings within the 
CDUS and AXR scans as currently performed. 
Many of these variables in isolation or combination may in fact produce such levels of 
interaction as to create almost total co-linearity with other variables. As such the 
backwards stepwise regression modelling was undertaken to ascertain if similar levels 
of discrimination and predictive accuracy could be obtained with fewer variables. This 
would both indicate which are the dominant variables in predicting and potentially, if 
accuracy did not change, variables that are superfluous measurements. The remaining 
variables are therefore good candidates for prospective study regarding their removal 
from protocols to improve efficiency. 
The backward stepwise process can be automated but, in this case, the interplay 
between variables was felt to be more important than the potential for bias and as such 
the process was undertaken manually. This potentially may influence the model created 
but also allows for the practicality of measuring variables to influence the model. 
2.5.2.4 Predictive Model 
The choice to use a PEM was one made based on the data in Figure 15, page 60, which 
shows variation in both risk of overall rate of secondary intervention at different times 
but also a different mix of indications for secondary intervention at differing times. 
Both these variables increased and decreased over time following EVAR. As such any 
model that did not capture the ability to vary increasing and then decreasing risk (or 
vice versa) over time was unlikely to ever achieve satisfactory discrimination and 
predictive ability for clinical use. 
Model creation was unremarkable. Data missingness was sufficiently rare in the 
selected variables that multiple imputation was not necessary and would have been 
demanding for such a complex internal validation process. Internal validation was 
computational demanding mainly due to the number of cycles being performed, this 
number was selected to ensure that the true AUC and Hosmer-Lemeshow values were 
obtained for the model. The co-efficient values for the model from internal validation 
were similar to the model creation values. While minor improvements in AUC could 
likely have been achieved by inclusion of further variables it was felt this may then 
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represent overfitting to local data that would have both reduced external validity and 
potentially the ability to find an adequate dataset to validate the model. 
Calculating the average time between surveillance visits was intended to compensate for 
the fact that there is a higher proportion of patient in their first year following EVAR in 
the surveillance programme than any other time. In that first year the patient should 
have undergone a scan 6 weeks following EVAR and one at 1 year post-operatively, 
this meant that the mean time between scans on a programme wide basis will be lower 
than the 1 year standard interval for the remaining time in surveillance. The only way of 
calculating this mean required individuals to have had a subsequent scan in the observed 
period of the study, this may introduce bias if there was an uneven number of 
individuals in the surveillance programme at the start compared to the end of the 
observation period. This is likely given the uneven distribution of procedures 
undertaken and the mentoring, both discussed in section 2.5.3.1, page 114. The 
calculation of the mean freedom from secondary intervention during that period gave an 
indication of the value to review the assessment patients on the exemplar graph. 
2.5.3 Results 
2.5.3.1 Demographics 
The demographics section demonstrated that the patients analysed within the study, had 
broadly similar demographics, Table 7 (page 52), to those patients undergoing EVAR 
within current UK practice.110 This adds weight to the position that these results are 
likely to be applicable to general UK practice. 
The EVAR stent-grafts inserted into some patients, Table 8 (page 53), are earlier 
iterations of those still available or are still available for insertion. The 17% who had a 
stent-graft in ‘others’ have generally been withdrawn from the market or no longer in 
regular use in UK practice. This analysis was performed at patient level rather than 
surveillance scan level and may not represent the proportions in each of the output 
analyses. 
The number of cases performed per a year, Figure 9 (page 53), demonstrates the gradual 
uptake of EVAR technology within the department between 1996 – 2004. Following the 
publication of the medium term outcomes of the UK EVAR trial 1,114 part way through 
2005, there is a marked increase in EVARs use consistent with those trial results. In 
2009 -2013 the department undertook mentoring in the intra-operative EVAR technique 
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to various other local vascular departments. This accounts for the sudden increase in the 
number of cases as these departments’ patients had their procedure within Liverpool 
under the mentorship of the local Liverpool surgeons. 2012 was the year of LiVES 
creation and merging of services and is an accurate representation of the number of 
annual endovascular aneurysm repairs performed subsequently. The decreased number 
of cases between 2012-2014 is partly accounted for by the use of the alternative 
Endovascular Aneurysm Sealing technique for some patients (not included in any part 
of this analysis). Finally the small number of cases in 2015 is the result of only part of 
this year being included in the analysis. 
Overall survival following EVAR in LiVES is very similar to the late survival in the 
UK EVAR trial 1,45 again showing applicability of these results to generality of UK 
practice. 
The cohort of patients who had their primary EVAR within the time-frame of the data 
collected in the study showed a freedom from secondary intervention rate similar to the 
UK EVAR trial 1.45 This has been reported to be lower in other contemporary series.92 
The numbers at risk in this analysis are heavily influenced by the mentoring patients 
who underwent EVAR and first post-op surveillance in LiVES but then had ongoing 
surveillance in another locality. 
2.5.3.2 Nature of Secondary Interventions 
This description of secondary indications is likely the largest detailed description of 
secondary interventions outside the RCTs.40 41 45 The actual secondary interventions 
undertaken, Table 11 (page 57), appears uncontroversial. The proportion of secondary 
interventions (48%) associated with maintaining flow through the EVAR stent-graft 
runs contrary to the premise of current European surveillance guidance that is based 
purely on aneurysm related secondary interventions.53 92 The fact that only 25% of 
secondary interventions occur in patients with symptoms is also markedly different 
from the literature. This 25% also include patients who had symptoms but failed or 
waited to present for clinical review. 
2.5.3.3 Incidence of Secondary Interventions 
Incidence of secondary intervention is not commonly reported in EVAR studies, 
“Freedom from [first] secondary intervention” being the preferred measure. This under 
recognises the total burden of secondary interventions as second and subsequent 
secondary interventions are rarely reported or accounted for. The actual rate (incidence) 
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rather than absolute number of secondary interventions is more useful in discussing risk 
with patients currently in EVAR surveillance rather than about to undergo EVAR. 
The number of patients at risk in this analysis (particularly between 1 and 8 years) are 
the largest in the published literature, with the exception of the combined UK EVAR 
trials and national registries (registries do not offer the same data standard). The overall 
incidence of secondary interventions in this study of 6.1 secondary interventions per 
1000 patient years, compares favourably to an analysis of stent grafts in the UK EVAR 
trails, which showed a rate of 7.0 and 9.4 for the two commonest stent-grafts over an 
median follow-up of 3.8 years.115 Such comparisons are broad but reassuring, however 
note should be given to the different time frames of post EVAR follow-up featured in 
them. The incidence of secondary interventions following EVAR, in this study, ranges 
between approximately 60 and 30 interventions / 1000 patient years over the 15 years 
following EVAR. This rate of interventions, along with the low rate of symptoms, 
makes a compelling argument for the ongoing use of surveillance.  
The incidence of aneurysm related secondary interventions is remarkably stable at 
approximately 25 interventions / 1000 patent years over the 15 years. Looking at the 
raw data a trend toward more significant interventions, i.e open conversions and total 
endovascular re-lining can be seen as time passes, however these are small numbers that 
would not withstand statistical analysis. 
The rate of flow related secondary interventions is more variable, between 
approximately 10 and 50 secondary interventions / 1000 patient years, over the first 15 
years following EVAR. The early predominance of secondary interventions is not 
surprising, but the late incidence is a novel observation not described in the literature 
and almost entirely accounts for the late increase in the total rate of interventions. 
Review of raw data does not seem to support the same pattern of complexity of 
interventions with open interventions appearing evenly distributed with endovascular 
procedures. Surveillance that detects impending flow related complications seems 
indicated particularly in the early and late surveillance periods. 
2.5.3.4 Compliance Following EVAR 
This analysis shows an exceptional high rate of compliance (>95%) till 10 years 
following EVAR. This high rate of compliance is almost certainly down to the 
systematic approach taken to achieving compliance with surveillance in the LiVES 
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EVAR programme. Compliance from 10 – 15 years following EVAR reduces to nearly 
50%, with relatively few individuals at risk during this period. 
This analysis confirms that excellent compliance is achievable through till 10 years 
following EVAR. The system in use in LiVES demonstrated the best compliance in 
EVAR-screen,88 and may offer a model for other centres in achieving compliance. 
The sudden deterioration in compliance from 10 years onwards does however indicate 
there is some other factor that influences compliance, this factor must be patient centred 
- as the same systematic approach to achieve compliance is used consistently through-
out follow-up. It may also indicate that measuring compliance just at the end of a study 
period may not give an accurate reflection of compliance throughout the period and may 
explain the differences between surveillance efficacy studies.70 71 88 This observation 
would make de Mestral et al. study, which uses a measure of compliance over the 
totality of follow-up, the most appropriate approach in the published literature. Their 
study demonstrated that the larger the proportion of time compliant with follow-up was 
associated with a lower risk of death.71 
2.5.3.5 Patient Characteristics Associated with Future Compliance 
Univariate (unadjusted) analysis, Table 14 (page 65) of these factors broadly concur 
with the literature suggesting: older patients, patients who are further into their 
surveillance and patients who had operations in earlier years are all less likely to be 
compliant with their next surveillance visit. Differing from the literature, increasing 
distance to surveillance centre (km) was associated with, a small, increase in 
compliance. This may indicate the short distance to surveillance experienced in this 
study is within the acceptable travel distance for patients. It may also indicate the small 
number of tertiary patients travelling very large distances have much higher compliance 
than local patients travelling short distances. There were insufficient numbers of tertiary 
referral patients to be able to investigate this further.  Gender notably showed no 
association with compliance, which is surprising given the literature on the subject that 
suggest males are less compliant with most healthcare interventions. All of these 
associations were small on an individual factor basis.   Adjusted analysis demonstrated 
the calendar year of operation and time after EVAR were dominant factors in 
compliance with advancing years being associated with decreasing compliance for both.  
Stepwise regression is a gross technique to reduce the number of variables so reducing 
co-linearity, but it is clinically indiscriminate in factors excluded. The simplified model, 
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Table 15 (page 65), maintained the same overall predictive ability therefore making it 
suggestive that gender and pre-operative AAA size are unlikely to have any significant 
association with compliance. Within the model, the dominance of ‘year of EVAR’ and 
‘time since EVAR’, with only a small effect of absolute age, suggest that patient 
attitude / understanding and attrition to tolerance of surveillance are potentially the most 
important factors to study in improving patient compliance. This hypothesis is 
theoretically supported by the improved association of compliance in those who have 
previously had a secondary intervention, thus having benefitted from surveillance and 
likely increased understanding of the importance of surveillance. 
All of these findings have to be taken in the context of the underlying system used to 
manage surveillance in LiVES. In particular the active discharge of patients 
physiologically unfit for secondary interventions that may still be invited, decline and 
therefore classed as non-compliant in alternative systems. This may account for this 
study finding a relative low significance of absolute age. 
Association is not causation. It is however an appropriate method of trying to define 
targets for causation research or targets for future studies to trial interventions to 
improve compliance. 
2.5.3.6 Surveillance Scan Findings: Interval of Effect 
The analysis of point hazard ratio for undergoing secondary intervention following 
surveillance scan, Figure 18 (page 67), demonstrates compelling evidence that 
secondary interventions are associated with surveillance scans. The replication of the 
curve shape, Figure 19 (page 67), at a lower ratio in scans that occurred after the initial 
post-operative period demonstrates that this is unlikely a cofounding effect of both 
events occurring in high proportions in early (<0.75 years) EVAR follow-up. 0.5 years 
is visually an appropriate time to select for review of causative effect given the shape of 
both of these curves, both had reached a stable base line risk by this time point. 
2.5.3.7 Surveillance Scan Findings: Correlation with Secondary 
Interventions  
Univariate analysis of the binary diagnostic/non-diagnostic variable on current CDUS 
scan showed no association with aneurysm or flow related secondary intervention. 
Analysis of the cumulative diagnostic/non-diagnostic on any CDUS scan similarly had 
no association with flow related secondary intervention. Aneurysm related secondary 
interventions however did show an association with such a cumulative finding of all 
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CDUS being diagnostic. This is logical if the undiagnostic finding is given more in 
scans of poor quality imaging, thus inhibiting the triggering of secondary interventions. 
The different but relatively consistent gradients in the Kaplan-Meier plot, Figure 23 
(page 72),  are suggestive of an underlying difference in risk of triggering a secondary 
intervention. This is potentially suggestive that patients with an undiagnostic CDUS are 
not having alternative imaging as likely to trigger secondary intervention as those who 
have diagnostic CDUS or alternatively it is a cofounding factor for patients less suitable 
or in need of secondary intervention. 
The findings of the univariate analysis of: any, graft related and Type II endoleaks can 
be discussed in concert, a finding of any endoleak was common (18% of scans) and 
graft related endoleaks rare (2% of scans) both are statistically associated with 
aneurysm related secondary intervention following CDUS scan. Type II endoleaks 
(15% of scans) were not statistically associated with secondary intervention (p=0.06), 
consistent with practice supported by publications suggesting that isolated type II 
endoleaks are not associated with increased rupture risk.54 The odds ratio, of secondary 
intervention, following graft related endoleak diagnosis on CDUS is very large but does 
not fully articulate that only approximately 30% of patients underwent intervention in 
the 6 months following CDUS. The intervention rate in all endoleaks is not totally 
accounted for by those which were classed as graft related and the presence of any 
endoleak has an ability to account for miss classification of type II endoleaks that were 
deemed to require intervention. 
The cumulative finding of all three endoleaks findings appeared to simply reduce the 
effect on odds ratios in all the classifications. It had been hypothesised that Type II 
endoleaks on a previous CDUS might increase secondary interventions following 
subsequent CDUS if growth was demonstrated. This was not seen in the 6 months 
following subsequent CDUSs analysed. As such the strongest associations in endoleak 
diagnosis on CDUS, in terms of triggering secondary intervention, are classification as a 
graft-related endoleak on current scan and presence of any endoleak on current scan. 
Finding a limb abnormality on CDUS was a common (12% of all CDUSs) finding and 
was associated with flow related secondary intervention in approximately 10% of cases 
by 6 months. The hazard ratio (14.9) and statistical significance (p<0.0001) suggest this 
is a highly effective measurement in terms of association with secondary interventions. 
It is, from this data, not possible to fully understand the threshold for reporting a limb 
abnormality, this would require further prospective evaluation. Similar to endoleak 
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diagnosis the cumulative finding diminished the association but not statistical 
significance of the finding. This suggests that most interventions are associated to de-
novo limb abnormalities being detected rather than progression of previously known 
abnormalities. 
Absolute AAA size was notably smaller on surveillance CDUS than the pre-op size 
(Median 56 vs 62mm) with scans having a median time after EVAR of 2.8 Years. This 
suggests, on a programme wide basis, that aneurysm regression after EVAR is likely 
approximately 2.1 mm/ year. This is very similar to linear models for expansion,19 
discussed in section 1.1.2 (page 3). Flow related secondary interventions had been 
hypothesised to be associated with an aneurysm size due to associated tortuosity. No 
association could be established, p=0.41. Aneurysm related secondary interventions 
were statistically associated with absolute size (p<0.0001), but with a very low hazard 
ratio 1.04 per 1mm size increase. Meaning only very large sized aneurysms were likely 
to trigger such interventions. This fitted with clinical practice where far more emphasis 
is placed on size changes rather than absolute size. 
Maximum AAA growth was the calculated variable to assess for size increases. Given 
the data set it was not possible to assess for total shrinkage as largest previous size was 
not recorded in the same manner as smallest. If the current scan was smaller than 
maximum size then this was recorded as 0mm. This had an unexpected association with 
flow related secondary interventions, making them less (rather than more) likely – 
hazard ratio 0.81 per 1mm size increase. This association is clinically significant 
enough to warrant consideration. It should be noted that inability to measure negative 
sizes may have introduced a measurement/analysis error that created this finding. 
Surprisingly, there was a lesser association to aneurysm related secondary intervention 
– hazard ratio 1.06 per 1mm size increase. 
Recent AAA Growth (size change) had no significant association with flow related 
secondary intervention and was able to measure reducing aneurysm size. It did however 
have a strong association (statistically and clinically) with aneurysm related secondary 
interventions. For each 1mm size increase hazard ratio was 1.11. This measure does not 
take account of the time frame this occurred over, that time frame between surveillance 
was felt clinically appropriate by the treating team. As such it may be a useful marker in 
any surveillance programme that uses differing surveillance intervals for individual 
patients. 
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Recent AAA growth rate uses the above information in addition to the time interval 
between scans. Once again that there was no association with flow related secondary 
intervention. It did have an association with aneurysm related secondary intervention, 
however this was less clinically important with a hazard ratio of 1.06 per 1mm/year size 
increase. This was likely due to the distribution of this finding being the same as recent 
AAA growth rate, potentially due to the annual surveillance programme meaning most 
scans were 12 months apart. 
Size measures in their totality appear to demonstrate that AAA size change since last 
scan and compared to smallest size have a stronger association with triggering 
secondary intervention than rate of that size change or the absolute AAA size. This 
would be a logical extension of a clinical practice in which there is a threshold of size 
change that clinicians will tolerate and above that trigger’s further investigation with a 
view to intervention. 
Effacement demonstrated on AXR is an unusual finding with only 7% of CDUS scans 
having a corresponding AXR that detected effacement. The hazard ratio, 7.03, is a 
reflection of the low number of patients with effacement who went on to have 
intervention (approximately 10%) in the six months following its discovery. This 
reflects that intervention for signs of a failing proximal landing zone are often complex, 
and frequently require extension into the visceral segment of the aorta. This complexity 
is likely reflected in the Kaplan-Meier plot, Figure 32 (page 84), showing that 
secondary interventions do not diverge till after 0.1 year (~ 6weeks). This delay reflects 
time being taken to further investigate, plan and acquire stent-grafts to allow secondary 
interventions to take place. Similar to CDUS findings cumulative finding of AXR 
effacement demonstrate a lesser association, hazard ratio 2.54, than currently detected 
effacement. 
A structural failure on AXR (excluding a single barb fracture) was a rare finding with 
only 2% demonstrating such a failure. The hazard ratio, 4.16, for secondary intervention 
was low considering the finding represents a physical breakage of the metallic stent-
graft structure. This is likely influenced by its rarity and uncertainty regarding its 
importance to durability. As with effacement a cumulative finding diminished the 
association to the point of not achieving statistical significance, p=0.42. 
Limb abnormality on AXR was again a rare finding with only 3% of CDUS scans 
associated with an AXR which demonstrated it. It was strongly statistically associated 
Surveillance Following Endovascular Repair of Abdominal Aortic Aneurysm 
122  Iain Nicholas Roy - August 2020 
with flow related secondary interventions, p=0.0003. The hazard ratio, 4.32, indicates 
strong clinical significance. A cumulative finding of limb abnormality again reduced 
association to the point of no longer being statistically significant. 
Migration on AXR was separated into groups in reports. Of these only ‘definite 
migration’ had a secondary intervention rate different to the other groups. A trend 
appears to be present that minor migration has a, not statistically significant, increased 
rate of secondary intervention compared to no finding of migration, but lesser effect 
than definite migration. This indicates that migration may be progressive and that higher 
granularity to movements would allow better diagnosis of requirement for intervention. 
The fact that small caudal movement labelled as barb engagement are not associated 
with secondary intervention would suggest that it is appropriately being segregated from 
other types of migration or may not be a significant finding.  
When all other groups were combined, a True/False finding for ‘definite migration’ on 
AXR it demonstrated significant differentiation between groups confirming its 
independent clinical utility. 
2.5.3.8 Assessment of Confounding and Co-Linearity Between 
Variables by Stepwise Regression 
The full multivariate model, Table 18 (page 95) relating to flow related secondary 
interventions shows the over whelming dominance of a current CDUS limb abnormality 
with a hazard ratio of 17.25. A limb abnormality on AXR show the second largest 
influence with a hazard ratio of 6.48, all the remaining variables show very minor 
effects. Aneurysm size variables are interesting in that the absolute aneurysm size has 
virtually no association with flow related secondary intervention will total size increase 
actually appears to have a protective effect and conversely shrinkage increases the risk. 
This can be explained by growing aneurysm changing morphology being more likely to 
pull limbs out from their seal zones leading to aneurysm related (not flow related) 
secondary interventions. Shrinking aneurysms are more likely to compress stent-grafts 
into a smaller space that can lead to limb kinking and the need for flow related 
secondary interventions. As such kinks are likely to be present or absent rather than 
degrees of kinking the absolute change in size rather that the rate of size change is the 
logical measure to discern this. Rate of change would be more likely to influence 
chance of future secondary intervention. 
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The stepwise regression bears out many of the above points with all but size variables, 
CDUS limb abnormality and AXR limb abnormality being excluded quite readily. The 
non-exclusion of AXR limb abnormality could be contested as it led to a 3 point rise in 
the AIC, however in the context of a modality that was required for aneurysm related 
secondary interventions its inclusion was felt appropriate. This meant that CDUS limb 
abnormality (with its non-specific nature), absolute size increase, most recent size 
change and AXR limb kink produced the simplified model, Table 19 (page 96). In 
practice this represent examining the limbs and taking an aneurysm measurement on 
CDUS and an AXR on each surveillance visit in the context of assessing for need of 
flow related secondary intervention. 
The full multivariate model, Table 18 (page 95) relating to aneurysm related secondary 
interventions shows a similar single variable predominance in the form of the presence 
of a graft related endoleak, hazard ratio 19.9. Presence of a type II endoleak, AXR 
effacement, AXR structural failure and AXR definite migration all have moderate 
influence but again size variables individually have surprisingly little influence.  
Stepwise regression again excluded absolute aneurysm size as well as structural failure 
on AXR – likely due to its rarity. The exclusion of AXR definite migration was 
surprising and may simply represent co-linearity with effacement. In reality migration is 
likely to easier to define on AXR than effacement as they may represent 10x larger size 
changes/movements on AXR for migration of effacement. The ongoing inclusion of 
change and rate of change in aneurysm size but exclusion of absolute sizes is probably 
the result of the complex anatomical changes that occur during size changes. The likely 
cause of most of this is the differing baseline size of patients undergoing EVAR but also 
the altering course of aneurysm sizes over time reflecting alterations in patient risk and 
the result of having already developed a complication. 
These complexities are unlikely to ever be adequately dealt with in a proportional 
hazard model and are well suited to linear discrimination analysis as has been proposed 
in sac rupture risk.36 The cross-sectional nature of this study means that we do not have 
serial size measurements for all patients from implant to current CDUS to allow this to 
be undertaken. 
In summary a CDUS looking for endoleak (absent/ graft related/ type II), aneurysm size 
(in comparison to previous measurements), limb abnormality (absent/ present) and AXR 
to assess for effacement (and possibly migration) within a model demonstrate the same 
predictive power as all the 10s of variables currently collected. A prospective study 
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looking at a simplified surveillance CDUS/AXR protocol would appear warranted. 
Similarly attempts to improve the granularity of migration diagnosis and effacement 
detection on AXR are likely to be beneficial. Finally, a tighter definition of presence / 
absence of limb abnormality on CDUS would potentially improve intra-operator 
reliability. 
2.5.3.9 Predictive Model 
PEM was created and internally validated, the resultant variable coefficients are 
interesting (Table 23, page 103) in that the initial main influence is from time after 
EVAR (Years). All time coefficients reduce likelihood of intervention from the high 
risks produced by the patient and CDUS variables. This is seen most significantly in the 
10-20year time frame where the reducing power of the time variable is more than twice 
that of 0-0.5years. This could be for two reasons one the CDUS variables become more 
extreme in this late stage follow-up and the other is that there is indeed a higher 
threshold for intervention (due to patient age and potentially failed previous 
interventions). This runs country to the secondary intervention prevalence element of 
the study which is more robust method of examining this area. Presence or absence of 
any endoleak on the CDUS and current CDUS AAA size (per mm) being the next most 
influential, dependent on how large the AAA is. In a large AAA, CDUS size could be 
the most influential variable of all. Finally the fixed variable of patient age at operation 
and pre-op AAA size both reduce the likelihood of intervention the larger they are. It is 
interestingly the CDUS and pre-op AAA size are exactly matched coefficients. If an 
aneurysm is larger than pre-op then there is an increased likelihood of intervention and 
vice versa, when they are equal they have no influence on the model. This is of course 
logical in that shrinking aneurysm sizes are an indication of current treatment success. 
Although reducing aneurysms may be associated with increased flow related secondary 
intervention the reduction in aneurysm related secondary interventions mean the overall 
risk of secondary intervention is reduced. 
An AUC of 0.72 is a good improvement on a surveillance programme that has no 
patient specific elements (e.g. everyone comes back at the same interval regardless of 
findings or time since operation). If that was the case and you fully implemented a risk 
model to define the interval to next surveillance that was based on not changing the 
mean risk of secondary intervention you would see an up to 44% increase in programme 
efficiency. In reality this is difficult to calculate as some patients are brought back for 
increased intervals of surveillance in the current programme and to fully realise the 
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possible increased efficiency some patients would be placed on uncomfortably long 
surveillance intervals that clinicians and patients are unlikely to be willing to accept. As 
such any implementation would have to have “collars” of minimal intervals to next 
surveillance – to allow changing findings to occur and maximum intervals to 
surveillance to account for the increasing confidence intervals and uncertainty around 
predictions that are further from scans. 
The tight IQR (0.68 – 0.76) of the AUC values and narrow distribution on the histogram 
(Figure 44, page 104), on internal validation demonstrate the stability and reliability of 
the PEM in this cohort. The fact that none of internal validation models had a AUC 
greater than 0.9 suggests that there are some secondary interventions that these set of 
data are simply not able to predict. The 13% of secondary interventions performed as an 
emergency would seems a remarkably similar number and might warrant further 
investigation. 
Figure 45 (page 105) shows a skewed distribution across the spectrum of p values from 
the Hosmer-Lemeshow test. It concentrates around p≈0.6 with less than the permissible 
2.5% falling below 0.05 demonstrating satisfactory calibration. 
The assessment patients allow the potential practical use of the PEM to be 
demonstrated. The patients represent Low/Mean/High risk variables into the model not 
a low risk output from the model. This is important to differentiate as it is unlikely the 
mean risk output from the model would suggest a 0.6year surveillance interval. These 
hypothetical patients do however clearly delineate the huge difference in individual 
patients risks over time and the potential folly of trying to treat them all the same as far 
as surveillance interval is concerned. 
2.6 Summary 
The findings of this study demonstrate the indication for secondary interventions to be 
split between maintaining aneurysm treatment efficacy and maintain flow to the lower 
extremities. This runs contrary to the focus of the majority of the current literature 
which often does not consider flow related secondary interventions. The secondary 
interventions include treatments for limb occlusion, acute limb ischemia and even lower 
limb amputation all of which demonstrate the importance of this area of surveillance.  
This study shows the global incidence of secondary interventions to be generally 
consistent, throughout the majority of the post-operative period, up to 15 years 
following EVAR. There is however a high initial and increasing late (10-15 years) 
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incidence of interventions. These are exclusively associated with increased rates of flow 
related interventions while aneurysm related interventions are grossly static. This may 
run counter to assumptions that with increased treatment failures in late follow-up, seen 
in the UK EVAR 1 trial, there may be an increased aneurysm related secondary 
intervention rate. This assumption was not demonstrated in this study. 
It has demonstrated that compliance with surveillance following EVAR can be 
maintained at very high levels for a prolonged period when the use of a systematic 
approach with safeguards in place is employed. There, however, does ultimately appear 
to be a limit to the time in or amount of surveillance patients will tolerate and in more 
recent years (as EVAR has become the most common treatment) this may be lowering. 
This study demonstrated that there is an increased rate of secondary interventions up to 
6 months following surveillance scan, this is a strong suggestion of causative effect of 
surveillance on triggering secondary interventions that is disputed in the literature. It 
demonstrates the large amount of confounding and co-linearity that exists between 
variables measured on CDUS and AXR in their association to secondary interventions. 
These scanning protocols should be rationalized and prospectively studied, so 
improving the efficiency with which these scans are undertaken. 
Finally, this study has demonstrated that it is possible to predict their future risk of 
secondary intervention based on their current surveillance findings, at any point in their 
post-op surveillance. This has been validated internally and shown to have good 
accuracy and discrimination between risk. This risk prediction can be used to adjust the 
interval to next surveillance scan so increasing the efficiency of the surveillance 
protocol and the efficiency (and therefore cost effectiveness) of post EVAR surveillance 
programs. 
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3 PROSPECTIVE STUDY 
COMPARING CONTRAST 
ENHANCED ULTRASOUND 
TO TIME-RESOLVED 
COMPUTER TOMOGRAPHY 
ANGIOGRAPHY 
Detection and correct characterisation are required for a complete diagnosis of any 
endoleak, such a diagnosis is an imperative feature of surveillance imaging in 
preventing failures of endovascular aneurysm repairs (EVARs). The gold standard for 
diagnosis of endoleaks is catheter directed digital subtraction angiography (DSA), 
which is not a practicable choice for surveillance. Computer Tomography Angiography 
(CTA) is the historical surveillance modality of choice but concerns over cost, potential 
nephrotoxicity of contrast agents and repeated radiation exposure led to Colour Duplex 
Ultrasound Scan (CDUS) becoming an established alternative. CDUS has a lower 
sensitivity and specificity for diagnosing endoleaks compared to CTA. Contrast 
Enhanced Ultrasound Scan (CEUS) represents an improvement of ultrasound imaging 
technology but comparisons against CTA report widely varying results, likely due to 
technical factors of CEUS and limitations of single-phase CTA.  
The development of time-resolved CTA (tCTA) offers timing information that more 
closely mirrors the dynamic information available from DSA. Theoretically CEUS and 
tCTA have the best potential for diagnostic accuracy, without using invasive catheter 
angiography. The aim of this study was to 1) compare diagnostic values of CEUS and 
tCTA and 2) investigate the utility of other measurements available from tCTA and 
CEUS. 
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3.1 Background 
EVAR is associated with complications which sometimes require secondary 
interventions to maintain the treatments efficacy. This has been recognised since the 
inception of the technique and confirmed by the secondary failure rate in observational 
studies as well as randomised controlled trials (RCT).40-43 Therefore periodic 
surveillance imaging is recommended for life following EVAR.17 68  The importance of 
post-EVAR surveillance remains enduring, its value further highlighted by the analysis 
of 15-year follow-up after EVAR in the landmark RCT,45 which showed late aneurysm 
related mortalities in the EVAR arm suggestive of treatment failure. 
The commonest complication in EVAR surveillance is an endoleak.47 Endoleaks are 
classified based on the source of blood flow,48 but can be grouped into stent-graft 
related (types I and III) and type II (non stent-graft related) endoleaks. Stent-graft 
related endoleaks generally transmit high pressure causing a high risk of aneurysm 
expansion/rupture (treatment failure)49 52. In contrast, type II endoleaks generally run a 
benign course, particularly in the absence of aneurysm expansion.52 With regards to 
endoleak imaging, accurate detection and characterisation improve diagnostic utility of 
surveillance, in particular with an emphasis on distinguishing stent-graft related 
endoleaks from type II endoleaks.  Digital subtraction angiography (DSA) in multiple 
planes and a high frame rate of acquisition is the diagnostic gold standard of endoleak 
imaging. High frame rates are required to demonstrate endoleak haemodynamics 
(inflow and outflow) for accurate characterisation. DSA is not tenable to be used as 
surveillance imaging due to its invasive nature, high cost and relatively high radiation 
exposure to the patient. 
Historically EVAR surveillance was undertaken using Computer Tomography 
Angiography (CTA). A single arterial phase CTA was the most frequently used 
modality, although selectively or routine additional phases can be added such as 
unenhanced, venous, and even delayed phases. Concerns over cost, use of potentially 
nephrotoxic contrast agent and repeated radiation exposure led to alternative imaging 
modalities being investigated and implemented in surveillance regimens. Colour Duplex 
Ultrasound Scan (CDUS) is the most widely used imaging modality in the UK, 
currently.87 CDUS is reported to have a lower sensitivity and specificity to detect stent-
graft related endoleaks compared to CTA. 73 
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Contrast Enhanced Ultrasound Scan (CEUS) has been investigated as an adjunct to 
CDUS in the hope of improving sensitivity to endoleak detection. CEUS involves 
intravenous injection of a microbubble contrast which remains in the blood, allowing 
improved detection of endoleaks, section 1.3.7 (page 21). CEUS also allows continuous 
(dynamic) or real time monitoring of the aneurysm and endoleak as the contrast agent 
arrives in the endoleak. Modern microbubble agents are eliminated by the respiratory 
system, thus avoiding nephrotoxicity. A recent review of 30,222 administrations of a 
CEUS contrast agent demonstrated a low adverse reaction rate of 0.020%.81 CEUS also 
obviates the radiation exposure associated with CTA.  
Time-resolved CTA (tCTA) was first described for endoleak detection in 2010.116 The 
single arterial phase is replaced by multiple phases in tCTA, which are typically of 
lower radiation dose. This allows the contrast to be observed as it passes into, through 
and out of the stent-graft and any endoleak present. tCTA therefore offers dynamic 
observations of endoleaks, such as flow direction and filling speed, while still retaining 
many of the advantages of CTA (3D multi-planar reconstruction etc.) which closely 
mirror the advantages of multi-planar DSA. A large enough number of measurements 
regarding endoleaks on tCTA117 are available to allow the technique to be refined. This 
means a standard arterial phase in CTA can be replaced with a tCTA that is aimed at 
detecting stent-graft related endoleaks, without increasing average radiation exposure 
for the patient. Given that the timings and interpretation of tCTA are sufficiently 
understood it is timely to do a comparison of CEUS to the improved comparator of 
tCTA. This is an improvement on the limitations of previous studies as it compares 
CEUS to a (semi) dynamic form of CTA imaging as an improved comparator standard. 
3.2 Aims 
We aimed to show the sensitivity and specificity of CEUS to detect graft related and 
other endoleaks, in comparison to the improved reference standard of tCTA. These data 
collected may help develop a more efficient protocol for CEUS and a new role in 
guiding the timing of phases in CTA. 
3.3 Methods 
The protocol for this research was submitted for publication before recruitment was 
completed and before any analysis was undertaken.118 
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3.3.1 Study Design 
This was a prospective single centre comparative study of paired diagnostic imaging 
modalities, designed to comply with the “Standards for Reporting Diagnostic accuracy 
studies” (STARD).119 120 Participants were recruited from Liverpool Vascular and 
Endovascular Service (LiVES), a city-wide vascular service in the UK. LiVES is 
arranged in a “hub and spoke” configuration locally and regularly accepts tertiary 
referrals for complications of previous aortic surgery at other centres. Routine EVAR 
surveillance is predominately undertaken using CDUS and abdominal radiograph 
(AXR).78 
3.3.2 Recruitment 
We recruited participants who potentially had a type I/III endoleak present, as this was 
the finding for the primary outcome of this study. To reduce the ethical apprehension 
regarding radiation exposure involved in the study we elected to recruit patients who 
were due to undergo dual phase CTA and CEUS in their standard care. Within the host 
institution these investigations are used to further investigate patients with aneurysm 
growth following EVAR, suspected graft related endoleaks or endoleaks of unknown 
characterisation. 
Focusing the study in this manner, we reduced the number of participants and so the 
total number of patients, that we change investigations away from standard practice. 
The above changes were felt to be sufficiently large enough away from standard care it 
was also considered imperative that participants gave personal informed consent, 
meaning those not able to consent where excluded. This established the Inclusion 
Criteria, Table 25 (page 130). 
Table 25: Inclusion criteria for prospective study comparing CEUS to tCTA for 
endoleak detection and characterisation 
Aged 18 or over 
Able to give informed consent 
Undergone an infra-renal EVAR of abdominal aortic aneurysm 
Planned for CTA and CEUS of EVAR 
 
Inclusion Criteria 
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There were two identified streams of recruitment; 
1. Immediately following EVAR when the operating surgeon felt that the 
participant had a type I/III endoleak on completion angiography. These participants are 
more at risk of having a type I/III endoleak on their routine initial post-operative CTA 
as it is already suspected. 
2. Participants who have had aneurysm expansion or type I/III endoleak suspected 
on standard surveillance (CDUS) who are planned for a CTA and CEUS. 
Patients were identified by staff involved in their clinical care and then referred to the 
study if the patient was interested in being considered for participation. This prevented 
the screening of identifiable patient details by study investigators. 
Once patients had been referred to the study investigators establish contact in person or 
by phone. Exclusion criteria were checked and the consent process commenced. 
Exclusion criteria, Table 26 (Page 131), were established by factors/characteristics that 
would prevent participation or make obtained imaging un-diagnostic. 
Table 26: Exclusion criteria for prospective study comparing CEUS to tCTA for 
endoleak detection and characterisation 
Unable to receive CTA Contrast  
Iodine contrast Allergy,  
  Insufficient renal function for standard outpatient contrast study (eGFR <45) 
  Hyperthyroidism 
Unable to receive CEUS contrast 
Previous reaction to Sonovue® (Ultrasound Contrast) 
 Allergy to sulphur hexafluoride (used in electrical industry in circuit breakers, 
switch gears and electrical equipment) 
 Recent acute coronary syndrome or unstable angina, typical angina at rest or 
frequent or repeated angina/chest pain – all within previous 7 days 
 Recent coronary intervention 
Previous embolization of artery in region of EVAR (affects imaging quality) 
BMI >30 (affects imaging quality) 
Exclusion Criteria 
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3.3.2.1 Recruitment Prediction 
Based on recent years data, section 2.3.2 (page 34), LiVES performs 590 CDUS 
scans/year, for infrarenal EVAR surveillance, Table 27(page 132). Previous analysis 
(Section 2.3.4.4, page 45) of a sample of 1592 of the above scans has shown an 
incidence of 2.3% of Type I/III endoleaks and 6.1% of unexplained aneurysm expansion 
>5mm of 6.1%. Giving a potential 49.6 (8.4% of 590) participants from CDUS 
surveillance. In addition to a small (unpredictable) number of participants who were 
referred following EVAR with Type I/III endoleaks on completion angiogram, we had 
estimated 2 / year. 
We anticipated 20% of participants would be excluded (predominately due to BMI>30) 
or decline to participate. We therefore based our recruitment predictions on 41 
participants recruited / year. This gave a predicted time to recruit 74 patients, section 
3.3.7.1 (page 137), of 22 months. 
Table 27: CDUS surveillance scans in LiVES in patient who have previously 
undergone infra-renal EVAR, numbers by year 
Average CDUS Scans / Year = 590 
3.3.3 Consent Process and Participant Journey 
The consent process was commenced during a clinical contact. A verbal description of 
the study was given including what would be involved for the participant, as well as the 
potential risks and benefits for them. The participant information leaflet, Appendix 4 
(page 236), and a consent form was left with the participant or posted to them and a 
time established for the study to re-contact them to confirm if they wish to participate. 
Year Number of CDUS scan for Infra renal EVAR Surveillance 
Apr08-Mar09 422 
Apr09-Mar10 564 
Apr10-Mar11 478 
Apr11-Mar12 1056 
Apr12-Mar13 525 
Apr13-Mar14 574 
Apr14-Mar15 514 
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The participant was re-contacted at the arranged time to confirm if they wish to 
participate. If they wish to participate a time/date was arranged for the study scans. 
If they did not wish to participate, a CEUS and standard CTA was arranged as planned, 
outside the study. Figure 47 (page 133) depicts the patients flow through the study 
compared to normal care outside the study. All participant involvement was limited to a 
single day. 
Participants were met in the outpatient department of LiVES by a study investigator on 
the arranged date of their scans. In a consultation room, confirmation of consent and 
wish to proceed was confirmed. All data were recorded onto a pro-forma, Appendix 5 
(page 242). The initial questionnaire was completed by the investigator and height and 
weight recorded following consent. 
Figure 47: Patient journey Inside/Outside Study 
 
Flow diagram demonstrates patient flow inside and outside of the study. 
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3.3.4 Contrast Enhanced Ultrasound Scan 
CEUS is performed in combination with a standard CDUS within LiVES. It is reported 
as a binary test yielding two values: presence or absence for each endoleak type. It is 
conducted by an experienced Clinical Vascular Scientist with extensive involvement in 
scans for EVAR surveillance. It is performed on a Philips IU22 ultrasound machine 
(Philips, Amsterdam, Netherlands), using the 2-5MHz abdominal curved array probe. 
Grey scale images of the aneurysm neck (when possible), iliac seal zones and maximum 
aneurysm dimensions are obtained and measured in maximum antero-posterior and 
medio-lateral dimensions. The echogenicity of thrombus within the aneurysm sac is 
noted. Using colour flow imaging and spectral Doppler, waveform characteristics and 
velocities are recorded in the common femoral arteries. The stent-graft is interrogated 
using colour and spectral Doppler to ascertain patency and flow haemodynamics of the 
neck, main body as well as both limbs. Any abnormalities in these parameters are 
reported. Colour Doppler is used to detect any endoleak. If present, its type, point of 
inflow, point of outflow and flow dynamics (using spectoral Doppler) are reported. 
Optimum views of the area of concern are obtained, prior to contrast injection, using 
appropriate machine set ups and controls as determined by the operator. 2.4ml Sulphur 
Hexafluoride Microbubble Contrast (SonoVue™, Bracco, Milan, Italy) is injected 
followed by 10mls of sodium chloride 0.9%, the on-screen timer is started at the point 
of commencing the injection. Flow direction and filling time ideally should be 
determined and anatomy of the endoleak established by interrogation. Passive 
elimination of the contrast agent is allowed to occur and the process repeated for a 
second injection. 
CEUS scan was reported by the performing vascular scientist to these data points, 
recorded in the data collection proforma, in addition to any clinically relevant points. 
The vascular scientist was blinded to the concurrent tCTA at the time of reporting, 
although was aware of the previous findings on EVAR surveillance. CEUS performed 
by multiple vascular scientists in the same sitting would have been desirable to allow 
inter-observer variability to be measured, this was not possible due to ethical concerns 
over multiple microbubble contrast injections. While these CEUSs were recorded for 
timings analysis, blind secondary reporting was not felt appropriate as image acquisition 
is user dependent and knowledge of probe position is an integral component to CEUS 
interpretation. 
Chapter 3: Prospective Study Comparing Contrast Enhanced Ultrasound To Time-Resolved Computer 
Tomography Angiography 
Iain Nicholas Roy - August 2020   135 
3.3.5 Time-Resolved Computer Tomography Angiography 
tCTA was performed on a Siemens Definition AS+ scanner (Siemens, Munich, 
Germany). Participants were positioned supine with arms raised above their head. The 
contrast injector was connected to a 20G (or larger) IV catheter in an anterior cubital 
fossa vein. A standard topogram scan was performed. Unless not required, a non-
contrast scan was performed. The maximum length that can be covered for the time 
resolution required is 27cm. This was centred over the EVAR stent-graft. Abdominal 
guides were placed at upper aspect of diaphragm and common femoral arteries for 
venous phase of scan. Abdominal aorta, just proximal to EVAR graft was selected as 
trigger area for time-resolved phases. 
Contrast (Ioversol 64%) is injected, using an auto injector, at 4ml/s for 96mls. 
Participants were asked to adopt shallow breaths and not to hold their breath. The time-
resolved phase was triggered by an increase in Hounsfield units (HU) >90 in trigger 
area. Phases occurred at 2, 4.5, 7, 9.5, 14.5, 19.5 and 24.5 seconds following the 
automatic trigger, these occurred in cranio-caudally acquisition, except the 5 and 7.5 
second phases which occur caudo-cranially direction. The venous phase was taken in 
full inspiration and was acquired 75s following the trigger. Tube setting and calculated 
predicted radiation exposure are presented in Table 28 (Page 135). 
Table 28: Tube setting and Radiation exposure for time-resolved and arterial 
phases of CT angiography 
*Average DLP used for an arterial phase scan in all CT angiography scans in LiVES in 
month of July 2015. DLP= Dose Length Product. 
All tCTA scans were reported by a single consultant vascular radiologist. This 
consultant was blinded to the results of the CEUS and collect data to the proforma, 
 Arterial phase (outside study) Time-resolved phases (inside study) 
Tube voltage 
(keV) 
120 80 
Tube Current (mA) 230 -(effective current–scanner 
automatically varies) 
120 
Scan Length (cm) Variable (dependent on body 
length) 
27 
Number of Phases 1 7 
Expected DLP 
(mGy/cm) 
Phases 
599.6* 552.3 (78.9 x 7 phases) 
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Appendix 5 (page 242). It was reported as a binary test yielding two values: presence or 
absence for each type of endoleak. 
Recruitment of participants, who were planned to undergo CTA in their care, and 
changing this to tCTA, meant that on average participants would not receive higher 
radiation exposure than they were already planned for Table 28 (page 135).  
3.3.6 Outcomes 
3.3.6.1 Primary Outcome 
The primary outcome is:  
• The predictive values of CEUS (index test) in comparison to tCTA (reference 
test) to detect stent-graft related endoleaks. 
3.3.6.2 Secondary Outcomes 
The Secondary outcomes are: 
i. The rate and type of adverse events for CEUS and tCTA 
ii. Predictive values of CEUS(index test) in comparison to tCTA (reference test) to 
detect:   any endoleak 
    type II endoleak  
iii. Predictive values of both tCTA (index test 1) and CEUS (index test 2) in 
detecting:  any endoleak 
    type II endoleak 
    graft-related endoleak  
in comparison to final endoleak diagnosis (reference standard), following any 
further investigations. 
iv. Evaluate the association between CEUS temporal delay (difference between 
contrast in endograft and contrast in endoleak) and evaluate its ability to 
differentiate between of endoleak types. 
v. Evaluate the association between “time for CEUS contrast in endoleak” to “time 
for tCTA contrast in endoleak” and assess potential as predictive tool, for 
optimum timing of CTA phases. 
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3.3.7 Statistical Analysis 
3.3.7.1 Power Calculation 
The power calculation was undertaken to a well described formula,121 and showed the 
required sample size to be 74. This was calculated based on a prevalence of stent-graft 
related endoleaks of 11% as demonstrated on previous tCTA studies of endoleaks.122 
The sample size was based on a presumed sensitivity of 0.95, taken from previous meta-
analysis72 73 and a decision to tolerate confidence interval of ±0.15 in the outcome. This 
confidence interval was based on calculations of sample sizes at different confidence 
intervals (Table 29, page 137) and ability to recruit patients in a timely manner 
(Heading 3.3.2.1, page 132). 
Table 29: Sample size required to show sensitivity of 0.95 to detected Type I and 
III Endoleak at given precisions of confidence interval. 
3.3.7.2 Predictive Values 
Predicative values (Sensitivity, specificity, positive predictive value and negative 
predictive value) were calculated along with binomial exact 95% confidence intervals. 
This was performed in RStudio v1.1.453 (RStudio, Inc., Boston, MA, USA) using 
DTComPair package v1.0.3. This performs McNemar test 123 and exact binomial test. 
Further it uses several methods to compute confidence intervals for differences in 
sensitivity and specificity. These methods are: generalised score statistic,124 weighted 
generalized score statistic125 and comparison of relative predictive values.126 
3.3.7.3 Association and Predictive Modelling 
Distribution of values was confirmed/refuted to be normal using graphical 
representations in the form of quantile-quantile plots. Following confirmation of 
normality or transformation to achieve normal distribution, associations was assessed 
with graphical analysis and appropriate further statistical testing of correlation within 
Tolerable Confidence Interval Precision Number participants required in study 
+/- 0.1 166 
+/- 0.15 74 
+/- 0.2 42 
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the framework of logistic regression e.g. Pearsons test for linear correlations.  If 
association could be established, then predictive modelling would be undertaken. 
3.3.8 Full Code for Data Processing and Analysis 
The full R code used to process and analyse these data is presented in appendix 6 (page 
249). 
3.3.9 Study Registration, Structure and Approvals 
The study was prospectively registered on clinicaltrials.gov, a clinical trials registry, 
reference: NCT02688751.127  
The Research Department of the Royal Liverpool University Hospital Hospitals NHS 
Trust granted full sponsorship (reference 5083). The study protocol was peer-reviewed 
by two clinical academics as part of the sponsorship application process. The trial was 
conducted in compliance with the principles of the Declaration of Helsinki (1996), the 
principles of GCP and in accordance with all applicable regulatory requirements 
including but not limited to the Research Governance Framework. The main ethical 
issue raised by the study was the change in CT scan from standard care. Participants 
received a tCTA instead of standard CTA and were asked a small number of non 
sensitive questions, as outlined in the data collection proforma, Appendix 5 (page 242) 
We felt this was ethically justifiable for 4 reasons; 
1. Participants made an informed choice to participate in the study 
2. The average radiation dose of a tCTA was predicted to be the same as a 
standard CTA 
3. tCTA has a methodological superiority in endoleak detection compared to 
standard CTA in other institutions 
4. If our hypothesis was proven it would produce evidence to support the use of 
CEUS instead of CTA which would reduce the use of potentially nephrotoxic contrast 
and ionising radiation within the EVAR surveillance population. 
The study protocol was reviewed by and a favourable ethical opinion was obtained from 
the NHS Health Research Authority, National Research Ethics Service, North West – 
Preston Research Ethics Committee, reference 15/NW/0908. Annual progress and 
safety reports and final report at conclusion of the study were submitted to the sponsor 
and ethics committee. 
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3.4 Results 
A total of 36 patients were referred for inclusion in the study. 30 patients were recruited 
over 17 months. Of the 6 patients not recruited; 4 had a BMI over 30, 1 had 
embolization material present and 1 declined to participate. The complete data, from 
those who participated is presented in Appendix 5 (page 242).  
3.4.1 Recruitment 
The study was suspended, then stopped, before full recruitment due to slower than 
anticipated recruitment of participants, Figure 48 (page 139) and an interim analysis 
performed. This decision was informed by the fact that the incidence of graft-related 
endoleaks was significantly higher in the study participants than anticipated for the 
power calculations, 30% vs an anticipated 11%. Recruitment was running at 52% of the 
predicted rate which would have nearly doubled the studies length to achieve its 
recruitment target. As such in discussion with the studies sponsor recruitment was 
suspended once the target number of endoleaks was achieved. Due to time lag between 
scan and reporting one further patient was included following this being achieved. 
Figure 48 : Predicted / Actual Recruitment and Graft-Related Endoleak Numbers 
in a Prospective Diagnostic Value of Imaging Modalities Study 
 
Cumulative number of patients recruited and graft-related endoleaks detected over the study period with 
pre-study predictions for comparison. 
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3.4.2 Demographics 
29 Males and 1 Female were recruited to participate. The mean age of participants at the 
time of operation was 75.6 years (range 62.9 – 88.3), the mean time elapsed between 
surgery and participation in the study was 4.2 years (range 0.1 – 11.8). The participants 
had EVAR stent grafts manufactured by :Medtronic® (Dublin, Ireland) 8 participants, 
W. L. Gore and Associates (Newark, Delaware, USA) 10 participants and Cook 
Medical ( Bloomington, Indiana , USA) 12 participants. The mean BMI of participants 
was 25.8 (range 17.8 – 30.0). 37% had established Ischemic heart disease, but only 13% 
had an established diagnosis of cardiac arrythmia. 13 participants (43%) were fully 
active, 14 (47%) participants could not carry out heavy physical work but otherwise of 
good functional status and 3 (10%) participants were less able to perform daily tasks. 
3.4.3 Primary Outcome 
The findings on CEUS, tCTA and the diagnosis each participant were eventually 
clinically treated as are summarised in  
Table 30 (page 140). 
 
Table 30: Summary of Individual Participant Endoleak Findings 
Participant ID 
CEUS Endoleak 
Diagnosis  
tCTA Endoleak 
Diagnosis  
Final Clinical 
Diagnosis 
7 Graft Related Graft Related Graft Related 
9 Type II Type II Type II 
14 Graft Related Type II Type II 
46 NONE NONE NONE 
48 Type II Graft Related Graft Related 
57 Type II Type II Type II 
59 Type II Type II Type II 
70 Type II Graft Related Type II 
75 Type II NONE NONE 
83 Type II Graft Related Graft Related 
85 NONE NONE NONE 
Chapter 3: Prospective Study Comparing Contrast Enhanced Ultrasound To Time-Resolved Computer 
Tomography Angiography 
Iain Nicholas Roy - August 2020   141 
95 Graft Related Graft Related Graft Related 
184 Type II Type II Type II 
205 Type II Type II Type II 
289 Type II Type II Type II 
301 Type II NONE Type II 
357 Graft Related Type II Type II 
409 NONE NONE Type II 
486 Type II Type II Type II 
533 Type II Type II Type II 
579 Graft Related Graft Related Graft Related 
660 Type II Type II Type II 
679 Type II Type II Type II 
705 Type II Type II Type II 
709 Type II Type II Type II 
750 Type II Type II Type II 
760 Graft Related Graft Related Graft Related 
774 Type II Type II Type II 
876 Type II Graft Related Graft Related 
879 Graft Related Graft Related Graft Related 
  
3.4.3.1 Predictive Values of CEUS to Detect Graft-Related Endoleak, 
with tCTA as the Reference Standard 
A total of 9 graft-related endoleaks were diagnosed on tCTA giving a prevalence of 
30%. 1 type Ia, 2 type Ib and 6 type III endoleaks were detected. 7 graft-related 
endoleaks were detected on CEUS: 4 type Ia, 1 type Ib, and 2 type III endoleaks but not 
all in the same participants. This provides the diagnostic values for CEUS to detect graft 
related endoleaks shown in Table 31 (page 142). 
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Table 31: Diagnostic Values of CEUS (Index) Compared to tCTA (Reference) in 
Detecting Graft-Related Endoleaks 
3.4.4 Secondary Outcomes 
3.4.4.1 Adverse Events for CEUS and tCTA 
No participant suffered any serious adverse event while undergoing either CEUS or 
tCTA.   One participant intravenous cannula occluded after the first injection of contrast 
for CEUS and on attempting the second injection the raised pressure cause by the 
occlusion ruptured the remaining microbubbles in the contrast rendering their second 
run non-diagnostic. The patient suffered no ill effects and the first run was diagnostic, 
so all required information was obtained for the participant’s ongoing care. 
3.4.4.2 Predictive Values of CEUS to Detect any Endoleak, with 
tCTA as the Reference Standard 
In total there were 5 participants who had no endoleak detected on tCTA (83% 
prevalence of endoleaks). 2 of these participants did have a type II endoleak detected on 
CEUS, 3 participants had no endoleak detected on either modality. These filled at 16 
and 50 seconds after contrast reached the graft, meaning that they may have not been 
detected on tCTA due to the specific tCTA protocol used was focused on detecting 
graft-related endoleaks. The diagnostic values for CEUS to detect any endoleak are 
shown in Table 32 (page 143). 
  
 Estimate 95% Confidence Interval 
Sensitivity 0.56 0.23 – 0.88 
Specificity 0.90 0.78 – 1.00 
Positive Preditive Value 0.71 0.38 – 0.96 
Negative Predictive Value 0.82 0.67 – 0.98 
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Table 32: Diagnostic Values of CEUS (Index) Compared to tCTA (Reference) in 
Detecting Any Endoleak 
3.4.4.3 Predictive Values of CEUS to Detect Type II Endoleak, with 
tCTA as the Reference Standard 
16 participants who did not have a graft related endoleak had a type II endoleak, on 
tCTA, giving a prevalence of 53%. The diagnostic values for CEUS to detect a type II 
endoleak are shown in Table 33 (page 143). 
Table 33: Diagnostic Values of CEUS (Index) Compared to tCTA (Reference) in 
Detecting Type II Endoleaks 
 
3.4.4.4 Predictive Values of CEUS and tCTA to Detect Graft-Related 
Endoleak, with Final Diagnosis as the Reference Standard 
A total of 8 participants (prevalence 26%) were treated on an ongoing basis with graft-
related endoleaks. One participant had a type III endoleak diagnosed on the tCTA but 
had a multiplanar DSA which failed to demonstrate the type III endoleak. The DSA 
instead showed a lumbar type II endoleak at the same anatomical position. The 
participant was observed, and the aneurysm failed to demonstrate any further growth. 
Of the remaining graft-related endoleaks diagnosed on tCTA 3 were confirmed on re-
intervention (1 DSA and 2 open surgery) and 5 were not intervened on (1 patient 
declined intervention, 2 patients unfit for intervention, 2 patient observed as growth rate 
 Estimate 95% Confidence Interval 
Sensitivity 1.00 1.00 – 1.00 
Specificity 0.60 0.17 – 1.00 
Positive Preditive Value 0.93 0.83 – 1.00 
Negative Predictive Value 1.00 1.00 – 1.00 
 Estimate 95% Confidence Interval 
Sensitivity 0.875 0.71 – 1.00 
Specificity 0.57 0.31 – 0.83 
Positive Preditive Value 0.70 0.50 – 0.90 
Negative Predictive Value 0.80 0.55 – 1.00 
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slow and good seal zone length). This demonstrated the diagnostic values of CEUS and 
tCTA compared to the best working diagnosis used to treat patients shown in Table 34 
(page 144). 
Table 34: Diagnostic Values of CEUS (Index 1) and tCTA (Index 2) compared to 
Final diagnosis (Reference) in Detecting a Graft Related Endoleak 
3.4.4.5 Predictive Values of CEUS and tCTA to Detect any Endoleak, 
with Final Diagnosis as the Reference Standard 
2 endoleaks seen only on CEUS (not tCTA) were deemed by the MDT to be sufficiently 
well visualised to be secure as a diagnosis. Giving a final prevalence of endoleaks in the 
participants of 90%. The diagnostic values of CEUS and tCTA when final diagnosis 
was used as the comparator are presented in Table 35 (page 144). 
Table 35: Diagnostic Values of CEUS (Index 1) and tCTA (Index 2) compared to 
Final diagnosis (Reference) in Detecting Any Endoleak 
3.4.4.6 Predictive Values of CEUS and tCTA to Detect Type II 
Endoleak, with Final Diagnosis as the Reference Standard 
The final diagnostic value of CEUS and tCTA are displayed in Table 36, page 144. 
Table 36: Diagnostic Values of CEUS (Index 1) and tCTA (Index 2) compared to 
Final diagnosis (Reference) in Detecting Type II Endoleaks 
 CEUS Estimate (95% CI) tCTA Esitimate (95% CI) 
Sensitivity 0.625 (0.29 – 0.96) 1.00 (1.00 – 1.00) 
Specificity 0.91 (0.79 – 1.00) 0.95 (0.87 – 1.00) 
Positive Preditive Value 0.71 (0.38 – 1.00) 0.89 (0.68 – 1.00) 
Negative Predictive Value 0.87 (0.73 – 0.98) 1.00 (1.00 – 1.00) 
 CEUS Estimate (95% CI) tCTA Esitimate (95% CI) 
Sensitivity 0.96 (0.89 – 1.00) 0.93 (0.83 – 1.00) 
Specificity 0.67 (0.13 – 1.00) 1.00 (1.00 – 1.00) 
Positive Preditive Value 0.96 (0.89 – 1.00) 1.00 (1.00 – 1.00) 
Negative Predictive Value 0.67 (0.13 – 1.00) 0.60 (0.17 – 1.00) 
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3.4.4.7 Evaluate the Association Between “Time For CEUS Contrast 
In Endoleak” to “Time For tCTA Contrast In Endoleak” and Assess 
Potential as Predictive Tool for Optimum Timing of CTA Phases. 
Distribution of time for contrast be seen in endoleak on both tCTA and CEUS was 
assessed using Q-Q plots demonstrated in Figure 49 (page 145).  
This demonstrated normality of the two distributions and therefore graphical assessment 
of association was undertaken, Figure 50 (page 146). No association of any form was 
evident. A best fit linear correlation was fitted, Figure 50 (page 146) and a Pearson 
correlation coefficient calculated of R=0.17 (p=0.46) was calculated. This confirmed no 
linear correlation existed. 
 
Figure 49: Quantile-Quantile plots of the distribution of Time for contrast to be 
seen in endoleaks on both tCTA (left) and CEUS (Right) 
 
Q-Q plot of time for contrast to arrive into endoleak on tCTA & CEUS. Both plots demonstrate 
approximal linearity within the confidence interval, suggesting both are normally distributed. 
 CEUS Estimate (95% CI) tCTA Esitimate (95% CI) 
Sensitivity 0.84 (0.68 -1.00) 0.84 (0.68 – 1.00) 
Specificity 0.64 (0.35 – 0.92) 1.00 (1.00 – 1.00) 
Positive Preditive 
Value 
0.80 (0.62 – 0.97) 1.00 (1.00 – 1.00) 
Negative Predictive 
Value 
0.70 (0.42 – 0.98) 0.79 (0.57 – 1.00) 
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Figure 50: Association plot of time for contrast to be seen in an endoleak on tCTA 
vs CEUS, best fit linear correlation line with 95% confidence interval 
superimposed. 
 
Scatter plot of paired times for contrast to arrive in to endoleak on tCTA & CEUS, demonstrating no 
apparent pattern of relationship. Solid line and grey confidence interval represent a best fit linear 
correlation demonstrating significant numbers of points outside confidence interval and therefore poor fit 
of model. 
3.4.4.8 Enhancement Data for EVAR Lumen and Endoleaks from 
tCTA 
There is large variability between participants in enhancement patterns, this is due to: 1) 
The large variability in the time to trigger the scan (range 14.5-34.9 s, interquartile 
range 18.4-22.6 s and median 20.5 s) and 2) The variability in peak opacification e.g. in 
EVAR lumen opacification (range 315-705 HU, interquartile range 430-508 HU, 
median 468.5 HU).  
Summaries of these raw data are presented in Table 37 (page 147) and Table 38 (page 
147). 
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Table 37: Summary of contrast evident in different findings on time-resolved CTA 
by time 
Table 38: Summary of timing of peak opacification of different findings on tCTA 
by time 
* One participant recorded equal peak opacification at two subsequent time points 
¥ these endoleaks had their highest enhancement recorded in the last time point of the 
time-resolved phase or in the venous phase meaning that potentially the peak 
enhancement may have fallen any-time in the 50s time elapse between these points. 
 Time Since time-resolved phase of CTA triggered (s) 
2 4.5 7 9.5 14.5 19.5 24.5 75 
Contrast evident in 
EVAR lumen 
100% 100% 100% 100% 100% 100% 100% 100% 
Contrast evident in 
graft related endoleak 
(if present) 
100% 100% 100% 100% 100% 100% 100% 100% 
Contrast evident in 
Type II endoleak (if 
present) 
19% 33% 52% 67% 86% 86% 95% 100% 
 Time Since time-resolved phase of CTA triggered (s) 
2 4.5 7 9.5 14.5 19.5 24.5 75 
Peak opacification in 
EVAR lumen 
0% 3% 0 33% 37% 33% 0 0 
Peak opacification in 
graft related endoleak 
(if present)* 
12.5
% 
0% 0% 0% 0% 37.5
% 
50%¥ 0% 
Peak opacification in 
Type II endoleak (if 
present) 
0% 5% 5% 0% 0% 10% 67%¥ 14%¥ 
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The individual enhancement patterns of the EVAR stent-grafts and any evident 
endoleaks seen on tCTA for each participant are presented in visual form in Figure 51 
(page 149). 
All participant information for enhancement of each endoleak type and stent-graft 
lumen can then be adjusted for the time for the time-resolved phase to be triggered and 
condensed into single scatter plots for each enhancement type, Figure 52 (page 149). 
These data can be transformed to allow a 2nd degree (quadratic) polynomial distribution 
best fit line, with confidence intervals, to be over laid. Endoleak type can be maintained 
but graphs are condensed to “class” of enhancement, Figure 53 (page 150). 
These data can then be condensed into class based best fit lines and displayed side by 
side, Figure 54 (page 151). 
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Figure 51: Enhancement Patterns of EVAR Stent-Grafts and Endoleaks on tCTA 
for Each Study participant 
 
Filling (enhancement) patterns over time of differing endoleak types in 30 time-resolved CTA studies in 
different patients. 
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Figure 52: Perfusion Data Points By Enhancement Type From Start Of tCTA 
Contrast Injection 
 
Combined enhancement values of 30 time-resolved CTA studies in different patients, divided in to plots 
by endoleak type. 
 
Figure 53: Perfusion data for different enhancement objects with best fit mean 
lines 
 
Combined enhancement values of 30 time-resolved CTA studies in different patients, divided into plots 
by endoleak class.  With individual endoleak types in separate colours with best fit lines to aid 
interpretation. 
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Figure 54: Best fit mean enhancement for different enhancement object classes 
 
Best fit lines by endoleak class from combined enhancement values of 30 time-resolved CTA studies in 
different patients.  Demonstrates near identical enhancement pattern of graft-related and type II 
endoleaks. 
3.4.5 Radiation Dose Data 
The radiation exposure and estimated absorption within the study, Table 39 (page 152), 
was lower than those calculated in the preparation of the study, Table 28 (page 135).  
This discrepancy may be accounted for by the selection criteria of individuals with a 
BMI below 30. The DLP for the time-resolved phases, 497mGy/cm, was essentially 
identical for all participants and lower than the mean value of the venous phase which 
replicated settings that would be have been used for a single arterial phase. The venous 
phase DLP had a wide range from 348 – 936 showing that some, lower BMI, patients 
had a slight increased radiation exposure from participation in the study due to a lack of 
ability to actively vary tube current within time-resolved phases, to manage patient 
radiation dose.  This possibility was detailed in the participant information leaflet, 
Appendix 4 (page 236). 
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Table 39: Tube Settings and Radiation Exposure for Time-resolved and Venous 
Phases of CT Angiography Within Study 
3.5 Discussion 
This study demonstrates the diagnostic values of CEUS to detect and characterise 
endoleaks compared to a methodologically superior reference standard than all the 
currently published literature. Its prospective blinded nature along with compliance with 
the STARD principles likely make it the most rigorous study performed in this area. It 
contains the largest sample of graft related endoleaks in any CEUS diagnostic values 
study. 
3.5.1 Power Calculation 
The power calculation was based on two assumptions. These two assumptions: a 
prevalence of graft related endoleaks of 11% and a sensitivity of CEUS to graft related 
endoleaks of 95%, were informed by the literature but were ultimately inaccurate. 
The prevalence of graft-related endoleaks was assumed to be 11% based on a Sommer 
et al’s previous tCTA study.122 Sommer et al recruited their participants from a pool of 
patients at increased risk of having an endoleak, which they defined as “The patient was 
suspected of having an endoleak at a previous imaging study, the patient was known to 
have postoperative endoleaks, or the patient was at high risk for endoleaks because of 
atypical anatomy (ie, aneurysmal widening of the iliac arteries or a short aortic neck for 
stent placement).” 46 of their participants were patients with infra-renal EVAR, 5 had a 
graft related endoleak to give the prevalence of 11%.  
In this study we recruited participants at increased risk of graft related endoleaks based 
on “the participant was having initial post-op imaging and had a type I/III endoleak on 
 Time-resolved phase(s) 
Mean (Range) 
Venous phase 
Mean (Range) 
Tube voltage (keV) 80 (-) 120 (-) 
Tube Current (mA) 120 (-) 190 (214 – 270) 
Number of Phases 7 1 
CTD/Vol (mGy/L) 18.01 (17.99-18.04) 12.91 (8.38 – 18.22) 
Total DLP (mGy/cm) 
Phases 
497 (496-498) 562 (348 – 936) 
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completion angiography OR participants who have had aneurysm expansion or type 
I/III endoleak suspected on standard surveillance (CDUS) and are planned for a CTA 
and CEUS”.118 In this study 9 graft related endoleaks were diagnosed in the 30 patients 
who participated in this study, giving a prevalence of 30%. 
The difference in methodology in recruiting patients at increased risk of endoleak 
almost certainly account for the difference in prevalence. Sommer et al.’s stated aim 
was to recruit patients at risk of [any] endoleak, in contrast this study was more focused, 
and aimed to recruit participants at high risk of, the more clinically important, graft 
related endoleaks. If we had also recruited patients without aneurysm expansion but 
type II endoleaks present on CDUS we would likely have had a graft related endoleak 
prevalence much more similar to that of Sommer et al. but conversely had to recruit 
more patients. This however would not have significantly bolstered the value of the 
study regarding its primary outcome. Recruiting such patients would have also had 
ethical dilemmas as they would not normally have a CTA in their routine care which we 
would then be subjecting them to. Finally, there would have been additional financial 
cost of recruiting such patients and performing tCTA that would not have otherwise 
been performed. 
The sensitivity of CEUS for the power calculation was predicted to be 95% based upon 
Karthikesalingam et al.’s meta-analysis.73 Karthikesalingam et al.’s 2012 meta-analysis 
is the only one that differentiates between any endoleak and graft related endoleaks in 
its analysis but does have other methodological flaws such as including all methods of 
CEUS scanning under one analysis, see section 1.3.7 (page 21). A secondary analysis 
performed of CEUS as the reference standard for CTA acknowledges the potential 
issues of presuming CTA to be a superior modality. The use of a potentially superior 
comparator in the form of tCTA should perhaps have prompted a lowering of the 
assumed sensitivity, however there would have been no way to quantify the extend of 
this. The final sensitivity 56% is much lower than would have been predictable. 
If the incidence of graft related endoleaks of 30% had been predictable and the tolerated 
confidence interval of +/- 15% had been maintained the power calculation would have 
suggested a sample size set out in Table 40 (page 153), for various sensitivities. 
Table 40: Suggested sample sizes by sensitivity from power calculation based on 
prevalence of 30% and tolerated confidence interval of +/- 15%. 
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If this had been used for initial calculation and the sensitivity was thought likely to be 
95% we would have recruited sufficient patients for analysis e.g. >28 participants. 
Assuming the sensitivity in the primary outcome is correct (despite its wide confidence 
interval) any future study which wished to show the sensitivity of CEUS to detect and 
correctly characterise graft related endoleaks to +/- 15% sensitivity would be required to 
recruit in excess of 140 participants while maintaining a prevalence of graft related 
endoleak rate of 30% within the study population. 
3.5.2 Recruitment 
Recruitment to the study averaged 1.8 participants a month, instead of the predicted 3.4 
participants. This prediction was based upon the calculation that 8.4% of CDUS scans 
show results that would require further investigation, making that patient a potential 
participant. This was multiplied by the average number of CDUS scans performed in 
the LiVES service each year of 590. This figure based on data, Table 27 (page 132), that 
included a year with almost double the number of scans in other years. If this year had 
not been included a more realistic 513 CDUS scans a year could have been included. 
This alone would have reduced the prediction for recruitment down to 3 
participants/month. A further factor that was not taken into account was that many of 
the CDUS findings were in the same individual patients who were having repeated 
surveillance scans. This was particularly important as the planned recruitment schedule 
covered more than 12 months, which is the normal interval for standard EVAR 
surveillance in LiVES. Meaning that after 12 months many patients who had already 
participated in the study were having repeated findings that would have made them 
eligible again. 
This slow recruitment was offset by the much higher than anticipated prevalence of 
graft related endoleaks which ultimately lead to the decision to perform an interim 
analysis once the target number of graft related endoleaks had been seen. The delay 
between tCTA scan and report ultimately meant we had 1 over target graft-related 
Assumed Sensitivity Number participants required in study 
95% 28 
75% 107 
55% 142 
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endoleaks, as 2 occurred in quick succession at the end of recruitment. Interim analysis 
showed a much lower than expected sensitivity of CEUS. When the above power 
calculations, Table 40 (page 153), were performed it was apparent that recruiting further 
participants was not going to significantly change the scientific value of the results of 
the study. As such the study was terminated early. This decision was taken in the 
context of the slow recruitment to date meaning that achieving initial sample size or 
even larger samples based upon a change to the protocol was not practical with the 
resources and time available. It would represent the largest sample of paired CEUS and 
CTA (of any type) samples if included in the meta-analysis of note.73 
3.5.3 Study Methodology and Limitations 
This study was the first to compare CEUS to tCTA in a blinded prospective 
comparative study. As such it is the first to compare CEUS to the methodologically 
superior tCTA as opposed to standard CTA. As such its results may more closely 
represent the true diagnostic values of CEUS compared to the gold standard of 
multiplanar DSA. It is methodologically superior to many published studies in that it 
was a prospective and blinded study that was designed to adhered to the STARD 
standards.119 The fact that all participants had the paired scans within 2 hours of each 
other has also not been achieved by any other study published in the literature and all 
but removed changing findings as a confounding factor. The prospective publication of 
the protocol, 118 before analysis, is also a quality indicator not achieved by any other 
study in this area. Finally the primary outcome was set as the diagnostic values for the 
detection and correct characterisation of graft-related endoleaks which is the most 
clinically relevant. Most other studies have examined simple detection of any endoleak 
as the primary outcome, with only a proportion looking at endoleak characterisation as a 
secondary outcome. Any endoleak detection is interesting but is unlikely to drive a 
change in clinical decisions without aneurysm growth which can accurately be shown 
on CDUS and would prompt further investigation without endoleak detection in LiVES 
practice.  
tCTA has not been proven to be superior to CTA, it is however a logical methodological 
assumption. It would be unethical to undertake such a comparison due to the need to 
double expose patients to the contrast and radiation of these tests. No study has 
compared the diagnostic values of any modality (CDUS, CEUS, CTA or tCTA) 
compared to multi-planer DSA. tCTA is demonstrated to be a strong diagnostic test in 
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this study compared to final diagnosis but is not perfect as it mischaracterised an 
endoleak compared to subsequent DSA examinations. This supports, but does not 
prove, the hypothesis that CTA would also be inaccurately characterising endoleaks as 
it has less haemodynamics information to deduce endoleak character from. 
The single individual interpreting and reporting of both tCTA and prevented the inter-
reporter variability being explored. Both CEUS and tCTA were reported by experienced 
personal in a large volume tertiary centre that regularly undertake examinations in 
patients with such conditions. An equal number of CEUSs were performed and reported 
by 3 different individuals, all of whom have in excess of 5 years experience of CEUS 
examinations in post EVAR patients. 
The single centre nature of the study and the underlying small sample also limit the 
scientific impact of this study. 
Finally the change to the protocol to allow interim analysis which lead to termination of 
the study could have introduced bias into the results. Although the decision making 
behind this was logical and informed by the information available it was not envisaged 
in the study protocol. The decision to terminate the study was based upon valid ethical 
consideration that enrolling further participants would add little scientific value. Given 
the power calculation included such an assumption about prevalence of the disease 
future studies should include an analysis to allow adjustment of sample size based on 
actual prevalence in the study population. If such a protocol had existed this study 
would have re-calculated its sample size to be 28. And the study would have undertaken 
analysis as a completed study not an interim analysis that led to the early conclusion of 
the study. 
3.5.4 Outcomes 
3.5.4.1 Graft Related Endoleaks 
The primary outcome: diagnostic values of CEUS to detect graft-related endoleaks, 
Table 31 (page 142) were markedly lower than expected. Sensitivity is the characteristic 
most important in these diagnostic values as a missed diagnosis of graft related 
endoleak may result in EVAR treatment failure and ultimately patient death. As such 
higher sensitivity at the expense of specificity is likely preferable. The sensitivity of 
0.56 (95% CI, 0.23 – 0.88) is far below any acceptable level for a diagnostic test or 
surveillance imaging modality for such a diagnosis. Even if the small sample size has 
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lead to a sampling error that has given a lower than true value, the highest value in the 
95% confidence interval is below that of any reported study. The methodological 
superiorities of this study compared to other published studies and the relatively large 
number of relevant findings compared to published literature mean that the accepted 
sensitivity of CEUS to detect graft related endoleaks must be questioned. 
The sensitivity demonstrated in this study is lower than reported in the majority of the 
literature and may simply be a result of the improved comparator standard, tCTA, over 
previous studies which used CTA. This is reinforced by the comparison of both CEUS 
and tCTA to eventual final MDT diagnosis, Table 34 (page 144), following gold 
standard imaging (multi-planar DSA) of some patients and serial CDUS of others. The 
CEUS sensitivity for this diagnosis is 0.625 (95% CI 0.29 – 0.96) and for tCTA is 1.00 
(95% CI 1.00 – 1.00). This confirms the hypothesised methodological benefits of tCTA 
as its perfect Sensitivity shows that even with all other information available to make 
the final diagnosis no further graft-related endoleaks were confirmed. The improved but 
still lower than anticipated CEUS sensitivity is in fact due to a single change in final 
diagnosis away from graft related endoleak to type II endoleak following a DSA 
examination. 
Specificity of CEUS is shown, Table 31 (page 142), to be only slightly poorer than most 
of the literature. This is less concerning as false positive results following a surveillance 
/ pragmatic diagnostic test can be resolved by gold standard imaging assuming the test 
produces tolerable level of false positives (specificity). The specificity results are 
similar between CEUS and tCTA when compared to final MDT diagnosis, Table 34 
(page 144). If there is an inverse relationship between sensitivity and specificity it is 
reassuring that these are closely match suggesting a similar “threshold to diagnosis” has 
been applied during the study. This threshold in current clinical practice in LiVES 
should likely be moved towards higher sensitivity with a converse lowering of 
sensitivity in CEUS examinations. 
Positive and negative predictive values have limited generalisation as they are 
influenced by prevalence of the condition being diagnosed. The high prevalence caused 
by highly selective criteria mean that these values have limited relevance to a 
generalised EVAR surveillance population. Predictive values calculated using a 
prevalence figure obtained by another form of imaging (not tCTA) would likely be 
misleading to present. 
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3.5.4.2 Any Endoleak 
The perfect sensitivity 1.0 (95% CI 1.0-1.0) to detect any endoleak on CEUS compared 
to tCTA, Table 32 (page 143) and near perfect sensitivity 0.96 (95% CI 0.89-1.0) 
compared to final diagnosis, Table 35 (page 144), fit with existing literature. It is also a 
logical extension of our understanding of modern CEUS. Contrast is often seen in an 
endoleak in dynamic filling, however it is not always possible to visualise the point of 
origin, and even when seen this is seen in 2D preventing full 3D localisation of inflow 
point. This potentially limits the characterisation of the endoleak but contrast all but 
guarantees its visualisation. Therefore sensitivity to detect an endoleak is very high but 
sensitivity to correctly characterise it as graft related is poorer. 
tCTA sensitivity 0.93 (95% CI 0.83 – 1.00) compared with final diagnosis was slightly 
lower than that of CEUS. Again this is logical as the protocol of the tCTA was designed 
to detect graft-related endoleaks and did not include a very delayed venous phase to 
detect slow filling type II endoleaks. The MDT final diagnosis accepted that some 
endoleaks were adequately seen solely on CEUS to warrant diagnosis as there was no 
corresponding tCTA phase, so depressing tCTA sensitivity. Some endoleaks seen solely 
on CEUS were not seen on corresponding phases of tCTA and as such the MDT was 
unable to confirm the diagnosis which, in turn, depressed the specificity of CEUS 
compared to final diagnosis, Table 35(page 144). 
3.5.4.3 Type II Endoleaks 
The diagnostic values for CEUS compared to tCTA, Table 33(page 143) and 
CEUS/tCTA compared to final diagnosis, Table 36 (page 144) are of limited extra value 
but were presented for completeness. They are essentially a reversal of the value for 
graft related endoleaks as any mis-characterisation between the classes of endoleaks 
subtracts from different elements of the diagnostic values. 
The diagnosis of type II endoleak is of limited clinical value unless graft related 
endoleak can be confidently excluded and aneurysm growth can confidently be 
confirmed. 
3.5.4.4 Correlation Data 
This study did not demonstrate a correlation between timing information observed on 
CEUS and tCTA. This would have potentially been clinically useful as patients 
undergoing CEUS before CTA could have then potentially have had the time of their 
CTA phases tailored according to the information available on CEUS. 
Chapter 3: Prospective Study Comparing Contrast Enhanced Ultrasound To Time-Resolved Computer 
Tomography Angiography 
Iain Nicholas Roy - August 2020   159 
These differences likely arise as a result of the differences in contrast medium and 
volume and the effect this ultimately has on infection time. CEUS is a small bolus that 
is completely infected very rapidly and therefore likely arrives in peak concentration 
over a small number of cardiac cycles. tCTA however has a much slower injection of 
contrast (due to volume) that means the contrast arrives over a significantly longer 
period / number of cardiac cycles and therefore takes a much more variable period to 
reach detectable concentrations. We can further hypothesis this variability will be 
worsened by different participants various cardiac outputs, intra-vascular volumes and 
the systemic vascular resistance within the lumens to and through the endoleaks in 
question. 
3.5.4.5 Perfusion Data 
The haemodynamics and often complex anatomy of endoleaks make the interpretation 
of these data complex.  
It is known that type II endoleaks can take several minutes to fill following CT contrast 
injection. The time-resolved CTA protocol used in this study was specifically designed 
to capture graft-related endoleaks so does not fully demonstrate all the haemodynamic 
characteristics of type II endoleaks that may be required to fully inform future CT 
protocol design. 
tCTA sacrifices some “on screen” resolution in each phase to allow more phases to be 
captured for the same radiation exposure. The premise being that the temporal or 
haemodynamic information gained about the endoleak provides more information to 
characterise any endoleak than the potential loss in anatomical information from the 
reduced resolution. This is further mitigated by the use of standard venous phase within 
tCTA that allows anatomical information to be defined as normal on screen resolution. 
Not all phases on tCTA add significant haemodynamic information and if they could be 
further rationalised/reduced the on screen resolution of tCTA could be improved so 
regaining some of the potentially sacrificed anatomical information. 
The objectives of performing a CTA vary depending on the situation but may include  
1) Aneurysm size measurement (that does not require contrast and can be 
performed on any phase with or without contrast) 
2) Assessing the length and quality of the seal zones, best performed with a high 
opacification of aortic lumen 
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3) Assessing for presence/absence of any endoleak – best performed with the 
highest opacification of the endoleak possible 
4) Characterising an endoleak as potentially graft related – best done by fully 
defining its anatomy (as above) and haemodynamics (defining its inflow as well 
as full anatomy) 
These data presented in Table 37(page 147) and Table 38 (page 147) demonstrate that 
objective 1 can be achieved at any time point, objective 2 by a phase at 14.5s following 
trigger, objective 3 by a phase between 14.5-19.5s for graft related endoleaks and 
between 19.5 and 75s for type II endoleaks and objective 4 by at least 1 phase around 2s 
for graft related endoleaks and multiple phases would be required to definitely capture 
all type II endoleaks. 
All this could potentially be achieved by a phase at 2s (to observe the 
inflow/haemodynamics) of graft-related endoleaks +/- a phase 2.5-5s later, a phase at 
19.5s (to get peak opacification of graft related endoleaks) and very near peak 
opacification of aortic lumen to assess seal zone length and quality, a “late” venous 
phase up to 75s after trigger to capture type II endoleaks not seen on earlier phases and 
to fully define the anatomy of endoleaks not fully visualised previously. 
It is therefore possible to get the majority of the useful haemodynamic information from 
a tCTA with only 3 or 4 phases. Minimising the need to reduce resolution by decreasing 
radiation dose. 
If only one phase is to be performed (as the haemodynamic information is not felt to 
warrant the extra radiation exposure) then it should be at 19.5 seconds following trigger 
as this will get peak graft-related endoleak opacification in 50% of cases (100% will be 
opacified to some extent), more than adequate EVAR lumen opacification to assess seal 
zones and 86% of type II endoleaks will be opacified. The selection criteria for this 
study may mean that the endoleaks represented, and therefore their haemodynamics, 
may not be representative of a general surveillance population. 
3.6 Summary 
This study has shown the sensitivity of CEUS to detect graft related endoleaks to be 
significantly lower than previous reported. It is hypothesised that this is due to CEUS 
being compared to a superior reference standard of tCTA. It has confirmed CEUSs 
sensitivity to detect any endoleaks is equivalent to the tCTA protocol in this study. 
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CEUSs weakness remains differentiating between endoleak types or classes.  
This study was carried out to more rigorous scientific standards than the majority of the 
published literature and this study contains more graft-related endoleaks than any other 
published study. It adds valuable information to the published literature which should 
influence the choice to use CEUS in clinical practice. CEUS likely does not have the 
diagnostic abilities to reliably differentiate endoleak classes of types but is a highly 
reliable way to diagnosis the presence of an endoleak in the absence of a known cause 
for aneurysm growth. 
The perfusion patterns of endoleaks seen on tCTAs within this study can be used to 
improve the timing of phases on tradition single or multi-phase CTA to allow optimum 
imaging dependent upon the objectives of that imaging. 
  
Surveillance Following Endovascular Repair of Abdominal Aortic Aneurysm 
162  Iain Nicholas Roy - August 2020 
 
 
  
Chapter 4: Discussion: Future of EVAR Surveillance research and clinical practice 
Iain Nicholas Roy - August 2020   163 
4 DISCUSSION: FUTURE OF 
EVAR SURVEILLANCE 
RESEARCH AND CLINICAL 
PRACTICE 
This thesis has presented novel data regarding the indication, incidence and distribution 
of secondary interventions following Endovascular aneurysm repair (EVAR). It has 
demonstrated that with a robust administrative process it is possible to achieve excellent 
compliance with EVAR surveillance. It shows that the factors associated with 
compliance are often co-linear and display potential confounding, and that relatively 
few of these factors are independently associated with compliance. It demonstrated that 
it is possible to accurately predict future secondary interventions based on the data 
available on a single routine Colour Duplex Ultrasound Scan (CDUS) performed for 
EVAR surveillance. It has also shown that it is likely to be possible to instigate required 
secondary interventions while collecting fewer observations on CDUS and Abdominal 
radiography (AXR).  Contrast Enhanced Ultrasound (CEUS) has been shown to have 
poorer diagnostic abilities than previously stated and likely has a very limited role in 
endoleak diagnosis in future EVAR surveillance programmes. The comparative data 
used from time-resolved Computer Tomography Angiography (tCTA) however offers 
exciting prospects for enhancing and improving the acquisition protocols for ‘standard’ 
Computer Tomography Angiography CTA. 
This chapter discusses the methodology used to obtain these data and suggested areas 
for improvement and potential benefits of further research and how to maintain the 
clinical applicability of EVAR research into the future. 
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4.1 Background 
The overall aim of this thesis was to produce an evidence base to facilitate the creation 
of an efficient, evidence based EVAR surveillance regimen. Initial surveillance 
regimens were empirically designed and remained remarkably similar to those described 
by Parodi et al. in 1991, despite surveillances objective being to identify complications 
and Parodi et al. objective being to prove the efficacy of endovascular aneurysm repair 
(EVAR).39 These early generations of EVAR surveillance regimens are still 
recommended by some stent-graft manufactures, including up to 4 visits for imaging in 
the first year.84 Incrementally imaging intensity in the first year after EVAR steadily 
decreased in clinical practice and research studies.93 CDUS is also used more frequently 
and CTA less frequently due to concerns over radiation exposure, financial cost, and 
potentially nephrotoxic contrast agents.78 Finally a binary method to stratify EVAR 
surveillance by patient risk level has just been adopted into European clinical 
guidance.53 These incremental changes to the original empirical design have occurred 
slowly and primarily made based on retrospective cohort studies, with or without 
external validation.78   
The cost associated with surveillance and secondary interventions are a significant 
portion of the overall cost of effective EVAR treatment.36 While the need for secondary 
interventions is a limitation of the technology and its applicability, the cost associated 
with surveillance has long been identified as a target for improvement.  Recent 
assessment of imaging techniques have shown a predominately CDUS and Abdominal 
Radiography (AXR) based surveillance regimen was highly likely to be more cost 
effective than a CTA and AXR regimen.128 A de novo design for an efficient 
surveillance regimen to detect EVAR complications (or impending complications) seen 
in current clinical practice would likely have a very different structure to those currently 
employed.  Such a design would also be capable of taking real world factors into 
consideration such as: compliance and cost effectiveness.  To aid the design of an 
efficient EVAR surveillance regimen the areas requiring better definition were: 
• The incidence and indication for secondary interventions and how they vary 
over time following EVAR 
• It is possible to accurately predict the risk of subsequent secondary intervention 
using current surveillance findings, at any time in EVAR surveillance. 
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• The importance of each finding recorded during CDUS amd AXR and assess the 
potential for reducing the number collected without reducing association with 
subsequent secondary interventions. 
• Investigate CEUSs endoleak diagnostic values, to define the evidence base for 
its role. 
• Quantify compliance over time following EVAR and association to other 
factors, so offering targets to potentially improve compliance. 
4.2 Epidemiology of EVAR Complications 
Prior to this work the various modes and methods of EVAR stent-graft failure were well 
described in the literature, section 1.3.2 (page 9), however the timing of these differing 
complications was not well described.  The number of individual patients undergoing 
secondary intervention was also well described by multiple studies which report 
“freedom from secondary intervention”,44 this analysis unfortunately masks all 
information about subsequent interventions in those patients which are essential for 
effective surveillance regimen design.  Finally the global incidence of secondary 
interventions across all follow-up is reported in some studies, notably the UK EVAR 
trial 1,36 but defining secondary intervention rates at differing times can inform differing 
imaging techniques optimised for differing complications at different times after EVAR. 
The use of secondary interventions as a surrogate of EVAR complications is well 
rehearsed in EVAR studies,44  Secondary interventions do not offer a total picture of 
EVAR complications because: some individuals who have a complication will decline a 
secondary intervention; some will be unsuitable for the required intervention; and 
unfortunately some will die of (or with) the complication before a secondary 
intervention is undertaken.  The main advantage of using the surrogate of secondary 
interventions is that it is a definitive standard (they either occurred or did not) and it 
also represents the reality of current clinical practice, which is why it was selected for 
this study.  These data can inform surveillance regimen design to clinical practice as it is 
today, i.e. it is inefficient to use data to create a regimen that discovers complications 
that are not intervened upon.   
A proportion of the complications that were not intervened upon will have been 
detected and reported in the imaging available in these data, with the addition of a 
complete set of “cause of death” data, from the office of national statistics (ONS), this 
would give a fuller picture of the complication rates of EVAR.  An even more 
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exhaustive method would to have been to obtain all clinical coding data from national 
hospital episode statistics (HES) data, which is methodological and ethically more 
complex.  ONS cause of death data and HES coding data are acknowledged to have an 
error rate in them, systemic review of coding data has shown a median error rate of 20% 
for primary diagnosis accuracy and 16% for procedure coding.129 This is normally 
compensated for by using large datasets that are not currently available in EVAR 
surveillance research. ONS cause of death data would have similar, less pronounced 
concerns. This technique would however have the benefit of identifying, after 
appropriate validation, EVAR complications that occurred outside the performing 
centre- which is a significant limitation of these presented data.  It would also highlight 
those that have died from an aneurysm related cause.  Ethically, written informed 
consent would be required to obtain such HES and ONS data as much of it may not 
directly relate to care associated with the individuals EVAR – as such this is probably 
unrealistic to obtain consent in a sufficiently large enough proportion of patients for 
meaningful research and certainly not in a single centre study.  
The 75% of secondary interventions that occurred prior to any symptoms occurring 
(section 2.4.2.1, page 55) suggest it may have been possible to define complications 
based primarily on findings within the imaging data that was available in these studies.  
While some complications in EVAR having defined criteria- such as migration (section 
1.3.2.2, page 11), others are not well defined- such as limb stenosis (section 1.3.2.3, 
page 12) and therefore definition of a complication becomes an issue that requires 
resolution prior to such analysis being performed.  This effectively needs to be 
investigated in two constituent parts, the risk that a finding gives of a complication 
occurring and also the effectiveness that secondary interventions then have at 
preventing that complication occurring.  The effectiveness of secondary interventions is 
not addressed in this work as these data, from this study, did not feature sufficient 
numbers of any individual secondary intervention to warrant investigation in this 
manner but a large multicentre data set may manage to collect such data.  
Thinking of future surveillance practice, it would ultimately be useful to know about 
EVAR complications regardless of secondary intervention both to allow targeted 
improvements in stent-graft design by manufacturers but would also allow separation of 
stent-graft complications (present/absent) from patient physiology (suitable/unsuitable) 
within the considerations of surveillance i.e. some patients in EVAR surveillance either 
shortly after EVAR or decades later becomes unsuitable for certain secondary 
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interventions.  This separation would allow the interplay between non-aneurysm related 
patient physiological limitations and aneurysm/stent-graft related limitations to be 
discerned therefore allowing further improvements in efficiency in surveillance regimen 
design. This would help account for changes in practice in EVAR implantation as well 
as changes in patient physiology over time e.g. increasing life expectancy and fitness at 
similar ages.  It could mean that a physiologically unfit patient may having increased 
intervals of surveillance as only complications that they could have treated by secondary 
intervention may be rarer than those that would not be intervened upon, equally the data 
collected on those surveillance visits may inform the risk of complication for a more 
physiological fit patient that had a similar aneurysm morphology and stent-graft.  
Liverpool Vascular and Endovascular Service (LiVES) already undertakes this 
differentiation at a high binary threshold in that, patients are discharged if unsuitable for 
any secondary intervention. In the future an assessment of functional status at each 
surveillance visit, and assessing how this correlates to suitability for various secondary 
interventions may offer a simple manner to graduate this process and would be a simple 
addition to each surveillance imaging visit. 
4.3 Compliance with EVAR surveillance 
Compliance with the entirety of EVAR surveillance regimens is undoubtedly poor, as 
reported in the literature.70 71 88 The maximum level of compliance that is achievable, 
how to achieve such levels and what level of compliance is actually necessary to 
maintain outcomes remains poorly investigated, reported and understood.  The excellent 
levels of compliance seen in LiVES till 10 years after EVAR is encouraging and 
unlikely to be significantly improved upon in the clinical practice, although this level is 
partly due to the definition of compliance used (imaging in the last 18 months),88 and 
that actively discharged patients were excluded means direct comparisons are difficult –
literature based on administrative datasets are not able to identify actively discharged 
patients. The cross-sectional nature of the study meant that it was not possible to 
perform similar cohort analysis such as those in the literature, such analysis would be 
given remarkably useful to benchmark these data to those already published.  It could 
have been explored for the subgroup of patients who had undergone their EVAR within 
the time frame of the study, unfortunately the study contained a significant number of 
patients who had their EVAR as part of local mentoring schemes with other units and as 
such the data would have been very skewed toward early review prior to surveillance 
Surveillance Following Endovascular Repair of Abdominal Aortic Aneurysm 
168  Iain Nicholas Roy - August 2020 
being transferred to their local unit.  The fact that at a similar timeframe LiVES 
demonstrated an 88% compliance rate with surveillance within the UK EVAR-screen 
study does demonstrate that retrospective and administrative data sets are likely to be 
reporting marginally lower compliance compared to the methodology used in this work.  
The study suggests that simply measuring compliance at the end of the observational 
period is likley to underestimate overall compliance with the regimen as a whole, 
binarily measuring compliance with the entire surveillance protocol is similarly unlikely 
to give an accurate assessment of efficacy. 
The EVAR-screen study, showed an association between increased distance to 
surveillance imaging and non-compliance,88 however these data presented here 
demonstrated the reverse association.  This may well be the result of greater compliance 
among tertiary referral patients than those referred locally and/or that the majority of 
local patients lived within the tolerable travel distances as LiVES has a relatively 
geographically compact referral area.  Further interrogation of these data regarding 
these factors may offer information to help target intervention research.  This in addition 
to the decreased compliance seen in patients who underwent operations more recently 
suggests that, anecdotally, the role of pre-operative counselling (which is likely to be 
more extensive in complex tertiary referrals and in patients operated on nearer the 
introduction of EVAR).  This hypothesis is re-inforced by the fact that patients who 
have undergone secondary intervention (thereby having understood the purpose of 
surveillance) are more compliant.  Therefore potentially more geographically disperse 
centres could undertake a relatively simple 4 arm RCT, were standard vs enhanced pre-
operative counselling and centralised vs localised surveillance imaging were compared, 
such a study with surveillance compliance as the outcome would be a relatively simple 
design and allow the interaction and co-linearity between these factors to be discerned, 
ethically it would not be contentious and may offer a definitive answer to optimising 
patient dependent factors for EVAR surveillance. 
LiVES surveillance regimen (imaging technique and intensity) is largely consistent with 
that of other centres in the UK EVAR-screen study, so it seems unlikely that this 
explains the higher levels of compliance observed in LiVES.  The administrative 
processes that are used to achieve compliance (with the surveillance regimen) are not 
described between differing centres and is likely to play a significant role in the levels 
of compliance observed.  The ‘fail safe’ method of an independent database, out with 
routine clinical systems, is the backbone of this system that prevents the possibility of 
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patients being passively lost to follow-up.  This supported by administrative staff time 
dedicated to ensuring EVAR surveillance imaging is requested and completed in a 
timely manner, and to chase missed appointments and record patient outcomes are what 
is locally attributed to the success of LiVES EVAR surveillance programme.  
Implementing such a programme in a centre with poor compliance would be the ideal 
method to test its’ relative effectiveness beyond what can be achieved using routine 
systems and clinician time, which is anecdotally what is used in the majority of UK 
centres.  This would allow the comparison of pre and post implementation compliance 
rates and interestingly would also allow the rates of secondary interventions to be 
measured (giving an indication if increased compliance does increase secondary 
interventions, as would seem logical). 
Such prospectively maintained databases will be essential if surveillance compliance is 
to be accurately measured and monitored in the era of personalised surveillance 
regimens, retrospective and administrative dataset studies will become difficult to 
perform as results will be so dependent on correct assessment of a patients expected 
next surveillance visit.  There will be, as there is now, a risk that “compliance” only 
infers that the patient did not attend for surveillance, while the administrative process of 
correctly instigating and inviting the patient for surveillance imaging is equally 
imperative.  Alternatively assessment of the percentage compliance in a centre and the 
number of patients presenting for secondary interventions with symptoms or as an 
emergency may offer alternative surrogate markers to monitor surveillance 
effectiveness rather than true compliance. 
4.4 Surveillance Efficiency – Risk Stratification 
The secondary intervention risk prediction model created from these data is a significant 
divergence from previous work on risk stratification in the arena of EVAR surveillance.  
Previous work has simply tried to divide patients into high/low risk groups, the most 
successful, validated by Baderkhan et al.,92 is now recommended in European 
guidance.53 This is based purely on ‘aneurysm related’ secondary interventions - which 
runs contrary to patient fears / preferences stated in the IMPROVE trail and the 
prevalence of stent-graft limb secondary interventions seen in these data, section 2.4.2.2 
(page 57).61  As such it assess the length of seal zones proximally and distally that have 
a protective effect against aneurysm expansion and subsequent effacement by having a 
longer zone that can undergo effacement before graft-related endoleaks occur.  Within 
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their model this is assessed on the first post-operative CTA to risk stratify the patient for 
5 years, however the theory of protective effect from long satisfactory seal zones should 
be true at any point in post-operative surveillance. It would have been interesting to 
include an analysis of the seal zone lengths in the CT’s performed in these data, as these 
both would have been an additional validation of Baderkhan et al.’s model, allowed 
assessment of risk stratification regarding stent-graft limb secondary interventions and 
likely added additional precision to the risk predictions given in our model throughout 
surveillance.  Unfortunately this was not possible under the ethical approval given but 
may have improved the accuracy of predictions.  The creation of an accurate model is 
only part of the process of using risk stratification in clinical practice, it must also be 
validated in clinical use to confirm that when used prospectively in a clinical setting that 
it does in fact reach the same accuracy and implementation dose not lead to excessive 
patient or clinician anxiety resulting in a slow regression to previous surveillance 
regimens due to familiarity.   
The fact that the stratification is repeated on each surveillance visit within the model 
presented in this thesis is a huge benefit and reduces the effect that extrinsic factors can 
have on the prediction’s accuracy – thereby improving accuracy. This repeated scoring 
on each patient means that smaller patient cohorts are required to create and validate the 
models’ predictions, thereby increasing the accuracy. The greater the accuracy of 
predictions the longer the intervals between surveillance can be extended in patients 
with a low risk of prediction error.  In the future adding the previously discussed 
functional status (section 4.4, page 169), may improve prediction accuracy further, the 
addition of a continuous measure related to the risk of limb stenosis may also make a 
reasonable addition.  If a dataset large enough could be created then addition of all data 
points and there interplay is likely to influence prediction accuracy, at a certain stage 
this would no longer lend itself to traditional statistical modelling and may instead be 
better performed by machine learning, likely in the form of a neural network.  A neural 
network by definition would allow the complex interplay and co-linearity between a 
large dataset. It is not currently available and is unlikely to have sufficient data accuracy 
or a sufficient volume of data without a nationwide common dataset that is collected in 
prospective routine practice.  This potentially fits well with the hypothesis regarding 
having a robust administrative process to improve compliance and such a database 
combined with standardised administrative process could produce such a dataset. 
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A modest increase in volume of these current data would have allowed the maximum 
possible accuracy of the model to have been predicted, such an analysis would be 
undertaken by using increasingly large proportions of the dataset and it would be 
possible to plot the Receiver Operator Characteristics (ROC) for that proportion of the 
data set.  As the proportion used increased the AUC should improve, but each increase 
in proportion will yield a lower increase in AUC until a plateau is reached.  With a 
larger dataset it would have been possible to project these ROC improvements and 
determine what volume of data is required to achieve a ROC near the plateau.  
Unfortunately the number of secondary interventions in the LiVES data set meant that it 
was not possible to attempt this as reducing the proportion of data used would mean 
some time-frames of the model would have no events to produce the model. 
4.5 Surveillance Efficiency – Optimising imaging 
Most EVAR imaging publications simply refer to the overarching technology used to 
acquire EVAR images and fail to adequately describe the; acquisition protocol, 
definition of findings and reporting standards / template used. Consequently, validation 
studies are difficult to perform, and diagnostic results are difficult to replicate in clinical 
practice.  Endoleak, the most investigated diagnosis in EVAR imaging studies, is a good 
example: to make a complete endoleak diagnosis the endoleak must be both detected 
and correctly characterised, most studies do not offer sufficient detail to confirm that the 
diagnostic values reported are for a full diagnosis or simply the detection of that 
endoleak.   In addition, the significant number of unblinded studies are likely to have 
suffered from confirmatory bias, between imaging modalities, regarding endoleak 
characterisation.  The comparison of contrast enhanced ultrasound scans (CEUS) and 
time-resolved CTA (tCTA) in these data address the above issues and report a markedly 
different sensitivity to diagnose a graft-related endoleak than the literature, 0.56 
reported vs ~0.95 in the literature.73 Given the unexpectedly low sensitivity the study 
was under powered and terminated early meaning that there is a wide confidence 
interval, however validation studies could easily be performed given the standard of the 
reporting within the study.  It would suggest that CEUS has little to add to CDUS in the 
sub-population going on to CT scan due to concerns during CDUS EVAR surveillance 
(the recruitment population).  As such the role of CEUS should likely to be limited to 
patient who have contra-indications to CT scanning or cases of persistent diagnostic 
uncertainty in which additional imaging modalities are required.  The addition of a 3D 
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CEUS imaging arm would have been an interesting addition to the study to discern what 
it adds to the diagnostic values of CEUS, although it is a static 3D picture that this 
technology can currently provide rather than 4D (time being the 4th dimension) imaging 
that tCTA is providing.  The cost of 3D CEUS prohibited its addition to this study and 
currently is likely also a barrier to use in clinical practice.  The calculation of intra- and 
inter- observer variability values of the CEUS and tCTA findings would have been a 
valuable addition to the study, adding additional validity, but previous tCTA studies 
have shown high level of agreement in reporting and CEUS has been investigated and 
they require additional staff, patient and resource time.122 The curtailment of the study 
prevented more detailed analysis of endoleak filling patterns on tCTA which potentially 
could have allowed exploration of the optimum timing of CTA phases for detecting 
different classes of endoleaks. There is now likely to be sufficient tCTAs within 
published studies that if combined into a single cohort they could be prospectively re-
analysed blindly by multiple radiologists in constituent parts to allow a focused logical 
process to develop such a protocol.  This would likely involve a series of blinded double 
reporting of contrast filling patterns to allow filling patterns to be robustly reported and 
validity of such measurements to be confirmed, then optimum timing of phases defined.  
Once these timings have been defined then a repeat process of only these selected 
phases being made available for blinding reporting by two radiologist and different 
times (who had not previously seen those examinations) could be undertaken to confirm 
inter- and intra- observer variability and diagnostic values to be defined.  This would be 
a laborious process but would allow optimum CTA timings to be definitively defined.  
The inability in this study to use the CTA reports due to diverse reporting does 
demonstrate a need for a minimum reporting set / standard. 
Colour Duplex Ultrasound Scan (CDUS) and abdominal X-ray (AXR) remain the most 
utilised EVAR surveillance imaging technique in the UK.  AXR has a standardised 
acquisition protocol, the Liverpool-Perth protocol,74 however CDUS does not currently 
have such a protocol within the scientific literature.  LiVES has a standard operating 
procedure (appendix 1, page 188) which was perspicaciously designed based on best 
knowledge and expert opinion, this allowed analysis of the constituent parts for 
association with subsequent secondary intervention.  The analysis of the associations 
between differing findings on CDUS and broad categories of secondary interventions is 
the first attempt, to our knowledge, to methodically / scientifically derive the findings 
required to discern if a secondary intervention is required.  Such moves to rationalise 
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findings investigated is a route to improve the efficiency of CDUS imaging within 
EVAR surveillance. It was limited by the quantity of data available and therefore 
findings that trigger rarer interventions were more likely to be excluded, this could be 
overcome by larger datasets.  These data particularly highlight the need for an efficient 
defined measurement to identify patients who may benefit from secondary intervention 
to prevent symptomatic stent-graft limb stenosis or occlusion.  The definition of 
significance within such a finding could be identified relatively simply with multiple 
measures taken on a single CDUS in a group of patients followed by a period of follow-
up in which they were monitored for limb occlusion or secondary intervention.  Once 
the optimum finding and cut off have been defined its collection should be emphasised 
in early and late surveillance following EVAR given that the early and late prominent 
incidence of these findings following EVAR (section 2.4.2.2, page 57) 
The analysis demonstrating increased association of secondary interventions in the 6 
months following EVAR surveillance imaging is perhaps the strongest demonstration in 
the literature that EVAR surveillance does indeed precipitate secondary interventions 
directly. The return to slow baseline relative risk demonstrates that there is a slow rate 
of secondary interventions that occur regardless of surveillance imaging, unfortunately 
these are insufficient in number to tease out the causation of these baseline 
interventions.  If these baseline interventions were predominantly symptomatic or the 
result of incidental findings on other forms of imaging this would be an interesting 
observation and add weight to the hypothesis that effective EVAR surveillance leads to 
a low rate of symptomatic presentations.  A clinical study to randomly compare no 
surveillance with surveillance imaging would unlikely be ethical and unlikely to recruit 
adequately- due to lack of equipoise in clinicians’ and patients attitudes, however a 
study of planned surveillance imaging or imaging delayed for 6 months for those in 
routine EVAR surveillance may be less controversial, if this detected different 
prevalence in planned and unplanned secondary interventions between the groups it 
would demonstrate surveillance having its intended effect, although would not prove its 
efficacy. Even such a study, that delayed surveillance, would be ethically challenging as 
it potentially puts those in the delayed surveillance group at risk of preventable harm, 
but the cost of EVAR surveillance should be justified and without a study 
demonstrating definitively that it does precipitate secondary interventions intended to 
prevent harm it may struggle to justify the costs associated with it. 
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These data show an apparent progressive relationship between minor then major 
migration reported on AXR (compared to no migration) and subsequent aneurysm 
related secondary intervention. While only major migration showed statistically 
different intervention rates this may simply be related to the sensitivity of detection. The 
multiple possible geometric confounders caused by comparison of single or two plane 
imaging used in EVAR surveillance AXR may simply be to complex for unassisted 
human interpretation to achieve better granularity/definition than this. Computer aided 
alignment and adjustment may well allow for better granularity/detection of migration 
and therefore more direct correlation between AXR and secondary intervention. This is 
appealing as CDUS based surveillance regimens are lower cost than CTA regimens but 
miss out on stent-graft structure and anatomical relationships, unless combined with 
AXR. 
Effacement correlates with migration, detection of the surrogate of effacement 
(proximal dilation) seen on AXR is more difficult than migration due to the smaller 
changes seen in terms of millimetres, however changes in form and geometry of the 
proximal stent are often also seen and were the isolated finding that precipitated 
aneurysm related secondary interventions in some patients.  As such shape (effacement) 
and position (migration) of the stent graft should be the focus of any attempts to 
automate the analysis of AXR’s. The main benefits I suspect would arise from the 
superior abilities from automated alignment of serial AXRs across EVAR surveillance, 
compared to manual visual comparison. 
4.6 Conclusion 
This thesis demonstrates: 
• An ongoing need for EVAR surveillance with secondary interventions 
remaining prevalent in a contemporary surveillance programme with the 
majority being undertaken electively in asymptomatic patients.  
• It establishes the indication and incidence of secondary interventions changes, 
over the post-operative course, following EVAR 
• It demonstrates it is possible to accurately and reliably predict the risk of 
secondary interventions at multiple time points.  
• It has established there is co-linearity and likely confounding between variables 
associated with poor EVAR surveillance compliance, but that good rates of 
compliance are possible.  
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• It has called into question the endoleak diagnostic accuracy of CEUS reported in 
the literature  
These data help progress the area of research in the area of surveillance following 
EVAR for the treatment of infra-renal AAA, they however do not offer sufficient 
evidence in themselves to unify the diverse range of surveillance regimens and imaging 
techniques / protocols used in the UK, they instead highlight a need and offer a potential 
pathway to such a unification of differing techniques through further targeted research. 
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1. LIVERPOOL VASCULAR AND ENDOVASCULAR 
SERVICE: COLOUR DUPLEX ULTRASOUND SCAN IN 
ENDOVASCULAR ANEURYSM REPAIR SURVEILLANCE – 
STANDARD OPERATING PROCEDURE 
Staff 
To be conducted by a Clinical Vascular Scientist 
Location 
Vascular Laboratory, Vascular Clinic, Royal Liverpool Hospital 
Measurements 
PSV in cm/s 
Diameter, length in mm 
Abbreviations 
LS – Longitudinal Section 
TS – Transverse Section 
AP – Antero Posterior 
ML – Medial Lateral 
Patient Positioning 
Please refer to Institute of Physics and Engineering in Medicine Vascular Laboratory 
Practice [ISBN 0903613051] 
Probe 
Abdominal 2-5MHz curved Array 
Procedure 
Using grey scale imaging the; aneurysm neck (when possible), iliac seal zone and 
maximum aneurysm dimensions are measured in LS and TS. The maximum TS (both 
AP and ML) dimensions are recorded for the aneurysm and iliac vessels and maximum 
LS dimensions for the aneurysm neck. 
Notes are to be made of the echogenicity of thrombus within the aneurysm sac i.e. echo 
lucent areas or homogenous. 
The native iliac system iliac artery and common femoral arteries are imaged using 
colour flow imaging and spectral Doppler, making note of the waveform characteristics 
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and velocity at this point. Any arterial disease of the iliac segment distal to the 
respective limb of the endograft is also to be noted, assessed and reported as per arterial 
duplex protocol.  
The Endograft is now interrogated using colour and spectral Doppler to ascertain 
patency and flow heamodynamics of the main body of the endograft as well as both 
limbs. Any abnormalities in these parameters are to be reported. Velocity changes are to 
be assessed as per arterial duplex protocol and the cause reported. 
The aneurysm is to be assessed using colour Doppler to identify arterial blood flow 
outside of the endograft but within the aneurysm sac (endoleak). If flow is identified it 
is confirmed with spectral Doppler and its source identified i.e. IMA, Lumbar, 
proximal/distal seal zone and the appropriate type of endoleak reported. 
Seromas and lymphoceles can be noted at the incision site in the groin. Size and 
location are to be noted. 
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2. R CODE FOR DATA PROCESSING AND ANALYSIS OF A 
COLOUR DUPLEX ULTRASOUND SCAN AND PLAIN 
ABDOMINAL X-RAY SURVEILLANCE REGIMEN 
A copy of this code is also available on the accompanying CD in the pocket attached to 
the inside back cover, along with the saved RData files created by it (to allow exact 
replication of the results presented). 
CD\database\analysis.R 
CD\database\midata.RData 
CD\database\data.RData 
CD\database\model.RData 
 
# Code Created by Iain N Roy, Institute of Ageing & Chronic Disease, 
University of Liverpool - Except were indicated 
# Contact via iainroy@liverpool.ac.uk 
# Code to process data for 
# Study Title: "Liverpool Vascular & Endovascular Service: 
Endovascular Aneurysm Repair Surveillance Data Analysis" 
# Study Ethical approval: NHS REC reference: 17/NS/0088 
 
# Code created in R Studio v1.1.463 using R version 3.5.2 
# The study data (patient_level_data.csv, secondary_interventions.csv, 
all_scans.csv) is assumed to be in the working directory 
 
# Loading Required Packages 
install.packages(c("tidyverse","survival","scales","survminer","Cairo"
,"Epitools", "caret","MASS", "corr", "mice", "survivalROC","pROC")) 
library(tidyverse) 
library(survival) 
library(scales) 
library(survminer) 
library(Cairo) 
library(epitools) 
library(caret) 
library(MASS) 
library(corrplot) 
library(mice) 
library(survivalROC) 
library(pROC) 
### Load & Catagorise Data 
patient_data <- read.csv("patient_level_data.csv", header = TRUE, 
col.names = c("Database ID","Calander Year of Operation","Age at 
Operation in Years","Gender","Max Pre-op Diameter in mm", "Max Pre-
op Iliac Diameter in mm", "EVAR Device Type", "EVAR Device 
Supplier", "Distance to Surveillance Centre in km", "Time from 
Operation to Death in Years", "Time from Operation to No Follow-Up in 
Years", "Reason No Follow-Up", "Time from operation to Start of 
Observational period in Years")) 
secondary_interventions <- read.csv("secondary_interventions.csv", 
header = TRUE, col.names = c("Database ID","Time since Operation in 
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Years","Emergency","Treating","Intervention", "side","Patient 
Symptomatic","Detected on Surveillance","Comments","SI_Type")) 
all_scans <- read.csv("all_scans.csv", header =TRUE, col.names = 
c("Database ID", "Time since Operation in Years","Examination","Exam 
Name","Surveillance Imaging", "Primary EVAR Procedure","Potential 
Secondary Intervention", "AXR Baseline","AXR Compared To AXR Years 
After Op","AXR Abnormal", "AXR Migration", "AXR Left Limb Kink","AXR 
Right Limb Kink","AXR Structural Failure","AXR Complication type","AXR 
Non EVAR Finding", "AXR Effacement","CDUS EVAR 
Surveillance","CDUS Diagnostic","CDUS Diagnostic Comments","CDUS AAA 
size in mm","CDUS Right CIA in mm","CDUS Left CIA in mm","CDUS 
Endoleak Present","CDUS Endoleak Type", "CDUS Endoleak Text","CDUS 
Mixed Thrombose in AAA", "CDUS Limb Complication","CDUS Limb 
Effected", "CDUS Limb Complication Type", "CDUS Comments")) 
 
###Global Manipulation of data### 
patient_data$old <- 
ifelse(0<=patient_data$Time.from.operation.to.Start.of.Observational.p
eriod.in.Years, TRUE, FALSE) 
#patient_data$fu_years <- 
patient_data$Time.from.operation.to.Start.of.Observational.period.in.Y
ears+7 
patient_data$start <- 
ifelse(0>patient_data$Time.from.operation.to.Start.of.Observational.pe
riod.in.Years, 0, 
patient_data$Time.from.operation.to.Start.of.Observational.period.in.Y
ears) 
patient_data$died <- 
ifelse(is.na(patient_data$Time.from.Operation.to.Death.in.Years),FALSE
,TRUE) 
patient_data$years<- 
ifelse(is.na(patient_data$Time.from.Operation.to.Death.in.Years),(pati
ent_data$Time.from.operation.to.Start.of.Observational.period.in.Years 
+ 7), patient_data$Time.from.Operation.to.Death.in.Years) 
patient_data$ends <- 
ifelse(is.na(patient_data$Time.from.Operation.to.No.Follow.Up.in.Years
), 
patient_data$years,patient_data$Time.from.Operation.to.No.Follow.Up.in
.Years) 
 
###Patient level Demographics### 
print(summary (patient_data)) 
print(summary (patient_data$EVAR.Device.Supplier)) 
print(summary(patient_data$EVAR.Device.Type)) 
#Create histogram of number of cases per year 
Cairo(file="time_of_evar.png", type="png",units="mm", width= 140, 
height = 100, dpi=600, ponitsize="1") 
ggplot(data=patient_data, aes(x=Calander.Year.of.Operation, 
fill=patient_data$old))+  
  geom_histogram(binwidth = 1)+ 
  xlab("Calander Year") +  
  ylab("Number of Patients")+ 
  scale_x_continuous(breaks =seq.int(1996,2014,2))+ 
  scale_fill_discrete(name="EVAR", 
                      breaks=c("FALSE", "TRUE"), 
                      labels=c("EVAR during observation Period    ", 
"EVAR before observation Period"))+ 
  theme(legend.title=element_blank(), legend.position = "bottom") 
dev.off()  
#Patient level all cause survival curve 
fit <- survfit(Surv(patient_data$years,patient_data$died)~1, data 
=patient_data) 
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Cairo(file="all_cause_survival.png", type="png",units="mm", width= 
140, height=100, dpi=600, ponitsize="1") 
ggsurvplot(fit,risk.table = TRUE, pval = FALSE, conf.int = TRUE, 
break.time.by = 2, censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.3, xlab="Years", ylab="All Cause Survival", surv.scale="percent", 
legend.title = " ", legend = "none", xlim = c(0, 18)) 
dev.off() 
rm(fit) 
#create data for Secondary intervention KM of EVAR during 
observational peroid 
secondary_interventions <- secondary_interventions %>% 
arrange(Time.since.Operation.in.Years) 
si <- left_join(patient_data, secondary_interventions, 
by="Database.ID", no.dups = FALSE) 
si <- si %>% arrange(Time.since.Operation.in.Years) 
si <- distinct(si, Database.ID, .keep_all = TRUE) 
si$si <- ifelse(is.na(si$Time.since.Operation.in.Years), FALSE, TRUE) 
si$siTIME <- ifelse(is.na(si$Time.since.Operation.in.Years), si$years, 
si$Time.since.Operation.in.Years) 
si <- subset(si, old == FALSE) 
#Create KM of secondary intervention 
fit <- survfit(Surv(siTIME,si)~1, data =si) 
Cairo(file="freedom_si.png", type="png",units="mm", width= 140, 
height=100, dpi=600, ponitsize="1") 
ggsurvplot(fit,risk.table = TRUE, pval = FALSE, conf.int = TRUE, 
break.time.by = 1, censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.3, xlab="Years", ylab="Freedom from \n Secondary Intervention", 
surv.scale="percent", legend.title = " ", legend = "none", xlim = c(0, 
7), ylim= c(0.5,1)) 
dev.off() 
rm(fit, si) 
 
###Secondary Intervention analysis### 
#Data work 
si_analysis <- left_join(secondary_interventions, patient_data, 
by="Database.ID", no.dups = FALSE) 
si_analysis$in_observational_peroid <- 
ifelse(si_analysis$Time.since.Operation.in.Years>=si_analysis$start,if
else(si_analysis$Time.since.Operation.in.Years<=si_analysis$ends,TRUE,
FALSE),FALSE) 
si_analysis$in_observational_peroid <- ifelse(si_analysis$Intervention 
== "Aneurysm Related Death", FALSE, 
si_analysis$in_observational_peroid) 
si_analysis <- subset(si_analysis, si_analysis$in_observational_peroid 
== TRUE) 
 
#Descriptive statistics for Secondary Interventions# 
print(count(si_analysis))##number of secondary interventions 
length(unique(si_analysis$Database.ID)) ##number of unique individuals 
those secondary interventions they are in 
summary(si_analysis) # general demographics of secondary interventions 
summary(subset(si_analysis$Treating,si_analysis$SI_Type=="Aneurysm")) 
##indication for secondary intervention in aneurysm related cases 
summary(subset(si_analysis$Treating,si_analysis$SI_Type=="Flow")) 
##indication for secondary intervention in flow related cases 
summary(si_analysis$Intervention) #interventions undertaken 
 
 
#Secondary Intervention Incidence Calculation# 
#Total at risk period from $start - $ends# 
#calculate portion of year at risk 
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span=1 
x=1       # time incidence measured over- 1=1year 0.5=6months 
y_vals<- c((x*100):1500)/100 #time points indicdence measure too 
incidence_graph <- as.data.frame(matrix(ncol = 3, nrow = 
length(y_vals))) 
 
for(j in seq(y_vals)){ 
  y= y_vals[j] 
  z=y-x 
  incidence <- left_join(patient_data, si_analysis, by="Database.ID", 
no.dups = FALSE) 
  incidence$Time.since.Operation.in.Years <- ifelse 
(incidence$Time.since.Operation.in.Years<z,NA,ifelse(incidence$Time.si
nce.Operation.in.Years>y,NA,incidence$Time.since.Operation.in.Years)) 
  incidence <- incidence %>% arrange(Time.since.Operation.in.Years) 
  incidence <- distinct(incidence, Database.ID, .keep_all = TRUE) 
  incidence$time_at_risk <- ifelse( 
    (ifelse(incidence$ends.x<y,incidence$ends.x,y)-
ifelse(z>incidence$start.x,z,incidence$start.x))<0, 
    0, 
    (ifelse(incidence$ends.x<y,incidence$ends.x-z, y-z))) 
   
  incidence_graph[j,1:3] <- 
c(y,sum(!is.na(incidence$Time.since.Operation.in.Years)), 
sum(incidence$time_at_risk)) 
  rm(j) 
} 
colnames(incidence_graph) <- c("year","events","years_at_risk") 
 
#table patients years at risk 
print(incidence_graph [c(1,seq(101,1401, by=100)),c(1,3)]) 
 
#calculate frequency of events 
incidence_graph$frequency <- (incidence_graph$events 
/incidence_graph$`years_at_risk`)*1000 
# produce the best fit loess model weighted to number of years at risk 
model <- loess(frequency ~sqrt(year), data=incidence_graph, weights = 
years_at_risk, span = span) 
smoothed_line <- data.frame(frequency=predict(model, incidence_graph), 
year=incidence_graph$year) 
 
Cairo(file="frequency_si.png", type="png",units="mm", width= 140, 
height = 86.5, dpi=600, ponitsize="1") 
ggplot(incidence_graph,aes(year,frequency))+ 
  geom_line()+ 
  scale_x_continuous(breaks = seq(1, 15, by = 1))+ 
  scale_y_continuous(breaks = seq(0, 130, by = 25))+ 
  xlab("Years Since Patient Underwent EVAR")+ 
  ylab("Incidence of Secondary Intervention\nin previous 12 months\n 
per 1000 patient years at risk")+ 
  geom_line(color='red',size=1,data = smoothed_line, aes(x=year, 
y=frequency)) 
dev.off() 
 
lines<-data.frame(smoothed_line,"All") 
colnames(lines) <- c("Frequency","Year","Group") 
 
 
#Graph of Aneursym preservation secondary interventions 
incidence_graph <- as.data.frame(matrix(ncol = 3, nrow = 
length(y_vals))) 
for(j in seq(y_vals)){ 
  y= y_vals[j] 
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  z=y-x 
  incidence <- left_join(patient_data, si_analysis, by="Database.ID", 
no.dups = FALSE) 
  incidence$Time.since.Operation.in.Years <- ifelse 
(str_detect(incidence$SI_Type,"Aneurysm"),incidence$Time.since.Operati
on.in.Years, NA) 
  incidence$Time.since.Operation.in.Years <- ifelse 
(incidence$Time.since.Operation.in.Years<z,NA,ifelse(incidence$Time.si
nce.Operation.in.Years>y,NA,incidence$Time.since.Operation.in.Years)) 
  incidence <- incidence %>% arrange(Time.since.Operation.in.Years) 
  incidence <- distinct(incidence, Database.ID, .keep_all = TRUE) 
  incidence$time_at_risk <- ifelse( 
    (ifelse(incidence$ends.x<y,incidence$ends.x,y)-
ifelse(z>incidence$start.x,z,incidence$start.x))<0, 
    0, 
    (ifelse(incidence$ends.x<y,incidence$ends.x-z, y-z))) 
   
  incidence_graph[j,1:3] <- 
c(y,sum(!is.na(incidence$Time.since.Operation.in.Years)), 
sum(incidence$time_at_risk)) 
  rm(j) 
} 
colnames(incidence_graph) <- c("year","events","years_at_risk") 
# plot raw frequency of 'Aneurysm' related secondary interventions per 
1000 patient risk years 
incidence_graph$frequency <- (incidence_graph$events 
/incidence_graph$`years_at_risk`)*1000 
model <- loess(frequency ~ sqrt(year), data=incidence_graph, weights = 
years_at_risk, span = span) 
smoothed_line <- data.frame(frequency=predict(model, incidence_graph), 
year=incidence_graph$year) 
# plot raw frequency of 'Aneurysm' related secondary interventions per 
1000 patient risk years 
Cairo(file="frequency_aneurysm_si.png", type="png",units="mm", width= 
140, height = 86.5, dpi=600, ponitsize="1") 
ggplot(incidence_graph,aes(year,frequency))+ 
  geom_line()+ 
  scale_x_continuous(breaks = seq(1, 15, by = 1))+ 
  ylim(0, 90)+ 
  xlab("Years Since Patient Underwent EVAR")+ 
  ylab("Incidence of 'Aneurysm Related' \n Secondary Intervention in 
previous \n 12 months / 1000 patient risk years")+ 
  geom_line(color='green',size=1,data = smoothed_line, aes(x=year, 
y=frequency)) 
dev.off() 
#Store trend line in dataframe 'lines' 
all <-data.frame(smoothed_line$frequency,smoothed_line$year,"Aneurysm 
Related") 
colnames(all) <- c("Frequency","Year","Group") 
lines <- rbind(lines,all) 
rm(all) 
#Create a table of flow related secondary interventions 
incidence_graph <- as.data.frame(matrix(ncol = 3, nrow = 
length(y_vals))) 
for(j in seq(y_vals)){ 
  y= y_vals[j] 
  z=y-x 
  incidence <- left_join(patient_data, si_analysis, by="Database.ID", 
no.dups = FALSE) 
  incidence$Time.since.Operation.in.Years <- ifelse 
(str_detect(incidence$SI_Type,"Flow"),incidence$Time.since.Operation.i
n.Years, NA) 
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  incidence$Time.since.Operation.in.Years <- ifelse 
(incidence$Time.since.Operation.in.Years<z,NA,ifelse(incidence$Time.si
nce.Operation.in.Years>y,NA,incidence$Time.since.Operation.in.Years)) 
  incidence <- incidence %>% arrange(Time.since.Operation.in.Years) 
  incidence <- distinct(incidence, Database.ID, .keep_all = TRUE) 
  incidence$time_at_risk <- ifelse( 
    (ifelse(incidence$ends.x<y,incidence$ends.x,y)-
ifelse(z>incidence$start.x,z,incidence$start.x))<0, 
    0, 
    (ifelse(incidence$ends.x<y,incidence$ends.x-z, y-z))) 
   
  incidence_graph[j,1:3] <- 
c(y,sum(!is.na(incidence$Time.since.Operation.in.Years)), 
sum(incidence$time_at_risk)) 
  rm(j) 
} 
colnames(incidence_graph) <- c("year","events","years_at_risk") 
# calculate frequency 
incidence_graph$frequency <- (incidence_graph$events 
/incidence_graph$`years_at_risk`)*1000 
# model trend line 
model <- loess(frequency ~ sqrt(year), data=incidence_graph, weights = 
years_at_risk, span = span) 
smoothed_line <- data.frame(frequency=predict(model, incidence_graph), 
year=incidence_graph$year) 
# plot raw frequency of 'Flow' related secondary interventions per 
1000 patient risk years 
Cairo(file="frequency_flow_si.png", type="png",units="mm", width= 140, 
height = 86.5, dpi=600, ponitsize="1") 
ggplot(incidence_graph,aes(year,frequency))+ 
  geom_line()+ 
  scale_x_continuous(breaks = seq(1, 15, by = 1))+ 
  ylim(c(0,90))+ 
  xlab("Years Since EVAR")+ 
  ylab("Incidence of 'Flow Related'\n Secondary Intervention in 
previous\n 12 months / 1000 patients years")+ 
  geom_line(color='blue',size=1,data = smoothed_line, aes(x=year, 
y=frequency)) 
dev.off() 
#Store Trend Line into dataframe lines 
all <-data.frame(smoothed_line$frequency,smoothed_line$year,"Flow 
Related") 
colnames(all) <- c("Frequency","Year","Group") 
lines <- rbind(lines,all) 
rm(all) 
 
###Plot all three trend lines 
Cairo(file="si_trend_lines.png", type="png",units="mm", width= 140, 
height=100, dpi=600, ponitsize="1") 
ggplot(lines, aes(Year,Frequency,colour = factor(Group)))+ 
  geom_line(size=1)+ 
  xlab("Years Since EVAR")+ 
  ylab("Incidence in previous 12 months\n/ 1000 patients years")+ 
  labs(colour="Secondary Interventions:")+ 
  scale_x_continuous(breaks = seq(1, 15, by = 1))+ 
  ylim(c(0,90))+ 
  theme(legend.position="bottom") 
dev.off() 
###Tidy 
rm(incidence_graph,incidence,lines, model, smoothed_line, span, x, 
y,z,y_vals) 
 
###Surveillance compliance analysis### 
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#data 
##all patients with all scans## 
compliance <- left_join(patient_data, subset(subset(all_scans, 
Surveillance.Imaging==TRUE),Examination!="XABDO"), by="Database.ID", 
no.dups = FALSE) 
#mark scans that didn't occur in the observational peroid# 
compliance$scan_count <- ifelse 
(compliance$Time.since.Operation.in.Years>=compliance$start,(ifelse(co
mpliance$Time.since.Operation.in.Years<=compliance$ends,TRUE,FALSE)),F
ALSE) 
compliance$scan_count <- ifelse (is.na(compliance$scan_count), FALSE, 
compliance$scan_count) 
 
##Graph 
x=18/12     # time incidence measured over- 1=1year 0.5=6months 
y_vals<- c((x*100):1500)/100 #time points indicdence measure too 
compliance_graph1 <- as.data.frame(matrix(ncol = 4, nrow = 
length(y_vals))) 
for(j in seq(y_vals)){ 
  y= y_vals[j] 
  z=y-x 
  compliance <- left_join(patient_data, subset(subset(all_scans, 
Surveillance.Imaging==TRUE),Examination!="XABDO"), by="Database.ID", 
no.dups = FALSE) 
  compliance$at_risk <- 
ifelse(compliance$ends>=y,ifelse(compliance$start<=z,TRUE,FALSE),FALSE
) 
  compliance <-subset(compliance,at_risk==TRUE) 
  compliance$scan_at_risk <- 
ifelse(compliance$Time.since.Operation.in.Years<=y,ifelse(compliance$T
ime.since.Operation.in.Years>=z,TRUE,FALSE),FALSE) 
  compliance$scan_at_risk <- 
ifelse(is.na(compliance$scan_at_risk),FALSE, compliance$scan_at_risk) 
  compliance <- compliance %>% arrange(desc(scan_at_risk)) 
  compliance <- distinct(compliance, Database.ID, .keep_all = TRUE) 
  compliance_graph1[j,1:4] <- 
c(y,sum(compliance$scan_at_risk),count(compliance),"18 Months") 
  rm(j) 
} 
colnames(compliance_graph1) <- c("year","compliant","number at 
risk","deff") 
compliance_graph_all <- compliance_graph1 
# calculate percentage compliant 
compliance_graph_all$percentage <- 
(compliance_graph_all$compliant/compliance_graph_all$`number at 
risk`)*100 
# number at risk 
print(compliance_graph_all 
[round(compliance_graph_all$year)==compliance_graph_all$year, 
c(1,3,4)]) 
 
# graph 
Cairo(file="surveillance_compliance_time.png", type="png",units="mm", 
width= 140, height = 86.5, dpi=600, ponitsize="1") 
ggplot(compliance_graph_all, aes(year,percentage, colour = 
factor(deff)))+ 
  geom_line()+ 
  xlab("Years Since EVAR")+ 
  ylab("Percetage of patients compliant (%)")+ 
  labs(colour="Compliant if EVAR surveillance scan in last")+ 
  theme(legend.position="bottom")+ 
  scale_x_continuous(breaks = seq(1, 15, by = 1))+ 
  scale_y_continuous(breaks = seq(0, 100, by = 5))+ 
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  ylim(c(50,100)) 
dev.off() 
 
##Patient Factors effecting Compliance## 
#Table of patient factors 
pf_compliance <- 
data.frame(patient_data$Database.ID,patient_data$Calander.Year.of.Oper
ation,patient_data$Age.at.Operation.in.Years,patient_data$Gender,patie
nt_data$Max.Pre.op.Diameter.in.mm,patient_data$Distance.to.Surveillanc
e.Centre.in.km,patient_data$start,patient_data$ends) 
colnames(pf_compliance) <- c("Database.ID","year of op", "age at 
op","gender", "max pre-op diameter", "distance", "start", "end") 
#create a row for each time point for each patient 
pf_compliance_alltimes <- pf_compliance 
pf_compliance_alltimes$time <- 0 
y_vals<- c(1:150)/10 #time points indicdence measure too 
for(j in seq(y_vals)){ 
a <- pf_compliance 
a$time <- y_vals[j] 
pf_compliance_alltimes <- rbind(pf_compliance_alltimes,a) 
} 
rm(y_vals) 
#remove rows were time points are not in observational peroid 
pf_compliance_alltimes$at_risk <- ifelse(pf_compliance_alltimes$time 
>= pf_compliance_alltimes$start, ifelse(pf_compliance_alltimes$time <= 
pf_compliance_alltimes$end, TRUE,FALSE),FALSE) 
pf_compliance <- subset(pf_compliance_alltimes, 
pf_compliance_alltimes$at_risk==TRUE) 
rm(pf_compliance_alltimes) 
#adds secondary interventions to allow calculation of previous 
intervention 
pf_compliance <- left_join(pf_compliance,secondary_interventions, 
by="Database.ID", no.dups = FALSE) 
pf_compliance$si_before <- 
ifelse(pf_compliance$Time.since.Operation.in.Years <= 
pf_compliance$time, TRUE, FALSE) 
pf_compliance$si_before <- 
ifelse(is.na(pf_compliance$si_before),FALSE,pf_compliance$si_before) 
#removes duplicate rows 
pf_compliance <- pf_compliance %>% arrange(desc(si_before)) 
pf_compliance <- distinct(pf_compliance,Database.ID,time, .keep_all = 
TRUE) 
#add surveillance scans & calculate if compliant 
pf_compliance <- left_join (pf_compliance,subset(subset(all_scans, 
Surveillance.Imaging==TRUE),Examination!="XABDO"), by="Database.ID", 
no.dups = FALSE) 
pf_compliance$sur_scan_in_18months <- 
ifelse(pf_compliance$Time.since.Operation.in.Years.y-
pf_compliance$time 
<=1.5,ifelse(pf_compliance$Time.since.Operation.in.Years.y-
pf_compliance$time > 0, TRUE, FALSE),FALSE) 
pf_compliance$sur_scan_in_18months <- 
ifelse(is.na(pf_compliance$sur_scan_in_18months),FALSE,pf_compliance$s
ur_scan_in_18months) 
#remove duplicates 
pf_compliance <- pf_compliance %>% arrange(desc(sur_scan_in_18months)) 
pf_compliance <- distinct(pf_compliance,Database.ID,time, .keep_all = 
TRUE) 
 
##Create final analysis table## 
analysis<- pf_compliance [,c("Database.ID","year of op","age at 
op","gender","distance","max pre-op 
diameter","time","at_risk","si_before","sur_scan_in_18months")] 
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analysis$'age at time' <- analysis$`age at op`+analysis$time 
###Explore and sort data### 
summary(analysis) 
ggplot(analysis,aes(x=analysis[,2],group=analysis[,10], 
fill=analysis[,10]))+ 
  geom_density(alpha=0.5)+ 
  theme(legend.position="bottom")+ 
  labs(x="Year of Operation", y="Density", fill="Compliant") 
# better compliance before 2009 worse after, converted to factor as 
year of repair is surrogate for type of operation 
analysis$'factor_year_of_op' <- ifelse(analysis$`year of op`<=2009, 
"Before 2010","2010 or after") 
analysis$'factor_year_of_op' <- 
as.factor(analysis$'factor_year_of_op') 
ggplot(analysis,aes(x=analysis[,3],group=analysis[,10], 
fill=analysis[,10]))+ 
  geom_density(alpha=0.5)+ 
  theme(legend.position="bottom")+ 
  labs(x="Age at Operation", y="Density", fill="Compliant") 
# some trend towards better compliance for younger patients 
 
summary(analysis$gender) 
## ???????how od you explore factors 
 
ggplot(analysis,aes(x=analysis[,6],group=analysis[,10], 
fill=analysis[,10]))+ 
  geom_density(alpha=0.5)+ 
  theme(legend.position="bottom")+ 
  labs(x="AAA Diameter at Operation", y="Density", fill="Compliant") 
 
#no apparent consistent pattern but contains NA's - replace with mean 
analysis$`max pre-op diameter`<-ifelse(is.na(analysis$`max pre-op 
diameter`),65,analysis$`max pre-op diameter`) 
ggplot(analysis,aes(x=analysis[,6],group=analysis[,10], 
fill=analysis[,10]))+ 
  geom_density(alpha=0.5)+ 
  theme(legend.position="bottom")+ 
  labs(x="AAA Diameter at Operation (mm)", y="Density", 
fill="Compliant") 
#no overt pattern 
 
ggplot(analysis,aes(x=analysis[,7],group=analysis[,10], 
fill=analysis[,10]))+ 
  geom_density(alpha=0.5)+ 
  theme(legend.position="bottom")+ 
  labs(x="Time Since Operation (Years)", y="Density", 
fill="Compliant") 
#density of non-compliance higher after 2.5 years 
analysis$time_factor <- ifelse(analysis[,7]>=10, "After 10 Years", 
"Before 10 years") 
analysis$time_factor <- as.factor(analysis$time_factor) 
summary(analysis$time_factor) 
 
## 
summary(analysis[,9]) 
##?need to explore above more 
 
ggplot(analysis,aes(x=analysis[,11],group=analysis[,10], 
fill=analysis[,10]))+ 
  geom_density(alpha=0.5)+ 
  theme(legend.position="bottom")+ 
  labs(x="Age at time", y="Density", fill="Compliant") 
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#Age at time ofscan strongly corrolates to compliance (younger more 
compliant) 
 
ggplot(analysis,aes(x=analysis[,5],group=analysis[,10], 
fill=analysis[,10]))+ 
  geom_density(alpha=0.5)+ 
  theme(legend.position="bottom")+ 
  labs(x="Distance from Surveillance", y="Density", fill="Compliant") 
#distance is vastly skewed - likley effect of teriary practice 
majority within 60km 
analysis$distance_factor <- ifelse(analysis$distance>=60, "Teriary", 
"Local") 
analysis$distance_factor <- 
ifelse(is.na(analysis$distance_factor),"Teriary", 
analysis$distance_factor) 
analysis$distance_factor <- as.factor(analysis$distance_factor) 
summary(analysis$distance_factor) 
#relook at distance for local patients only 
local_patients <- subset(analysis,analysis$distance_factor=="Local") 
ggplot(local_patients,aes(x=local_patients[,5],group=local_patients[,1
0], fill=local_patients[,10]))+ 
  geom_density(alpha=0.5)+ 
  theme(legend.position="bottom")+ 
  labs(x="Distance from Surveillance", y="Density", fill="Compliant") 
#distance still squewed 
local_patients <- subset(analysis,analysis$distance_factor=="Local") 
local_patients$sqrt_distance<- sqrt(local_patients[,5]) 
ggplot(local_patients,aes(x=local_patients$sqrt_distance,group=local_p
atients[,10], fill=local_patients[,10]))+ 
  geom_density(alpha=0.5)+ 
  theme(legend.position="bottom")+ 
  labs(x="Distance from Surveillance", y="Density", fill="Compliant") 
#apparent better compliance before <~9km, worse between ~9-12km then 
equal >~12km 
###???should i be changing this to 3 factors?? 
 
#corroletion of continious variables (whole cohort) 
cor<- cor(analysis[,c(2,3,6,7,11)]) 
corrplot(cor, method="circle") 
#corrolation of continious variables (local patients only) 
cor<- cor(local_patients[,c(2,3,5,6,7,11,15)]) 
corrplot(cor, method="circle") 
##??can look at corelation between factos and other variables 
= 
# Split the data into training and test set 
set.seed(123) 
training.samples <- analysis$Database.ID %>% createDataPartition(p = 
0.8, list = FALSE) 
train.data  <- analysis[training.samples,c(2:14)] 
test.data <- analysis[-training.samples,c(2:14)] 
 
###added function to calculate odds ratios 
summLogistic <- function(mod){ 
  co.tab <- summary(mod)$coef 
   
  or <- exp(co.tab[,1]) 
  up <- exp(co.tab[,1]+1.96*co.tab[,2]) 
  lo <- exp(co.tab[,1]-1.96*co.tab[,2]) 
   
  c1 <- paste(round(co.tab[,1],2)," (",round(co.tab[,2],3),")",sep="") 
  c2 <- paste(round(or,2)," (",round(lo,3),", 
",round(up,3),")",sep="") 
  c3 <- round(co.tab[,4],3) 
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  zero.id <- which(c3==0) 
  if(length(zero.id)>0) c3[zero.id] <- "<0.001" 
   
  res <- data.frame(cbind(c1,c2,c3)) 
  names(res) <- c("est (se)","OR (95% CI)","Pval") 
   
  res  
} 
 
#Individual variable odds ratio's risks 
variable.model <- glm(sur_scan_in_18months ~ `year of op`+`year of 
op`^5, data = train.data, family = binomial) 
summLogistic(variable.model) 
variable.model <-glm (sur_scan_in_18months ~ `factor_year_of_op`, data 
= train.data, family = binomial) 
summLogistic(variable.model) 
variable.model <- glm(sur_scan_in_18months ~ pt_age_at_operation, data 
= train.data, family = binomial) 
summLogistic(variable.model) 
variable.model <- glm(sur_scan_in_18months ~ gender, data = 
train.data, family = binomial) 
summLogistic(variable.model) 
variable.model <- glm(sur_scan_in_18months ~ distance_factor, data = 
train.data, family = binomial) 
summLogistic(variable.model) 
variable.model <- glm(sur_scan_in_18months ~ distance, data = 
train.data, family = binomial) 
summLogistic(variable.model) 
variable.model <- glm(sur_scan_in_18months ~ `max pre-op diameter`, 
data = train.data, family = binomial) 
summLogistic(variable.model) 
variable.model <- glm(sur_scan_in_18months ~ time, data = train.data, 
family = binomial) 
summLogistic(variable.model) 
variable.model <- glm(sur_scan_in_18months ~ time_factor, data = 
train.data, family = binomial) 
summLogistic(variable.model) 
variable.model <- glm(sur_scan_in_18months ~ si_before, data = 
train.data, family = binomial) 
summLogistic(variable.model) 
variable.model <- glm(sur_scan_in_18months ~ `age at time`, data = 
train.data, family = binomial) 
summLogistic(variable.model) 
 
#Remove data with missing point 
train.data <- na.omit(train.data) 
#create a full (adjusted) model  
full.model <- glm(sur_scan_in_18months ~`age at time`+`time`+`year of 
op`+`age at op`+`gender`+`distance`+`si_before`+`max pre-op diameter`, 
data = train.data, family = binomial) 
#odds ratios of the full model 
summLogistic(full.model) 
 
#stepwise regression to remove less important and confounding 
veriables 
step.model <- stepAIC(full.model) 
#odds ratios of stepwise (simplfied) model 
summLogistic(step.model) 
 
#ensure stepwise regression hasn't significantly effected predictive 
power 
#Full model 
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# Make predictions 
test.data <- na.omit(test.data) 
probabilities <- full.model %>% predict(test.data, type = "response") 
predicted.classes <- ifelse(probabilities > 0.5, TRUE , FALSE) 
# Prediction accuracy 
observed.classes <- test.data$sur_scan_in_18months 
mean(predicted.classes == observed.classes) 
#Step Model 
# Make predictions 
probabilities <- step.model %>% predict(test.data, type = "response") 
predicted.classes <- ifelse(probabilities > 0.5, TRUE , FALSE) 
# Prediction accuracy 
observed.classes <- test.data$sur_scan_in_18months 
mean(predicted.classes == observed.classes) 
 
## complete for local patients only 
training.samples <- local_patients$Database.ID %>% 
createDataPartition(p = 0.8, list = FALSE) 
lptrain.data  <- local_patients[training.samples,c(2:15)] 
lptest.data <- local_patients[-training.samples,c(2:15)] 
 
#Remove data with missing point 
lptrain.data <- na.omit(lptrain.data) 
#create a full (adjusted) model  
full.model <- glm(sur_scan_in_18months ~`age at 
time`+time+factor_year_of_op+. , data = lptrain.data, family = 
binomial) 
#odds ratios of the full model 
summLogistic(full.model) 
 
#stepwise regression to remove less important and confounding 
veriables 
step.model <- stepAIC(full.model) 
#odds ratios of stepwise (simplfied) model 
summLogistic(step.model) 
step.model$anova 
 
 
#tidy 
rm(probabilities, predicted.classes,observed.classes,step.model, 
full.model, test.data, train.data, lptest.data, 
lptrain.data,training.samples, variable.model) 
 
 
### Data Manipulation for Surveillance Scan analysis ## 
##AXR Data## 
rm(AXR) 
AXR <- subset(all_scans, !is.na(AXR.Baseline)) 
AXR <-AXR[,c(1:17)] 
AXR <- AXR %>% arrange(Time.since.Operation.in.Years) 
AXR <- AXR %>% arrange(Database.ID) 
#Create a cumulative finding for "any abnormality" 
AXR <- left_join(AXR,AXR, by="Database.ID", no.dups = FALSE) 
AXR$calculation <- (AXR$Time.since.Operation.in.Years.x - 
AXR$Time.since.Operation.in.Years.y) 
AXR$calculation <- ifelse(is.na(AXR$calculation), 100, 
AXR$calculation) 
AXR <- subset(AXR, AXR$calculation >=0) 
AXR$abnormal_any_time <- as.logical (AXR$AXR.Abnormal.x + 
AXR$AXR.Abnormal.y) 
AXR <- AXR %>% arrange(Time.since.Operation.in.Years.x) 
AXR <- arrange(AXR, desc(abnormal_any_time)) 
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AXR <- distinct(AXR, Database.ID, Time.since.Operation.in.Years.x, 
.keep_all = TRUE) 
AXR <-AXR[,c(1:17,35)] 
names <- names(AXR) 
names <- str_remove(names,fixed(".x")) 
names(AXR) <- names 
rm(names) 
AXR <- AXR %>% arrange(Time.since.Operation.in.Years) 
AXR <- AXR %>% arrange(Database.ID) 
#Create a cumulative finding for migration 
AXR <- left_join(AXR,AXR, by="Database.ID", no.dups = FALSE) 
AXR$calculation <- (AXR$Time.since.Operation.in.Years.x - 
AXR$Time.since.Operation.in.Years.y) 
AXR <- subset(AXR, AXR$calculation >=0) 
AXR$migration_any_time <- as.logical (AXR$AXR.Migration.x + 
AXR$AXR.Migration.y) 
AXR <- AXR %>% arrange(Time.since.Operation.in.Years.x) 
AXR <- arrange(AXR, desc(migration_any_time)) 
AXR <- distinct(AXR, Database.ID, Time.since.Operation.in.Years.x, 
.keep_all = TRUE) 
AXR <-AXR[,c(1:18,37)] 
names <- names(AXR) 
names <- str_remove(names,fixed(".x")) 
names(AXR) <- names 
rm(names) 
AXR <- AXR %>% arrange(Time.since.Operation.in.Years) 
AXR <- AXR %>% arrange(Database.ID) 
#Create a cumulative finding for any limb kink (bilateral) 
AXR <- left_join(AXR,AXR, by="Database.ID", no.dups = FALSE) 
AXR$calculation <- (AXR$Time.since.Operation.in.Years.x - 
AXR$Time.since.Operation.in.Years.y) 
AXR <- subset(AXR, AXR$calculation >=0) 
AXR$any_limb_kink_any_time <- as.logical (AXR$AXR.Left.Limb.Kink.x + 
AXR$AXR.Left.Limb.Kink.y + AXR$AXR.Right.Limb.Kink.x + 
AXR$AXR.Right.Limb.Kink.y) 
AXR <- AXR %>% arrange(Time.since.Operation.in.Years.x) 
AXR <- arrange(AXR, desc(any_limb_kink_any_time)) 
AXR <- distinct(AXR, Database.ID, Time.since.Operation.in.Years.x, 
.keep_all = TRUE) 
AXR <-AXR[,c(1:19,39)] 
names <- names(AXR) 
names <- str_remove(names,fixed(".x")) 
names(AXR) <- names 
rm(names) 
AXR <- AXR %>% arrange(Time.since.Operation.in.Years) 
AXR <- AXR %>% arrange(Database.ID) 
#Create a cumulative finding for any structural failure 
AXR <- left_join(AXR,AXR, by="Database.ID", no.dups = FALSE) 
AXR$calculation <- (AXR$Time.since.Operation.in.Years.x - 
AXR$Time.since.Operation.in.Years.y) 
AXR <- subset(AXR, AXR$calculation >=0) 
AXR$any_structural_failure <- as.logical (AXR$AXR.Structural.Failure.x 
+ AXR$AXR.Structural.Failure.y) 
AXR <- AXR %>% arrange(Time.since.Operation.in.Years.x) 
AXR <- arrange(AXR, desc(any_structural_failure)) 
AXR <- distinct(AXR, Database.ID, Time.since.Operation.in.Years.x, 
.keep_all = TRUE) 
AXR <-AXR[,c(1:20,41)] 
names <- names(AXR) 
names <- str_remove(names,fixed(".x")) 
names(AXR) <- names 
rm(names) 
AXR <- AXR %>% arrange(Time.since.Operation.in.Years) 
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AXR <- AXR %>% arrange(Database.ID) 
#Create a cumulative finding for any effacement 
AXR <- left_join(AXR,AXR, by="Database.ID", no.dups = FALSE) 
AXR$calculation <- (AXR$Time.since.Operation.in.Years.x - 
AXR$Time.since.Operation.in.Years.y) 
AXR <- subset(AXR, AXR$calculation >=0) 
AXR$any_effacement <- as.logical (AXR$AXR.Effacement.x + 
AXR$AXR.Effacement.y) 
AXR <- AXR %>% arrange(Time.since.Operation.in.Years.x) 
AXR <- arrange(AXR, desc(any_effacement)) 
AXR <- distinct(AXR, Database.ID, Time.since.Operation.in.Years.x, 
.keep_all = TRUE) 
AXR <-AXR[,c(1:21,43)] 
names <- names(AXR) 
names <- str_remove(names,fixed(".x")) 
names(AXR) <- names 
rm(names) 
AXR <- AXR %>% arrange(Time.since.Operation.in.Years) 
AXR <- AXR %>% arrange(Database.ID) 
AXR <- AXR [,c(1,3,2,8:22)] 
##AXR data## 
 
##CDUS Data## 
rm(CDUS) 
CDUS <- subset(all_scans, !is.na(CDUS.Diagnostic)) 
CDUS <- CDUS[,c(1:4,18:31)] 
#Create GRaft related endoleak TRUE/FALSE 
CDUS$graft_related_unknown_endoleak <- 
ifelse(CDUS$CDUS.Endoleak.Type=="Type 
III"|CDUS$CDUS.Endoleak.Type=="Type IA"|CDUS$CDUS.Endoleak.Type=="Type 
IB"|CDUS$CDUS.Endoleak.Type=="Other/Unknown",TRUE,FALSE) 
#Create a Type II ENdoleak TRUE/FALSE 
CDUS$typeII_endoleak <- ifelse(CDUS$CDUS.Endoleak.Type=="Type 
II",TRUE,FALSE) 
#Create a undiagnostic variable 
CDUS$undiagnostic <- !CDUS$CDUS.Diagnostic 
#Order Favorably for combining 
CDUS <- CDUS %>% arrange(Time.since.Operation.in.Years) 
CDUS <- CDUS %>% arrange(Database.ID) 
#Create a cumulative finding for "CDUS Undiagnostic" 
CDUS <- left_join(CDUS,CDUS, by="Database.ID", no.dups = FALSE) 
CDUS$calculation <- (CDUS$Time.since.Operation.in.Years.x - 
CDUS$Time.since.Operation.in.Years.y) 
CDUS <- subset(CDUS, CDUS$calculation >=0) 
CDUS$undiagnostic_any_time <- as.logical (CDUS$undiagnostic.x + 
CDUS$undiagnostic.y) 
CDUS <- CDUS %>% arrange(Time.since.Operation.in.Years.x) 
CDUS <- arrange(CDUS, desc(undiagnostic_any_time)) 
CDUS <- distinct(CDUS, Database.ID, Time.since.Operation.in.Years.x, 
.keep_all = TRUE) 
CDUS <- CDUS[,c(1:21,43)] 
names <- names(CDUS) 
names <- str_remove(names,fixed(".x")) 
names(CDUS) <- names 
rm(names) 
CDUS <- CDUS %>% arrange(Time.since.Operation.in.Years) 
CDUS <- CDUS %>% arrange(Database.ID) 
#Create a cumulative finding for "Any ENdoleak Present" 
CDUS <- left_join(CDUS,CDUS, by="Database.ID", no.dups = FALSE) 
CDUS$calculation <- (CDUS$Time.since.Operation.in.Years.x - 
CDUS$Time.since.Operation.in.Years.y) 
CDUS <- subset(CDUS, CDUS$calculation >=0) 
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CDUS$any_endoleak_any_time <- as.logical (CDUS$CDUS.Endoleak.Present.x 
+ CDUS$CDUS.Endoleak.Present.y) 
CDUS <- CDUS %>% arrange(Time.since.Operation.in.Years.x) 
CDUS <- arrange(CDUS, desc(any_endoleak_any_time)) 
CDUS <- distinct(CDUS, Database.ID, Time.since.Operation.in.Years.x, 
.keep_all = TRUE) 
CDUS <- CDUS[,c(1:22,45)] 
names <- names(CDUS) 
names <- str_remove(names,fixed(".x")) 
names(CDUS) <- names 
rm(names) 
CDUS <- CDUS %>% arrange(Time.since.Operation.in.Years) 
CDUS <- CDUS %>% arrange(Database.ID) 
#Create a cumulative finding for "Graft related / Unknown Endoleak" 
CDUS <- left_join(CDUS,CDUS, by="Database.ID", no.dups = FALSE) 
CDUS$calculation <- (CDUS$Time.since.Operation.in.Years.x - 
CDUS$Time.since.Operation.in.Years.y) 
CDUS <- subset(CDUS, CDUS$calculation >=0) 
CDUS$graft_related_unknown_endoleak_any_time <- as.logical 
(CDUS$graft_related_unknown_endoleak.x + 
CDUS$graft_related_unknown_endoleak.y) 
CDUS <- CDUS %>% arrange(Time.since.Operation.in.Years.x) 
CDUS <- arrange(CDUS, desc(graft_related_unknown_endoleak_any_time)) 
CDUS <- distinct(CDUS, Database.ID, Time.since.Operation.in.Years.x, 
.keep_all = TRUE) 
CDUS <- CDUS[,c(1:23,47)] 
names <- names(CDUS) 
names <- str_remove(names,fixed(".x")) 
names(CDUS) <- names 
CDUS <- CDUS %>% arrange(Time.since.Operation.in.Years) 
CDUS <- CDUS %>% arrange(Database.ID) 
#Create a cumulative finding for "Type II Endoleak" 
CDUS <- left_join(CDUS,CDUS, by="Database.ID", no.dups = FALSE) 
CDUS$calculation <- (CDUS$Time.since.Operation.in.Years.x - 
CDUS$Time.since.Operation.in.Years.y) 
CDUS <- subset(CDUS, CDUS$calculation >=0) 
CDUS$typeII_endoleak_any_time <- as.logical (CDUS$typeII_endoleak.x + 
CDUS$typeII_endoleak.y) 
CDUS <- CDUS %>% arrange(Time.since.Operation.in.Years.x) 
CDUS <- arrange(CDUS, desc(typeII_endoleak_any_time)) 
CDUS <- distinct(CDUS, Database.ID, Time.since.Operation.in.Years.x, 
.keep_all = TRUE) 
CDUS <- CDUS[,c(1:24,49)] 
names <- names(CDUS) 
names <- str_remove(names,fixed(".x")) 
names(CDUS) <- names 
rm(names) 
CDUS <- CDUS %>% arrange(Time.since.Operation.in.Years) 
CDUS <- CDUS %>% arrange(Database.ID) 
#Create a cumulative finding for "Limb Complication" 
CDUS <- left_join(CDUS,CDUS, by="Database.ID", no.dups = FALSE) 
CDUS$calculation <- (CDUS$Time.since.Operation.in.Years.x - 
CDUS$Time.since.Operation.in.Years.y) 
CDUS <- subset(CDUS, CDUS$calculation >=0) 
CDUS$limb_complication_any_time <- 
as.logical(CDUS$CDUS.Limb.Complication.x + 
CDUS$CDUS.Limb.Complication.y) 
CDUS <- CDUS %>% arrange(Time.since.Operation.in.Years.x) 
CDUS <- arrange(CDUS, desc(limb_complication_any_time)) 
CDUS <- distinct(CDUS, Database.ID, Time.since.Operation.in.Years.x, 
.keep_all = TRUE) 
CDUS <- CDUS[,c(1:25,51)] 
names <- names(CDUS) 
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names <- str_remove(names,fixed(".x")) 
names(CDUS) <- names 
rm(names) 
CDUS <- CDUS %>% arrange(Time.since.Operation.in.Years) 
CDUS <- CDUS %>% arrange(Database.ID) 
 
#Create a cumulative finding for smallest aneurysm size in 
surveillance 
CDUS <- left_join(CDUS,CDUS, by="Database.ID", no.dups = FALSE) 
CDUS$smallest_AAA_years_ago <- (CDUS$Time.since.Operation.in.Years.x - 
CDUS$Time.since.Operation.in.Years.y) 
CDUS <- subset(CDUS, CDUS$smallest_AAA_years_ago >=0) 
CDUS$smallest_AAA_size_any_time <- ifelse(CDUS$CDUS.AAA.size.in.mm.x 
<= CDUS$CDUS.AAA.size.in.mm.y, CDUS$CDUS.AAA.size.in.mm.x, 
CDUS$CDUS.AAA.size.in.mm.y) 
CDUS$smallest_AAA_size_any_time <- 
ifelse(is.na(CDUS$smallest_AAA_size_any_time), 
CDUS$CDUS.AAA.size.in.mm.x, CDUS$smallest_AAA_size_any_time) 
CDUS$smallest_AAA_size_any_time <- 
ifelse(is.na(CDUS$smallest_AAA_size_any_time), 
CDUS$CDUS.AAA.size.in.mm.y, CDUS$smallest_AAA_size_any_time) 
CDUS <- CDUS %>% arrange(Time.since.Operation.in.Years.x) 
CDUS <- arrange(CDUS, smallest_AAA_size_any_time) 
CDUS <- distinct(CDUS, Database.ID, Time.since.Operation.in.Years.x, 
.keep_all = TRUE) 
CDUS <- CDUS[,c(1:26,52,53)] 
names <- names(CDUS) 
names <- str_remove(names,fixed(".x")) 
names(CDUS) <- names 
rm(names) 
CDUS <- CDUS %>% arrange(Time.since.Operation.in.Years) 
CDUS <- CDUS %>% arrange(Database.ID) 
#Create a size measurement for previous CDUS over 3 months ago 
CDUS <- left_join(CDUS,CDUS, by="Database.ID", no.dups = FALSE) 
CDUS$last_AAA_size_years_ago <- (CDUS$Time.since.Operation.in.Years.x 
- CDUS$Time.since.Operation.in.Years.y) 
CDUS$previous_AAA_size <- ifelse(CDUS$last_AAA_size_years_ago >=0.25, 
CDUS$CDUS.AAA.size.in.mm.y, NA) 
CDUS <- subset(CDUS, CDUS$last_AAA_size_years_ago >=0) 
CDUS$last_AAA_size_years_ago <- ifelse(CDUS$last_AAA_size_years_ago 
>=0.25, CDUS$last_AAA_size_years_ago, NA) 
CDUS <- CDUS %>% arrange(last_AAA_size_years_ago) 
CDUS <- distinct(CDUS, Database.ID, Time.since.Operation.in.Years.x, 
.keep_all = TRUE) 
CDUS <- CDUS[,c(1:28,56,57)] 
names <- names(CDUS) 
names <- str_remove(names,fixed(".x")) 
names(CDUS) <- names 
rm(names) 
CDUS <- CDUS %>% arrange(Time.since.Operation.in.Years) 
CDUS <- CDUS %>% arrange(Database.ID) 
 
## Add AXR data onto CDUS 
CDUS_AXR <- left_join(CDUS,AXR, by="Database.ID", no.dups = FALSE) 
CDUS_AXR$calculated <- (CDUS_AXR$Time.since.Operation.in.Years.x - 
CDUS_AXR$Time.since.Operation.in.Years.y) 
CDUS_AXR$calculated <- ifelse(is.na(CDUS_AXR$calculated), 100, 
CDUS_AXR$calculated) 
CDUS_AXR$calculated <- ifelse(CDUS_AXR$calculated < 0, 100, 
CDUS_AXR$calculated) 
CDUS_AXR <- subset(CDUS_AXR, CDUS_AXR$calculated >=0) 
CDUS_AXR <- CDUS_AXR %>% arrange(calculated) 
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CDUS_AXR <- distinct(CDUS_AXR, Database.ID, 
Time.since.Operation.in.Years.x, .keep_all = TRUE) 
a <- subset(CDUS_AXR, CDUS_AXR$calculated ==100) 
a[,c(31:48)] <- NA 
CDUS_AXR  <-rbind(subset(CDUS_AXR, CDUS_AXR$calculated !=100),a) 
rm(a) 
 
#Combine CDUS_AXR Data with Secondary Intervention Data 
CDUS_AXR_si <- left_join(CDUS_AXR, secondary_interventions, 
by="Database.ID", no.dups = FALSE) 
CDUS_AXR_si$time_to_prev_si_in_years <- 
(CDUS_AXR_si$Time.since.Operation.in.Years - 
CDUS_AXR_si$Time.since.Operation.in.Years.x) 
CDUS_AXR_si$previous_si <- ifelse(CDUS_AXR_si$time_to_prev_si_in_years 
< 0, TRUE, FALSE) 
CDUS_AXR_si$previous_si <- ifelse(is.na(CDUS_AXR_si$previous_si), 
FALSE, CDUS_AXR_si$previous_si) 
CDUS_AXR_si <- CDUS_AXR_si %>% arrange(desc(previous_si)) 
CDUS_AXR_si <- distinct(CDUS_AXR_si, Database.ID, 
Time.since.Operation.in.Years.x, .keep_all = TRUE) 
 
CDUS_AXR_si <- left_join(CDUS_AXR_si, secondary_interventions, 
by="Database.ID", no.dups = FALSE) 
CDUS_AXR_si$time_to_si_in_years_x <- 
(CDUS_AXR_si$Time.since.Operation.in.Years.x.x - 
CDUS_AXR_si$Time.since.Operation.in.Years.x) 
a <- subset(CDUS_AXR_si, CDUS_AXR_si$time_to_si_in_years_x >= 0) 
a$next_si <- TRUE 
b <- subset(CDUS_AXR_si, is.na(CDUS_AXR_si$time_to_si_in_years_x)) 
c <- subset(CDUS_AXR_si, CDUS_AXR_si$time_to_si_in_years_x < 0) 
CDUS_AXR_si <-rbind(b,c) 
CDUS_AXR_si$next_si <- FALSE 
CDUS_AXR_si <-rbind(CDUS_AXR_si,a) 
rm(a,b,c) 
CDUS_AXR_si <- CDUS_AXR_si %>% arrange(time_to_si_in_years_x) 
CDUS_AXR_si <- distinct(CDUS_AXR_si, Database.ID, 
Time.since.Operation.in.Years.x, .keep_all = TRUE) 
CDUS_AXR_si <- CDUS_AXR_si[,c(1:59)] 
CDUS_AXR_si <- CDUS_AXR_si %>% 
arrange(Time.since.Operation.in.Years.x) 
CDUS_AXR_si <- CDUS_AXR_si %>% arrange(Database.ID) 
 
#Combine AXR & CDUS with patient level data 
data <- merge (CDUS_AXR_si ,patient_data, by="Database.ID") 
data$smallest_AAA_size_any_time <- 
ifelse(is.na(data$smallest_AAA_size_any_time), 
data$Max.Pre.op.Iliac.Diameter.in.mm, data$smallest_AAA_size_any_time) 
data$max_growth <- data$CDUS.AAA.size.in.mm-
data$smallest_AAA_size_any_time 
data$recent_growth <- data$CDUS.AAA.size.in.mm - 
data$previous_AAA_size 
data$recent_growth_rate <- 
data$recent_growth/data$last_AAA_size_years_ago 
data$axr_delay <- data$Time.since.Operation.in.Years.x - 
data$Time.since.Operation.in.Years.y 
data$limb_kink <- as.logical (data$AXR.Left.Limb.Kink + 
data$AXR.Right.Limb.Kink) 
 
all_data$op_end <- 
all_data$Time.from.operation.to.Start.of.Observational.period.in.Years 
+ 7 
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all_data$Time.from.Operation.to.No.Follow.Up.in.Years <- 
ifelse(is.na(all_data$Time.from.Operation.to.No.Follow.Up.in.Years), 
1000, all_data$Time.from.Operation.to.No.Follow.Up.in.Years) 
all_data$time <- ifelse(all_data$op_end < 
all_data$Time.from.Operation.to.No.Follow.Up.in.Years, 
all_data$op_end, 
all_data$Time.from.Operation.to.No.Follow.Up.in.Years) 
all_data$Time.from.Operation.to.Death.in.Years <- 
ifelse(is.na(all_data$Time.from.Operation.to.Death.in.Years), 1000, 
all_data$Time.from.Operation.to.Death.in.Years) 
all_data$time <- ifelse(all_data$time < 
all_data$Time.from.Operation.to.Death.in.Years, all_data$time, 
all_data$Time.from.Operation.to.Death.in.Years) 
all_data$Time.since.Operation.in.Years.y <- 
ifelse(is.na(all_data$Time.since.Operation.in.Years.y),1000,all_data$T
ime.since.Operation.in.Years.y) 
all_data$time <- all_data$time - 
all_data$Time.since.Operation.in.Years.x 
all_data <- subset(all_data, time>0) 
 
all_data$time_to_si_in_years <- 
all_data$Time.since.Operation.in.Years.x.x - 
all_data$Time.since.Operation.in.Years.x 
all_data$time_to_si_in_years <- ifelse(all_data$time_to_si_in_years<0, 
NA, all_data$time_to_si_in_years) 
 
all_data$event <- ifelse(all_data$time_to_si_in_years <= 
all_data$time, TRUE, FALSE) 
all_data$event <- ifelse(is.na(all_data$event),FALSE,all_data$event) 
all_data$time <- ifelse(all_data$event==TRUE, 
all_data$time_to_si_in_years,all_data$time) 
 
all_data <- all_data %>% mutate_all(na_if,"") 
 
DATA <- data.frame(all_data$Database.ID, 
all_data$Time.since.Operation.in.Years.x,all_data$undiagnostic,all_dat
a$undiagnostic_any_time,all_data$CDUS.Endoleak.Present,all_data$any_en
doleak_any_time,all_data$graft_related_unknown_endoleak,all_data$graft
_related_unknown_endoleak_any_time,all_data$typeII_endoleak,all_data$t
ypeII_endoleak_any_time,all_data$CDUS.Limb.Complication,all_data$limb_
complication_any_time,all_data$CDUS.Mixed.Thrombose.in.AAA,all_data$CD
US.AAA.size.in.mm,all_data$max_growth,all_data$recent_growth,all_data$
recent_growth_rate,all_data$axr_delay,all_data$AXR.Abnormal,all_data$a
bnormal_any_time,all_data$AXR.Migration,all_data$migration_any_time,al
l_data$limb_kink,all_data$any_limb_kink_any_time,all_data$AXR.Structur
al.Failure,all_data$any_structural_failure,all_data$AXR.Effacement,all
_data$any_effacement,all_data$previous_si,all_data$Calander.Year.of.Op
eration,all_data$Age.at.Operation.in.Years,all_data$Gender,all_data$Di
stance.to.Surveillance.Centre.in.km,all_data$Max.Pre.op.Diameter.in.mm
,all_data$time,all_data$event,all_data$SI_Type.x,all_data$Patient.Symp
tomatic.x, all_data$Detected.on.Surveillance.x) 
names(DATA) = 
c("pt_id","time_since_op","cdus_undiagnostic","cdus_undiagnostic_cumul
ative", "cdus_any_endoleak", 
"cdus_any_endoleak_cumulative","cdus_gru_endoleak","cdus_gru_endoleak_
cumulative","cdus_t2_endoleak","cdus_t2_endoleak_cumulative","cdus_lim
bs","cdus_limbs_cumulative", 
"cdus_mixed_thrombus","cdus_aaa_size","cdus_max_growth","cdus_recent_g
rowth","cdus_recent_growth_rate", 
"axr_delay","axr_abnormal","axr_abnormal_cumulative","axr_migration","
axr_migration_cumulative","axr_limb_kink","axr_limb_kink_cumulative","
axr_structural","axr_structural_cumulative","axr_effacement","axr_effa
cement_cumulative","pt_previous_si","pt_year_of_operation","pt_age_at_
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operation","pt_sex","pt_distance_to_surveillance","pt_max_preop_AAA_si
ze","follow_up_time", "event", "si_type", 
"symptomatic","surv_detected") 
 
###Description of Variables in DATA### 
#pt_id                          patient unique identifier 
#time_since_op                  years after opertaion that CDUS 
(Ultrasound) occured 
#cdus_diagnostic                this CDUS (Ultrasound) was not 
diagnostic (TRUE) or diagnostic (FALSE) 
#cdus_undiagnostic_cumulative   any (previous or current) CDUS was not 
diagnostic (TRUE) or all were diagnostic (FALSE) 
#cdus_any_endoleak              any endoleak detected (TRUE) or none 
(FALSE) on this CDUS (Ultrasound) 
#cdus_any_endoleak_cumulative   any endoleak detected (TRUE) or none 
(FALSE) on any (previous or current) CDUS 
#cdus_gru_endoleak              graft-related or unknown source 
endoleak detected (TRUE) or none (FALSE) on this CDUS (Ultrasound) 
#cdus_gru_endoleak_cumulative   graft-related or unknown source 
endoleak detected (TRUE) or none (FALSE) on any (previous or current) 
CDUS 
#cdus_t2_endoleak               type II endoleak detected (TRUE) or 
none (FALSE) on this CDUS (Ultrasound) 
#cdus_t2_endoleak_cumulative    type II endoleak detected (TRUE) or 
none (FALSE) on any (previous or current) CDUS 
#cdus_limbs                     any limb finding (TRUE) or none 
(FALSE) on this CDUS (Ultrasound) 
#cdus_limbs_cumulative          any limb finding (TRUE) or none 
(FALSE) on any (previous or current) CDUS 
#cdus_mixed_thrombus            thrombus between EVAR stent-graft & 
AAA wall is hetrogenous (TRUE) or Homogenous (FALSE) on this CDUS 
#cdus_aaa_size                  max aaa diameter (mm) on this CDUS 
(ultrasound) 
#cdus_max_growth                difference in diameter (mm) between 
current CDUS and smallest diameter measured 
#cdus_recent_growth             difference in diameter (mm) between 
current CDUS and last CDUS (which must have been over 0.25 years ago) 
#cdus_recent_growth_rate        growth rate (mm/year) between current 
CDUS and last CDUS (which must have been over 0.25 years ago) 
#axr_delay                      number of years beofre CDUS that AXR 
(x-ray) was performed 
#axr_abnormal                   any abnormality detected (TRUE) or not 
(FALSE) on this AXR (x-ray) 
#axr_abnormal_cumulative        any abnormality detected (TRUE) or not 
(FALSE) on any (previous or current) AXR 
#axr_migration                  any migration detected (TRUE) or not 
(FALSE) on this AXR (x-ray) 
#axr_migration_cumulative       any migration detected (TRUE) or not 
(FALSE) on any (previous or current) AXR 
#axr_limb_kink                  any limb kink detected (TRUE) or not 
(FALSE) on this AXR (x-ray) 
#axr_limb_kink_cumulative       any limb kink detected (TRUE) or not 
(FALSE) on any (previous or current) AXR 
#axr_structural                 any structural failure detected (TRUE) 
or not (FALSE) on this AXR (x-ray) 
#axr_structural_cumulative      any structural failure detected (TRUE) 
or not (FALSE) on any (previous or current) AXR 
#axr_effacement                 any effacement detected (TRUE) or not 
(FALSE) on this AXR (x-ray) 
#axr_effacement_cumulative      any effacement detected (TRUE) or not 
(FALSE) on any (previous or current) AXR 
#pt_previous_si                 has the patient previously undergone 
(TRUE) or not (FALSE) a secondary intervention 
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#pt_year_of_operation           the calander year the primary EVAR was 
performed in 
#pt_age_at_operation            the patients age at the time of the 
primary EVAR 
#pt_sex                         patients recorded sex (Male/Female) 
#pt_distance_to_surveillance    distance (km) from patients last 
recorded address to surveillance centre 
#pt_max_preop_AAA_size          max diameter (mm) measured pre-op 
#follow_up_time                 time (years) between scan and end of 
observation 
#event                          secondary intervention (TRUE) or 
censored (FALSE) 
#si_type                        secondary intervention Flow or 
Aneurysm related 
#symptomatic                    was the patient symptomatic at time of 
SI 
#surv_deteceted                 was the SI triggered by surveillance 
 
##determining time frame over which surveillance scans raise 
intervention rates above that of baseline 
#Select dataset 
DATA1 <- DATA 
#Add in this line for data exclusing first 9 months after EVAR as by 
far the highest re-intervention rate 
#DATA1 <- subset(DATA1,DATA1$time_since_op>=0.75) 
#Star of analyiss 
DATA1 <- DATA1[order(DATA1$follow_up_time),] 
#censor data at 2 years 
x<-2 #correct with final value# 
##Limit dat to timeframe "x"## 
j <- 1:length(DATA1[,1]) 
for (i in j) { 
  if (DATA1$follow_up_time[i] > x) { 
    DATA1$follow_up_time[i] <- (x+0.00001)#survminer needs for at risk 
table 
    DATA1$event[i] <- FALSE 
  } else { 
    DATA1$follow_up_time[i] <- DATA1$follow_up_time[i] 
    DATA1$event[i] <- DATA1$event[i] 
  } 
} 
rm(x) 
#basic data 
str(unique(DATA1$pt_id)) 
summary(DATA1$event) 
#Hazard Ratio Analysis for all data 
x <- nelsonaalen(DATA1, follow_up_time, event) 
plot <-data.frame(DATA1$follow_up_time,x,diff(c(0,x))) 
 
un.time <- unique(plot[,1]) 
diff.time <- diff(c(0,un.time)) 
 
 
mod <- lm((plot[,2])~-
1+plot[,1]+I(plot[,1]^2)+I(plot[,1]^3)+I(plot[,1]^4)+I(plot[,1]^5)+I(p
lot[,1]^6)+I(plot[,1]^7)) 
anova(mod) 
 
#### Differentiating 
co <- coef(mod) 
x <- plot[,1] 
x.pow <- cbind(1,2*x,3*x^2,4*x^3,5*x^4,6*x^5,7*x^6) 
diff <- (co)%*%t(x.pow) 
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fit.y <- log(t((coef(mod))%*%t(model.matrix(mod)))) 
##Cumulative Hazard Ratio 
Cairo(file="cumulative_hazard_ratio.png", type="png",units="mm", 
width= 140, height = 86.5, dpi=600, ponitsize="1") 
plot(plot[,1],log(plot[,2]),ylab="log(Cumulative Hazard 
Ratio)",xlab="Time After Surveillance Scan (Years)", xlim=c(0,1.2), 
pch = 20, cex=0.4) 
lines(plot[,1],fit.y,lwd=5,col=alpha(rgb(1,0,0), 0.5)) 
legend("bottom", legend=c("Absolute Values", "Best Fit 
Line"),col=c("Black", alpha(rgb(1,0,0), 0.5)), lty=c(0,1), pch = 
c(20,NA), lwd = c(NA,5)) 
dev.off() 
#Point Hazard Ratio 
Cairo(file="absolute_hazard_ratio.png", type="png",units="mm", width= 
140, height = 86.5, dpi=600, ponitsize="1") 
plot(plot[,1],diff,typ="l",lwd=5,col=alpha(rgb(1,0,0), 
1),ylab="Absolute Point Hazard Ratio",xlab="Time After Surveillance 
Scan (Years)", xlim=c(0,1.2), ylim=c(0,0.25)) 
abline(v=0.5,col="gray",lty=2) 
legend("topright", legend="Best Fit Line",col=alpha(rgb(1,0,0), 1), 
lty=1, lwd = 5) 
dev.off() 
 
rm(co,x,x.pow,diff,fit.y,DATA1) 
# basic data 
a<-subset(DATA1,time_since_op>=0.75) 
str(a) 
str(unique(a$pt_id)) 
summary(a$event) 
subset(DATA1,time_since_op>=0.75) 
#Hazard Ratio Analysis for scans performed after .75 years after 
operation. 
x <- nelsonaalen(subset(DATA1,time_since_op>=0.75), follow_up_time, 
event) 
plot <-
data.frame(subset(DATA1,time_since_op>=0.75)$follow_up_time,x,diff(c(0
,x))) 
un.time <- unique(plot[,1]) 
diff.time <- diff(c(0,un.time)) 
mod <- lm((plot[,2])~-
1+plot[,1]+I(plot[,1]^2)+I(plot[,1]^3)+I(plot[,1]^4)+I(plot[,1]^5)+I(p
lot[,1]^6)+I(plot[,1]^7)) 
anova(mod) 
#### Differentiating 
co <- coef(mod) 
x <- plot[,1] 
x.pow <- cbind(1,2*x,3*x^2,4*x^3,5*x^4,6*x^5,7*x^6) 
diff <- (co)%*%t(x.pow) 
fit.y <- log(t((coef(mod))%*%t(model.matrix(mod)))) 
#check plot for anlysis for 0.75 year cohort 
plot(plot[,1],log(plot[,2]),ylab="log(Cumulative Hazard 
Ratio)",xlab="Time After Surveillance Scan (Years)", xlim=c(0,1.2), 
pch = 20, cex=0.4) 
lines(plot[,1],fit.y,lwd=5,col=alpha(rgb(1,0,0), 0.5)) 
#plot for best fir line for 0.75 year cohort 
Cairo(file="absolute_hazard_ratio_late.png", type="png",units="mm", 
width= 140, height = 86.5, dpi=600, ponitsize="1") 
plot(plot[,1],diff,typ="l",lwd=5,col=alpha(rgb(1,0,0), 
1),ylab="Absolute Point Hazard Ratio",xlab="Time After Surveillance 
Scan (Years)", xlim=c(0,1.2), ylim=c(0,0.08)) 
abline(v=0.5,col="gray",lty=2) 
legend("topright", legend="Best Fit Line",col=alpha(rgb(1,0,0), 1), 
lty=1, lwd = 5) 
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dev.off() 
 
 
##### As such time that surveillance scans felt to influence re-
intervention rates over was 0.5 years ### 
## Add in AXR migration Factor## 
migration_data <- read.csv("axr_migration_factor.csv", header = TRUE, 
col.names = c("pt_id","time_since_op","migration_factor")) 
DATA1 <- DATA 
DATA1$axr_time <- DATA1$time_since_op - DATA1$axr_delay 
DATA1 <- left_join (DATA1, migration_data, 
by=c("pt_id","axr_time"="time_since_op")) 
DATA1$migration_factor <- 
ifelse(is.na(DATA1$axr_delay),NA,ifelse(is.na(DATA1$migration_factor),
"None",as.character(DATA1$migration_factor))) 
DATA1$migration_factor <- as.factor(DATA1$migration_factor) 
DATA1$migration_factor1 <- DATA1$migration_factor 
DATA1$migration_factor1 <- ifelse(DATA1$migration_factor1=="Definite 
Migration","Definite Migration","No Migration / Other") 
DATA1$migration_factor1 <- ifelse(DATA1$migration_factor1=="Definite 
Migration", TRUE, FALSE) 
 
DATA1 <- DATA1[,c(1:39,41,42)] 
 
x<-0.5 
##Limit dat to timeframe "x"## 
j <- 1:length(DATA1[,1]) 
for (i in j) { 
  if (DATA1$follow_up_time[i] > x) { 
    DATA1$follow_up_time[i] <- (x+0.00001)#survminer needs for at risk 
table 
    DATA1$event[i] <- FALSE 
  } else { 
    DATA1$follow_up_time[i] <- DATA1$follow_up_time[i] 
    DATA1$event[i] <- DATA1$event[i] 
  } 
} 
 
##Investigate findings associated with flow related secondary 
intervention## 
#Events only count if flow related - Otherwise cencored at right 
censor or other si 
DATA1$flow <- ifelse (DATA1$event==TRUE & DATA1$si_type=="Flow", TRUE, 
FALSE) 
DATA1$aneurysm <- ifelse (DATA1$event==TRUE & 
DATA1$si_type=="Aneurysm", TRUE, FALSE) 
 
#Create Multiple Imputations for NA's in DATA1 dataset 
DATA1_MI <- 
mice(DATA1[,c(2:36,40:43)],method=c("","","","","","","","","","","","
","pmm","pmm","pmm","pmm","pmm","logreg","logreg","logreg","","logreg"
,"","logreg","","logreg","","","","","","pmm","pmm","","","polyreg","l
ogreg","",""), m=50) 
##NOTE## Cumulative AXR data excluded due to poor imputational output 
#save(DATA1_MI, file="midata.RData") 
#Load above Multiple Imputations data 
load("midata.RData") 
 
stripplot(DATA1_MI$data$cdus_recent_growth_rate, pch = 20, cex = 1.2) 
 
 
#Basic data 
str(DATA1$pt_id) 
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unique(DATA1$pt_id) 
summary(DATA1$flow) 
summary(DATA1$aneurysm) 
#Related AXR data 
summary(DATA1$axr_delay) 
 
###CDUS Diagnostic - Flow - NOT SIgnificant 
summary(DATA1$cdus_undiagnostic)#no missing data (no NA) 
#KM Graph 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$flow)~DATA1$cdus_undiagnostic, 
data = DATA1) 
Cairo(file="km_cdus_undiagnostic_flow.png", type="png",units="mm", 
width= 177, height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("CDUS Diagnostic", 
"CDUS Undiagnostic"), risk.table = TRUE, pval = TRUE, conf.int = TRUE, 
break.time.by = 0.1, censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.4, xlab="Years Since Surveillance Scan", ylab="Freedom From\n'Flow 
Related'\nSecondary Intervention", surv.scale="percent", legend.title 
= "Key: ", xlim = c(0, x), ylim=c(0.95,1), pval.coord = c(0.1, 0.96)) 
dev.off() 
#CoxPH Model 
coxph(Surv(DATA1$follow_up_time,DATA1$flow)~DATA1$cdus_undiagnostic) 
exp(0.3540-(1.93*0.3356)) 
exp(0.3540+(1.93*0.3356)) 
#Hazard Ratio of 1.42 (0.74 - 2.72) 
rm(fit) 
 
###CDUS Diagnostic - Aneurysm - NOT SIgnificant 
summary(DATA1$cdus_undiagnostic)#no missing data (no NA) 
#KM Graph 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_undiagnos
tic, data = DATA1) 
Cairo(file="km_cdus_undiagnostic_aneurysm.png", type="png",units="mm", 
width= 177, height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("CDUS Diagnostic", 
"CDUS Undiagnostic"), risk.table = TRUE, pval = TRUE, conf.int = TRUE, 
break.time.by = 0.1, censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.4, xlab="Years Since Surveillance Scan", ylab="Freedom 
From\n'Aneurysm Related'\nSecondary Intervention", 
surv.scale="percent", legend.title = "Key: ", xlim = c(0, x), 
ylim=c(0.95,1), pval.coord = c(0.1, 0.96)) 
dev.off() 
#CoxPH Model 
coxph(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_undiagnosti
c) 
exp(0.1848-(1.93*0.4358)) 
exp(0.1848+(1.93*0.4358)) 
#Hazard Ratio of 0.83 (0.52 - 2.79) 
rm(fit) 
 
###CDUS Cumulative Diagnostic - Flow - NOT SIgnificant 
summary(DATA1$cdus_undiagnostic_cumulative)#no missing data (no NA) 
#KM Graph 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$flow)~DATA1$cdus_undiagnostic_
cumulative, data = DATA1) 
Cairo(file="km_cdus_undiagnostic_cumulative_flow.png", 
type="png",units="mm", width= 177, height=115, dpi=600, ponitsize="1") 
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ggsurvplot(fit, legend = "bottom", legend.labs = c("All CDUS 
Diagnostic", "\u2265 1 CDUS Undiagnostic"), risk.table = TRUE, pval = 
TRUE, conf.int = TRUE, break.time.by = 0.1, censor=FALSE, 
risk.table.title="Number at Risk", risk.table.y.text=FALSE, 
risk.table.y.text.col=TRUE, risk.table.height = 0.4, xlab="Years Since 
Surveillance Scan", ylab="Freedom From\n'Flow Related'\nSecondary 
Intervention", surv.scale="percent", legend.title = "Key: ", xlim = 
c(0, x), ylim=c(0.95,1), pval.coord = c(0.1, 0.96)) 
dev.off() 
#CoxPH Model 
coxph(Surv(DATA1$follow_up_time,DATA1$flow)~DATA1$cdus_undiagnostic_cu
mulative) 
exp(-0.3941-(1.93*0.3077)) 
exp(-0.3941+(1.93*0.3077)) 
#Hazard Ratio of 0.67 (0.37 - 1.22) 
rm(fit) 
 
###CDUS Cumulative Diagnostic - Aneurysm -Significant 
summary(DATA1$cdus_undiagnostic_cumulative)#no missing data (no NA) 
#KM Graph 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_undiagnos
tic_cumulative, data = DATA1) 
Cairo(file="km_cdus_undiagnostic_aneurysm_cumulative.png", 
type="png",units="mm", width= 177, height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("All CDUS 
Diagnostic", "\u2265 1 CDUS Undiagnostic"), risk.table = TRUE, pval = 
TRUE, conf.int = TRUE, break.time.by = 0.1, censor=FALSE, 
risk.table.title="Number at Risk", risk.table.y.text=FALSE, 
risk.table.y.text.col=TRUE, risk.table.height = 0.4, xlab="Years Since 
Surveillance Scan", ylab="Freedom From\n'Aneurysm Related'\nSecondary 
Intervention", surv.scale="percent", legend.title = "Key: ", xlim = 
c(0, x), ylim=c(0.95,1), pval.coord = c(0.1, 0.96)) 
dev.off() 
#CoxPH Model 
coxph(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_undiagnosti
c_cumulative) 
exp(-0.9054-(1.93*0.3865)) 
exp(-0.9054+(1.93*0.3865)) 
#Hazard Ratio of 0.40 (0.19 - 0.85) 
rm(fit) 
 
###CDUS Any Endoleak### - SIGNIFICANT 
summary(DATA1$cdus_any_endoleak) # no missing data(no NA) 
#KM Graph 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_any_endol
eak, data = DATA1) 
Cairo(file="km_cdus_any_endoleak_aneurysm.png", type="png",units="mm", 
width= 177, height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("No Endoleak 
Detected", "\u2265 1 Endoleak(s) Detected"), risk.table = TRUE, pval = 
TRUE, conf.int = TRUE, break.time.by = 0.1, censor=FALSE, 
risk.table.title="Number at Risk", risk.table.y.text=FALSE, 
risk.table.y.text.col=TRUE, risk.table.height = 0.4, xlab="Years Since 
Surveillance Scan", ylab="Freedom From\n'Aneurysm Related'\nSecondary 
Intervention", surv.scale="percent", legend.title = "Key: ", xlim = 
c(0, x), ylim=c(0.9,1), pval.coord = c(0.1, 0.925)) 
dev.off() 
#CoxPH Model 
coxph(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_any_endolea
k) 
exp(2.1168-(1.93*0.2963)) 
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exp(2.1168+(1.93*0.2963)) 
#  Harzard Ratio of 8.30 (4.69 - 14.71) 
rm(fit) 
 
###CDUS Any endoleak cumulative- much less effect 
summary(DATA1$cdus_any_endoleak_cumulative)#no missing data (no NA) 
#KM Graph 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_any_endol
eak_cumulative, data = DATA1) 
Cairo(file="km_cdus_any_endoleak_cumulative_aneurysm.png", 
type="png",units="mm", width= 177, height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("No Endoleak Dected 
on any CDUS", "\u2265 1 Endoleak(s) detected on any CDUS"), risk.table 
= TRUE, pval = TRUE, conf.int = TRUE, break.time.by = 0.1, 
censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.4, xlab="Years Since Surveillance Scan", ylab="Freedom 
From\n'Aneurysm Related'\nSecondary Intervention", 
surv.scale="percent", legend.title = "Key: ", xlim = c(0, x), 
ylim=c(0.95,1), pval.coord = c(0.05, 0.965)) 
dev.off() 
#CoxPH Model 
coxph(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_any_endolea
k_cumulative) 
exp(1.6839-(1.93*0.3162)) 
exp(1.6839+(1.93*0.3162)) 
#Hazard Ratio of 5.38 (2.93 - 9.92) 
rm(fit) 
 
 
###CDUS GR Endoleak### - SIGNIFICANT 
summary(DATA1$cdus_gru_endoleak) # no missing data(no NA) 
#KM Graph 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_gru_endol
eak, data = DATA1) 
Cairo(file="km_cdus_gr_endoleak_aneurysm.png", type="png",units="mm", 
width= 177, height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("No Graft Related 
Endoleak Detected", "\u2265 1 Graft Related Endoleak(s) Detected"), 
risk.table = TRUE, pval = TRUE, conf.int = TRUE, break.time.by = 0.1, 
censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.4, xlab="Years Since Surveillance Scan", ylab="Freedom 
From\n'Aneurysm Related'\nSecondary Intervention", 
surv.scale="percent", legend.title = "Key: ", xlim = c(0, x), 
ylim=c(0.5,1), pval.coord = c(0.1, 0.6)) 
dev.off() 
#CoxPH Model 
coxph(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_gru_endolea
k) 
exp(3.4173-(1.93*0.2934)) 
exp(3.4173+(1.93*0.2934)) 
#  Harzard Ratio of 30.49 (17.31 - 53.71) 
rm(fit) 
 
###CDUS GR endoleak cumulative- much less significant 
summary(DATA1$cdus_gru_endoleak_cumulative)#no missing data (no NA) 
#KM Graph 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_gru_endol
eak_cumulative, data = DATA1) 
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Cairo(file="km_cdus_gr_endoleak_cumulative.png", 
type="png",units="mm", width= 177, height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("No Graft Related 
Endoleak Detected", "\u2265 1 Graft Related Endoleak(s) detected"), 
risk.table = TRUE, pval = TRUE, conf.int = TRUE, break.time.by = 0.1, 
censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.4, xlab="Years Since Surveillance Scan", ylab="Freedom 
From\n'Aneurysm Related'\nSecondary Intervention", 
surv.scale="percent", legend.title = "Key: ", xlim = c(0, x), 
ylim=c(0.85,1), pval.coord = c(0.05, 0.875)) 
dev.off() 
#CoxPH Model 
coxph(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_gru_endolea
k_cumulative) 
exp(2.3533-(1.93*0.2873)) 
exp(2.3533+(1.93*0.2873)) 
#Hazard Ratio of 10.52 (6.04 - 18.32) 
rm(fit) 
 
###CDUS Type II Endoleak### - NOT SIGNIFICANT 
summary(DATA1$cdus_t2_endoleak) # no missing data(no NA) 
#KM Graph 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_t2_endole
ak, data = DATA1) 
Cairo(file="km_cdus_t2_endoleak_aneurysm.png", type="png",units="mm", 
width= 177, height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("No Type II 
Endoleak Detected", "\u2265 1 Type II Endoleak(s) Detected"), 
risk.table = TRUE, pval = TRUE, conf.int = TRUE, break.time.by = 0.1, 
censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.4, xlab="Years Since Surveillance Scan", ylab="Freedom From\n 
'Aneurysm Related'\nSecondary Intervention", surv.scale="percent", 
legend.title = "Key: ", xlim = c(0, x), ylim=c(0.95,1), pval.coord = 
c(0.1, 0.975)) 
dev.off() 
#CoxPH Model 
coxph(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_t2_endoleak
) 
exp(0.6111-(1.93*0.3322)) 
exp(0.6111+(1.93*0.3322)) 
#  Harzard Ratio of 1.84 (0.97 - 3.50) 
rm(fit) 
 
###CDUS Type II endoleak cumulative- much less significant 
summary(DATA1$cdus_t2_endoleak_cumulative)#no missing data (no NA) 
#KM Graph 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_t2_endole
ak_cumulative, data = DATA1) 
Cairo(file="km_cdus_t2_endoleak_cumulative.png", 
type="png",units="mm", width= 177, height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("No Type II 
Endoleak Detected", "\u2265 1 Type II Endoleak(s) detected"), 
risk.table = TRUE, pval = TRUE, conf.int = TRUE, break.time.by = 0.1, 
censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.4, xlab="Years Since Surveillance Scan", ylab="Freedom 
From\n'Aneurysm Related'\nSecondary Intervention", 
surv.scale="percent", legend.title = "Key: ", xlim = c(0, x), 
ylim=c(0.95,1), pval.coord = c(0.05, 0.975)) 
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dev.off() 
#CoxPH Model 
coxph(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_t2_endoleak
_cumulative) 
exp(0.5171-(1.93*0.2932)) 
exp(0.5171+(1.93*0.2932)) 
#Hazard Ratio of 1.68 (0.95 - 2.95) 
rm(fit) 
 
###CDUS Limb ABnormality### 
summary(DATA1$cdus_limbs) # no missing data(no NA) 
#KM Graph for 'flow related' 
fit <-survfit(Surv(DATA1$follow_up_time,DATA1$flow)~DATA1$cdus_limbs, 
data = DATA1) 
Cairo(file="km_cdus_limb_issue.png", type="png",units="mm", width= 
177, height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("No Limb 
abnormality detected on CDUS", "\u2265 1 Limb abnormality detected on 
CDUS"), risk.table = TRUE, pval = TRUE, conf.int = TRUE, break.time.by 
= 0.1, censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.4, xlab="Years Since Surveillance Scan", ylab="Freedom From\n'Flow 
Related'\nSecondary Intervention", surv.scale="percent", legend.title 
= "Key: ", xlim = c(0, x), ylim=c(0.75,1), pval.coord = c(0.1, 0.8)) 
dev.off() 
#CoxPH Model 
coxph(Surv(DATA1$follow_up_time,DATA1$flow)~DATA1$cdus_limbs) 
exp(2.704-(1.93*0.281)) 
exp(2.704+(1.93*0.281)) 
#  Harzard Ratio of 14.935 (8.69 - 25.70) 
rm(fit) 
 
###CDUS Limb abnormality cumulative- much less significant 
summary(DATA1$cdus_limbs_cumulative)#no missing data (no NA) 
#KM Graph 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$flow)~DATA1$cdus_limbs_cumulat
ive, data = DATA1) 
Cairo(file="km_cdus_limb_issue_cumulative.png", type="png",units="mm", 
width= 177, height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("No Limb 
abnormality detected on any CDUS", "\u2265 1 Limb abnormality detected 
on any CDUS"), risk.table = TRUE, pval = TRUE, conf.int = TRUE, 
break.time.by = 0.1, censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.4, xlab="Years Since Surveillance Scan", ylab="Freedom From\n'Flow 
Related'\nSecondary Intervention", surv.scale="percent", legend.title 
= "Key: ", xlim = c(0, x), ylim=c(0.75,1), pval.coord = c(0.1, 0.8)) 
dev.off() 
#CoxPH Model 
coxph(Surv(DATA1$follow_up_time,DATA1$flow)~DATA1$cdus_limbs_cumulativ
e) 
exp(2.164-(1.93*0.285)) 
exp(2.164+(1.93*0.285)) 
#Hazard Ratio of 8.71 (5.02 - 15.09) 
rm(fit) 
 
 
###CDUS AAA Size - Not Significant 
summary(DATA1$cdus_aaa_size)#125 NA's 
#Dummy variable for NA's-flow 
DATA1$cdus_aaa_size_nadum <- ifelse(is.na(DATA1$cdus_aaa_size), 0, 1) 
Chapter 6: Appendices 
Iain Nicholas Roy - August 2020   217 
DATA1$cdus_aaa_size <- ifelse(DATA1$cdus_aaa_size_nadum==0, 0, 
DATA1$cdus_aaa_size) 
summary(coxph(Surv(DATA1$follow_up_time,DATA1$flow)~DATA1$cdus_aaa_siz
e_nadum/DATA1$cdus_aaa_size), method="breslow") 
summary(coxph(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_aaa
_size_nadum/DATA1$cdus_aaa_size), method="breslow") 
#Missing data is important to both flow and aneurysm related SI's 
 
#Models using Multiple Imputated data for flow related SI 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,flow)~cdus_aaa_size)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
exp(summary$estimate)#Hazard Ratio 
exp(summary$estimate-(1.93*summary$std.error))#Lower 95% CI 
exp(summary$estimate+(1.93*summary$std.error))#Upper 95% CI 
summary$p.value# p Value 
#Hazard Ratio of 1.01 (0.99 - 1.02) p=0.41 
rm(fit,models,pool_models,summary) 
 
#Models using Multiple Imputated data for aneurysm related SI 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,aneurysm)~cdus_aaa_si
ze)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
exp(summary$estimate)#Hazard Ratio 
exp(summary$estimate-(1.93*summary$std.error))#Lower 95% CI 
exp(summary$estimate+(1.93*summary$std.error))#Upper 95% CI 
summary$p.value# p Value 
#Hazard Ratio of 1.04 (1.03 - 1.05) p<0.0001 
rm(fit,models,pool_models,summary) 
 
####CDUS max growth 
summary(DATA1$cdus_max_growth)#125 NA's 
#125 NA's 
#Dummy variable for NA's 
DATA1$cdus_max_growth_nadum <- ifelse(is.na(DATA1$cdus_max_growth), 0, 
1) 
DATA1$cdus_max_growth <- ifelse(DATA1$cdus_max_growth_nadum==0, 0, 
DATA1$cdus_max_growth) 
summary(coxph(Surv(DATA1$follow_up_time,DATA1$flow)~DATA1$cdus_max_gro
wth_nadum/DATA1$cdus_max_growth), method="breslow") 
summary(coxph(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_max
_growth_nadum/DATA1$cdus_max_growth), method="breslow") 
 
#Missing data is important in flow model 
#Models using Multiple Imputated data for 'flow related' SI 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,flow)~cdus_max_growth
)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
exp(summary$estimate)#Hazard Ratio 
exp(summary$estimate-(1.93*summary$std.error))#Lower 95% CI 
exp(summary$estimate+(1.93*summary$std.error))#Upper 95% CI 
summary$p.value# p Value 
#Hazard Ratio of 0.81 (0.67 - 0.98) p=0.03 
rm(fit,models,pool_models,summary) 
 
#Model using Available data for 'aneurysm related' SI 
DATA1$cdus_max_growth <- ifelse(DATA1$cdus_max_growth_nadum==0, NA, 
DATA1$cdus_max_growth) 
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coxph(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_max_growth) 
exp(0.06087-(1.93*0.01237)) 
exp(0.06087+(1.93*0.01237)) 
#Hazard Ratio of 1.06 (1.04 - 1.09) p<0.0001 
 
###CDUS recent growth 
summary(DATA1$cdus_recent_growth) #988 NA's 
#Dummy variable for NA's 
DATA1$cdus_recent_growth_nadum <- 
ifelse(is.na(DATA1$cdus_recent_growth), 0, 1) 
DATA1$cdus_recent_growth <- ifelse(DATA1$cdus_recent_growth_nadum==0, 
0, DATA1$cdus_recent_growth) 
summary(coxph(Surv(DATA1$follow_up_time,DATA1$flow)~DATA1$cdus_recent_
growth_nadum/DATA1$cdus_recent_growth), method="breslow") 
summary(coxph(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_rec
ent_growth_nadum/DATA1$cdus_recent_growth), method="breslow") 
#Missing data is  not missing at random 
 
#Cox model with MI data for flow model 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,flow)~cdus_recent_gro
wth)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
exp(summary$estimate)#Hazard Ratio 
exp(summary$estimate-(1.93*summary$std.error))#Lower 95% CI 
exp(summary$estimate+(1.93*summary$std.error))#Upper 95% CI 
summary$p.value# p Value 
#Hazard Ratio of 1.03 (0.94 - 1.12) p=0.54 
rm(fit,models,pool_models,summary) 
 
#Models using Multiple Imputated data for 'aneurysm related SI 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,aneurysm)~cdus_recent
_growth)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
exp(summary$estimate)#Hazard Ratio 
exp(summary$estimate-(1.93*summary$std.error))#Lower 95% CI 
exp(summary$estimate+(1.93*summary$std.error))#Upper 95% CI 
summary$p.value# p Value 
#Hazard Ratio of 1.11 (1.07 - 1.16) p<0.0001 
rm(fit,models,pool_models,summary) 
 
###CDUS recent growth rate 
summary(DATA1$cdus_recent_growth_rate) #988 NA's 
#Dummy variable for NA's-flow 
DATA1$cdus_recent_growth_rate_nadum <- 
ifelse(is.na(DATA1$cdus_recent_growth_rate), 0, 1) 
DATA1$cdus_recent_growth_rate <- 
ifelse(DATA1$cdus_recent_growth_rate_nadum==0, 0, 
DATA1$cdus_recent_growth) 
summary(coxph(Surv(DATA1$follow_up_time,DATA1$flow)~DATA1$cdus_recent_
growth_rate_nadum/DATA1$cdus_recent_growth_rate), method="breslow") 
summary(coxph(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$cdus_rec
ent_growth_rate_nadum/DATA1$cdus_recent_growth_rate), 
method="breslow") 
#Missing data is  not missing at random 
 
#Models using Multiple Imputated data for 'flow related' SI 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,flow)~cdus_recent_gro
wth_rate)) 
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pool_models <- pool(models) 
summary<- summary(pool_models) 
exp(summary$estimate)#Hazard Ratio 
exp(summary$estimate-(1.93*summary$std.error))#Lower 95% CI 
exp(summary$estimate+(1.93*summary$std.error))#Upper 95% CI 
summary$p.value# p Value 
#Hazard Ratio of 1.01 (0.95 - 1.07) p=0.82 
rm(fit,models,pool_models,summary) 
 
#Models using Multiple Imputated data for 'aneurysm related' SI 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,aneurysm)~cdus_recent
_growth_rate)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
exp(summary$estimate)#Hazard Ratio 
exp(summary$estimate-(1.93*summary$std.error))#Lower 95% CI 
exp(summary$estimate+(1.93*summary$std.error))#Upper 95% CI 
summary$p.value# p Value 
#Hazard Ratio of 1.06 (1.04 - 1.09) p<0.0001 
rm(fit,models,pool_models,summary) 
 
###AXR effacement 
summary(DATA1$axr_effacement)# 76 NA's 
#KM Graph 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$axr_effacement
, data = DATA1) 
Cairo(file="km_axr_effacement.png", type="png",units="mm", width= 177, 
height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("No effacement 
detected on AXR", "Effacement detected on AXR"), risk.table = TRUE, 
pval = TRUE, conf.int = TRUE, break.time.by = 0.1, censor=FALSE, 
risk.table.title="Number at Risk", risk.table.y.text=FALSE, 
risk.table.y.text.col=TRUE, risk.table.height = 0.4, xlab="Years Since 
Surveillance Scan", ylab="Freedom From\n'Aneurysm Related'\nSecondary 
Intervention", surv.scale="percent", legend.title = "Key: ", xlim = 
c(0, x), ylim=c(0.825,1), pval.coord = c(0.1, 0.85)) 
dev.off() 
#Asessment for missingness 
table(DATA1$axr_effacement,DATA1$aneurysm,useNA="always") 
#Missing data is important 
#Models using Multiple Imputated data 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,aneurysm)~axr_effacem
ent)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
exp(summary$estimate)#Hazard Ratio 
exp(summary$estimate-(1.93*summary$std.error))#Lower 95% CI 
exp(summary$estimate+(1.93*summary$std.error))#Upper 95% CI 
summary$p.value# p Value 
#Hazard Ratio of 7.03 (3.00 - 16.46) p<0.0001 
rm(fit,models,pool_models,summary) 
 
###AXR effacement cumulative 
summary(DATA1$axr_effacement_cumulative)# 76 NA's 
#KM Graph 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$axr_effacement
_cumulative, data = DATA1) 
Cairo(file="km_axr_effacement_cumulative.png", type="png",units="mm", 
width= 177, height=115, dpi=600, ponitsize="1") 
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ggsurvplot(fit, legend = "bottom", legend.labs = c("No effacement 
detected on any AXR", "Effacement detected on \u2265 1 AXR"), 
risk.table = TRUE, pval = TRUE, conf.int = TRUE, break.time.by = 0.1, 
censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.4, xlab="Years Since Surveillance Scan", ylab="Freedom 
From\n'Aneurysm Related'\nSecondary Intervention", 
surv.scale="percent", legend.title = "Key: ", xlim = c(0, x), 
ylim=c(0.925,1), pval.coord = c(0.1, 0.95)) 
dev.off() 
#Asessment for missingness 
table(DATA1$axr_effacement_cumulative,DATA1$aneurysm,useNA="always") 
#Missing data is important 
#Models using Multiple Imputated data 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,aneurysm)~axr_effacem
ent_cumulative)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
exp(summary$estimate)#Hazard Ratio 
exp(summary$estimate-(1.93*summary$std.error))#Lower 95% CI 
exp(summary$estimate+(1.93*summary$std.error))#Upper 95% CI 
summary$p.value# p Value 
#Hazard Ratio of 2.54 (1.14 - 5.64) p=0.02 
rm(fit,models,pool_models,summary) 
 
###AXR structural 
summary(DATA1$axr_structural)# 76 NA's 
#KM Graph aneurysm 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$axr_structural
, data = DATA1) 
Cairo(file="km_axr_structural.png", type="png",units="mm", width= 177, 
height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("No Structural 
Failure detected on AXR", "Structural Failure detected on AXR"), 
risk.table = TRUE, pval = TRUE, conf.int = TRUE, break.time.by = 0.1, 
censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.4, xlab="Years Since Surveillance Scan", ylab="Freedom 
From\n'Aneurysm Related'\nSecondary Intervention", 
surv.scale="percent", legend.title = "Key: ", xlim = c(0, x), 
ylim=c(0.875,1), pval.coord = c(0.1, 0.9)) 
dev.off() 
#Asessment for missingness 
table(DATA1$axr_structural,DATA1$aneurysm,useNA="always") 
#Models using Multiple Imputated data 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,aneurysm)~axr_structu
ral)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
exp(summary$estimate)#Hazard Ratio 
exp(summary$estimate-(1.93*summary$std.error))#Lower 95% CI 
exp(summary$estimate+(1.93*summary$std.error))#Upper 95% CI 
summary$p.value# p Value 
#Hazard Ratio of 4.16 (1.51 - 11.48) p=0.007 
rm(fit,models,pool_models,summary) 
 
###AXR structural cumulative 
summary(DATA1$axr_structural_cumulative)# 76 NA's 
#KM Graph 
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fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$axr_structural
_cumulative, data = DATA1) 
Cairo(file="km_axr_structural_cumulative.png", type="png",units="mm", 
width= 177, height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("No structural 
failure detected on any AXR", "Structural Failure detected on \u2265 1 
AXR"), risk.table = TRUE, pval = TRUE, conf.int = TRUE, break.time.by 
= 0.1, censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.4, xlab="Years Since Surveillance Scan", ylab="Freedom 
From\n'Aneurysm Related'\nSecondary Intervention", 
surv.scale="percent", legend.title = "Key: ", xlim = c(0, x), 
ylim=c(0.95,1), pval.coord = c(0.1, 0.965)) 
dev.off() 
#Asessment for missingness 
table(DATA1$axr_structural_cumulative,DATA1$aneurysm,useNA="always") 
#Missing data is important 
#Models using Multiple Imputated data 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,aneurysm)~axr_structu
ral_cumulative)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
exp(summary$estimate)#Hazard Ratio 
exp(summary$estimate-(1.93*summary$std.error))#Lower 95% CI 
exp(summary$estimate+(1.93*summary$std.error))#Upper 95% CI 
summary$p.value# p Value 
#Hazard Ratio of 1.53 (0.55 - 4.21) p=0.42 
rm(fit,models,pool_models,summary) 
 
###AXR limb kink - SIGNIFICANT 
summary(DATA1$axr_limb_kink)# 76 NA's 
#KM Graph 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$flow)~DATA1$axr_limb_kink, 
data = DATA1) 
Cairo(file="km_axr_limb_issue.png", type="png",units="mm", width= 177, 
height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("No Limb 
abnormality detected on AXR", "\u2265 1 Limb abnormality detected on 
AXR"), risk.table = TRUE, pval = TRUE, conf.int = TRUE, break.time.by 
= 0.1, censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.4, xlab="Years Since Surveillance Scan", ylab="Freedom From\n'Flow 
Related'\nSecondary Intervention", surv.scale="percent", legend.title 
= "Key: ", xlim = c(0, x), ylim=c(0.85,1), pval.coord = c(0.1, 0.875)) 
dev.off() 
#assessment for missingness 
table(DATA1$axr_limb_kink,DATA1$flow,useNA="always") 
#Models using Multiple Imputated data 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,flow)~axr_limb_kink)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
exp(summary$estimate)#Hazard Ratio 
exp(summary$estimate-(1.93*summary$std.error))#Lower 95% CI 
exp(summary$estimate+(1.93*summary$std.error))#Upper 95% CI 
summary$p.value# p Value 
#Hazard Ratio of 4.32 (1.98 - 9.46) p=0.0003 
rm(fit,models,pool_models,summary) 
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#AXR limb kink cumulative - NOT SIGNIFICANT 
summary(DATA1$axr_limb_kink_cumulative)# 76 NA's 
#KM Graph 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$flow)~DATA1$axr_limb_kink_cumu
lative, data = DATA1) 
Cairo(file="km_axr_limb_issue_cumulative.png", type="png",units="mm", 
width= 177, height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("No Limb 
abnormality detected on any AXR", "\u2265 1 Limb abnormality detected 
on any AXR"), risk.table = TRUE, pval = TRUE, conf.int = TRUE, 
break.time.by = 0.1, censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.4, xlab="Years Since Surveillance Scan", ylab="Freedom From\n'Flow 
Related'\nSecondary Intervention", surv.scale="percent", legend.title 
= "Key: ", xlim = c(0, x), ylim=c(0.94,1), pval.coord = c(0.1, 0.95)) 
dev.off() 
#assessment for missingness 
table(DATA1$axr_limb_kink_cumulative,DATA1$flow,useNA="always") 
#Models using Multiple Imputated data 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,flow)~axr_limb_kink_c
umulative)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
exp(summary$estimate)#Hazard Ratio 
exp(summary$estimate-(1.93*summary$std.error))#Lower 95% CI 
exp(summary$estimate+(1.93*summary$std.error))#Upper 95% CI 
summary$p.value# p Value 
#Hazard Ratio of 1.80 (0.86 - 3.77) p=0.13 
rm(fit,models,pool_models,summary) 
 
#AXR migration factors 
summary(DATA1$migration_factor)# 76 NA's 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$migration_fact
or, data = DATA1) 
Cairo(file="km_migration_factor.png", type="png",units="mm", width= 
177, height=125, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("Barb 
Engagement","Definite Migration","Minor Migration","None","Unknown"), 
risk.table = TRUE, pval = TRUE, conf.int = TRUE, break.time.by = 0.1, 
censor=FALSE, risk.table.title="Number at Risk", 
risk.table.y.text=FALSE, risk.table.y.text.col=TRUE, risk.table.height 
= 0.4, xlab="Years Since Surveillance Scan", ylab="Freedom 
From\n'Aneurysm Related'\nSecondary Intervention", 
surv.scale="percent", legend.title = "Key: ", xlim = c(0, x), 
ylim=c(0.85,1), pval.coord = c(0.1, 0.875)) 
dev.off() 
#rationalised factor to denitine (TRUE/FALSE) 
fit <-
survfit(Surv(DATA1$follow_up_time,DATA1$aneurysm)~DATA1$migration_fact
or2, data = DATA1) 
Cairo(file="km_migration_definite.png", type="png",units="mm", width= 
177, height=115, dpi=600, ponitsize="1") 
ggsurvplot(fit, legend = "bottom", legend.labs = c("No Migration / 
Other on AXR", "Definite Migration on AXR"), risk.table = TRUE, pval = 
TRUE, conf.int = TRUE, break.time.by = 0.1, censor=FALSE, 
risk.table.title="Number at Risk", risk.table.y.text=FALSE, 
risk.table.y.text.col=TRUE, risk.table.height = 0.4, xlab="Years Since 
Surveillance Scan", ylab="Freedom From\n'Aneurysm Related'\nSecondary 
Intervention", surv.scale="percent", legend.title = "Key: ", xlim = 
c(0, x), ylim=c(0.85,1), pval.coord = c(0.1, 0.95)) 
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dev.off() 
#HR data 
models <- 
with(data=DATA1_MI1,exp=coxph(Surv(follow_up_time,aneurysm)~migration_
factor1)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
exp(summary$estimate)#Hazard Ratio 
exp(summary$estimate-(1.93*summary$std.error))#Lower 95% CI 
exp(summary$estimate+(1.93*summary$std.error))#Upper 95% CI 
summary$p.value# p Value 
#Hazard Ratio of 4.57 (1.44 - 14.52) p=0.01 
 
########Rationalise flow related variables 
DATA2 <- na.omit(DATA1[,c(1:36,40:43)]) 
DATA2 <-DATA2[order(-DATA2$flow),] 
##Full Model 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,flow)~cdus_undiag
nostic+cdus_undiagnostic_cumulative+cdus_limbs+cdus_limbs_cumulative+c
dus_aaa_size+cdus_max_growth+cdus_recent_growth+cdus_recent_growth_rat
e+axr_limb_kink+axr_limb_kink_cumulative))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500  
aic # AIC 741 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,flow)~cdus_undiagnost
ic+cdus_undiagnostic_cumulative+cdus_limbs+cdus_limbs_cumulative+cdus_
aaa_size+cdus_max_growth+cdus_recent_growth+cdus_recent_growth_rate+ax
r_limb_kink+axr_limb_kink_cumulative)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
a<- as.data.frame(summary) 
a$hr <- exp(a$estimate) 
a$lci <-exp(a$estimate-(1.93*a$std.error))#Lower 95% CI 
a$uci <-exp(a$estimate+(1.93*a$std.error))#Upper 95% CI 
a 
#####. Manually calculating linear predictor 
lpdata <- 
DATA2[,which(names(DATA2)%in%c("cdus_undiagnostic","cdus_undiagnostic_
cumulative","cdus_limbs","cdus_limbs_cumulative","cdus_aaa_size","cdus
_max_growth","cdus_recent_growth","cdus_recent_growth_rate","axr_limb_
kink","axr_limb_kink_cumulative"))] 
lpmat <- model.matrix(~.,data=lpdata)[,-1] 
lp.null <- a$estimate%*%t(lpmat) 
null.roc<- roc(DATA2$flow,a$estimate%*%t(lpmat)) 
auc(null.roc) 
##### 
 
##Create simplfied model## 
#drop CDUS cumulative limbs 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,flow)~cdus_undiag
nostic+cdus_undiagnostic_cumulative+cdus_limbs+cdus_aaa_size+cdus_max_
growth+cdus_recent_growth+cdus_recent_growth_rate+axr_limb_kink+axr_li
mb_kink_cumulative))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500 
aic # AIC 738 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,flow)~cdus_undiagnost
ic+cdus_undiagnostic_cumulative+cdus_limbs+cdus_aaa_size+cdus_max_grow
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th+cdus_recent_growth+cdus_recent_growth_rate+axr_limb_kink+axr_limb_k
ink_cumulative)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
a<- as.data.frame(summary) 
a$hr <- exp(a$estimate) 
a 
#drop CDUS diagnostic cumulative 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,flow)~cdus_undiag
nostic+cdus_limbs+cdus_aaa_size+cdus_max_growth+cdus_recent_growth+cdu
s_recent_growth_rate+axr_limb_kink+axr_limb_kink_cumulative))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500 
aic # AIC 741 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,flow)~cdus_undiagnost
ic+cdus_limbs+cdus_aaa_size+cdus_max_growth+cdus_recent_growth+cdus_re
cent_growth_rate+axr_limb_kink+axr_limb_kink_cumulative)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
a<- as.data.frame(summary) 
a$hr <- exp(a$estimate) 
a 
#drop AXR limb kink cumulative 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,flow)~cdus_undiag
nostic+cdus_limbs+cdus_aaa_size+cdus_max_growth+cdus_recent_growth+cdu
s_recent_growth_rate+axr_limb_kink))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500 
aic # AIC 741 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,flow)~cdus_undiagnost
ic+cdus_limbs+cdus_aaa_size+cdus_max_growth+cdus_recent_growth+cdus_re
cent_growth_rate+axr_limb_kink)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
a<- as.data.frame(summary) 
a$hr <- exp(a$estimate) 
a 
#remove recent growth rate 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,flow)~cdus_undiag
nostic+cdus_limbs+cdus_aaa_size+cdus_max_growth+cdus_recent_growth+axr
_limb_kink))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500 
aic # AIC 741 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,flow)~cdus_undiagnost
ic+cdus_limbs+cdus_aaa_size+cdus_max_growth+cdus_recent_growth+axr_lim
b_kink)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
a<- as.data.frame(summary) 
a$hr <- exp(a$estimate) 
a 
#remove CDUS undiagnostic 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,flow)~cdus_limbs+
cdus_aaa_size+cdus_max_growth+cdus_recent_growth+axr_limb_kink))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
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aic <- sum(aic)/500 
aic # AIC 740 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,flow)~cdus_limbs+cdus
_aaa_size+cdus_max_growth+cdus_recent_growth+axr_limb_kink)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
a<- as.data.frame(summary) 
a$hr <- exp(a$estimate) 
a 
#remove CDUS max growth 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,flow)~cdus_limbs+
cdus_aaa_size+cdus_recent_growth+axr_limb_kink))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500 
aic # AIC 753 
#add back CDUS max growth, remove cdus recent growth 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,flow)~cdus_limbs+
cdus_aaa_size+cdus_max_growth+axr_limb_kink))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500 
aic # AIC 747 
#add back CDUS recent growth, remove CDUS aaa size 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,flow)~cdus_limbs+
cdus_max_growth+cdus_recent_growth+axr_limb_kink))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500 
aic # AIC 742 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,flow)~cdus_limbs+cdus
_max_growth+cdus_recent_growth+axr_limb_kink)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
a<- as.data.frame(summary) 
a$hr <- exp(a$estimate) 
a 
#remove CDUS recent growth 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,flow)~cdus_limbs+
cdus_max_growth+axr_limb_kink))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500 
aic # AIC 750 
#add back CDUS recent growth, remove CDUS max growth 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,flow)~cdus_limbs+
cdus_recent_growth+axr_limb_kink))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500 
aic # AIC 753 
#add back CDUS max growth 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,flow)~cdus_limbs+
cdus_max_growth+cdus_recent_growth+axr_limb_kink))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500 
aic # AIC 742 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,flow)~cdus_limbs+cdus
_max_growth+cdus_recent_growth+axr_limb_kink)) 
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pool_models <- pool(models) 
summary<- summary(pool_models) 
a<- as.data.frame(summary) 
a$hr <- exp(a$estimate) 
a$lci <- exp(a$estimate-(1.93*a$std.error))#Lower 95% CI 
a$uci <- exp(a$estimate+(1.93*a$std.error))#Upper 95% CI 
a 
#remove CDUS max growth or CDUS recent growth leads to large increase 
in AIC 
 
##Final Simplfied flow model### 
#####. Manually calculating linear predictor 
lpdata <- 
DATA2[,which(names(DATA2)%in%c("cdus_limbs","cdus_max_growth","cdus_re
cent_growth","axr_limb_kink"))] 
lpmat <- model.matrix(~.,data=lpdata)[,-1] 
lp.simp <- a$estimate%*%t(lpmat) 
simp.roc<-roc(DATA2$flow,lp.simp) 
auc(simp.roc) 
##### 
##### 
Cairo(file="flow_models_rocs.png", type="png",units="mm", width= 140, 
height=70, dpi=600, ponitsize="1") 
par(mfrow=c(1,2)) 
plot(null.roc,main="Full Model",xlim=c(1,0), ylim=c(0,1)) 
mtext("AUC = 0.95", side=1) 
plot(simp.roc,main="Simplified Model",xlim=c(1,0), ylim=c(0,1)) 
mtext("AUC = 0.95", side=1) 
dev.off() 
Cairo(file="flow_models_comparison.png", type="png",units="mm", width= 
140, height=140, dpi=600, ponitsize="1") 
plot(lp.simp,lp.null,col=DATA2$flow+1, pch=3, cex=0.25, xlim=c(-
10,5),ylim=c(-10,5), xlab="Simplified Model", ylab="Full Model") 
abline(h=0,lty=2, col="#CCCCCC") 
abline(v=0,lty=2, col="#CCCCCC") 
dev.off() 
lin.mod <- lm(c(lp.simp)~c(lp.null)) 
summary(lin.mod) ### slope of linear model is close to 1 although 
there is some shift (-0.57) actually looking to improve diagnostic 
performance 
 
 
################################################### 
 
DATA2 <-DATA2[order(-DATA2$aneurysm),] 
##Rationalise aneurysm related variables 
##Full Model (any endoleak droped to prevent confounding with Type II 
And GR enoleak findings) 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,aneurysm)~cdus_un
diagnostic+cdus_gru_endoleak+cdus_t2_endoleak+cdus_aaa_size+cdus_max_g
rowth+cdus_recent_growth+cdus_recent_growth_rate+migration_factor1+axr
_effacement+axr_structural))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500  
aic # AIC 515 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,aneurysm)~cdus_undiag
nostic+cdus_gru_endoleak+cdus_t2_endoleak+cdus_aaa_size+cdus_max_growt
h+cdus_recent_growth+cdus_recent_growth_rate+migration_factor1+axr_eff
acement+axr_structural)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
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a<- as.data.frame(summary) 
a$hr <- exp(a$estimate) 
a$hr <- exp(a$estimate) 
a$lci <- exp(a$estimate-(1.93*a$std.error))#Lower 95% CI 
a$uci <- exp(a$estimate+(1.93*a$std.error))#Upper 95% CI 
format(a, scientific=F) 
#####. Manually calculating linear predictor 
lpdata <- 
DATA2[,which(names(DATA2)%in%c("cdus_undiagnostic","cdus_gru_endoleak"
,"cdus_t2_endoleak","cdus_aaa_size","cdus_max_growth","cdus_recent_gro
wth","cdus_recent_growth_rate","migration_factor1","axr_effacement","a
xr_structural"))] 
lpmat <- model.matrix(~.,data=lpdata)[,-1] 
lp.null <- a$estimate%*%t(lpmat) 
null.roc<- roc(DATA2$aneurysm,a$estimate%*%t(lpmat)) 
##### 
 
#backwards stepwise regression 
# drop undiagnostic 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,aneurysm)~cdus_gr
u_endoleak+cdus_t2_endoleak+cdus_aaa_size+cdus_max_growth+cdus_recent_
growth+cdus_recent_growth_rate+migration_factor1+axr_effacement+axr_st
ructural))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500  
aic # AIC 513 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,aneurysm)~cdus_gru_en
doleak+cdus_t2_endoleak+cdus_aaa_size+cdus_max_growth+cdus_recent_grow
th+cdus_recent_growth_rate+migration_factor1+axr_effacement+axr_struct
ural)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
a<- as.data.frame(summary) 
a$hr <- exp(a$estimate) 
format(a, scientific=F) 
 
# drop recent growth rate 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,aneurysm)~cdus_gr
u_endoleak+cdus_t2_endoleak+cdus_aaa_size+cdus_max_growth+cdus_recent_
growth+migration_factor1+axr_effacement+axr_structural))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500  
aic # AIC 529 
#add back growth rate remove axr structural 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,aneurysm)~cdus_gr
u_endoleak+cdus_t2_endoleak+cdus_aaa_size+cdus_max_growth+cdus_recent_
growth+cdus_recent_growth_rate+migration_factor1+axr_effacement))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500  
aic # AIC 515 
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,aneurysm)~cdus_gru_en
doleak+cdus_t2_endoleak+cdus_aaa_size+cdus_max_growth+cdus_recent_grow
th+cdus_recent_growth_rate+migration_factor1+axr_effacement)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
a<- as.data.frame(summary) 
a$hr <- exp(a$estimate) 
format(a, scientific=F) 
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#trial remove t2 endoleak - ot kept  
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,aneurysm)~cdus_gr
u_endoleak+cdus_aaa_size+cdus_max_growth+cdus_recent_growth+cdus_recen
t_growth_rate+migration_factor1+axr_effacement))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500  
aic # AIC 519 
 
#remove aa size 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,aneurysm)~cdus_gr
u_endoleak+cdus_t2_endoleak+cdus_max_growth+cdus_recent_growth+cdus_re
cent_growth_rate+migration_factor1+axr_effacement))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500  
aic # AIC 517  
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,aneurysm)~cdus_gru_en
doleak+cdus_t2_endoleak+cdus_max_growth+cdus_recent_growth+cdus_recent
_growth_rate+migration_factor1+axr_effacement)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
a<- as.data.frame(summary) 
a$hr <- exp(a$estimate) 
format(a, scientific=F) 
 
# remove migration factor 
models_aic <- 
with(data=DATA1_MI,exp=AIC(coxph(Surv(follow_up_time,aneurysm)~cdus_gr
u_endoleak+cdus_t2_endoleak+cdus_max_growth+cdus_recent_growth+cdus_re
cent_growth_rate+axr_effacement))) 
aic <- as.data.frame(models_aic$analyses)[1,] 
aic <- sum(aic)/500  
aic # AIC 516  
models <- 
with(data=DATA1_MI,exp=coxph(Surv(follow_up_time,aneurysm)~cdus_gru_en
doleak+cdus_t2_endoleak+cdus_max_growth+cdus_recent_growth+cdus_recent
_growth_rate+axr_effacement)) 
pool_models <- pool(models) 
summary<- summary(pool_models) 
a<- as.data.frame(summary) 
a$hr <- exp(a$estimate) 
a$hr <- exp(a$estimate) 
a$lci <- exp(a$estimate-(1.93*a$std.error))#Lower 95% CI 
a$uci <- exp(a$estimate+(1.93*a$std.error))#Upper 95% CI 
format(a, scientific=F) 
#removal of any remaing factor results in AIC gain.  Add in any 
removed factor does not result in significant AIC fall. 
 
##Final Simplfied flow model### 
#####. Manually calculating linear predictor 
lpdata <- 
DATA2[,which(names(DATA2)%in%c("cdus_gru_endoleak","cdus_t2_endoleak",
"cdus_max_growth","cdus_recent_growth","cdus_recent_growth_rate","axr_
effacement"))] 
lpmat <- model.matrix(~.,data=lpdata)[,-1] 
lp.simp <- a$estimate%*%t(lpmat) 
simp.roc<-roc(DATA2$aneurysm,lp.simp) 
##### 
##### 
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Cairo(file="aneurysm_models_rocs.png", type="png",units="mm", width= 
140, height=70, dpi=600, ponitsize="1") 
par(mfrow=c(1,2)) 
plot(null.roc,main="Full Model",xlim=c(1,0), ylim=c(0,1)) 
mtext("AUC = 0.92", side=1) 
plot(simp.roc,main="Simplified Model",xlim=c(1,0), ylim=c(0,1)) 
mtext("AUC = 0.91", side=1) 
dev.off() 
Cairo(file="aneurysm_models_comparison.png", type="png",units="mm", 
width= 140, height=140, dpi=600, ponitsize="1") 
plot(lp.simp,lp.null, pch=3, cex=0.25, xlab="Simplified Model", 
ylab="Full Model") 
abline(h=0,lty=2, col="#CCCCCC") 
abline(v=0,lty=2, col="#CCCCCC") 
dev.off() 
lin.mod <- lm(c(lp.simp)~c(lp.null)) 
summary(lin.mod) ### slope of linear model is 0.83 although there is 
some shift (-0.81) actually looking to improve diagnostic performance 
 
################################ 
 
#####develop predictive model#### 
##Dr Richard Jackson's Code### 
library(ResourceSelection) 
library(DescTools) 
 
#data <- DATA 
#save (data,file="data.Rdata") 
load (file="data.Rdata") 
#Summary of data follow-up 
survfit(with(data, Surv(follow_up_time,event))~1) # Number of events 
summary(data$follow_up_time) # Follow-up time 
#dividing data 
data$int <- cut(data$time_since_op,c(0,0.5,1,2,3,4,5,7.5,10,20)) 
tab <- table(data$int,data$event) 
round(tab[,2]/rowSums(tab),2) 
data$dum <- substr(data$int,2,2) 
 
data$off <- log(data$time_since_op-as.numeric(data$dum)+1) 
 
### Centering Size & Age 
median(DATA$size,na.rm=T) 
data$pt_max_preop_AAA_size <- data$pt_max_preop_AAA_size-
mean(data$pt_max_preop_AAA_size[-
which(is.na(data$pt_max_preop_AAA_size))]) 
data$cdus_aaa_size <- data$cdus_aaa_size-mean(data$cdus_aaa_size[-
which(is.na(data$cdus_aaa_size))]) 
data$pt_age_at_operation <- data$pt_age_at_operation-
mean(data$pt_age_at_operation) 
data$cdus_recent_growth <- data$cdus_recent_growth-
mean(data$cdus_recent_growth)mean(data$cdus_recent_growth[-
which(is.na(data$cdus_recent_growth))]) 
 
### Model 
pois.mod <- glm(event~-1+int+pt_max_preop_AAA_size+cdus_aaa_size+ 
pt_age_at_operation 
+cdus_any_endoleak,family="poisson",data=data,offset=off) 
AIC(pois.mod) 
anova(pois.mod,test="Chisq") 
summary(pois.mod) 
 
### Measures of Discrimination 
cs <- Cstat(pois.mod) 
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### Measures of Calibration 
hl <- hoslem.test(as.numeric(pois.mod$y),fitted(pois.mod)) 
 
 
### AUC 
pred <- prediction(fitted(pois.mod),as.numeric(pois.mod$y)) 
auc <- attributes(performance(pred,"auc"))$"y.values"[[1]] 
 
plot(performance(pred,"sens","fpr"),col=4,lwd=3) 
abline(a=0,b=1,lty=2,lwd=2) 
 
summ <- c(cs,hl$p.value,auc) 
 
 
##### Function model 
 
## Wrapping the model up in a function makes it easier for 
bootstrapping 
 
model <- function(data){ 
   
  ### Model  
  pois.mod <- glm(event~-1+int+pt_max_preop_AAA_size+cdus_aaa_size+ 
pt_age_at_operation 
+cdus_any_endoleak,family="poisson",data=data,offset=off) 
  AIC(pois.mod) 
  anova(pois.mod,test="Chisq") 
  summary(pois.mod) 
   
   
  ### Measures of Discrimination 
  cs <- Cstat(pois.mod) 
   
  ### Measures of Calibration 
  ## Hoslem 
  #hlt <- hoslem.test(as.numeric(valid$event[-miss.id]),exp(pr[-
miss.id]),g=10) 
   
  #x2 <- sum((hlt$observed[,1]-hlt$expected[,1])^2/hlt$expected[,1]) 
  #hl <- 1-pchisq(x2,2) 
   
  ### AUC 
  pred <- prediction(fitted(pois.mod),as.numeric(pois.mod$y)) 
  auc <- attributes(performance(pred,"auc"))$"y.values"[[1]] 
   
  #plot(performance(pred,"sens","fpr"),col=4,lwd=3) 
  #abline(a=0,b=1,lty=2,lwd=2) 
   
  summ <- c(cs,hl,auc) 
   
  ret <- list(pois.mod,summ) 
} 
 
### settting up bootstrap 
un.pat <- unique(data$pt_id) 
n.pat <- length(un.pat) 
nboot <- 5000 
 
co <- matrix(NA,nboot,13) 
hl <- rep(NA,nboot) 
hlob <- matrix(NA,10,nboot) 
hlex <- matrix(NA,10,nboot) 
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auc <- rep(NA,nboot) 
devPerc <- rep(NA,nboot) 
 
 
for(sim in 1:nboot){ 
   
  sample <- sample(n.pat,n.pat*0.2) 
  id <- which(data$pt_id%in%un.pat[sample]) 
   
  train <- data[-id,] 
  valid <- data[id,] 
   
  ### Training model 
  mod <- model(train)[[1]] 
   
  ### Getting predictions 
  val <- 
valid[,which(names(valid)%in%c("int","pt_max_preop_AAA_size","cdus_aaa
_size","pt_age_at_operation","cdus_any_endoleak","off"))] 
  pr <- predict(mod,val) 
  miss.id <- which(is.na(pr)) 
   
  pred <- prediction(pr[-miss.id],valid$event[-miss.id]) 
  auc[sim] <- attributes(performance(pred,"auc"))$"y.values"[[1]] 
   
  #plot(performance(pred,"sens","fpr"),col=4,lwd=3) 
  #abline(a=0,b=1,lty=2,lwd=2) 
  #boxplot(pr[-miss.id]~valid$event[-miss.id]) 
   
   
  ## Hoslem 
  hlt <- hoslem.test(as.numeric(valid$event[-miss.id]),exp(pr[-
miss.id]),g=10) 
   
   
  x2 <- sum((hlt$observed[,1]-hlt$expected[,1])^2/hlt$expected[,1]) 
  hl[sim] <- 1-pchisq(x2,2) 
   
  ### COEF 
  co[sim,] <- coef(mod)[] 
   
  #### Percentage of deviance explained 
  devPerc[sim] <- 1-mod$deviance/mod$null.deviance 
} 
auc <- ifelse(auc<0.5,1-auc,auc) 
 
###Save / Load Point### 
#save validation data 
#save(auc,hl,devPerc,co, file ="model.Rdata") 
# load validation 
load(file="model.Rdata") 
###End Save/Load Point### 
 
#Creating model with mean coefficents from internal validation 
test <- NA 
for(a in 1:13){ 
  test[a]<- as.double(mean(co[,a])) 
} 
pois.mod1 <- pois.mod 
pois.mod1$coefficients <- test 
rm(test) 
pois.mod$ 
##Output from internal validation 
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summary(auc) 
summary(hl) 
summary(devPerc) 
summary(pois.mod1) 
# Histogram of Model AUC with density plot 
Cairo(file="auc_histogram_validation.png", type="png",units="mm", 
width= 140, height=100, dpi=600, ponitsize="1") 
ggplot()+ 
  aes(auc) +  
  geom_histogram(aes(y=..density..), colour="black", fill="white")+ 
  geom_density(alpha=.2, fill="#FF6666")+ 
  scale_x_continuous(breaks = seq(0.5, by = 0.1))+ 
  xlim (0.5,1)+ 
  scale_y_continuous(breaks = seq(0, 10, by = 2))+ 
  xlab("Area Under Curve")+ 
  ylab("Percentage of Validation Models") 
dev.off() 
# Histogram of Hosmer-Lemeshow test p value with density plot 
Cairo(file="HL-test_histogram_validation.png", type="png",units="mm", 
width= 140, height=100, dpi=600, ponitsize="1") 
ggplot()+ 
  aes(hl) +  
  geom_histogram(aes(y=..density..), colour="black", fill="white")+ 
  geom_density(alpha=.2, fill="#FF6666")+ 
  scale_x_continuous(breaks = seq(0,1, by = 0.1))+ 
  #geom_vline(aes(xintercept=median(hl)), color="blue", 
linetype="dashed", size=1)+ 
  xlab("p Value of Hosmer-Lemeshow Test")+ 
  ylab("Percentage of Validation Models") 
dev.off() 
 
##Risk Plots for 3 (Low, Mean & High risk) Patients 
#Average interval to next scan for cross-section of whole programe 
datatest <- data 
b <- as.numeric(count(datatest)) 
datatest$interval <-NA  
for(a in 1:b){ 
  datatest$interval[a] <- 
ifelse(datatest$pt_id[a]==datatest$pt_id[a+1],datatest$time_since_op[a
+1]-datatest$time_since_op[a],NA) 
} 
z<- mean(datatest$interval[!is.na(datatest$interval)]) 
rm(datatest,b) 
#Risk of secondary intervention in that time 
x <- summary(survfit(Surv(data$follow_up_time,data$event)~1), times=z) 
 
#Create time matrix 
time <-seq(0,20,length=100) 
co.mat <- matrix(seq(0,20,length=100),100,9) 
co <- coef(pois.mod1) 
co.mat[which(co.mat[,1]>0.5),1] <- 0.5 
co.mat[which(co.mat[,2]<0.5),2] <- 0 
co.mat[which(co.mat[,2]>1),2] <- 1 
co.mat[which(co.mat[,3]<1),3] <- 0 
co.mat[which(co.mat[,3]>2),3] <- 2 
co.mat[which(co.mat[,4]<2),4] <- 0 
co.mat[which(co.mat[,4]>3),4] <- 3 
co.mat[which(co.mat[,5]<3),5] <- 0 
co.mat[which(co.mat[,5]>4),5] <- 4 
co.mat[which(co.mat[,6]<4),6] <- 0 
co.mat[which(co.mat[,6]>5),6] <- 5 
co.mat[which(co.mat[,7]<5),7] <- 0 
co.mat[which(co.mat[,7]>7.5),7] <- 7.5 
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co.mat[which(co.mat[,8]<7.5),8] <- 0 
co.mat[which(co.mat[,8]>10),8] <- 10 
co.mat[which(co.mat[,9]<10),9] <- 0 
co.mat[,2] <- co.mat[,2]-0.5 
co.mat[,3] <- co.mat[,3]-1 
co.mat[,4] <- co.mat[,4]-2 
co.mat[,5] <- co.mat[,5]-3 
co.mat[,6] <- co.mat[,6]-4 
co.mat[,7] <- co.mat[,7]-5 
co.mat[,8] <- co.mat[,8]-7.5 
co.mat[,9] <- co.mat[,9]-10 
co.mat[which(co.mat<0)] <- 0 
rowSums(co.mat) 
#High Risk Patient: Time of CDUS scan after operation = 0.11 years, 
Pre-op AAA size = 57mm, Current CDUS size =65mm, Patient age at 
operation = 70 years and CDUS Endoleak = TRUE 
#Mean Risk Patient:  Time of CDUS scan after operation = 3.16 years, 
Pre-op AAA size = 65mm, Current CDUS size =57mm, Patient age at 
operation = 75 years and CDUS Endoleak = FALSE 
#Low Risk Patient:  Time of CDUS scan after operation = 4.34 years, 
Pre-op AAA size = 70mm, Current CDUS size =45mm, Patient age at 
operation = 80 years and CDUS Endoleak = FALSE 
 
base <- c(exp(co[1:9])%*%t(co.mat));base 
vc <- vcov(pois.mod1) 
se <- sqrt(diag(vc[1:9,1:9])) 
se2 <- sum(diag(vc[10:13,10:13])) 
 
co.lo <- co[1:9]-1.96*se 
co.up <- co[1:9]+1.96*se 
 
base.lo <- c(exp(co.lo[1:9])%*%t(co.mat));base.lo 
base.up <- c(exp(co.up[1:9])%*%t(co.mat));base.up 
 
co2 <- co[10:13] 
co2.lo <- co2-1.96*se2 
co2.up <- co2+1.96*se2 
 
### Hi Iain, I haven't got the exact centering values for age and 
pre/post aaa size but i've used 60 for everything - can you cahnge to 
be more accurate? 
pat1.hr <- c(exp(co2%*%c(57-64.99,65-56.94,70-75.15,1)));pat1.hr 
pat1.hr.lo <- c(exp(co2.lo%*%c(57-64.99,65-56.94,70-
75.15,1)));pat1.hr.lo 
pat1.hr.up <- c(exp(co2.up%*%c(57-64.99,65-56.94,70-
75.15,1)));pat1.hr.up 
 
pat2.hr <- c(exp(co2%*%c(65-64.99,57-56.94,75-75.15,0)));pat2.hr 
pat2.hr.lo <- c(exp(co2.lo%*%c(65-64.99,57-56.94,75-
75.15,0)));pat2.hr.lo 
pat2.hr.up <- c(exp(co2.up%*%c(65-64.99,57-56.94,75-
75.15,0)));pat2.hr.up 
 
pat3.hr <- c(exp(co2%*%c(70-64.99,45-56.94,80-75.15,0)));pat3.hr 
pat3.hr.lo <- c(exp(co2.lo%*%c(70-64.99,45-56.94,80-
75.15,0)));pat3.hr.lo 
pat3.hr.up <- c(exp(co2.up%*%c(70-64.99,45-56.94,80-
75.15,0)));pat3.hr.up 
 
H1 <- 1-exp(-base)^pat1.hr;H1 
H1.lo <- 1-exp(-base.lo)^pat1.hr.lo;H1.lo 
H1.up <- 1-exp(-base.up)^pat1.hr.up;H1.up 
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H2 <- 1-exp(-base)^pat2.hr;H2 
H2.lo <- 1-exp(-base.lo)^pat2.hr.lo;H2.lo 
H2.up <- 1-exp(-base.up)^pat2.hr.up;H2.up 
 
H3 <- 1-exp(-base)^pat3.hr;H3 
H3.lo <- 1-exp(-base.lo)^pat3.hr.lo;H3.lo 
H3.up <- 1-exp(-base.up)^pat3.hr.up;H3.up 
 
##Output Plot 
png(filename="patient_risk_plots.png", units="mm", width= 140, 
height=100, res=600, pointsize="12") 
plot(ylab="Cumulative Risk of Secondary Intervention",xlab="Time after 
Surveillance Scan (Years)",(time),H1,col=1,typ="l",lwd=2,xlim=c(0,3), 
ylim=c(0,0.4)) 
lines((time),H1.lo,lty=10,lwd=1) 
lines((time),H1.up,lwd=1,lty=10) 
lines((time),H2,col=2,lwd=2) 
lines((time),H2.lo,col=2,lwd=1,lty=10) 
lines((time),H2.up,col=2,lwd=1,lty=10) 
lines((time),H3,col=3,lwd=2) 
lines((time),H3.lo,col=3,lwd=1,lty=10) 
lines((time),H3.up,col=3,lwd=1,lty=10) 
cbind(time,H1,H1.lo,H1.up,H2,H2.lo,H2.up,H3,H3.lo,H3.up) 
abline(h=(1-x$surv),lty=3, col="#505050") 
legend(-0.075,0.425,c("High Risk Patient","Mean Risk Patient","Low 
Risk Patient"),lwd=2,col=c(1,2,3),bty="n") 
dev.off() 
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3. ANONYMISED PATIENT DATA AND IMAGING 
VARIABLES FROM THE LIVES DATABASE 
Copies of the following files are on the accompanying CD in the pocket attached to the 
inside back cover. 
CD\database\patient_level_data.csv 
CD\database\secondary_interventions.csv 
CD\database\all_scans.csv 
CD\database\axr_migration_factor.csv 
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4. PARTICIPANT INFORMATION LEAFLET 
 
Participant Information Leaflet 
 
Contrast Enhanced Ultrasound in  
EVAR Surveillance for Endoleak Detection:  
Compared to Time-Resolved CT Angiography 
 
We invite you to take part in a research study, which is 
taking place at The Royal Liverpool Hospital.   
 
 
 
Before you decide whether to take part, it is important for 
you to understand what’s involved and why the research is 
being done.   
 
Please read this information carefully & feel free to talk it 
over with family or friends.  If you are unclear about anything 
please feel free to ask questions or ask for more information. 
 
It’s your decision if you wish to take part or not.  If you 
choose not to take part it will not affect the care you receive 
from your doctors. 
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Why have I been asked to participate? 
Your own medical team have identified you as someone suitable to 
take part in the study because: 
You have previously had an EndoVascular Aneurysm Repair (EVAR), 
which is often called “stenting” of an aneurysm 
& 
Your medical team now feel you need to have two types of scans to 
ensure the stent is working the way it should.  
1. A Computerised Tomography (CT) scan.  
  X-Rays are taken by a table moving through a scanner, 
as dye is put through a needle in your arm. You will have had a 
CT Scan before you had your EVAR operation.  
2. A Contrast Enhanced Ultrasound.  
  This is a scan that involves a sonographer moving a 
probe over your tummy with some “jelly” on it.  This type of 
ultrasound also involves an injection in your arm. You may not 
have had this before. 
Why are you doing the research? 
We currently use ultrasound (without contrast) as the main scan to 
check that EVAR stents are working as they should.   
We already know that standard CT scans can give us clearer 
information. However, they carry some risks. They involve x-rays and a 
dye that can damage the kidneys. So we only use them when we have 
a concern. 
Contrast Enhanced Ultrasound is a promising new scan and may reduce 
the number of CT scans we need to do.   
Previous studies comparing the two types of scan have shown very 
different results.  We want to find out which type of scan gives the best 
information of how your stent is working. 
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What is involved in the study? 
If you choose to participate in the research study you would be asked 
to attend the Royal Liverpool Hospital for approximately half a day. 
During the visit you would;   
1. be asked a series of questions about your health 
2. have a cannula/tube placed in an arm vein for the scans 
3. have a Contrast Enhanced Ultrasound Scan 
4. have a special CT scan - which is slightly different to a planned 
CT Scan. 
Researchers would also access your hospital records;  
1. to record that you participated in the trial,  
2. to look up details of any previous scans you’ve had  
3. to review the results of any other investigations you’ve had of 
your heart  
4. to see what effect the study scans have on your care. 
Is there anything else involved? 
No. Once you’ve had your scans, there is no other time commitment or 
input required. 
The reports of the scans will be made available to your own surgeon 
who will then decide if you require anything else done and look after 
you as normal. 
How is the CT scan in the research study different? 
A ‘standard’ CT scan has two sets of images of your whole tummy.  The 
first is shortly after the injection of the dye and the second, a minute or 
two later. 
The research CT scan performed in the study has several sets of images  
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of just the stent, followed by one set of the whole tummy a minute or 
two later. 
This means the table you lie down on during the CT scan will move 
backwards and forwards several times through the scanner, instead of 
just twice.  Also you will be asked to try and hold your breath for a bit 
longer than you might otherwise be. 
Is it risky to take part? 
The study has been designed so that the amount of x-rays from the 
two different types of CT scans would be similar. It is impossible to say 
it will be exactly the same.   
The scanner calculates the amount of radiation needed based on the 
shape of your body as it is performing the scan. 
Although there are more sets of images taken within the research CT 
Scan they are of a smaller area and using a lower dose of x-rays, so the 
overall amount should be roughly the same. 
 
The x-rays used in CT scans are associated with some risk of causing 
cancer. However this risk is small. The older you are the smaller this 
risk is.   
Your own surgeon/team feel that this risk is justified to ensure your 
EVAR stent is working properly. 
Any other risks to do with the scans are the same if you choose to take 
part or not. If you wish to discuss these then please ask. 
What if I choose not to take part? 
If you choose not to take part in the research study, the ‘standard’ 
scans will be arranged by your own team and the researchers will not 
have any access to them or to your medical records. 
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What if something goes wrong? 
The risk of you suffering harm as a result of taking part is minimal, and 
study has insurance in place to provide compensation for any negligent 
harm caused by taking part. 
Who will be told if I take part? 
Your GP is the only person outside the hospital who will be informed 
that you have taken part in the research.  If you do not wish your GP to 
be informed you can tell us this on the consent form. 
Will I receive any money for taking part? 
No.  There is no provision for financial reimbursement, as these scans 
would be part of your normal care. 
Potentially you will save a visit to the hospital as both scans will 
definitely be done the same day within the study. 
 
Will I find out the results of the research? 
Your own clinical team will be able to tell you the results of your scans 
and what they mean for your care. 
If you choose to, we will write to you with the results of the study as a 
whole once it is completed. 
 
What happens now? 
The researcher who gave you, or sent you this leaflet will arrange to 
contact you again after you have had a chance to read it.  Please feel 
free to ask them as many questions as you wish. 
If you wish to take part in the research study then they will arrange a 
time for you to come to the hospital.   
If you don’t wish to take part in the research study then they will let 
your doctor know to arrange the scans in the normal way. 
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Version 1.3 (2/12/2015)  Page 1 
What if I have questions? 
Please ask us if there is anything you would like clarified.  
If you’d like to look something up your-self http://www.nhs.uk/ is a 
good source of information if you’re unsure of anything described in 
this leaflet. Simple use the search feature in the top right corner. 
What if I have a complaint about the study? 
If you wish to make a complaint regarding the study this can be made 
to Prof Vallabhaneni (details below). If you would prefer someone 
independent you can discuss your concerns with the Patient advice and 
liaison services (PALS).  
PALS Tel: 0151 706 4903 
PALS 
The Royal Liverpool University Hospital 
Prescot Street 
Liverpool 
L7 8XP 
How to contact us? 
If you have any questions please contact the doctors who are 
organising the study; 
Prof Vallabhanenior Mr Iain Roy,  
Tel: 0151 706 3457 
e-mail: iain.roy@rlbuht.nhs.uk 
Link 8c 
The Royal Liverpool University Hospital 
Prescot Street 
Liverpool 
L7 8XP 
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5. DATA COLLECTION PRO-FORMA  
 
 
 
Participant Study ID: 
Participant Questionnaire: 
Reason for further investigation: 
Height (cm): 
Weight (kg): 
Blood Pressure: 
Pulse rate: 
Functional Status: 
0 - you are fully active, more or less as you were before your illness 
1 - you cannot carry out heavy physical work, but can do anything else 
2 - you are up and about more than half the day. You can look after yourself, but cannot work 
Estimated walking distance: 
Previous Heart Disease: 
Known to have AF or other arythmia: Yes/No 
Known IHD (Angina, ACS, MI): Yes/No   Details:…………………………………………… 
Previous Treatments: 
 
Patients had echo in past: Yes/No    Details…………………………………….. 
 
Current Medications: 
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CDU:   
Participant Study ID: 
Completed by (investigators name): 
Time start:      Time Completed: 
 
Diagnostic images obtained of: 
Aortic neck    Yes/No 
Aneurysm body with graft in situ Yes/No 
Bifurcation    Yes/No 
Right CIA (Midpoint of limb)  Yes/No  Left CIA (Midpoint of limb) Yes/No 
Right Limb/native transition  Yes/No  Left Limb/native transition  Yes/No 
 
Aortic Measurements: 
PSV in native aorta: 
Native Aorta PI: 
Neck / D2 diameter (mm): 
Aneurysm /D3 diameter (mm): 
Endoleak seen: Yes/No 
Details:     Endoleak 1  Endoleak 2  Endoleak 3 
  Type:    Ia/Ib/II/III/Other Ia/Ib/II/III/Other Ia/Ib/II/III/Other 
  Inflow point(s): 
  Outflow point(s): 
 Certain of flow direction: Yes/No  Yes/No   Yes/No 
Limbs: 
    Right    Left 
Distal PSV measurement 
PI 
Wave form   Mono / Bi / Triphasic   Mono / Bi / Triphasic  
 
Comments: 
 
Common Femoral Arteries: 
     Right    Left 
Distal PSV measurement 
PI 
Wave form   Mono / Bi / Triphasic   Mono / Bi / Triphasic  
 
Comments:
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CEUS: 
Participant Study ID: 
Completed by (investigators name): 
Time start:      Time Completed: 
First Contrast Injection: (all timings from start of contrast injection) 
Time till seen in graft(s): 
Time till seen in endoleak (s): 
Contrast seen in Endoleak 1: Yes / No   Endoleak 1 Type: Ia/Ib/II/III/Other 
Contrast Seen in Endoleak 2: Yes / No   Endoleak 2 Type: Ia/Ib/II/III/Other 
Contrast seen in Endoleak 3: Yes / No    Endoleak 3 Type: Ia/Ib/II/III/Other 
Second Contrast Injection: 
Time till seen in graft(s): 
Time till seen in endoleak (s): 
Contrast seen in Endoleak 1: Yes / No   Endoleak 1 Type: Ia/Ib/II/III/Other 
Contrast Seen in Endoleak 2: Yes / No   Endoleak 2 Type: Ia/Ib/II/III/Other 
Contrast seen in Endoleak 3: Yes / No    Endoleak 3 Type: Ia/Ib/II/III/Other 
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Temporal CTA (in scan measurements) 
Participant Study ID:      Completed by (investigators name): 
Time start:      Time Completed: 
Temporal CTA (reporting) 
Completed by (investigators name): 
Time reporting started:     Time reporting finished: 
Phase 2.5 Seconds 
Image quality: Fully diagnostic  5 4 3 2 1 Non-diagnostic 
Endoleak seen:   Yes/No 
Details:     Endoleak 1  Endoleak 2  Endoleak 3 
  Type:    Ia/Ib/II/III/Other Ia/Ib/II/III/Other Ia/Ib/II/III/Other 
  Inflow point(s): 
  HU at inflow: 
  Outflow point(s): 
  HU at outflow: 
 Certain of flow direction: Yes/No  Yes/No   Yes/No 
 
Hounsfield Unit measurements: (excluding any calcification of graft structures) 
Inferior vena cava:      ………………. HU 
Aortic lumen at superior fabric markers of endograft:  ………………. HU 
Aortic lumen at bifurcation of endograft:   ………………. HU 
Iliac lumen at Distal end of right limb of endograft  ………………. HU 
Iliac lumen at distal end of left limb of endograft  ………………. HU 
Phase 5 Seconds 
Image quality: Fully diagnostic  5 4 3 2 1 Non-diagnostic 
Endoleak seen:   Yes/No 
Details:     Endoleak 1  Endoleak 2  Endoleak 3 
  Type:    Ia/Ib/II/III/Other Ia/Ib/II/III/Other Ia/Ib/II/III/Other 
  Inflow point(s): 
  HU at inflow: 
  Outflow point(s): 
  HU at outflow: 
 Certain of flow direction: Yes/No  Yes/No   Yes/No 
 
Hounsfield Unit measurements: (excluding any calcification of graft structures) 
Inferior vena cava:      ………………. HU 
Aortic lumen at superior fabric markers of endograft:  ………………. HU 
Aortic lumen at bifurcation of endograft:   ………………. HU 
Iliac lumen at Distal end of right limb of endograft  ………………. HU 
Iliac lumen at distal end of left limb of endograft  ………………. HU 
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Phase 7.5 Seconds 
Image quality: Fully diagnostic  5 4 3 2 1 Non-diagnostic 
Endoleak seen:   Yes/No 
Details:     Endoleak 1  Endoleak 2  Endoleak 3 
  Type:    Ia/Ib/II/III/Other Ia/Ib/II/III/Other Ia/Ib/II/III/Other 
  Inflow point(s): 
  HU at inflow: 
  Outflow point(s): 
  HU at outflow: 
 Certain of flow direction: Yes/No  Yes/No   Yes/No 
 
Hounsfield Unit measurements: (excluding any calcification of graft structures) 
Inferior vena cava:      ………………. HU 
Aortic lumen at superior fabric markers of endograft:  ………………. HU 
Aortic lumen at bifurcation of endograft:   ………………. HU 
Iliac lumen at Distal end of right limb of endograft  ………………. HU 
Iliac lumen at distal end of left limb of endograft  ………………. HU 
Phase 10 Seconds 
Image quality: Fully diagnostic  5 4 3 2 1 Non-diagnostic 
Endoleak seen:   Yes/No 
Details:     Endoleak 1  Endoleak 2  Endoleak 3 
  Type:    Ia/Ib/II/III/Other Ia/Ib/II/III/Other Ia/Ib/II/III/Other 
  Inflow point(s): 
  HU at inflow: 
  Outflow point(s): 
  HU at outflow: 
 Certain of flow direction: Yes/No  Yes/No   Yes/No 
 
Hounsfield Unit measurements: (excluding any calcification of graft structures) 
Inferior vena cava:      ………………. HU 
Aortic lumen at superior fabric markers of endograft:  ………………. HU 
Aortic lumen at bifurcation of endograft:   ………………. HU 
Iliac lumen at Distal end of right limb of endograft  ………………. HU 
Iliac lumen at distal end of left limb of endograft  ………………. HU 
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Phase 15 Seconds 
Image quality: Fully diagnostic  5 4 3 2 1 Non-diagnostic 
Endoleak seen:   Yes/No 
Details:     Endoleak 1  Endoleak 2  Endoleak 3 
  Type:    Ia/Ib/II/III/Other Ia/Ib/II/III/Other Ia/Ib/II/III/Other 
  Inflow point(s): 
  HU at inflow: 
  Outflow point(s): 
  HU at outflow: 
 Certain of flow direction: Yes/No  Yes/No   Yes/No 
 
Hounsfield Unit measurements: (excluding any calcification of graft structures) 
Inferior vena cava:      ………………. HU 
Aortic lumen at superior fabric markers of endograft:  ………………. HU 
Aortic lumen at bifurcation of endograft:   ………………. HU 
Iliac lumen at Distal end of right limb of endograft  ………………. HU 
Iliac lumen at distal end of left limb of endograft  ………………. HU 
Phase 20 Seconds 
Image quality: Fully diagnostic  5 4 3 2 1 Non-diagnostic 
Endoleak seen:   Yes/No 
Details:     Endoleak 1  Endoleak 2  Endoleak 3 
  Type:    Ia/Ib/II/III/Other Ia/Ib/II/III/Other Ia/Ib/II/III/Other 
  Inflow point(s): 
  HU at inflow: 
  Outflow point(s): 
  HU at outflow: 
 Certain of flow direction: Yes/No  Yes/No   Yes/No 
 
Hounsfield Unit measurements: (excluding any calcification of graft structures) 
Inferior vena cava:      ………………. HU 
Aortic lumen at superior fabric markers of endograft:  ………………. HU 
Aortic lumen at bifurcation of endograft:   ………………. HU 
Iliac lumen at Distal end of right limb of endograft  ………………. HU 
Iliac lumen at distal end of left limb of endograft  ………………. HU 
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Phase 25 Seconds 
Image quality: Fully diagnostic  5 4 3 2 1 Non-diagnostic 
Endoleak seen:   Yes/No 
Details:     Endoleak 1  Endoleak 2  Endoleak 3 
  Type:    Ia/Ib/II/III/Other Ia/Ib/II/III/Other Ia/Ib/II/III/Other 
  Inflow point(s): 
  HU at inflow: 
  Outflow point(s): 
  HU at outflow: 
 Certain of flow direction: Yes/No  Yes/No   Yes/No 
 
Hounsfield Unit measurements: (excluding any calcification of graft structures) 
Inferior vena cava:      ………………. HU 
Aortic lumen at superior fabric markers of endograft:  ………………. HU 
Aortic lumen at bifurcation of endograft:   ………………. HU 
Iliac lumen at Distal end of right limb of endograft  ………………. HU 
Iliac lumen at distal end of left limb of endograft  ………………. HU 
Venous Phase 
Image quality: Fully diagnostic  5 4 3 2 1 Non-diagnostic 
Endoleak seen:   Yes/No 
Details:     Endoleak 1  Endoleak 2  Endoleak 3 
  Type:    Ia/Ib/II/III/Other Ia/Ib/II/III/Other Ia/Ib/II/III/Other 
  Inflow point(s): 
  HU at inflow: 
  Outflow point(s): 
  HU at outflow: 
 Certain of flow direction: Yes/No  Yes/No   Yes/No 
 
Hounsfield Unit measurements: (excluding any calcification of graft structures) 
Inferior vena cava:      ………………. HU 
Aortic lumen at superior fabric markers of endograft:  ………………. HU 
Aortic lumen at bifurcation of endograft:   ………………. HU 
Iliac lumen at Distal end of right limb of endograft  ………………. HU 
Iliac lumen at distal end of left limb of endograft  ………………. HU 
 
Other comments / diagnostic findings: 
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6. R CODE TO PROCESS PROSPECTIVE STUDY 
A copy of this code is also available on the accompanying CD in the pocket attached to 
the inside back cover 
CD\ceus_tcta\final_data_analysis.R 
# Code Created by Iain N Roy, Institute of Ageing & Chronic Disease, 
University of Liverpool 
# Contact via iainroy@liverpool.ac.uk 
# Code to process data for: 
# Study Title "Contrast Enhanced Ultrasound Endoleak Detection 
Compared To Time-Resolved Computer Tomography Angiography in high risk 
Endovascular Aneurysm Repair (EVAR) surveillance patients. 
# Study Ethical approval: NHS REC reference: 15/NW/0908 
# Code shared as part of the publication under a CCBY  
 
# Code created in R Studio v1.1.463 using R version 3.5.2 
 
# The studies final data (final_data.xlsx) is assumed to be in the 
working directory for this R script 
 
# Loading Required Packages 
install.packages(c("readxl", "DTComPair", "ggplot2", "ggpubr","egg")) 
library(readxl) 
library(DTComPair) 
library(ggplot2) 
library(ggpubr) 
library(egg) 
library(MASS) 
library(dplyr) 
 
# Load Data 
demographics <- read_excel("final_data.xlsx", sheet = 1, 
col_names=TRUE, 
col_types=c("numeric","text","numeric","numeric","numeric","numeric","
numeric","numeric","numeric","logical","logical", 
"numeric","numeric","text"), na=c("NA")) 
cdus <- read_excel("final_data.xlsx", sheet = 2, col_names=TRUE, 
col_types=c("numeric", 
"text","text","logical","logical","logical","logical","logical","logic
al","numeric","numeric","numeric","text","numeric","logical","logical"
,"logical","text","text","text","text","text","text","numeric","numeri
c","text","numeric","numeric","text","numeric","numeric","text","numer
ic","numeric","text","text","text","text","text"),na=c("NA")) 
ceus <- read_excel("final_data.xlsx", sheet = 3) 
tcta <- read_excel("final_data.xlsx", sheet = 4) 
final <- read_excel("final_data.xlsx", sheet = 5) 
tcta_monitoring <- read_excel("final_data.xlsx", sheet = 6) 
tcta_enhhancement <- read_excel("final_data.xlsx", sheet = 7) 
tcta_radiation <- read_excel("final_data.xlsx", sheet = 8) 
tcta_addition_enhacement_data <- read_excel("final_data.xlsx", sheet = 
9) 
tcta_ceus_timings <- read_excel("ceus_tcta_el_timings.xlsx") 
 
#Data Catagorisation 
#Demographics 
demographics$`Sex (Male / Female)` <- as.factor(demographics$`Sex 
(Male / Female)`) 
demographics$`Height (m)` <- as.numeric(demographics$`Height (m)`) 
demographics$`Weight (Kg)` <- as.numeric(demographics$`Weight (Kg)`) 
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demographics$`Estimated Walking Distance (m)` <- 
as.integer(demographics$`Estimated Walking Distance (m)`) 
demographics$`Known Ischemic Heart Disease (True / False)` <- 
as.logical(demographics$`Known Ischemic Heart Disease (True / False)`) 
demographics$`Known Arythmia (True / False)` <- 
as.logical(demographics$`Known Arythmia (True / False)`) 
demographics$`Functional Status (add clasification)` <- 
as.factor(demographics$`Functional Status (add clasification)`) 
demographics$Graft <- as.factor(demographics$Graft) 
#CEUS 
ceus$`CEUS Graft-Related Endoleak (True/False)`<- 
as.integer(as.logical(ceus$`CEUS Graft-Related Endoleak 
(True/False)`)) 
ceus$`CEUS Any Endoleak  (True/False)`<- 
as.integer(as.logical(ceus$`CEUS Any Endoleak  (True/False)`)) 
ceus$`CEUS Type II Endoleak (True / False)`<- 
as.integer(as.logical(ceus$`CEUS Type II Endoleak (True / False)`)) 
#tCTA 
tcta$`tCTA Graft-Related Endoelak (True/False)`<- 
as.integer(as.logical(tcta$`tCTA Graft-Related Endoelak 
(True/False)`)) 
tcta$`tCTA Any Endoleak (True / False)` <- 
as.integer(as.logical(tcta$`tCTA Any Endoleak (True / False)`)) 
tcta$`tCTA Type II Endoleak (True / False)`<-
as.integer(as.logical(tcta$`tCTA Type II Endoleak (True / False)`)) 
#final 
final$`Any Endoleak (TRUE / FALSE)` <- 
as.integer(as.logical(final$`Any Endoleak (TRUE / FALSE)`)) 
final$`Graft Related Endoleak (TRUE / FALSE)` <- 
as.integer(as.logical(final$`Graft Related Endoleak (TRUE / FALSE)`)) 
final$`Type II Endoleak (TRUE / FALSE)` <- 
as.integer(as.logical(final$`Type II Endoleak (TRUE / FALSE)`)) 
#tCTA Enhancment Data 
tcta_enhhancement$`Participant ID` <- 
as.numeric(tcta_enhhancement$`Participant ID`) 
tcta_enhhancement$`Phase (s)` <- as.numeric(tcta_enhhancement$`Phase 
(s)`) 
tcta_enhhancement$`Enhancement (HU)` <- 
as.numeric(tcta_enhhancement$`Enhancement (HU)`) 
tcta_enhhancement$Measurement <- 
as.factor(tcta_enhhancement$Measurement) 
tcta_enhhancement$`Measurement Class` <- 
as.factor(tcta_enhhancement$`Measurement Class`) 
tcta_enhhancement <- 
tcta_enhhancement[!(is.na(tcta_enhhancement$Measurement)),] 
tcta_enhhancement <- 
tcta_enhhancement[!tcta_enhhancement$Measurement=="Left Limb",] 
tcta_enhhancement <- 
tcta_enhhancement[!tcta_enhhancement$Measurement=="Right Limb",] 
 
tcta_addition_enhacement_data$`Participant ID` <- 
as.factor(tcta_addition_enhacement_data$`Participant ID`) 
tcta_addition_enhacement_data$`Phase (s)` <- 
as.numeric(tcta_addition_enhacement_data$`Phase (s)`) 
tcta_addition_enhacement_data$`Enhancement (HU)` <- 
as.numeric(tcta_addition_enhacement_data$`Enhancement (HU)`) 
tcta_addition_enhacement_data$Measurement <- 
as.factor(tcta_addition_enhacement_data$Measurement) 
tcta_addition_enhacement_data$`Measurement Class` <- 
as.factor(tcta_addition_enhacement_data$`Measurement Class`) 
tcta_addition_enhacement_data <- 
tcta_addition_enhacement_data[!(is.na(tcta_addition_enhacement_data$Me
asurement)),] 
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tcta_addition_enhacement_data <- 
tcta_addition_enhacement_data[!tcta_addition_enhacement_data$Measureme
nt=="Left Limb",] 
tcta_addition_enhacement_data <- 
tcta_addition_enhacement_data[!tcta_addition_enhacement_data$Measureme
nt=="Right Limb",] 
 
tcta_monitoring$`tCTA Time For Monitoring to Trigger i.e. >90HU (s)` 
<- as.numeric(tcta_monitoring$`tCTA Time For Monitoring to Trigger 
i.e. >90HU (s)`) 
 
 
# Data Processing 
demographics$bmi <- as.numeric(demographics$`Weight 
(Kg)`/(demographics$`Height (m)`*demographics$`Height (m)`)) 
 
# Creating data frames for diagnostic value analysis 
ceusvtcta <- merge(ceus,tcta, by= "Participant ID") 
ceusvtctavfinal <-merge(ceusvtcta,final,by= "Participant ID") 
 
GREL_tab <-tab.1test(d=ceusvtcta$`tCTA Graft-Related Endoelak 
(True/False)`,y=ceusvtcta$`CEUS Graft-Related Endoleak (True/False)`) 
ANYEL_tab <-tab.1test(d=ceusvtcta$`tCTA Any Endoleak (True / 
False)`,y=ceusvtcta$`CEUS Any Endoleak  (True/False)`) 
T2EL_tab <-tab.1test(d=ceusvtcta$`tCTA Type II Endoleak (True / 
False)`,y=ceusvtcta$`CEUS Type II Endoleak (True / False)`) 
 
GRELFD_tab <- tab.paired(d=ceusvtctavfinal$`Graft Related Endoleak 
(TRUE / FALSE)`, y1=ceusvtctavfinal$`tCTA Graft-Related Endoelak 
(True/False)`,y2=ceusvtctavfinal$`CEUS Graft-Related Endoleak 
(True/False)`) 
ANYELFD_tab <- tab.paired(d=ceusvtctavfinal$`Any Endoleak (TRUE / 
FALSE)`, y1=ceusvtctavfinal$`tCTA Any Endoleak (True / False)`, 
y2=ceusvtctavfinal$`CEUS Any Endoleak  (True/False)`) 
T2ELFD_tab <- tab.paired(d=ceusvtctavfinal$`Type II Endoleak (TRUE / 
FALSE)`, y1=ceusvtctavfinal$`tCTA Type II Endoleak (True / False)`, 
y2=ceusvtctavfinal$`CEUS Type II Endoleak (True / False)`) 
 
# Creating dataframe for intial enhancment analysis 
a<- data.frame (tcta_monitoring$`Participant ID`, 
tcta_monitoring$`tCTA Time For Monitoring to Trigger i.e. >90HU (s)`) 
colnames(a) <- c("Participant ID","tCTA Time For Monitoring to Trigger 
i.e. >90HU (s)") 
 
all_enhancement_data <- merge (tcta_enhhancement, a, by= "Participant 
ID", no.dups=FALSE) 
all_enhancement_data$`Participant ID`<- 
as.factor(all_enhancement_data$`Participant ID`) 
all_enhancement_data$timing <-all_enhancement_data$`Phase (s)` + 
all_enhancement_data$`tCTA Time For Monitoring to Trigger i.e. >90HU 
(s)` 
#all_enhancement_data$timing[all_enhancement_data$timing>=75] <- 75 
 
#creating dataframe for second enhament analysis 
tcta_addition_enhacement_data$'tCTA Time For Monitoring to Trigger 
i.e. >90HU (s)' <- 0 
tcta_addition_enhacement_data$timing <- 
tcta_addition_enhacement_data$`Phase (s)` 
additional_enhacement_data <- rbind(tcta_addition_enhacement_data, 
all_enhancement_data) 
additional_enhacement_data$`Participant ID` <- 
as.factor(additional_enhacement_data$`Participant ID`) 
additional_enhacement_data <- as.numeric(additional_enhacement_data) 
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#test <- data.frame(levels(all_enhancement_data$`Participant 
ID`),0,"EVAR Lumen",0) 
#colnames(test) <- c("Participant ID","Phase (s)","Enhancement 
(HU)","timing") 
#?rbind() 
#a<-merge(test, all_enhancement_data) 
#Analysis 
#Primary Outcome 
print("Graft Related Endoleaks - CEUS Index, tCTA as Refference") 
acc.1test(GREL_tab) 
#miss one out Cross validation - This is a binary test ?what is 
correct method of cross validation 
x<- nrow(ceusvtcta) 
y <- c(2:x) 
a <- ceusvtcta [c(2:x),] 
a <- tab.1test(d=na.omit(a$`tCTA Graft-Related Endoelak 
(True/False)`),y=na.omit(a$`CEUS Graft-Related Endoleak 
(True/False)`)) 
a <- acc.1test(a) 
sensitivity <- a$sensitivity 
specificity <- a$specificity 
ppv <- a$ppv 
npv <- a$npv 
 
for(j in y){ 
  #a<-ceusvtcta[(j:x),] 
    a <- ceusvtcta [c(0:(j-1),(j+1):x),] 
    a <- tab.1test(d=na.omit(a$`tCTA Graft-Related Endoelak 
(True/False)`),y=na.omit(a$`CEUS Graft-Related Endoleak 
(True/False)`)) 
    a <- acc.1test(a) 
    sensitivity <- rbind(sensitivity, a$sensitivity) 
    specificity <- rbind(specificity, a$specificity) 
    ppv <- rbind(ppv,a$ppv) 
    npv <- rbind(npv,a$npv) 
    rm(a) 
      } 
sensitivity <- na.omit(sensitivity) 
specificity <- na.omit(specificity) 
ppv <- na.omit(ppv) 
npv <- na.omit(npv) 
# ????i assume its the mean value used for the cross validation 
summary(sensitivity) 
summary(specificity) 
summary(ppv) 
summary(npv) 
 
#Diagnostic values 
#tCTA as Refference 
print("Any Endoleaks - CEUS Index, tCTA as Refference") 
acc.1test(ANYEL_tab) 
print("Type II Endoleaks - CEUS Index, tCTA as Refference") 
acc.1test(T2EL_tab) 
#Final DIagnosis as Refference 
print("Graft Related Enoleaks - tCTA Index 1, CEUS Index 2, Final 
Diagnosis as Refference") 
acc.paired(GRELFD_tab) 
print("Any Enoleaks - tCTA Index 1, CEUS Index 2, Final Diagnosis as 
Refference") 
acc.paired(ANYELFD_tab) 
print("Type II Enoleaks - tCTA Index 1, CEUS Index 2, Final Diagnosis 
as Refference") 
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acc.paired(T2ELFD_tab) 
 
#exploratory analysis for association 
#data processing for correlation between CEUS and tCTA 
correlation <- merge(ceus, tcta_monitoring, by="Participant ID") 
correlation$`CEUS Run One (Recording)- Contrast Arrival (s)` <- 
as.numeric(correlation$`CEUS Run One (Recording)- Contrast Arrival 
(s)`) 
correlation$`CEUS Run Two (Recording)- Contrast Arrival (s)` <- 
as.numeric(correlation$`CEUS Run Two (Recording)- Contrast Arrival 
(s)`) 
correlation$`CEUS Run One Temporal Delay (s)` <- 
as.numeric(correlation$`CEUS Run One Temporal Delay (s)`) 
correlation$`CEUS Run Two Temporal Delay (s)` <- 
as.numeric(correlation$`CEUS Run One Temporal Delay (s)`) 
correlation$`CEUS Run One (Operator) - Temporal Delay (s)` <- 
as.numeric(correlation$`CEUS Run One (Operator) - Temporal Delay (s)`) 
correlation$`CEUS Run Two (Operator) - Temporal Delay (s)` <- 
as.numeric(correlation$`CEUS Run Two (Operator) - Temporal Delay (s)`) 
 
data <-data.frame(correlation$`tCTA Time For Monitoring to Trigger 
i.e. >90HU (s)`, correlation$`CEUS Run One (Recording)- Contrast 
Arrival (s)`, correlation$`CEUS Run One (Operator) - Temporal Delay 
(s)`,correlation$`CEUS Run One Temporal Delay (s)`) 
colnames(data) = c("tCTA","CEUS","OP_TD","rec_TD") 
data1 <- data.frame(correlation$`tCTA Time For Monitoring to Trigger 
i.e. >90HU (s)`, correlation$`CEUS Run Two (Recording)- Contrast 
Arrival (s)`, correlation$`CEUS Run Two (Operator) - Temporal Delay 
(s)`,correlation$`CEUS Run Two Temporal Delay (s)`) 
colnames(data1) = c("tCTA","CEUS","OP_TD","rec_TD") 
data2 <- rbind(data,data1) 
data2 
 
#Correlation plot between time for contrast to arrive in STENT in CEUS 
vs time to trigger tCTA 
qq1 <- ggqqplot(data2$tCTA, ylab = "Time after contrast injection 
started to trigger tCTA (s)") 
qq2 <- ggqqplot(data2$CEUS, ylab = "Time after contrast injection 
strated till contrast seen in EVAR lumen on CEUS (s)") 
qq <- ggarrange(qq1,qq2,ncol=2) 
ggsave("contrast_in_endoleak_qqplots.png", qq, device = NULL, path = 
NULL, 
       scale = 1, width = 210, units = "mm", 
       dpi = 600, limitsize = TRUE) 
ggplot(data2, aes(x=data2$tCTA,y=data2$CEUS))+ 
 geom_point()+ 
  geom_smooth(method = "lm")+ 
xlab("Time for density to >90HU in monitoring for tCTA (s)")+ 
ylab("Time for contrast to arrive in EVAR stent\ngraft after injection 
in CEUS (s)") 
 
 
#correlation plot between time for contrast in endoleak on CEUS and 
tCTA 
colnames(tcta_ceus_timings) <- c("tCTA","CEUS") 
 
qq1 <- ggqqplot(tcta_ceus_timings$tCTA, ylab = "Time for contrast into 
tCTA endoleak (s)") 
qq2 <- ggqqplot(tcta_ceus_timings$CEUS, ylab = "Time for contrast into 
CEUS endoleak (s)") 
qq <- ggarrange(qq1,qq2,ncol=2) 
ggsave("contrast_in_endoleak_qqplots.png", qq, device = NULL, path = 
NULL, 
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scale = 1, width = 210, units = "mm", 
dpi = 600, limitsize = TRUE) 
 
ggscatter(tcta_ceus_timings, x="tCTA", y="CEUS", xlab = "Time for 
contrast into CEUS endoleak (s)", ylab = "Time for contrast into CEUS 
endoleak (s)", add = "reg.line", conf.int = TRUE, cor.coef = FALSE, 
cor.coeff.args = list(method = "pearson", label.x.npc = "middle", 
label.y.npc = "top")) 
ggsave("correlation_of_endoleak_timing.png", plot = last_plot(), 
device = NULL, path = NULL, 
       scale = 1, width = 210, units = "mm", 
       dpi = 600, limitsize = TRUE) 
   
##Perfusion phases 
#individual patoemt plots 
ggplot(all_enhancement_data, aes(x=all_enhancement_data$`Phase (s)`, 
y=all_enhancement_data$`Enhancement (HU)`, 
col=all_enhancement_data$Measurement))+ 
  geom_jitter()+ 
  theme(legend.position="bottom")+ 
  xlab("Time Since tCTA Phase Triggered (s)") +  
  ylab("Enhancement (HU)")+ 
  guides(color=guide_legend(title=""))+ 
  facet_wrap(~ all_enhancement_data$`Participant ID`)+ 
  geom_line() 
 
ggsave("perfusion_by_participant.png", plot = last_plot(), device = 
NULL, path = NULL, 
       scale = 1, width = 210, height = 297, units = "mm", 
       dpi = 600, limitsize = TRUE) 
# by type from 9oHU trigger 
ggplot(all_enhancement_data, aes(x=all_enhancement_data$`Phase (s)`, 
y=all_enhancement_data$`Enhancement (HU)`, 
col=all_enhancement_data$`Measurement Class`), xlim=25)+ 
  geom_point(show.legend = FALSE)+ 
  geom_smooth(method = loess, formula=y~log(x+1), span=1, se=TRUE)+ 
  ##bestfit line chosen entirley vissually 
  theme(legend.position="none")+ 
  xlab("Time Since tCTA Phase Triggered (s)") +  
  ylab("Enhancement (HU)")+ 
  xlim(0,80)+ 
  facet_wrap(~ all_enhancement_data$`Measurement Class`) 
ggsave("perfusion_by_type.png", plot = last_plot(), device = NULL, 
path = NULL, 
       scale = 1, width = 210, units = "mm", 
       dpi = 600, limitsize = TRUE) 
 
# by time from start of injection 
ggplot(additional_enhacement_data, 
aes(x=additional_enhacement_data$timing, 
y=additional_enhacement_data$`Enhancement (HU)`, 
col=additional_enhacement_data$`Measurement`), xlim=25)+ 
  geom_point(show.legend = FALSE)+ 
  #geom_smooth(method = loess, formula=y~log(x+1,10), span=1, 
se=FALSE)+ 
  theme(legend.position="none")+ 
  xlab("Time Since tCTA Contast Injection Started (s)") +  
  ylab("Enhancement (HU)")+ 
  xlim(0,110)+ 
  facet_wrap(~ additional_enhacement_data$`Measurement`) 
ggsave("perfusion_by_type_from_injection.png", plot = last_plot(), 
device = NULL, path = NULL, 
       scale = 1, width = 210, units = "mm", 
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       dpi = 600, limitsize = TRUE) 
## by LOg10 of time from start of injection 
additional_enhacement_data$sr <- 
log10(additional_enhacement_data$timing) 
ggplot(additional_enhacement_data, 
aes(x=additional_enhacement_data$sr, 
y=additional_enhacement_data$`Enhancement (HU)`, 
col=additional_enhacement_data$`Measurement`), xlim=25)+ 
  geom_point(show.legend = FALSE)+ 
  geom_smooth(method = 'lm', formula=y~poly(x-1,2), se=TRUE)+ 
  theme(legend.position="bottom")+ 
  xlab(expression(paste("Log 10 "^"(Time Since tCTA Contast Injection 
Started (s))")))+ 
  ylab("Enhancement (HU)")+ 
  guides(color=guide_legend(title=""))+ 
  facet_wrap(~ additional_enhacement_data$`Measurement`) 
 
ggsave("perfusion_by_type_from_injection_transformed.png", plot = 
last_plot(), device = NULL, path = NULL, 
       scale = 1, width = 210, units = "mm", 
       dpi = 600, limitsize = TRUE) 
 
# by time from start of by Class 
ggplot(additional_enhacement_data, 
aes(x=additional_enhacement_data$sr, 
y=additional_enhacement_data$`Enhancement (HU)`, 
col=additional_enhacement_data$`Measurement`), xlim=25)+ 
  geom_point(show.legend = FALSE)+ 
  geom_smooth(method = 'lm', formula=y~poly(x-1,2), se=FALSE)+ 
  theme(legend.position="bottom")+ 
  xlab(expression(paste("Log 10 "^"(Time Since tCTA Contast Injection 
Started (s))")))+ 
  ylab("Enhancement (HU)")+ 
  guides(color=guide_legend(title=""))+ 
  facet_wrap(~ additional_enhacement_data$`Measurement Class`) 
 
ggsave("perfusion_by_class_from_injection_transformed.png", plot = 
last_plot(), device = NULL, path = NULL, 
       scale = 1, width = 210, units = "mm", 
       dpi = 600, limitsize = TRUE) 
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7. FULL DATA FROM PROSPECTIVE COMPARATIVE 
STUDY  
A copy of the following file is on the accompanying CD in the pocket attached to the 
inside back cover. 
CD\ceus_tcta\final_data.xlsx 
